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Rheumatoid arthritis (RA) is an immune-mediated inflammatory systemic disease. RA af-
fects 0.5-1% of the civilized population, three times more women than men and the 
prevalence rises with age.1 RA has a clinical manifest of symmetric polyarthritis of especially 
the small hand and foot joints and can progress into a very immobilizing and disabling 
disease, without effective treatment and leads on socio-economic perspective to high costs 
and loss of work force.
RA is an auto-immune disease, with inflammation against own tissue in primarily the 
joints. Due to interaction between T cells, B cells, macrophages and fibroblast-like syn-
oviocytes several pro-inflammatory cytokines are overproduced, like; tumor necrosis factor 
alpha (TNF-α), interleukin 1 (IL-1), interleukin 6 (IL-6) and B cells start producing antibodies. 
These inflammatory cascades lead towards persistent synovial inflammation and destruc-
tion of cartilage and bone.1 However, whether rheumatoid arthritis starts from inside the 
bone and spreads further into the tissue in the joint, or it starts with inflammation of the 
joint tissue which leads to bone involvement from outside, still remains unknown.2
RA is characterized by auto-antibodies like Rheumatoid Factor (RF) and anti-citrullinated 
peptide antigens (ACPA). ACPA and RF have a high specificity (80-90%) and a moderate 
sensitivity for the diagnosis of RA.3 Approximately 55% of the RA patients are RF posi-
tive and 60% ACPA positive.4-6 In addition, ACPA and RF positivity is also important for 
the disease course, because these are risk factors for a persistent and more destructive 
disease.7 Furthermore, from previous studies we learned that these auto-antibodies are 
a median of 5 years present before the first symptoms of RA start and thus precede the 
clinical presentation phase of RA.8 This might suggest that there is a pre-clinical stage 
present in RA.
From literature we learned that early recognition and treatment will result in a better 
outcome.9,10 Some studies even suggest that treatment within this early ‘window of op-
portunity’ might alter the natural course of RA.11
UnClAssiFieD ARthRitis
A patient with at least one swollen joint has arthritis. Together with other clinical symp-
toms, results from blood tests, imaging and other techniques the Rheumatologist will try 
to classify this patient. When all diagnoses, such as osteoarthritis, gout, reactive arthritis, 
spondyloarthropathy, systemic lupus erythematosis and of course rheumatoid arthritis are 
excluded, the patient can be classified as unclassified arthritis (UA).12 Therefore UA is called 
a diagnosis per exclusion. 35% to 54% of the arthritis patients are classified as UA in the 
early arthritis cohorts.5,13 However, the frequency is dependent on the duration of symp-
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toms. Especially UA patients with a monoarthritis or oligoarthritis could not be classified as 
RA. Patients with unclassified arthritis can progress into rheumatoid arthritis (70% of the 
ACPA positive UA patients within 1 year) over time or can achieve remission or self-limiting 
disease.14 The percentage of remission (40%-55%) in unclassified arthritis patients is larger 
than the percentage of remission in rheumatoid arthritis (10%-15%) and also the time to 
remission is shorter in unclassified arthritis patients.14,15 This all suggests that the group of 
UA patients is a very heterogeneous group of patients and that remission is less common 
when the disease is more mature. However, UA can be pre-RA, but can also be a different 
disease and never progress to RA (Figure 1).
ARthRAlGiA
When taking a look even earlier in the course of the disease, even before the patient has 
arthritis, patients generally experience a period in which they have tender or painful joints, 
without the presence of a swollen joint. This is called arthralgia. Arthralgia can be accom-
panied by other symptoms. Some of these symptoms and characteristics about that patient 
with arthralgia can make the patient more suspect to finally progress into rheumatoid 
arthritis. The presence of ACPA and/or RF does increase the risk of arthritis development. A 
prediction model defined several additional risk factors for arthritis development in ACPA+ 
and/or RF arthralgia patients.16 ACPA positive arthralgia patients have a 30% chance of RA 
development within 1 year.17
ClAssiFiCAtion CRiteRiA AnD PReDiCtion moDels FoR RA 
DeveloPment
In 1987 a set of criteria has been developed to classify patients with arthritis as having 
rheumatoid arthritis.18 These classification criteria were soon implanted as a diagnostic 
tool for Rheumatologists. However, the focus of diagnosing RA became more and more 
on early diagnosing and this criteria set is lacking in classifying early RA patients the 2010 
classification criteria have been developed to classify more early RA patients.19 Although, 
normal popula on arthralgia unclassied arthri s (UA) rheumatoid arthri s (RA) 
mild 
severe 
Figure 1. Disease phases of RA. Patients do not have to pass through all phases before RA eventually 
develops.
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1officially these criteria are classification criteria to discriminate patients with and without 
RA in order to include in trials and to have a common definition in research communication 
and not to define patients who need early treatment, these criteria are more and more 
implanted in daily clinical practice (Figure 2).
These new criteria have resulted in classification of more early RA patients, but likewise 
a more heterogeneous group of RA patients with some over classification (patients with 
































Figure 2. 1987 and 2010 classification criteria for RA, in patients with arthritis.
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lower the prevalence of UA patients, but will also change the characteristics and outcomes 
of both the RA and UA patients.
Another important development in classifying UA patients was the coming of prediction 
models for the individual UA patient. Two important prediction models to predict disease 
outcome in UA patients are the ‘Van der Helm prediction model’ and the ‘Visser prediction 
model’. These prediction models can help the Rheumatologist to decide whether or not 
treating the UA patient.23,24
PReDiCtinG DiseAse oUtCome oF RA
When a patient is classified as RA, the disease course is not yet known, due to a lot of 
variation in the disease course of RA patients. Some patients will rapidly progress in a 
very erosive and disabling disease, while others will develop (spontaneous) remission. It 
can be very useful to know the disease course of a patient, not only to inform the patient 
about his prognosis but also whether or not to start (more aggressive) treatment. This 
is very important to avoid undertreatment, because we know that early treatment will 
have a positive effect on the disease course. Nevertheless, overtreatment can be even that 
important, as a lot of the treatments have their (toxic) side effects.
Radiographic outcome
To measure the severity of the disease, an outcome measure has to be defined. Severe 
RA is not uniformly defined. Patients often refer to the degree of pain or fatigue and the 
ability to perform daily activities and work. Rheumatologists are more concerned with the 
level of inflammation (expressed by the number of inflamed joints), the level of acute phase 
reactants, and pooled severity indices such as disease activity scores. Scientists focus on 
outcome measures that can be assessed objectively, such as joint destruction and mortality. 
These perspectives are essentially similar, since levels of impaired functionality, inflamma-
tion, and structural damage are partly correlated.25
Furthermore, radiographic progression is highly variable between RA patients and cor-
relates with the cumulative burden of inflammation over time, is highly linked with physical 
function and other outcomes such as work disability, and is inexpensive to measure using 
validated scoring methods; consequently, the rate of radiographic progression is a compre-
hensive endpoint in observational studies.
The most common and in RA research field widely accepted measure for radiographic 
joint destruction of hands and feet is the Sharp-van der Heijde score. This is a quantitative 
score that can be used by trained readers, and comprises an erosive and narrowing (reflec-
tion of cartilage damage) score of both hands and feet with a range of 0-448.26
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Risk factors for a more severe disease outcome
An important risk factor for RA development is to have a relative with RA. This suggests that 
genetic background is of importance in RA and therefore the severity of the disease course 
could also have a genetic background. Twin studies have indicated that the radiographic 
progression rate is in part heritable.27 Recent estimations on an Icelandic RA population 
yielded a heritability of 45-58%.28 Over 40 genetic variants have been identified in RA sus-
ceptibility, by genome-wide association studies (GWAS), evaluating thousands of cases and 
controls. These susceptibility genes are prone to be of importance in RA severity, measured 
by radiographic progression. Another, approach of unravelling the genetic variants for 
radiographic progression, are more dedicated candidate gene studies focusing on pathways 
important in RA, such as genes involved in inflammation and bone cartilage pathways.
The presence or high levels of several serological markers are also predictors for radio-
graphic progression in RA. Serological markers that are important for radiographic progres-
sion are auto-antibodies and other markers related to inflammation and bone and cartilage 
destruction, like RF, ACPA, anti-CarP , ESR, CRP, MMP3, CTX-I, CTX-II, COMP, TIMP1, PYD, 
RANKL/OPG and CXCL13.29-52
In addition, some studies investigated whether environmental risk factors, like smoking, 
could be of importance in risk predicting of radiographic progression in RA.53-55
mRi
MRI is becoming an important tool in RA research. MRI has important advantages over 
conventional radiographs as, in addition to structural damage, inflammation of the 
synovium of the joint, tendons and bone marrow edema (BME) can be visualized and 
quantified. MRI produces images by detecting signal from H+ ions. The detection of H+ 
ions by MRI means that tissues with high concentrations of water reflect a high signal on 
T2-weighted sequences. This can be used to detect free fluid and inflammation. In RA this 
means detection of synovitis, tenosynovitis, synovial effusion and bone marrow edema. 
When making sequences after infusion of gadolinium containing contrast a region can 
be specified as an active inflammation when there is enhanced vascularity, which could 
distinguish between synovitis and synovial effusion.
In order to evaluate MR images an international Outcome Measures in Rheumatology 
Clinical Trials (OMERACT) MRI in RA working group developed and validated a semi-
quantitative scoring system; the RA MRI scoring system (RAMRIS). This scoring system was 
developed to assess RA inflammation and damage. The scoring system recommends having 
at least the following sequences: imaging in two planes with T1-weighted images before 
and after intravenous gadolinium contrast and a T2-weighted fat saturated sequence. This 
scoring system measures the following RA joint pathologies; synovitis, erosion and BME.56-
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58 Haavardsholm et al described the additional scoring of tenosynovitis.59 The sum score 
ranges in unilateral MCP2-5, wrist and MTP1-5 for synovitis 0-36, erosion 0-330, BME 0-99 
and tenosynovitis 0-84.
Especially BME is of special interest in RA research. Normal bone marrow is a fatty-tissue 
inside the bone and is visualized as a bright signal on T1-weighted images and as a dark 
signal on T2-weighted images. When bone marrow edema is present the fatty tissue is 
replaced by more water-rich material and will be visualized as a dark signal on T1-weighted 
images and as a bright signal on T2-weighted images.60 Previous studies have proven by 
histology of a pre-surgical defined region with bone marrow edema, that these regions 
reveal a lymphoplasmacytic inflammatory infiltrate within trabecular bone.61-63 Several 
studies showed that BME has an additive value to known diagnostic criteria, to give a 
higher diagnostic accuracy.64-66 Furthermore, BME is a very strong independent predictor of 
radiographic progression.67-72
In addition, because BME has a diagnostic value for predicting RA and has a prognostic 
value for predicting radiographic progression, MRI detected inflammation in RA is likely to 
become more important in the earlier phases of RA and also the pre-clinical phase without 
the presence of arthritis. Recent studies showed that MRI-detected subclinical inflamma-
tion is present in patients that are in clinical remission.73-77




The major part of this thesis was investigated in the early arthritis clinic (EAC) in Leiden. 
This is an ongoing observational cohort that started in 1993. Patients presenting at the 
outpatient clinic at the Rheumatology department at the Leiden University Medical Centre, 
with at least one confirmed swollen joint and symptoms less than two years were included. 
At baseline, patients and Rheumatologist completed questionnaires, physical examinations 
were performed, radiographs were taken and blood was obtained to measure acute phase 
reactants, RF and ACPA. From 2010 on also MRI’s were taken. After two weeks, when 
blood and radiographs results were known, a rheumatologist diagnosed the patients as 
having RA, UA or another diagnosis. Thereafter yearly visits with radiographs followed.5
Part i is focused on unclassified arthritis and the risk on development of rheumatoid 
arthritis. In 2010 new criteria were developed to classify also the early RA patient. Some 
studies thereafter showed what the new group of RA looked like in characteristics and 
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1outcome. The most important findings were that the group of RA, according to the 2010 
criteria, were more heterogeneous and less severe in presentation and outcome.4,6,20 In 
chapter two we determined the characteristics and outcomes of unclassified arthritis, 
when applying the 2010 and 1987 criteria for RA. We compared these two groups on 
baseline characteristics and outcomes like; DMARD initiation in the first year, fulfilling the 
1987 criteria for RA during the first year and achieving remission.
In chapter three we analyzed UA patients according to the 2010 criteria from our own 
Leiden EAC cohort and compared them to UA patients from two other cohorts. We inves-
tigated the risk of development of RA in this group of patients and we tried to explorer 
whether the Leiden prediction rule or ACPA positivity could help identify these UA patients 
that progress to RA.
Part ii is focused on serologic and genetic factors in predicting the severity of joint destruc-
tion in rheumatoid arthritis. When a patient can be classified as RA, nothing is known 
about the prognosis yet. There is a lot of variability in the disease course of RA. Several risk 
factors for a more severe disease course are already known, such as ACPA and several ge-
netic variants. In chapter four the thus far known risk factors (or biomarkers) for a severe 
disease course in RA, measured by radiographic progression, are summarized. In chapter 
five genetic variants in IL-15 and the association with severity of joint damage in RA was 
investigated in four cohorts. In chapter six we investigated whether genetic variants in the 
IL-4 and IL-4 receptor genes were associated with the severity of joint damage in RA, in 7 
cohorts. Furthermore, in chapter seven we investigated genetic variants in granzyme-B 
and the association with severity of joint damage in RA, in four cohorts.
In chapter eight the collagen crosslink in cartilage and bone, pyridinoline, was analyzed 
in relation to the severity of joint destruction in RA. We investigated whether the levels of 
pyridinoline on baseline and during follow-up were associated to radiographic progression 
in RA patients.
Part iii is focused on MRI in patients with arthralgia and early arthritis. Last decades, MRI 
is becoming a relevant tool in RA research. MRI can be used in different stages of the 
disease; arthralgia, early arthritis, early RA, RA and for different purposes; for better insight 
in disease pathogenesis in the pre-clinical or clinical stage, or for predicting diagnosis or 
prognosis. In chapter nine we evaluated MRI inflammation in hand and foot joints in 
ACPA positive arthralgia patients, by comparing these joints to joints of healthy controls 
and ACPA positive RA patients. This pilot study was to investigate MRI pathologies in an 
early phase of the disease; in arthralgic joints, without clinical arthritis. In chapter ten we 
determined the concordance between inflammation at physical examination and on MRI 
in early arthritis patients. These two chapters give a better insight on the pathogenesis in 
the early clinical and clinical phase. In chapter eleven the relevance of the MRI detected 
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subclinical inflammation was investigated. We calculated the relative risk of radiographic 
progression in joints with MRI detected subclinical inflammation compared to that in joints 
without MRI detected subclinical inflammation. In chapter twelve we analyzed the dif-
ferentiating capacity of MRI for diagnosing RA in a group of early arthritis patients.
Part iv is focused on revisiting of the MRI scan protocol. The OMERACT group developed 
the semi-quantitative scoring method for scoring MRI in RA; the RAMRIS method. This 
method also describes the scanning protocol that is needed to have the necessary MRI 
sequences to score the images according to this protocol. The protocol recommends to 
make T1 images, primarily to score erosions, a T2 or STIR sequence to score BME and a T1 
post-contrast sequence to score synovitis and tenosynovitis, for every joint. This resulted 
in a long scanning time which is costly and in which a patient needs to keep the hand or 
foot motionless or otherwise will lead to artefacts. To improve this, we tried to shorten the 
scanning protocol, with the same accuracy and validity of scoring. First, we compared in 
chapter thirteen scoring of BME on T2 and on T1 post-contrast sequences, which could 
result in removing the T2 sequences from the scanning protocol. And in chapter fourteen 
we compared scoring of synovitis on T1 post-contrast and on T2 sequences, which could 
result in removing the T1 post-contrast from the scanning protocol and no contrast infu-
sion would be needed.
MRI is a very sensitive tool to measure inflammation and destruction and therefore could 
result in a reasonable percentage of false-positives, especially when normal daily activi-
ties could influence MRI measured pathologies in RA. In chapter fifteen we investigated 
whether wearing of high heels can influence MRI results.
Finally, in chapter sixteen the findings of this thesis are summarized and discussed.
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Undifferentiated arthritis (UA) is a diagnosis ‘per exclusionem’. Therefore this patient 
population may change since the development of the ACR/EULAR 2010-criteria for RA. 
This study evaluated characteristics and outcomes of UA in its new shape. Second, it was 
evaluated whether the 2010-criteria and the Leiden prediction rule were congruent in 
categorizing UA-patients.
methods
2,472 early arthritis patients were studied. RA was classified according to either the 1987 
or the 2010-criteria. UA was defined as not fulfilling existing classification criteria. UA-
patients were compared for baseline characteristics and outcomes. In 1987-UA- patients 
both the 2010-criteria and the Leiden prediction rule were applied and categorization 
compared.
Results
2010-UA-patients (n=776) had milder baseline characteristics than 1987-UA-patients 
(n=1,166). During follow-up, still 24% of the 2010-UA-patients fulfilled the 1987 RA-
criteria compared to 32% of the 1987-UA-patients. The 2010-UA-patients started less 
frequent DMARD- therapy and reached more frequent sustained DMARD-free remission. 
30% of 2010-criteria-positive patients were predicted to have a low risk on RA; these pa-
tients achieved more frequent DMARD-free sustained remission than other 2010-criteria-
positive patients.
Conclusion
UA in the era of the 2010-criteria is less prevalent and milder at presentation and in out-
come. This implies that UA-patients with unfavorable characteristics are now more often 
classified as RA.
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intRoDUCtion
A considerable proportion of the patients presenting with synovitis of recent onset have 
undifferentiated arthritis. Undifferentiated arthritis is identified when none of the existing 
classification criteria for definitive diagnoses are fulfilled and arthritis is not septic or caused 
by crystals. The 2010 American College of Rheumatology (ACR)/European League Against 
Rheumatism (EULAR) classification criteria for rheumatoid arthritis (RA) were recently devel-
oped.1 Recent studies have indicated that these criteria are fulfilled earlier in the disease and 
more frequently than with the 1987 ACR criteria.2,3 Since undifferentiated arthritis is a disease 
‘per exclusionem’, we questioned how this disease entity is characterized when applying the 
2010 criteria. Therefore, the first aim of this study was to explore the characteristics and the 
outcome of undifferentiated arthritis in its new form. Before the 2010 criteria were formu-
lated, a prediction rule was developed that aimed to determine individual undifferentiated 
arthritis patient’s chances of developing RA (according to the 1987 criteria).4 Both methods 
are particularly applicable to patients who could not be diagnosed otherwise, thus to former 
undifferentiated arthritis patients. We also evaluated whether the 2010 criteria and the 
prediction rule were congruent in categorizing early undifferentiated arthritis patients.
PAtients AnD methoDs
Patients
Two thousand four hundred and seventy-two early arthritis patients, included in the Leiden 
Early Arthritis Clinic (EAC) between 1993 and February 2010 and who had a follow-up 
of at least 1 year, were studied. The EAC is a population-based prospective cohort that 
includes patients with confirmed arthritis and symptoms for less than 2 years.5 At baseline, 
patients and rheumatologists completed questionnaires, physical examinations (including 
68 tender and 66 swollen joint counts) were performed, radiographs were taken, and blood 
was obtained for determination of the C-reactive protein level, erythrocyte sedimentation 
level, IgM rheumatoid factor and anti-citrullinated protein antibodies. After 2 weeks, when 
blood and radiographic results were known, a rheumatologist diagnosed the patients as 
having RA, undifferentiated arthritis, or another diagnosis; this was done using the 1987 
criteria for RA. This resulted in 1166 patients with undifferentiated arthritis (the so-called 
1987 undifferentiated arthritis patients). We applied the 2010 criteria to the same patients 
and subsequently identified the so-called 2010 undifferentiated arthritis patients (n=776). 
Written informed consent was obtained from all participants. The study was approved by 
the local medical ethics committee.
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outcome
Follow-up visits were performed annually. After 1 year it was evaluated whether the 1987 
criteria were fulfilled and whether disease-modifying anti-rheumatic drugs (DMARD) were 
initiated. Patients treated according to a randomized trial were not studied (n=145) for 
this outcome. The prescribed DMARD in RA patients differed in time; hydroxy- choroquine, 
penicillamine, or sulfasalazine were the initial DMARD in the 1990s, and methotrexate was 
the initial DMARD since 1999. During a follow-up of 7 years, it was evaluated whether a 
patient achieved sustained remission. Sustained remission was defined as the absence of 
synovitis for at least 1 year after the cessation of eventual DMARD therapy.6 Furthermore, 
the functional ability was measured annually by the health assessment questionnaire (HAQ) 
score. The difference in the HAQ score over 7 years was also evaluated.
Comparison of categorization
In order to determine whether classification according to the 2010 criteria was congruent 
with risk estimation by the prediction rule, both methods were applied to 1,162 1987 
undifferentiated arthritis patients. The congruency of classification was evaluated, as well 
as the disease outcome. The primary outcome here was having persistent disease (absence 
of sustained DMARD-free remission).
Analysis
Patient characteristics were compared using the χ2 test for nominal variables, the Student’s 
t test for continuous variables and the Mann-Whitney U-test for non-parametric testing. 
Analyses of sustained DMARD-free remission were performed using univariate Cox regres-
sion analyses. The difference in HAQ score between 1987 undifferentiated arthritis patients 
and 2010 undifferentiated arthritis patients was compared using a multivariate normal 
regression analysis. As the HAQ changed over time, the interaction of the undifferentiated 
arthritis groups with time was entered into the model as categorical variables. p Values 
≤0.05 were considered significant. Analyses were done using SPSS, version 17.0.
ResUlts
Characteristics at presentation
Among all 2472 early arthritis patients, 772 (31.2%) patients were diagnosed other than 
undifferentiated arthritis or RA. Using the 1987 criteria for RA, 534 (21.6%) patients had 
RA and 1166 (47.2%) patients had undifferentiated arthritis. In four patients only one 
serological test and one acute-phase response measure was obtained and therefore they 
could not be classified according to the 2010 criteria.1 Subsequently, the 2010 criteria were 
applied to 1696 undifferentiated arthritis and RA patients. Now 920 (54.2%) patients were 
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Age, mean ± SD in years 51.6 ± 17.1 50.3 ± 17.2 0.12
Female sex 699 (59.9) 443 (57.1) 0.21
BMI, mean ± SD in kg/m2 25.9 ± 4.3 25.6 ± 4.4 0.26
Current or past smoker 286 (28.0) 197 (29.1) 0.97
Onset of complaints
(Sub)acute 657 (58.8) 465 (62.4) 0.12
Gradual 460 (41.2) 280 (37.6)
Morning stiffness, median (IQR) in minutes 30 (0-60) 30 (0-60) 0.06
0-29 457 (41.0) 337 (45.6) 0.14
30-59 190 (17.0) 117 (15.8)
≥60 468 (42.0) 285 (38.6)
Symptom duration, median (IQR) in weeks 15.7 (6.9-31.9) 13.4 (5.3-29.2) 0.01
Localization of affected joints
Small joints hands/feet 908 (81.1) 631 (84.8) 0.04
Localization of affected joints
Symmetrical 563 (54.0) 328 (47.7) 0.01
Localization of affected joints
Upper extremities 722 (72.1) 507 (75.7) 0.10
Swollen joint count, median (IQR) 3 (1-7) 2 (1-5) <0.001
0-3 joints 607 (53.1) 494 (65.3) <0.001
4-10 joints 364 (31.8) 218 (28.8)
>10 joints 172 (15.0) 44 (5.8)
Tender joint count, median (IQR) 5 (2-12) 2 (1-6) <0.001
0-3 joints 301 (40.2) 266 (59.2) <0.001
4-10 joints 223 (29.8) 158 (35.2)
>10 joints 225 (30.0) 25 (5.6)
ESR, median (IQR) mm/hour 19 (8-39) 16 (8-36) 0.02
CRP, median (IQR) mg/liter 9 (3-24.5) 8 (3-23) 0.29
RF positive 294 (25.5) 76 (9.9) <0.001
Low positive 118 (10.2) 32 (4.2) 0.83
High positive 176 (15.3) 44 (5.7)
Anti-CCP-2 positive 234 (24.1) 61 (9.6) <0.001
Low positive 44 (4.5) 44 (6.9) <0.001
High positive 190 (19.6) 17 (2.7)
HAQ, mean ± SD 0.8 ± 0.7 0.7 ± 0.6 0.01
2010 criteria score, mean ± SD 4.9 (2.4) 3.2 (1.4) <0.001
* Except where indicated otherwise, values are the number (%) of patients.
IQR = interquartile range.
Localization of affected joint: ‘upper joints’ stands for upper joints with or without involvement of the 
lower joints, whereas ‘small joints’ stands for smaller joints with or without involvement of the large 
joints.
In the group of all patients with UA, some data were missing, as follows: for BMI, n=351; for smoking, 
n=146; for onset of complaints, n=48; for morning stiffness, n=51; for symptom duration, n=95; for 
small joints involved, n=46, for symmetrical joint involvement, n=123; for upper extremity joints in-
volved, n=164; n=25; for ESR, n=8; for CRP, n=81; for RF, n=11; for CCP, n=197; for HAQ score, n=245.
A chi-square test was used for nominal variables and the Student’s t-test or Mann-Whitney U-test for 
continuous variables. Student’s t-test was performed when variables are presented as mean and a Mann-
Whitney U-test was performed when variables are presented as median.
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classified as having RA; therefore 776 (45.8%) 2010 undifferentiated arthritis patients 
were identified.
The baseline characteristics of the 2010 undifferentiated arthritis patients and 1987 
undifferentiated arthritis patients were compared (table 1). Overall, 2010 undifferentiated 
arthritis patients had milder disease characteristics than the 1987 undifferentiated arthritis 
patients.
outcome
After 1 year of follow-up, 23.8% of the 2010 undifferentiated arthritis patients fulfilled 
the 1987 criteria, compared with 32.2% of the 1987 undifferentiated arthritis patients 
(p=0.001). Likewise, in 32.7% of the 2010 undifferentiated arthritis patients a DMARD 
was initiated during the first year compared with 45.0% of the 1987 undifferentiated 
arthritis patients (p<0.001).
During 7 years of follow-up, the 2010 undifferentiated arthritis patients achieved 
sustained remission more often (45.9%) than the 1987 undifferentiated arthritis patients 
(34.2%) (HR 1.45, 95% CI 1.20 to 1.75; figure 1). This implies that more than half of the 
2010 undifferentiated arthritis patients have persistent disease. The baseline characteristics 
of these patients are presented in supplementary table S1, available online only. The HAQ 
scores were not significantly different between the two undifferentiated arthritis groups 
during 7 years of follow-up (p=0.92).
Comparison of categorization
All 1,162 1987 undifferentiated arthritis patients were classified according to the 2010 
criteria and the prediction rule (table 2). Only 0.6% of all undifferentiated arthritis patients 
were classified as 2010 criteria-negative but were predicted to have a high risk of RA. In 
contrast, 30.3% (148/489) of the 2010 criteria- positive patients were in the low risk of RA 


















Figure 1. Kaplan-Meier curve of the percentage of patients with sustained disease-modifying antirheu-
matic drug (DMARD)-free remission in 1987-UA-patients compared to 2010-UA-patients. 
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group. During follow-up 62.9% of these latter patients had persistent disease, which is a 
bit lower than the other 2010 criteria-positive patients (table 2).
DisCUssion
This study aimed to characterize undifferentiated arthritis in its recent form, after new 
classification criteria for RA have been developed. It was observed that undifferentiated 
arthritis is still prevalent but less frequent compared with when the 1987 ACR criteria for 
table 2. Comparison of categorization, according to the prediction model and the 2010 criteria, applied 
to 1987-UA-patients and outcome of these patients over time.
2010 criteria negative 2010 criteria positive Total
Low risk on RA
score ≤6 





-Persistent disease 49.1% -Persistent disease 62.9% 
-Initiation DMARD 29.3% -Initiation DMARD 48.2% 
-Fulfilling 1987 criteria 11.6% -Fulfilling 1987 criteria 31.1% 
Intermediate risk 
on RA
score >6 and ≤8 





-Persistent disease 46.9% -Persistent disease 81.4% 
-Initiation DMARD 41.2% -Initiation DMARD 64.5% 
-Fulfilling 1987 criteria 35.6% -Fulfilling 1987 criteria 63.0% 
High risk on RA
score >8 





-Persistent disease 100.0% -Persistent disease 92.0% 
-Initiation DMARD 0.0% -Initiation DMARD 77.9% 
-Fulfilling 1987 criteria 85.7% -Fulfilling 1987 criteria 74.6% 
Total 673 (57.9%) 489 (42.0%)
1162 
(100%)
Both the 2010 criteria and the prediction rule were applied to 1,162 UA patients, according to the 1987 
criteria. Patients were categorized in the groups ‘2010 criteria negative’ or ‘2010 criteria positive’ and 
stratified in three groups according to the prediction model. Accordingly these patients were subdivided 
in six cells. Three outcome measures were studied in each cell of patients; disease persistency during 
seven years of follow-up, initiation of a DMARD in the first year of follow-up and fulfilling the 1987 
criteria at one year of follow-up.
26 Chapter 2
RA are applied. In addition, we observed that both characteristics at disease presentation 
and the disease outcome of 2010 undifferentiated arthritis patients were milder than those 
of the 1987 undifferentiated arthritis patients.
With regard to the implication of the changing concept of undifferentiated arthritis, 
differences in disease outcome are more essential than differences at disease onset. Impor-
tantly, 2010 undifferentiated arthritis patients more often achieved sustained DMARD-free 
remission than 1987 undifferentiated arthritis patients. This implies that undifferentiated 
arthritis patients with unfavorable characteristics are now more often classified as having 
RA. The finding that 23.8% of the 2010 undifferentiated arthritis patients fulfilled the 
1987 criteria for RA within 1 year of follow-up suggests that although the 2010 criteria 
classify RA earlier than the 1987 criteria,3 the 2010 criteria do not recognize approximately 
a quarter of the RA patients already at baseline.
We also evaluated whether the 2010 criteria and a previously derived prediction rule 
were congruent in categorizing 1987 undifferentiated arthritis patients as having (a high 
probability of) RA. It was observed that the majority who did not fulfil the 2010 criteria 
were also in the low-risk group of the prediction rule. However, one-third of the 2010 
criteria-positive patients were predicted to have a low risk of RA. During the course of the 
disease, these latter 2010 criteria-positive patients less frequently had persistent arthritis 
than the other 2010 criteria-positive patients.
Interpretation of the outcome initiation of a DMARD within the first year should be done 
with some caution. In the 2000s DMARD were prescribed more frequently in undifferenti-
ated arthritis than in the 1990s. Consequently, the frequency of DMARD initiation was 
higher in the second compared to the first time period. Nevertheless, patients belonging 
to the different inclusion years were equally distributed among the categories depicted in 
table 2, allowing comparisons between groups. In addition, a stratified analysis in patients 
included before and after 2000 yielded comparable results (data not shown).
A second argument that DMARD use or fulfilling the 1987 criteria are not optimal out-
come measures for the present comparison is that the first was the outcome measure used 
when deriving the prediction rule and the latter the outcome measure used when deriving 
the 2010 criteria. This might result in circle effects. Disease persistence was not used while 
deriving either tool, and is therefore the most neutral outcome for the purpose of this 
comparison. Another consideration is that 213 of the presently studied patients were also 
used in the data-driven phase of the derivation of the 2010 criteria and 570 of the 1166 
undifferentiated arthritis patients were used for the derivation of the prediction rule.
Evaluation of congruency of both methods is formally not correct, as the 2010 criteria 
were meant for classification and the prediction rule was derived to estimate individual 
patients’ probability of fulfilling the 1987 criteria at an early stage. On the other hand, the 
2010 criteria will most likely also be used for individual patients in the clinic. Although a 
comparison of the disease outcomes of the concordantly and discordantly classified pa-
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tients should be considered reluctantly, an evaluation as to whether both the classification 
criteria and the prediction rule identify patients with RA early is clinically relevant.
In conclusion, the present data revealed that undifferentiated arthritis when applying 
the 2010 criteria is less prevalent and milder at presentation and in outcome. In addition, 
it was observed that 24% of 2010 criteria-negative patients fulfilled the 1987 criteria 
within 1 year. This implies that although undifferentiated arthritis patients with unfavor-
able characteristics are now more often classified as having RA, careful clinical observation 
of 2010 undifferentiated arthritis patients is indicated.
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supplementary table 1: Baseline characteristics of patients that at inclusion were 2010-criteria positive 


















Morning stiffness, median (IQR) in minutes 12.5 (0-60) 17.5 (0-60) 60 (15-120) <0.001
Swollen joint count (66 joint count), median (IQR) 1 (1-4) 2 (1-4) 7 (3-12) <0.001
Tender joint count, median (IQR) 1 (1-3.3) 2 (1-5) 12 (6-20) <0.001
ESR, median (IQR) mm/hour 15 (7-75) 18 (8-37) 28 (12-46) <0.001
CRP, median (IQR) mg/liter 7 (3-21) 9 (3-22.8) 11 (5-28) 0.061
RF positive 7 (3.8) 11 (5.6) 183 (54.5) <0.001
Anti-CCP-2 positive 3 (1.9) 9 (4.9) 167 (50.6) <0.001
HAQ, mean ± SD 0.6 ± 0.6 0.7 ± 0.7 0.9 ± 0.7 0.002
2010 criteria score, mean ± SD 2.9 ± 1.4 3.2 ± 1.4 7.4 ± 1.2 <0.001
* Except where indicated otherwise, values are the number (%) of patients.
IQR = interquartile range.
#For this p-value the 2010-criteria-negative patients with persistent disease were compared to the 
2010-criteria-positive patients.
Analysis were done on patients that had enough follow-up and data on remission and persistency of 
the disease.
A chi-square test was used for nominal variables and the Student’s t-test or Mann-Whitney U-test for 
continuous variables. Student’s t-test was performed when variables are presented as mean and a Mann-
Whitney U-test was performed when variables are presented as median.
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Early recognition and treatment of RA is associated with an improved outcome. The 2010 
ACR/EULAR criteria for RA identify RA patients earlier than the 1987 ACR criteria. Nev-
ertheless, we recently observed that 24% of the 2010 unclassified arthritis (UA) patients 
develop RA during follow-up. Here we studied this frequency in other cohorts and evalu-
ated the prognostic accuracy of ACPA and the Leiden prediction rule in 2010 UA patients.
methods
The 2010 UA patients from three Early Arthritis Clinics were studied: 776 from Leiden, 121 
from Birmingham and 322 from Amsterdam. Fulfilment of the 1987 ACR criteria during 
follow-up was studied as the primary outcome. DMARD prescription during the year and 
having a persistent course of arthritis over 7 years were studied as secondary outcomes in 
one cohort. The presence of ACPA and the prediction score at baseline were evaluated in 
relation to these outcomes.
Results
In the three cohorts, 24%, 26% and 12%, respectively, of the 2010 UA patients fulfilled 
the 1987 criteria after 1 year. However, some of these patients already fulfilled the 1987 
criteria at baseline. In 1987 and 2010 UA patients, 15%, 21% and 9%, respectively, devel-
oped RA (1987) at 1 year. In these patients, 0-6% of the patients were ACPA positive and 
0-1% had high prediction scores. Consequently a large majority of the UA patients with an 
unfavorable outcome was not recognized by these prognostic tools.
Conclusion
A proportion of 2010 UA patients progress to RA. ACPA and the Leiden prediction rule are 
not useful in identifying these patients. These results imply that other predictive markers 
should be developed for 2010 UA patients.
Risk of RA development in 2010 UA patients 33
3
intRoDUCtion
Persistence of inflammation and destruction of joints are hallmarks of RA. Several obser-
vational cohort studies and clinical trials demonstrate that early initiation of treatment is 
associated with more remission and less joint destruction.1-3 In order to initiate treatment 
early, adequate referral strategies are required, as well as tools that identify RA patients 
among all patients with early unclassified arthritis (UA)4 Several biomarkers have been 
identified, of which ACPAs are among the most potent. Combining several risk factors 
resulted in the construction of prediction models; of these the Leiden prediction rule is 
widely validated.5,6 However, these studies were performed in patients with UA when RA 
was defined using the 1987 ACR criteria.
Recently, the 2010 ACR/EULAR criteria for RA were developed. A major reason to derive 
new criteria was to obtain criteria that are fulfilled at an early stage of RA.7 Current data 
show that the 2010 criteria are indeed fulfilled earlier than the 1987 criteria.8-10 Con-
sequently the group of patients classified as UA when the 2010 criteria are applied has 
changed. The so-called 2010 UA patients have milder characteristics at disease onset and 
as a group also have a less severe disease outcome.8,10 Nonetheless, not all patients who 
are eventually diagnosed with RA fulfil the 2010 criteria at first presentation. We recently 
observed that 24% of the early 2010 UA patients fulfilled the 1987 criteria during the first 
year of followup.11 Ideally these patients should also be identified at initial presentation in 
order to achieve early and individualized treatment strategies.
This study aimed to evaluate (i) the proportion of 2010 UA patients who fulfil the 1987 
criteria during the first year of the disease in other independent early arthritis cohorts and 
(ii) the prognostic value of available prognostic markers (ACPA and the Leiden prediction 
rule) in 2010 UA patients in all three cohorts.
PAtients AnD methoDs
Patients
The study comprised early arthritis patients of three different cohorts. First, patients from 
the Leiden Early Arthritis Clinic (EAC) cohort were studied. This population-based longi-
tudinal cohort started in 1993 and included patients with arthritis of at least one joint 
and symptom duration <2 years. At first visit, questionnaires were completed, physical 
examination performed, radiographs taken and blood obtained for determination of CRP, 
ESR, IgM-RF and ACPA. Follow-up visits were performed yearly.12
The second studied cohort comprised patients from the Birmingham very early arthritis 
clinic that started in 2000. Patients were included in cases of clinical synovitis of at least one 
joint and symptom duration (of any symptom attributed by the rheumatologist to inflam-
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matory arthritis) of 43 months with no prior DMARD treatment. At baseline, demographic 
data, physical examination and radiographs were obtained and blood was obtained for 
determination of CRP, ESR, IgM-RF and ACPA. Follow-up visits were performed at 1, 2, 3, 
6, 12 and 18 months.9
Third, early arthritis patients from the EAC at the Jan van Breemen Research Institute/
Reade in Amsterdam, The Netherlands, which started in 1995, were studied. Patients were 
included with at least two swollen joints, symptom duration of <2 years and no prior 
DMARD treatment. Patients with OA, crystal arthropathy, SpA, SLE, SS and infectious ar-
thritis were excluded. At baseline, demographic data were collected, physical examination 
was performed, radiographs were taken and blood was obtained for determination of CRP, 
ESR, IgM-RF and ACPA. Follow-up visits were performed at 3 month intervals during the 
first year (Table 1).8







Age, mean±SD, years 50.3±17.2 47.9±18.3 50.1±15.0
Female sex, n (%) 443 (57.1) 65 (53.7) 197 (61.2)
Morning stiffness, median (IQR), min 30 (0-60) 30 (0-120) 30 (8-60)
Swollen joint count (66 joint count), 
median (IQR)
2 (1-5) 2 (1-3) 3 (1-5)
Tender joint count (68 joint count), 
median (IQR)
2 (1-6) 2 (1-4) 3 (1-5)
Localisation of affected joints
Small joints hands/feet, n (%) 492 (66.1) 92 (76.0) 135 (41.9)
Symmetrical, n (%) 328 (47.7) 20 (16.5) 243 (75.5)
Upper extremities, n (%) 468 (69.8) 75 (62.0) 98 (30.4)
CRP, median (IQR), mg/l 8 (3-23) 17 (<5-45) 7 (3-21)
ACPA positive, n (%) 61 (9.6) 1 (0.8) 15 (4.7)
RF positive, n (%) 76 (9.9) 3 (2.5) 14 (4.3)
Except where indicated otherwise, values are the number (%) of patients. IQR = interquartile range, SD 
= standard deviation. Localisation of affected joint: ‘upper extremities’ stands for upper joints with or 
without involvement of the lower joints, whereas ‘small joints’ stands for smaller joints with or without 
involvement of the large joints.
*In the Leiden-EAC cohort, some data were missing, as follows: for morning stiffness, n=37; for swol-
len joint count (SJC), n=22; for tender joint count (TJC), n=337; for small joints involved, n=32, for 
symmetrical joint involvement, n=89; for upper extremity joints involved, n=106; for C-reactive protein 
(CRP), n=58; for anti-citrullinated-peptide antibodies (ACPA), n=143; for rheumatoid factor (RF), n=10.
**In the Birmingham-EAC, some data were missing, as follows: for morning stiffness, n=1, for CRP, 
n=4, for ACPA, n=3, for RF, n=8.
***In the Amsterdam-EAC cohort, some data were missing, for morning stiffness, swollen joint count 
(SJC), tender joint count (TJC), symmetrical joint involvement and upper extremity joints involvement, 
n=8.
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In all three cohorts, the baseline diagnosis was assessed. First, other diagnoses were 
excluded, such as ReA, PsA, crystal arthropathy, SpA, SLE and sarcoidosis. Subsequently, 
RA was classified according to the 2010 criteria where radiologic information was not 
taken into account.9,10 Then the remaining patients were classified as 2010 UA and were 
studied here. Furthermore, we evaluated which of the 2010 UA patients fulfilled the 1987 
criteria at baseline. Patients who were classified as UA according to both the 1987 and 
2010 criteria (1987 and 2010 UA patients) were also studied (see supplementary Fig. S1 
for an overview, available at Rheumatology Online). All three cohorts obtained written 
informed consent from the participants. The studies were approved by the local medical 
ethic committees.
outcome
Fulfilling the 1987 criteria during the first year of follow-up was the outcome measure 
studied. The 1987 criteria could be fulfilled cumulatively during follow-up. Although fulfill-
ing the 1987 criteria may not be an early phenomenon, these criteria still reflect the core 
phenotype of RA. Since it can be argued that this outcome is subject to some degree 
of circularity, two other outcomes were studied in the Leiden dataset, DMARD initiation 
during the first year and disease persistency over 7 years of follow-up. Patients treated 
according to a randomized trial were not studied for the outcome DMARD initiation during 
the first year. Arthritis persistency was defined as the absence of a sustained DMARD-free 
remission, which was described as the absence of synovitis for at least 1 year after cessa-
tion of eventual DMARD therapy.13
Analysis
Analyses were done both on 2010 UA patients and 1987 and 2010 UA patients using 
SPSS version 17.0. The proportion of 2010 UA patients and 1987 and 2010 UA patients 
who progressed to RA was determined. ACPA positivity and the Leiden prediction score 
(grouped as score 46, >6 and <8 and 58) were evaluated in relation to the development of 
RA. The Leiden prediction model consists of nine items. Each prediction score varied from 
0 to 14 and corresponded to the percent chance of developing RA. The higher the score, 
the higher the chance of progressing to RA. A score of 46 is associated with a negative 
predictive value (NPV) of 91% and a score 58 with a positive predictive value (PPV) of 
84%. The area under the receiver operator characteristic curve (AUC) was determined; the 
prediction score was analyzed as continuous variable.
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ResUlts
In total, 1219 2010 UA patients, originating from three different early arthritis clinics, 
were studied: 776 from Leiden, 121 from Birmingham and 322 from Amsterdam (see 
supplementary Fig. S1 for an overview, available at Rheumatology Online). In these three 
cohorts, 24%, 26% and 12% of the 2010 UA patients, respectively, fulfilled the 1987 ACR 
criteria during the first year of follow-up.
As a proportion of the 2010 UA patients fulfilled the 1987 criteria at baseline (103, 7, 86 
patients in the three cohorts, respectively), progression to RA was subsequently studied in 
the subgroup of patients who were classified as UA according to both sets of criteria. Now 
673, 114 and 236 1987 and 2010 UA patients were studied, of whom 15%, 21% and 9%, 
respectively, progressed to RA.
Next, we evaluated the extent to which UA patients who fulfil the 1987 criteria during 
follow-up could be identified at baseline using ACPA or the Leiden prediction rule. First, 
2010 UA patients were studied. The frequency of ACPA positivity in the different cohorts 
with 2010 UA patients varied between 0% and 7%. When evaluating the prediction 
scores, it was observed that a prediction score of 58 was seldom obtained. The AUC of 
ACPA ranged between 0.49 and 0.60 and that of the prediction score between 1.59 and 
0.81.
Subsequently, the 1987 and 2010 UA patients were evaluated. The frequency of ACPA 
positivity or high prediction scores was even lower here (Table 2). This prohibited determi-
nation of PPVs and reduced the clinical utility of these markers in these patients. The NPVs 
of ACPA were 83%, 79% and 91%, respectively. The NPVs of prediction scores 46 were 
88%, 81% and 90%, respectively. Although these NPVs seem adequate, these chances 
were comparable to the prior chances of not developing RA, which were 85%, 79% and 
91%, respectively. The AUCs of both predictive markers ranged between 0.49 and 0.55 for 
the ACPA and between 0.53 and 0.78 for the prediction score (supplementary Table S1, 
available at Rheumatology Online).
Since we observed that the majority of 1987 and 2010 UA patients who progressed to 
RA within the first year of follow-up were ACPA negative and had low prediction scores, 
we studied the baseline characteristics of these patients in more depth. This revealed an 
overall milder phenotype at baseline of 1987 and 2010 UA patients who did not progress 
to RA compared with those who did (supplementary Table S2, available at Rheumatology 
Online).
The main outcome studied was fulfilling the 1987 ACR criteria after 1 year of follow-up. 
DMARD initiation during year 1 and disease persistency over 7 years (absence of sustained 
DMARD-free remission) were also assessed as secondary outcomes. During the first year, 
39% of the 2010 UA patients and 34% of the 1987 and 2010 UA patients initiated a 
DMARD. Over the 7-year follow-up in the Leiden dataset, 54% of the 2010 UA patients 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































and 53% of the 1987 and 2010 UA patients had persistent disease. However, with these 
outcomes the majority of patients with DMARD initiation and/or persistent arthritis were 
not recognized by ACPA or the prediction model, which was due to the low prevalence of 
ACPA and high prediction scores in these UA patients (Table 2).
DisCUssion
This study evaluated the frequency of development of RA (1987 criteria) in 2010 UA pa-
tients in three independent cohorts and showed that a large number of 2010 UA patients 
fulfil the 1987 criteria during follow-up. Second, it was evaluated whether ACPA or a previ-
ously derived prediction rule is useful in identifying which 2010 UA patients will progress 
to RA (1987). Analyses on 2010 UA patients from three clinics consistently revealed that 
the majority of patients were ACPA negative and had low prediction scores, indicating that 
they are not relevant prognostic markers in UA (2010 criteria).
The very low frequency of ACPA positivity or of high prediction scores may be explained 
by the fact that ACPA and the majority of variables composing the prediction rule are also 
included in the 2010 criteria and hence have already been used for classification. Appar-
ently, after having been used for risk estimation via the 2010 criteria, neither ACPA nor 
the prediction rule is able to subsequently identify the individual patients who are missed 
by the 2010 criteria.
It was observed that some of the 2010 UA patients already fulfil the 1987 criteria at 
baseline. These data confirm previous reports, showing that not all 1987 RA patients are 
classified as RA according to the 2010 criteria9, 10. This may suggest that it is appropriate 
to use both the 2010 and 1987 criteria in individual patients. Finally, we studied 1987 and 
2010 UA patients; the findings regarding ACPA and the prediction rule in these patients 
were comparable to those in the 2010 UA patients.
A strength of the present study is that three different early arthritis cohorts were studied. 
These cohorts had slightly different inclusion and exclusion criteria, which can be seen 
as a limitation. Despite this heterogeneity, the observed findings were remarkably similar 
between cohorts, strengthening the validity of the findings and the conclusion that ACPA 
and the Leiden prediction rule are not accurate prognostic tools in 2010 UA patients.
There are several caveats to this study. A potential drawback is that the replication 
cohorts were smaller than the first cohort. On the other hand, as mentioned, the trend 
in the data is comparable in all three cohorts, suggesting that the results regarding ACPA 
and the prediction rule are not false negatives. Second, a majority of the patients studied 
were enrolled when aggressive DMARD treatment of UA was uncommon. Nonetheless, 
we cannot exclude that some of the patients who were classified as not fulfilling the 1987 
criteria during follow-up are misclassified due to DMARD treatment. This implies that the 
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actual proportion of UA patients who have an early form of RA is even higher. However, in 
this scenario, the conclusions regarding the studied predictive markers would not change. 
Third, in a portion of the Leiden patients, ACPA data were not available, especially on 
those UA patients who did not progress to be 1987 criteria positive over time. Theoretically 
some of the patients may have been falsely classified as 2010 UA at baseline. However, 
considering the similarity in results between the cohorts, this influence is probably small.
In conclusion, a proportion of 1987 RA patients were not identified at baseline by the 
2010 criteria. Assuming also that in UA patients who fulfil the RA criteria later in time a 
window of opportunity effect is present, these patients are preferably identified at baseline 
to this end. The ACPA test and the Leiden prediction rule are also not useful in identifying 
these patients. Hence other prognostic markers are needed with significantly different 
sensitivity and specificity characteristics to clinical examination; these may include imaging 
modalities such as ultrasound or extremity MRI.14,15
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supplementary table 1: The area under the receiver operator characteristic curve (AUC) of anti-CCP 
antibodies and the prediction score in ‘2010-UA-patients’ and ‘1987-and-2010-UA-patients’ from each 



















0.60±0.03 0.55±0.03 0.52±0.06 0.52±0.07 0.49±0.05 0.49±0.07
Prediction 
rule score
0.81±0.02 0.76±0.02 0.81±0.04 0.78±0.05 0.59±0.04 0.53±0.06
Expressed are AUC +/- standard error (SE). The AUC of anti-CCP positivity was dichotomously evaluated.








supplementary Figure 1. In total 2,472 early arthritis patients from the Leiden EAC were studied. 
772 patients were diagnosed other than unclassifi ed arthritis or RA. Subsequently, RA was classifi ed 
according to the 2010 criteria and the remaining patients were classifi ed as 2010-UA. This resulted in 
776 2010-UA patients from the Leiden EAC. 673 of these 2010-UA patients were also classifi ed as UA 
according to the 1987 criteria; the ‘1987-UA & 2010-UA patients’. In the 4 ‘missing’ patients only one 
serological test and one acute-phase response measure was obtained and therefore they could not be 
classifi ed according to the 2010 criteria. The same classifi cation was performed in the other two cohorts 
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Treatment of patients with rheumatoid arthritis (RA) is rarely personalized, since predictors 
of disease course are lacking. The severity of RA can be measured objectively by radio-
graphic progression. The most reliable way to measure radiographic progression is in a 
longitudinal cohort with serial time points, scoring on a quantitative scale, with a validated 
scoring method and trained readers.
Current models used to predict radiographic progression are based on C-reactive protein 
and anti-citrullinated protein antibodies. Other biomarkers could increase the prognostic 
ability of these models. In this review, we evaluated the published (and partly not published) 
data on genetic, serologic, and imaging biomarkers for the severity of joint destruction in 
RA.
We evaluated variants in 10 genes (CD40, IL2RA, IL4R, IL15, OPG, DKK1, SOST, GRZB, 
MMP9, and SPAG16). In 5 variants (IL2RA, DKK1, GRZB, MMP9, and SPAG16), we found 
evidence of an association at the functional level. We evaluated several serological bio-
markers, namely, autoantibodies (RF, ACPA, anti-CarP), markers related to inflammation 
(ESR, CRP), and proteinases or components of the extracellular matrix of bone and cartilage 
(MMP3, CTX-I, CTX-II, COMP, TIMP1, PYD, RANKL/OPG, CXCL13). Finally, we evaluated 
markers that can be visualized by ultrasound or MRI, including erosions, bone marrow 
edema, synovitis, and tenosynovitis. Several studies showed that bone marrow edema and 
synovitis on MRI are robust predictors of radiographic progression. Some studies showed 
that inflammation detected with ultrasound predicted radiographic progression.
Future studies will reveal whether adding and combining all these different biomarkers 
will increase the accuracy of risk models predicting radiographic progression in RA.
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intRoDUCtion
Providing personalized medicine in rheumatoid arthritis (RA) is one of the great challenges 
for the near future. In order to achieve this goal, it is necessary to fulfil 2 conditions: 
adequate estimation of severity so that the patients who develop severe disease can be 
differentiated from patients with mild disease; and identification of an individual patient’s 
responsiveness to specific disease-modifying anti-rheumatic drugs (DMARDs) or biologics. 
The present review focuses on the first issue: predictors of the severity of the course of RA.
measurement of the severity of RA
Severe RA is not uniformly defined. Patients often refer to the degree of pain or fatigue 
and the ability to perform daily activities and work. Rheumatologists are more concerned 
with the level of inflammation (expressed by the number of inflamed joints), the level of 
acute phase reactants, and pooled severity indices such as disease activity scores. Scientists 
focus on outcome measures that can be assessed objectively, such as joint destruction and 
mortality.1 These perspectives are essentially similar, since levels of impaired functionality, 
inflammation, and structural damage are correlated.2 Fluctuations in disease activity are 
directly related to changes in radiographic progression, although this relationship is less 
present in specific treatments such as tumor necrosis factor (TNF) blockers.3 Joint inflamma-
tion and joint destruction both play an independent role in impaired physical functioning.4
Deciding which measure of severity is best depends on the reason it is selected. The 
advantages and disadvantages of several severity measures are summarized in Table 1. For 
research purposes, the rate of joint damage, as visualized on radiographs of the hands and 
feet, is the most common outcome measure. The main advantage is that it can be assessed 
objectively using a validated scoring method. The radiographs can be scored by the same 
reader, thus making it possible to evaluate within-reader variation and between-reader 
variation (in the case of ≥1 reader). Another advantage of measuring the severity of joint 
damage is that it accumulates over time and thus reflects disease history. In summary, the 
rate of joint destruction correlates with the cumulative burden of inflammation over time, 
is highly linked with physical function and other outcomes such as work disability, and is 
inexpensive to measure using validated scoring methods; consequently, the rate of joint 
destruction is a comprehensive endpoint in observational studies. In this review, we focus 
on radiographic joint damage as an outcome for identifying new risk factors for severity 
of RA.
measurement of the severity of radiographic damage in RA
The absence or presence of joint damage can be assessed based on “erosiveness” or 
“erosive disease”. This qualitative method has 2 disadvantages. First, the degree of joint 
damage cannot be discerned. The fact that 70%-75% of patients with early RA developed 
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erosions within the first years of follow-up indicates that this measure is suitable in very 
early phases of the disease, but not in more advanced stages.5 Second, no uniform defini-
tion for erosiveness or erosive disease exists. Performing analyses with non-validated out-
come measures increases inter-observer variation and variation between studies. Indeed, 
the various descriptions for erosive RA include any radiographic evidence of erosions,6,7 a 
cortical break of ≥2 mm (8), and presence of ≥2 or ≥3 erosions.9;10 According to the 2010 
ACR/EULAR criteria, typical erosive disease is defined as at least 3 small hand or foot joints 
table 1 Measures of severity of RA and advantages and disadvantages for the use as outcome measures 
in studies that aim to identify biomarkers
RA severity measures Advantages (+) and disadvantages (–)
Disease course measures
Tender or swollen joint count – Does not reflect cumulative severity of RA
Lansbury articular indexa – Fluctuates over time
DAS
AUC of DAS over time + Reliable if DAS is assessed ≥3 times a year
HAQ + Reflects disease activity
– Influenced by age, disease duration, social and 
psychosocial factors
Extra-articular symptoms – Frequency nowadays decreasing thanks to introduction of 
potent treatment strategies
Disease outcome measures
Mortality + Objective measure
– May be influenced by non-RA-related causes
– No increased mortality risk observed in case of DAS-
guided treatmentb
DMARD-free sustained remissionc + Most favourable outcome of RA as it approximates cure
– Long follow-up necessary in order to achieve this outcome 
and to assure that remission is sustained
Rate of radiographic joint destruction + Objective and well validated, quantitative scoring 
methods available
+ Quality of scoring can be easily expressed
+ Reflects cumulative severity of RA
+ No fluctuation in time
– Scoring is time and cost consuming (need a trained scorer) 
(and eventually taken extra radiographs besides normal 
clinical care)
aIn the Lansbury articular index, the joint counts are weighted for the joint size. Such weighting may be 
preferable, as the volume of inflamed synovial tissue would be proportional to the serum CRP level and 
the level of disability.
b(111;112)
c(113)
RA, rheumatoid arthritis; DAS, disease activity scale; AUC, area under the curve; HAQ, health assessment 
questionnaire; DMARD, disease-modifying antirheumatic drug.
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with an interrupted cortex. This condition was associated with a specificity of >85% for 
prescription of methotrexate and >90% for disease persistency.11
Currently used quantitative scoring methods to measure joint damage severity include 
the Sharp van der Heijde score (SHS) and (modified) Larsen score. These quantitative mea-
surements are more discriminative than binary outcome measures, have been validated, 
and can be used in all phases of the disease.12,13 Both the SHS and Larsen score are used to 
assess the joints of the hands and feet. Of the two, SHS is the only one that differentiates 
between bone erosions and cartilage damage, which is visualized as joint space narrowing. 
Compared to the Larsen score, the SHS is more sensitive for detecting changes over time, 
although it is also more time-consuming to apply.12
Given that quantitative outcomes are more accurate than qualitative outcomes and 
repeated outcomes are even more accurate, the number of time points is a key element of 
optimal assessment of joint destruction. Within-patient correlation of serial measurements 
is important when scoring radiographs. Unlike damage on radiographs from different 
patients, the severity of damage on serial radiographs from the same patient is highly cor-
related. Compared to measuring radiographs at only 1 time point, scoring radiographs at 
subsequent time points substantially diminishes within-patient variability in joint damage. 
Consequently, the power of the study is increased, a smaller number of patients is needed 
to detect a difference, and phenotypic misclassification is reduced.14 Hence, a more precise 
estimation of the rate of joint destruction facilitates differentiation between true effects 
and noise.
Although radiographs are scored with a quantitative scoring method, sometimes only 1 
radiograph per patient is available and the time point at which the radiographs were made 
varies between patients. Since radiographs are made at different phases of the disease, 
scores cannot be easily compared. In order to estimate the effect of risk factors on joint 
damage in this circumstance, the estimated radiographic progression per year can be 
determined by dividing the total radiographic score by the disease duration at the time the 
radiograph was taken. This approach is limited in that it assumes that the baseline score 
was zero and includes both patients with early RA and patients with advanced RA, thus 
precluding comparison of estimated radiographic progression rate. The course of joint 
damage is frequently linear in the early years and slows down as the disease progresses.15 
Inaccurate estimation of disease duration has a larger impact on patients with short disease 
duration. Consequently, the estimated radiographic progression per year may be overes-
timated in patients with short disease duration. An extreme situation is that of a patient 
with a long disease duration in which the maximal level of joint destruction has been 
reached but no further destruction has evolved since then; consequently, the level of joint 
destruction remains unchanged during further follow-up. If the single radiography is taken 
during this period with a stable SHS score, the estimated annual progression decreases 
with every year of follow-up. Therefore, the use of the estimated annual progression is 
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restricted to a short follow-up duration and harbors a risk of phenotypic misclassification 
in advanced disease stages.
In conclusion, the rate of joint destruction in longitudinal studies should be assessed 
at serial time points on a quantitative scale using validated scoring methods and trained 
readers.
Analysis of the rate of joint destruction in longitudinal studies
Radiographic data are by definition skewed, as many patients have little progression and 
few patients have marked progression. This skewness makes it difficult to apply statistical 
tests, many of which presume a normal distribution. However, a normal distribution can 
frequently be achieved by log-transformation of the data. Given that several radiographic 
measurements may be made, it is beneficial to use a statistical method that takes ad-
vantage of within-patient correlations, as this will yield more precise estimations of the 
progression rate and, therefore, increase the possibility of detecting differences. Repeated 
analyses based on covariance matrices, for instance, linear mixed models, also make it 
possible to include patients with missing radiographs over time. This possibility is relevant, 
since missing data are often not completely random but related to the severity of the 
disease course; over time, patients with the most severe disease can die and those with 
the least severe disease are often lost to follow-up. Excluding these patients will make the 
obtained effect size less generalizable to the general patient population. In other words, 
including all patients in a specific population reduces the likelihood of selection bias that 
will be introduced if per protocol analysis is performed.
treatment effects and other confounding factors
The effect of potential biomarkers on the rate of joint destruction should ideally evalu-
ated in longitudinal cohorts of patients in whom the disease course of RA is natural (ie, 
untreated patients). Such may be the case of patients diagnosed and recruited in the 
1980s or early 1990s, although such datasets are rare today. When studying more recently 
diagnosed patients, analyses should be adjusted for treatment effects to discern the role 
of the risk marker. Other potential confounding factors are age and gender. Whereas the 
effect of gender is different between cohorts, the effect of age is consistent: in almost all 
studies, older age at onset is associated with a more severe disease course.
biomARkeRs
A biomarker is defined as a characteristic that can be objectively measured and evaluated 
as an indicator of a normal biological or pathogenic process; it may also be an indicator of 
response to a therapeutic intervention.16
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According to this definition, the term biomarker covers any type of characteristic. 
Biomarkers are classified into 3 groups: genetic markers, serologic markers, and imaging 
markers.
An OMERACT task force proposed a much more stringent definition for a biomarker, 
namely, that it reflects structural damage in RA.17 The definition is based on 14 require-
ments, which include not only criteria for the reliability of the assay and the discrimina-
tive ability of the marker, but also items reflecting the “truth”. The criteria include the 
following: evidence that a biomarker reflects tissue remodeling demonstrated in animal 
models, immunohistochemical localization in joint tissue, and correlation between levels 
of the biomarker and scores of other surrogates for structural damage. These criteria were 
developed for serological markers but may also be applicable to other types of biomarkers. 
Nonetheless, this definition of a biomarker is more challenging to fulfill than the definition 
provided above. In this manuscript, we define biomarkers as genetic, serologic, and imag-
ing markers that are predictive of radiographic progression in patients with RA.
types of biomarkers for joint damage progression in RA
Twin studies have indicated that radiographic progression is in part heritable. Recent 
estimations on the Icelandic RA population yielded a heritability of 45%-58%.18 The other 
42%-55% can be explained by environmental or random factors. Genetic factors may 
predispose to serologic risk factors that are also predictive of the severity of joint damage 
and to joint damage via unknown mechanisms.
Serologic biomarkers are produced under the influence of both genetic and environ-
mental factors, as illustrated by anti-citrullinated protein antibodies (ACPA). Their pres-
ence is associated with severe disease course, and certain HLA-DRB1 alleles and smoking 
predispose to the development of these autoantibodies.19
Imaging characteristics can also act as biomarkers, as they can indicate a pathogenic 
process. Among the 3 categories of biomarkers discussed, serologic and imaging biomark-
ers are closest to the phenotype, because advanced imaging techniques actually visualize 
subclinical (and clinical) disease features (Figure 1).
GenetiC biomARkeRs FoR the seveRity oF RADioGRAPhiC joint 
DestRUCtion in RA
Interest in the genetic background for susceptibility to RA has grown during recent years, 
and more than 40 predisposing genetic variants have been identified.20 The vast majority 
were identified in genome-wide studies evaluating thousands of cases and controls.
Severity of RA is studied by making comparisons within patients, thus necessitating 
long-term longitudinal outcome data. Such datasets are scarce and consequently; studies 
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with equal sizes as in the RA susceptibility field, are out of reach. Most genetic studies on 
progression of joint damage are relatively small. In addition, they were not performed with 
a hypothesis-free genome-wide approach, but rather investigated dedicated candidate 
genes.
It is difficult to know when a genetic association is real. Figure 2 depicts possible levels 
of evidence. The first level is the P value; in our view this level is insufficient to indicate 
whether a variant is true. In high-throughput studies, where many variants are typed and 
analyzed, P values <5x10-8 are generally considered to be valid. This cutoff is derived from 
a Bonferroni correction of 0.05 (alpha)/500,000 (number of single-nucleotide polymor-
phisms [SNPs] analyzed). If this number of SNPs is actually studied, the P value reflects a 
probability <5% that the finding is based on chance. However, the P value is also largely 
influenced by the number of subjects being studied. Hence, a P value obtained in a study 
including several thousands of subjects may still indicate a finding that is based on chance, 
Figure 1 Illustration of different biomarkers of radiographic progression in RA; in general, the closer to 
the phenotype a marker is, the higher the effect size is
From left to right: genetic biomarkers (SNPs), serological biomarkers (auto-antibodies, acute-phase reac-
tants, other markers related to inflammation or components of the bone or cartilage), imaging biomark-
ers (bone marrow edema, synovitis, tenosynovitis, and erosions visualized by MRI or ultrasound) and the 
outcome (radiographic progression or no radiographic progression). In this review, we observed that the 
effect increased from left to right, probably because the markers located at the right are more closely 
related to the phenotype.
Biomarkers for radiographic progression 55
4
and a similar or higher P value obtained in a study containing several hundreds of patients 
may be indicative of a “true variant”. In conclusion, using the P value as a measure to 
evaluate the reliability of findings is spurious. A more reliable method is replication. If 
a variant is statistically associated in several independent cohorts, the chance that the 
observation reflects chance finding is greatly reduced. Even more convincing are data that 
support the finding at a different level. Examples include genetic variants associated with 
changed expression at mRNA or protein level. Genetic associations that are not supported 
by expression data may also be genuine, although the presence of associations at the level 
of expression does increase reliability and may act as an initial step in better understanding 
the consequences of carrying a certain genetic variant. In the ideal situation, the pathway 
or mechanism via which a genetic risk factor influences disease is known.
During the last 2 decades, many studies have evaluated genetic markers in relation to 
the severity of RA. The results were often inconsistent, probably owing to small samples 
and different types of outcome measure.
We reviewed the literature and included unpublished data on genetic variants associated 
with progression of joint damage. We only reviewed genetic variants that were assessed 
in several populations. Variants that were assessed in only 1 cohort were not addressed, 
because of the low level of evidence, since the study was not replicated. The studies that 
were available measured joint damage in different ways, thus precluding a meta-analysis.
The candidate genes evaluated to date can be categorized as markers associated with 









Figure 2 Level of evidence of data obtained in genetic studies; the higher up in the pyramid, the higher 
the level of evidence.
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markers associated with the development of RA
HLA-DRB1
The HLA-DRB1 alleles coding for the so-called shared epitope are the oldest genetic risk 
factor associated with progression of joint damage. This marker is also the most widely 
validated genetic risk factor. The presence of shared epitope alleles is a risk factor for 
ACPA, which are associated with progression of joint damage. Interestingly, in a recent 
study on progression in ACPA-negative RA, the HLA region was not identified as a marker 
for radiographic progression (manuscript under review), thus providing further evidence 
that the relevance of the HLA-DRB1 region for progression lies in predisposition to develop-
ment of autoantibodies. The HLA-DRB1 region that codes for the shared epitope alleles can 
also code for the DERAA amino acid motif. The presence of this variant has been associ-
ated with protection against radiographic progression.21 To our knowledge, this effect has 
never been studied in other cohorts and therefore has not been replicated. The mechanism 
by which HLA-DRB1 alleles predispose to ACPA and progression of joint damage is not 
completely understood, although the hypothesis is that these genetic variants influence 
the immune response by affecting the antigen-binding site.
PTPN22
A coding variant in PTPN22 (rs2476601) has been studied in 8 populations to establish an 
association with the severity of joint damage. Although the minor allele was associated 
with more severe progression in 2 studies,22,23 subsequent studies in 5 other cohorts did 
not reveal a significant association (Table 1).24-27 Performing a meta-analysis of these stud-
ies is difficult, owing to the different quantitative and qualitative outcome measures used.
TNFAIP3-OLIG3
Several variants in this region are associated with the risk of developing RA. rs6920220 was 
associated with progression of joint damage in a UK study consisting of 685 radiographs 
from 700 ACPA-positive RA patients.28 In a Dutch study consisting of 844 radiographs 
from 181 ACPA-positive RA patients, this association was not replicated,29 and no associa-
tion was present in unpublished data from several North American cohorts. (Table 2) Most 
available data are for rs675520, which was studied in 8 cohorts; a meta-analysis of 7 of 
these cohorts did not reveal a significant association with RA.29,30
C5-TRAF1
Although a significant association was observed for rs2900180 in the C5-TRAF1 region in 
2 UK cohorts,31 other datasets did not reveal a significant association (Table 2). A meta-
analysis of these data is required to draw conclusions on the relevance of this SNP for 
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progression of joint damage. An initial positive association was observed for rs10818488, 
which is another variant in this region; however, this association was not maintained in a 
meta-analysis of 7 cohorts.30,32
CD40
A genetic variant in CD40 (rs4810485) was shown to be a risk factor for development of 
ACPA-positive RA. This marker was subsequently studied in relation to radiographic pro-
gression in 2 cohorts of ACPA-positive RA patients. A significant association was observed 
in both. Intriguingly, the minor allele that was associated with a decreased risk of RA was 
associated with more severe progression of joint damage. No ready explanation is available 
for this observation.33
IL2RA
The polymorphism rs2104286, which is found in the gene coding for the IL2 receptor α 
chain (CD25), is clearly associated with progression of joint damage. Significant associations 
were demonstrated in Dutch, Icelandic, and North American RA populations. Furthermore, 
the minor allele, which is associated with reduced progression, was also associated with 
lower serum levels of IL2RA, which correlated with progression.34 A multivariate analysis 
including both IL2RA and serum IL2RA showed that only serum levels were independently 
associated with progression, suggesting that the genetic variant affects progression by a 
mechanism that also affects serum levels. rs2104286 is the only genetic variant predis-
posing to development and progression of RA for which functional data are available. 
Interestingly, this variant also predisposes to other autoimmune disorders such as multiple 
sclerosis and type 1 diabetes.
Variants in a further 2 susceptibility genes (AFF3 rs11676922 and BLK rs13277113) have 
been studied in several cohorts, but no evident association with the severity of joint dam-
age was found.
inflammatory markers as candidates for joint damage progression
Joint damage results from deregulated inflammation or disturbances in bone or cartilage 
homeostasis (Figure 3). Joint destruction, as visualized on hand and foot radiographs, is 
the local loss of cartilage and bone resulting from inflammation. The presence of specific 
autoantibodies is thought to propagate the level and chronicity of inflammation and may 
directly and indirectly affect the level of structural damage.35 Genes coding for inflamma-
tory markers can also influence the level of inflammation and are therefore likely subjects 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































TNF-α and IL-1 are pro-inflammatory markers that are overexpressed in RA. However, 
while few studies have been performed on genetic variants in TNFA, several studies have 
addressed variants in IL1. The activity of IL-1 reflects the function of 2 molecules, IL-1α 
and IL-1ß. IL-1α is cell-bound and IL-1ß is a secreted cytokine. No associations have been 
reported between variants in IL1A and the severity of radiographic damage in RA. For IL1B, 
rs16944 was evaluated in 3 studies but no effect was observed.23,36,37 Similarly, despite a 
significant association between rs1143634 in IL1B and both serum levels and joint destruc-
tion in a study of 297 patients and 273 radiographs,38 further studies (2762 patients and 
5956 radiographs) could not replicate this association (Table 3).23,37,39 Based on these data, 
variants in TNFA, IL1B, and IL1A do not predispose to severe destructive RA.
Figure 3 In RA, joint damage is the result of several processes: inflammation, auto-antibodies, and resis-
tance of cartilage and bone against degradation.
The genetic markers that are replicated are presented; the genetic variants that are observed to be as-
sociated with differences at the level of expression are indicated in bold.
IL2RA, interleukin 2 receptor alpha; IL4R, interleukin 4 receptor; IL15, interleukin 15; HLA-DRB1, human 
leukocyte antigens-DRB1; GRZB, granzyme B; SPAG16, sperm associated antigen 16; MMP9, matrix 
metallopeptidase 9; OPG, osteoprotegerin; DKK1, dickkopf-related protein 1; SOST, sclerostin.
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IL4 and IL4R
SNPs in IL4 and IL4R have been studied in several RA populations. IL4 is considered rel-
evant, as it mainly promotes differentiation of T cells towards TH2 cells. The role of IL4 is 
underscored by observations that IL4 knockout mice are characterized by extensive joint 
damage and that low synovial concentrations of IL4 have been detected in patients with 
established RA. Nevertheless, no clear associations have been detected between genetic 
variants in IL4 and severity or progression of joint damage. The effect of IL4 is mainly 
mediated via the IL4Rα chain. An amino acid–changing variant in IL4R (rs1805010) was 
shown to associate with the presence of erosions.40 Some indications were also found 
for functional readouts in this variant. Nonetheless, subsequent studies in UK and Dutch 
RA populations could not replicate the association between rs1805010 and progression 
of joint damage.41,42 A recent study of tagging SNPs in IL4R observed and independently 
replicated 2 additional IL4R variants associated with radiographic progression (rs1119132 
and rs1805011).41 These 2 variants were in low linkage disequilibrium (R2 < 0.01) with 
rs1805010. No data are available on the functional level of these 2 variants.
IL6
Marinou et al. found that rs1800795 in IL6 was associated with less severe joint dam-
age.23 This association was not replicated in a Dutch cohort (Table 3), in which 3 other 
variants were associated with the severity of joint damage and were subsequently studied 
in other cohorts; 2 of these variants were significantly associated with joint damage in a 
meta-analysis that included the Dutch cohort (Table 3). Without the Dutch cohort, the as-
sociation was no longer significant. Based on this observation and the difference in effect 
direction between the cohorts, no clear conclusions can be drawn on genetic variants in 
IL6 and progression of joint damage.
IL10
Several lines of research suggest an important role for IL10 in the pathogenesis of joint 
destruction in RA. Preclinical studies showed that IL10 inhibits the generation of pro-
inflammatory cytokines and the proliferation of TH1 cells. In a rodent model of chronic 
arthritis, IL10 inhibited the severity of the disease.43 The minor allele of a promoter poly-
morphism at position –1082 (rs1800896) was associated with less severe joint damage in 
a cohort of 91 female RA patients.43 A similar significant observation was made in a UK 
study.23 Furthermore, not significant findings were observed with a similar effect direction 
in several cohorts (Table 3).44 Therefore, it would be very interesting to perform a meta-
analysis of this variant, especially given the correlation observed between rs1800896 and 
expression, since patients with the severity risk allele produced lower IL10 levels. Similar 
findings were obtained by studying haplotypes of the –1082A/G, –819C/T, and –592A/C 
variants.45 The –592 (rs1800872) variant in this haplotype (R2 = 0.29 with rs1800896) was 
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also found to be associated with the severity of joint damage in one study, although other 
studies did not support this finding.23;45 Whole-genome association studies showed that 
variants in the IL10 gene were a relevant risk factor for Crohn disease and Behçet disease.
IL15
IL15 levels are increased in the serum, synovium, and bone marrow of patients with RA. 
IL15 influences both the innate and the adaptive immune response; it is mainly responsible 
for activation and proliferation of T cells. Emerging data show that this cytokine affects 
osteoclastogenesis. A tagging approach revealed several variants in IL15 to be associated 
with the severity of progression of joint damage. Furthermore, in a meta-analysis of 4 
cohorts, 4 variants were associated with progression.46
FCRL3
The Fc receptor–like family has potential immunoregulatory functions. FCRL3 has attracted 
research interest, since it is associated with several autoimmune diseases. It has been 
observed to be a risk factor for development of RA in Asian patients. It is preferentially 
expressed in B cells, and the –169C allele of FCRL3 (rs7528684) has been associated with 
higher ACPA levels. In a Korean study, RA patients with the CC genotype have higher ra-
diographic progression rates.47 In a Norwegian study, ACPA-positive patients carrying both 
CC alleles also had more severe progression.48 In a large Dutch cohort, no association was 
observed between FCRL3 genotypes and radiographic progression in RA or ACPA-positive 
RA (Table 3). A meta-analysis of these data would be required to determine whether or not 
FCLR3 is associated with severity of RA.
TGFβ1
The TGFβ1 –869T/C variant was observed to be a susceptibility factor for RA in the Japanese 
population.49 Subsequently, the TGFβ1 –869T/C variant, which is related to the severity of 
joint damage, was investigated in 2 studies. In a Korean study, no significant association 
was observed.50 A study from the UK found an association between this variant and joint 
damage, although the association was no longer significant when disease duration at the 
point the radiographs were taken was included in the analysis.51 Considering the available 
data, this variant is not evidently associated with severity of joint damage.
markers related to bone or cartilage
Destruction of bone or cartilage and the ability of bone and cartilage to resist inflammatory 
pressure may in part be explained by the patient’s genetic constitution. Several markers 
have been studied to this end (Table 4).
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RANK, RANKL, OPG, and TRAF6
The balance between osteoblast and osteoclast activity is crucial for healthy bone, and 
osteoclast-related bone loss is mediated by the OPG/RANK/RANKL/TRAF6 pathway. Recep-
tor activator for nuclear factor κβ ligand (RANKL) is expressed and released by osteoblasts 
and activated T lymphocytes. RANKL promotes osteoclast formation and perpetuates its 
function and survival through binding of receptor activator of nuclear factor κβ (RANK). 
Subsequently, the RANK signal is mediated by TRAF6, a member of the TNF receptor as-
sociated factor (TRAF) protein family, which functions as a signal transducer in the NF-κβ 
family. The process of osteoclast formation and bone resorption is negatively regulated by 
osteoprotegerin (OPG), as binding of OPG inhibits activation of RANKL. The bone loss in 
RA points to an imbalance in the OPG-RANKL axis favoring bone resorption and resulting in 
erosion. This potential imbalance is supported by the association between the OPG/RANKL 
ratio in serum and joint destruction in RA. Genetic variants in OPG, RANK, and RANKL have 
been associated with bone mineral density and osteoporosis, and TRAF6 has also been 
identified as a risk factor for development of RA. The variants tagging these 4 genes were 
evaluated recently in a candidate gene study. Variants that were significantly associated in 
the first cohort were subsequently studied in 3 additional cohorts. None of the variants in 
RANK, RANKL, or TRAF6 were replicated after correction for multiple testing, although 1 
variant in OPG, rs1485305, was significantly associated with more severe joint damage in 
a meta-analysis of the 4 cohorts and again after Bonferroni correction. This variant has also 
been associated with loss of bone mineral density (unpublished data) (Table 4).
DKK1, SOST, LRP5, and KREMEN1
Another pathway that is relevant for bone homeostasis is the canonical WNT/ß-catenin 
pathway, which involves binding of WNT proteins to a co-receptor complex comprising 
LRP5 or LRP6 and a member of the frizzled family of proteins. This binding leads to a 
signalling cascade resulting in the release of catenin in the cytoplasm, which eventually 
stimulates osteoblast differentiation. The cascade is negatively regulated by dickkopf 1 
(DKK1) and sclerostin (SOST). DKK1 can also bind to cell surface receptor KREMEN1 and 
LRP5, thus strengthening the negative regulatory effect. Genetic variants in LRP5 and KRE-
MEN1 were explored but not associated with the severity of progression of joint damage. 
However, several variants in DKK1 and SOST were associated with progression of structural 
damage. In particular, when the severity risk alleles of both variants were present, a gene-
gene interaction was observed, and patients with 4 risk alleles had very severe progression 
of damage. The relevance of the DKK1 variants was substantiated by the finding that the 
risk genotypes were associated with higher serum DKK1 levels and that higher serum levels 
were associated with more severe joint damage in other studies. These data support the 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Granzyme B (GRZB) is a serine protease found in lytic granules of NK cells and cytotoxic 
T lymphocytes.53 In vitro studies showed that granzyme B has enzymatic activity for the 
cleavage of aggrecan proteoglycans from cultured cartilage matrix.53 The observations 
that loss of cartilage proteoglycans is an early event in the course of destructive arthritis 
and that many granzyme B–positive cells are present in the pannus of patients with RA 
increased interest in GRZB as a biomarker for progression of joint damage. Four cohorts 
were studied, and 1 polymorphism (rs8192916) was shown to increase the risk of a more 
destructive course of RA. Furthermore, mapping expression of quantitative trait loci in 
whole blood revealed that the risk alleles were also associated with higher levels of mRNA 
expression.53
ADAMTS5
ADAMTS5, previously known as aggrecanase 2, is a member of the large ADAMTS family 
of zinc-dependent proteases. Aggrecan is a major proteoglycan that is responsible for 
the compressibility and stiffness of cartilage.54 One of the earliest changes observed in 
arthritis is depletion of cartilage aggrecan due to increased proteolytic cleavage within the 
interglobular domain.55 Two major cleavage sites have been identified, and ADAMTS5 is 
thought to cleave aggrecan at one of these sites. Murine osteoarthritis models and inflam-
matory arthritis models supported the relevance of ADAMTS5 for aggrecan degradation.56 
Based on the hypothesis that variants in ADAMTS5 might influence the severity of progres-
sion of joint damage, a candidate gene study was performed in 4 cohorts that were scored 
according to the Sharp van der Heijde method (in which the joint space narrowing score 
reflects the severity of loss of cartilage). No clear associations were observed in the 1418 
patients and 4885 radiographs studied (Table 4).
MMP3
Matrix metalloproteinases (MMP) comprise a group of zinc- and calcium-dependent 
enzymes that are implicated in the destruction of articular cartilage and bone. MMP3 is 
abundantly present in the synovium and synovial fluid of RA patients and is considered to 
be the main MMP in cartilage degradation. It is secreted by fibroblasts, synovial cells, and 
chondrocytes and activates other MMPs, such as MMP9 and MMP2. Serum levels of MMP3 
are elevated in both early and advanced RA, and elevated serum levels are correlated with 
more severe joint damage. Two studies reported a significant association between the 
promoter polymorphism 5A/6A and joint destruction in patients with RA.57,58 A third study 
did not find this association for MMP3 5A/6A itself, but identified a haplotype in this region 
that predisposed to more severe joint destruction.59 Other authors reported an association 
between the 5A/6A polymorphism and MMP3 serum levels and found that this promoter 
polymorphism was functionally relevant. Altogether, these data indicate an association 
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between this variant and the severity of joint damage in RA. Unfortunately, this 5A/6A 
variant is not included in regular high-throughput platforms, and no data are available on 
the association between this variant and severity of joint damage in larger cohorts.
MMP9
Fewer data are available on the association between MMP9 and progression of RA. How-
ever, a genetic variant in MMP9 has recently been identified as a risk factor for progression 
of joint damage (rs11908352). The variant was not identified using a candidate gene 
approach, but by evaluating polymorphisms located on 186 loci that were associated with 
autoimmune disorders and included on the Immunochip. rs11908352 was inserted into 
this platform because it is located near CD40. Nevertheless, it was observed to be associ-
ated with progression of joint damage, independently of variants in CD40. Furthermore, 
the risk allele for severity was also associated with higher serum MMP9 levels at disease 
onset. These data support the relevance of MMP9 for progression of joint damage in RA.60
Genome-wide study of progression of joint damage
In addition to the candidate gene studies described above, one genome-wide study inves-
tigated the ACPA-positive subset of RA. The study was performed in 3 stages. In the first 
stage, a cluster of SNPs located at chromosome 2q34 was found to be associated with 
progression of joint damage. In the second and third stages, rs7607479 was replicated 
as a risk factor for progression. The effect was protective, as patients carrying the minor 
allele had less severe joint damage. This polymorphism is located within the gene cod-
ing for sperm-associated antigen 16 (SPAG16), which is expressed in the joint and, more 
specifically, in fibroblast-like synoviocytes. Fibroblast-like synoviocytes carrying the minor 
allele expressed and secreted less MMP3, and RA patients with the minor allele had lower 
MMP3 levels in their serum. Subsequently, serum levels of MMP3 were associated with the 
severity of joint damage. These data point to a novel factor mediating MMP3 production 
and progression of joint damage and were further supported by the results of a multivari-
ate analysis showing that when both the genetic variant and serum levels were included 
in the model, only serum levels were independently associated with progression of joint 
damage. Consequently, the effect of rs7607479 on joint damage is mediated via an effect 
on MMP3 production.61
Genetic factors: Conclusion
Many studies have evaluated genetic factors as risk factors or biomarkers for progres-
sion of joint destruction in RA. Given that genetic markers generally have small effect 
sizes in complex disorders, the number of patients and radiographs included in many of 
these studies was relatively low; consequently, the power of several studies was also low. 
Therefore, meta-analyses combining data from all available cohorts are necessary in order 
78 Chapter 4
to draw robust conclusions. For several of the markers discussed here, such meta-analyses 
are difficult with published data, since the outcome measures used are different. The ge-
netic variants for which it would be particularly interesting to combine the data available 
in meta-analyses are rs2900180 in C5/TRAF1, rs1800896 in IL10, rs1800795 in IL6, and 
rs758684 in FCLR3. Moreover, current data suggest that the 5A/6A variant in MMP3 is also 
associated with joint damage. Further validation in larger studies would be useful.
Nonetheless, meta-analyses have been performed and published, and in all of the co-
horts included, the severity of progression of joint damage was measured quantitatively 
(Sharp van der Heijde and Larsen scores). Variants in 10 genes have been significantly 
associated with progression of joint damage in several independent studies and in meta-
analyses (Figure 2). These variants are related to inflammation (eg, IL2RA, IL4R, and IL15), 
autoimmunity (eg, HLA-DRB1), bone homeostasis (eg, DKK1, SOST, OPG), and cartilage 
destruction (eg, GRZB). Some of these genetic variants were also associated with different 
expression levels in blood serum and blood plasma (eg, IL2RA, DKK1, MMP9, GRZB).
seRoloGiC biomARkeRs oF RADioGRAPhiC joint DestRUCtion in RA
Serologic markers associated with disease severity include autoantibodies, other markers 
related to inflammation and proteinases, and components of the extracellular matrix of 
bone and cartilage (Table 5).
Autoantibodies
Many studies have shown that both rheumatoid factor and ACPA are independently associ-
ated with a destructive disease course.62-70 The most widely studied ACPA are the anti-CCP2 
antibodies. Van der Linden et al compared the anti-CCP2 test with the anti-CCP3 test and 
the anti-MCV test for predicting radiographic progression in early RA patients. When each 
test was performed alone, all 3 had comparable predictive abilities. Furthermore, when the 
results of the anti-CCP2 test were known, the other tests had no additive value, indicating 
that a single ACPA test is sufficient for estimation of risk in RA.71
Other autoantibodies have also been explored in RA. One such autoantibody acts directly 
against the protein arginine deaminase type 4 (PAD4). PAD are enzymes that catalyze the 
citrullination reaction. PAD4 has been detected in inflamed synovium, and anti-PAD4 anti-
bodies were associated with joint damage and erosions in a single cross-sectional study.72 
However, no confirmative studies have been reported since. Novel autoantibodies also 
include the anti-Carp antibodies (anti-carbamylated protein antibodies). Carbamylation is 
also a post-translational modification. This reaction is enhanced in smokers, in patients 
with renal failure, and in (chronic) inflammation. Anti-Carp antibodies are prevalent in RA. 
In ACPA-negative patients they were associated with the severity of joint destruction in 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































an early RA population.73 Since this association has thus far not been replicated, the value 
of these novel antibodies as biomarkers for progression of joint damage in RA remains 
undetermined.
Acute-phase reactants
Since RA is an inflammatory disease, it is no surprise that C-reactive protein (CRP) and the 
erythrocyte sedimentation rate (ESR) are associated with the severity of disease course. 
Nonetheless, these markers explain only a fraction of the total variance in joint destruction. 
A recent study calculated the variance of joint destruction explained by cumulative inflam-
mation (area under the curve of serial CRP levels over time) to be 15-19%.74 Hence, other 
markers or processes also play a role.
MMP3
The function of MMP3 has been discussed above. There is overwhelming evidence that 
serum MMP3 levels are associated with progression of joint damage, as a positive associa-
tion has been reported in 8 of the 9 studies on this subject. The only study that did not 
reveal an association was small and analyzed only 36 patients. Intriguingly, several of the 
other studies that reported higher serum levels to be associated with future joint damage 
were small (24-46 patients). Given that hundreds of patients were necessary to identify 
genetic variants, it is clear that the effect size of serum markers is generally larger than that 
of genetic markers. It is noteworthy that MMP3 levels are increased throughout disease 
course, thus making it a stable biomarker of progression.75
CTX-I and CTX-II
Urinary C-terminal crosslinking telopeptide type I (CTX-I) and type II (CTX-II) collagen are 
markers of bone and cartilage degradation. CTX-I was associated with the severity of joint 
damage in all the studies that measured this parameter.76,77 Only one study could not 
detect this association, although it evaluated the presence but not the severity of erosive 
disease.78 Interestingly, CTX-I was a potent predictor whose effect was independent of the 
association between progression of joint damage and rheumatoid factor, disease activity 
score, or ESR. CTX-II is a specific marker of type II collagen cleavage in cartilage. Excre-
tion of CTX-II was predictive of future joint damage, independently of other inflammatory 
markers.76,79 None of these studies made adjustments for ACPA status.
COMP
Cartilage oligomeric matrix protein (COMP) is expressed at high levels in the matrix of 
chondrocytes. This marker was increased in patients with a more destructive disease 
course. It is interesting to note that significant associations were established in relatively 
small studies. It has not been determined whether or not the association between COMP 
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and joint damage was independent of other biomarkers.67,79-81 In the largest study to date 
(containing 183 RA-patients), serum COMP was an independent predictor for joint dam-
age after 5 years, although after 10 years of disease, this association was lost and only 
anti-CCP and CRP were independently associated with the severity of damage in hand and 
foot joints.67
TIMP
It is unclear whether tissue inhibitor of metalloproteinases 1 (TIMP) is a biomarker for 
severe destructive RA. Two studies have been published, both with the quantitative Larsen 
score as the outcome; an association was observed in one study but not in the other.79,81
PYD
Pyridinoline (PYD) is a major cross-linking compound of collagen fibers in cartilage that is 
present in the collagen of bone and tissues such as synovium. Pyridinoline levels are higher 
in RA patients than in healthy persons and patients with other rheumatologic disorders. 
In addition, some cross-sectional studies indicated that pyridinoline levels are higher in 
cases of active or severe RA. Prospective studies have been performed based on serum 
and urine pyridinoline levels. Both markers were elevated in patients who developed more 
severe joint destruction.78,79,82-84 Intriguingly, this serum marker was also predictive in the 
early and advanced stages of RA, suggesting that it is also a stable biomarker for severity 
of joint damage in RA.84
RANKL/OPG
The genetic variants in OPG and RANKL have been discussed above. OPG is a soluble decoy 
receptor produced by osteoblasts that inhibits differentiation of the osteoclast precursor by 
neutralizing the receptor activator of NF-κβ ligand (RANKL). Although it was first observed 
that serum OPG levels were associated with joint damage in RA,85 a subsequent study 
by Geussens et al revealed that the RANKL/OPG ratio in particular is predictive of joint 
destruction.86,87
CXCL13
CXCL13 is also known as B lymphocyte chemo-attractant and has been reported to inter-
act with the receptor CXCR5, which is expressed by B cells and follicular B helper T cells. 
High levels of CXCR5 were also found in human osteoblasts, and activation by its ligand 
CXCL13 induced the release of extracellular matrix–degrading enzymes. CXCL13 levels are 
elevated in the serum of patients with RA. Based on these observations, CXCL13 could 
play an important role in the process of bone remodelling. Indeed, high CXCL13 levels 
were shown to be associated with more severe joint destruction over time in 2 Dutch 
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cohorts. This biomarker was most valuable in the anti–CCP-2–negative subpopulation of 
RA patients.88
IL2RA
IL2RA (CD25), the high affinity a chain of the IL2 receptor, is expressed on many immune 
cells and measurable in serum after cleavage from the membrane. It is considered a marker 
of T-cell proliferation. Several studies in other autoimmune diseases and healthy persons 
showed that the genetic variant described above (rs2104286) is associated with higher 
serum levels. In RA, higher serum levels are associated with more severe joint damage.34 If 
this association is replicated in other cohorts, it could prove to be a relevant biomarker that 
is also more easily measurable than the genetic variant.
imAGinG biomARkeRs AnD the seveRity oF RADioGRAPhiC joint 
DestRUCtion in RA
The most frequently investigated imaging biomarkers for predicting radiographic joint 
destruction in RA patients are markers that are visible with MRI and ultrasound, namely, 
bone marrow edema, synovitis, tenosynovitis, and erosions.
mRi
MRI is increasingly used to measure disease states and treatment response in RA research. 
MRI has important advantages over conventional radiographs; in particular, it makes it 
possible to visualize and quantify inflammation of synovium, tendons, and bone (bone 
marrow edema), as well as structural damage. Bone marrow edema is common in RA and 
is estimated to occur in 68%-75% of patients with early RA.89 Bone marrow edema is not 
detected by ultrasound or other imaging modalities and is a strong predictor of erosive 
progression. In a randomized controlled trial consisting of 130 RA patients, Hetland et 
al showed that bone marrow edema is an independent predictor of 2-year radiographic 
progression (coefficient, 0.59-0.75; P<0.001; R2=25%-41%). Bone marrow edema also 
predicted radiographic progression at 5 years (coefficient, 0.83; P<0.001; R2=23%).90;91 In 
an observational cohort of 84 early RA patients, Boyesen and Haavardsholm et al identified 
baseline bone marrow edema as an independent predictor of both 1-year radiographic ero-
sive progression (OR=2.8, P=0.04) and 1-year MRI erosive progression (OR=1.3; P=0.04).92-
94 In an observational cohort of 42 patients, McQueen et al also demonstrated that 1-year 
radiographic erosions were more frequent in patients who had a total MRI score at baseline 
> 13 (OR=12.4; P=0.002)95. Additionally, they followed 31 of these patients over 6 years and 
observed that bone marrow edema at baseline also predicted the severity of radiographic 
joint destruction after 6 years (R2=0.20; P=.01).96 In an observational cohort of 24 early RA 
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patients, Lindegaard et al showed an RR of 4.0 for 1-year radiographic erosion when bone 
marrow edema was observed on the MRI; when erosion was observed on the MRI scan, the 
RR was 12.1.97 In an observational cohort of 40 early RA patients, Conaghan et al showed 
a clear relationship between baseline MRI synovitis and development of subsequent MRI 
erosive destruction (area under the curve for MRI synovitis, r=0.42, P<0.007).98 However, 
they did not assess the relationship with radiographic destruction. Boyesen et al showed 
that baseline synovitis on MRI independently predicted 3-year radiographic progression 
(beta=0.14; P=0.03).92 Altogether, these studies confirm that the presence of synovitis and 
bone marrow edema on MRI is predictive of radiographic progression in patients with early 
RA. Again, the number of patients included in these studies was relatively low, and the 
observed effect sizes large.
An association between inflammation markers on MRI and radiographic joint destruction 
cannot always be identified. This can in part be explained by the short follow-up; assuming 
that bone marrow edema is a pre-erosive lesion, it takes time for a lesion to evolve from 
osteitis to erosion. Hoving et al observed that only half of the patients with erosions on 
MRI at baseline progressed to erosions on radiographs after a follow-up of 6 months.99 
Kamishima et al did not find a significant correlation between bone marrow edema and 
1-year radiographic progression in 29 RA patients treated with anti-interleukin 6 receptor 
antibody. However, they did find a significant correlation between erosion on MRI and 
1-year radiographic progression.100 Furthermore, Ostergaard et al showed that MRI is con-
siderably more sensitive than conventional radiographs; most new radiographic erosions 
(78%) were visualized at least 1 year earlier by MRI than by conventional radiograph, 
and MRI detection of new radiographic erosions preceded radiographic detection by a 
median of 2 years.101 In a sample of 16 RA patients, Scheel et al showed that 41% of 
the erosions on MRI at baseline were seen on the radiograph at 7 years.102 Although not 
every bone edema lesion evolves to erosion on the radiograph, most studies show that the 
development of radiographic erosions in the short term was highly unlikely in the absence 
of baseline MRI inflammatory changes. McQueen et al found a positive predictive value 
of 0.53 and a negative predictive value of 0.92 for bone marrow edema at baseline and 
radiographic erosions at 1 year.95 Mundwiler et al reported similar findings only in the 
metatarsophalangeal joints of RA patients.103
Ultrasound
Although MRI is a potentially powerful technique for evaluation of inflammation and 
structural damage in RA, it is not a routine procedure owing to limited availability and high 
costs. Ultrasound is more available, less expensive, and does not require administration 
of contrast medium. It can be used to evaluate inflammation of joints and tendons and 
erosions. Synovitis is usually scored semi-quantitatively for both gray scale synovitis and 
power Doppler activity.
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In an observational cohort of 84 RA patients, Boyesen et al showed that ultrasound gray-
scale inflammation predicted 1-year MRI erosive progression (OR=2.01, p=0.02).92 In their 
study of 59 RA patients starting anti-TNF therapy, Dougados et al. showed that baseline 
synovitis increased the risk of structural radiographic progression. The results of this study 
also implied that ultrasonographic examinations are not superior to clinical examination for 
predicting structural radiographic progression in RA.104
Tenosynovitis of the extensor carpi ulnaris was an imaging biomarker with an indepen-
dent predictor for MRI erosive progression in the cohort of Lillegraven et al.105
Early RA bone erosions are detected with greater sensitivity using ultrasound than using 
conventional radiography, most probably as a direct function of their size. Szkudlarek et al. 
found more and larger erosions in the finger and toe joints of patients with established RA 
than in early RA.106 In their study of 16 RA patients, Scheel et al showed that 22% of the 
erosions on ultrasound at baseline were seen on radiograph at 7 years; this percentage was 
lower than that detected by MRI.102
Ultrasound is limited by its capacity to detect lesions at some locations, such as the wrist 
and intra-articular surfaces of the third and fourth metacarpophalangeal joints. In addition, 
discrimination between cortical irregularity and erosions is problematic. Furthermore, with 
ultrasound, it is not possible to visualize inflammation of the bone (bone marrow edema). 
Ultrasound is also highly operator-dependent and time-consuming.
More research is necessary before ultrasound can be considered a useful tool for predict-
ing radiographic progression of joint damage in RA.
CombininG biomARkeRs
Treatment of RA is not adjusted to individual prognoses but to measured disease activity. 
Consequently, some RA patients may be undertreated if disease activity is not suitably 
suppressed (generally patients with severe disease). Undertreatment could be attributed 
to the fact that aggressive combination therapy or biologics are not universally prescribed 
because of costs and concerns over toxicity. This reasoning underlines the need for a good 
prediction metric to identify patients with a potentially severe disease course. Although 
several prediction models or risk matrices have been developed, none have been validated. 
Furthermore, these models adequately predicted outcome in only about 50% of patients. 
Better models are necessary.
The existing models for evaluation of the severity of the course of RA are based on 
CRP, ACPA titer, baseline erosions, and the number of swollen joints.69,107-110 This review 
of biomarkers of progression in RA shows that most of the biomarkers identified had not 
yet been integrated in prediction models. The addition of more recently identified genetic, 
serologic, and imaging markers will increase predictive ability.
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ConClUsion
Progression of joint destruction is an objective measure of the severity of RA and is 
frequently used to identify biomarkers that can be used to evaluate disease course. The 
highest sensitivity is observed with hand and foot radiographs taken serially over time 
and scored using a validated quantitative scoring method. Precise measurements increase 
statistical power, which is very relevant in genetic studies, since most genetic factors have 
small effect sizes. Serologic and imaging factors generally have larger effect sizes, probably 
because they are more closely related to the phenotype (Figure 3). The present manuscript 
provides an overview of genetic markers of severity studied in multiple cohorts; several 
markers for which a positive association was established in older studies were not replicated 
in more recent studies. For some markers, no definite conclusion could be drawn, thus 
necessitating a meta-analysis. Nonetheless, more than 10 genetic risk factors have been 
identified and replicated. Furthermore, various serologic and imaging risk factors were 
described. Most of these known risk factors have not yet been included in risk models. 
Combination of these markers to achieve adequate predictive value requires further study.
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Interleukin (IL)-15 levels are increased in serum, synovium and bone marrow of patients 
with rheumatoid arthritis (RA). IL-15 influences both the innate and the adaptive immune 
response; its major role is activation and proliferation of T cells. There are also emerging 
data that IL-15 affects osteoclastogenesis. The authors investigated the association of 
genetic variants in IL15 with the rate of joint destruction in RA.
method
1418 patients with 4885 x-ray sets of both hands and feet of four independent data sets 
were studied. First, explorative analyses were performed on 600 patients with early RA 
enrolled in the Leiden Early Arthritis Clinic. Twenty-five single-nucleotide polymorphisms 
(SNPs) tagging IL15 were tested. Second, SNPs with significant associations in the explor-
ative phase were genotyped in data sets from Groningen, Sheffield and Lund. In each data 
set, the relative increase of the progression rate per year in the presence of a genotype 
was assessed. Subsequently, data were summarized in an inverse weighting meta-analysis.
Results
Five SNPs were significantly associated with rate of joint destruction in phase 1 and typed 
in the other data sets. Patients homozygous for rs7667746, rs7665842, rs2322182, 
rs6821171 and rs4371699 had respectively 0.94-, 1.04-, 1.09-, 1.09- and 1.09-fold rate 
of joint destruction compared to other patients (p=4.0×10−6, p=3.8×10−4, p=5.0×10−3, 
p=5.0×10−3 and p=9.4×10−3).
Discussion
Independent replication was not obtained, possibly due to insufficient power. Meta-
analyses of all data sets combined resulted in significant results for four SNPs (rs7667746, 
p<0.001; rs7665842, p<0.001; rs4371699, p=0.01; rs6821171, p=0.01). These SNPs were 
also significant after correction for multiple testing.
Conclusion
Genetic variants in IL-15 are associated with progression of joint destruction in RA.
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IL15 and radiographic progression
intRoDUCtion
Rheumatoid arthritis (RA) is an autoimmune disorder that affects 0.5–1% of the population 
and is associated with significant morbidity, disability and costs for society. Radiographic 
joint destruction reflects the cumulative burden of inflammation and is conceived as an ob-
jective measure of RA severity. The degree of joint destruction varies significantly between 
patients. The processes behind this difference are incompletely understood. Inflammatory 
markers and autoantibodies are potent risk factors for joint destruction but account for 
approximately 30% of the variance in joint destruction.1 Recent data indicate that genetic 
factors influence the severity of joint destruction in RA.2 Hence, to increase the understand-
ing of progression mediating disease processes, it is relevant to study genetic variants that 
could predispose for a severe outcome of RA.
In this article, we describe a candidate gene study to investigate the association of 
interleukin (IL)-15 with the rate of joint destruction. IL-15 is expressed primarily by macro-
phages, as well as by fibroblast-like synoviocytes and endothelial cells.3 IL-15 produced by 
synoviocytes has been implicated in the pathogenesis of RA as it serves as T lymphocyte 
activator and proliferator in the synovial membrane as well as in the bone marrow.4-6 IL-15 
may be implicated in the perpetuation of synovial inflammation by generating a positive 
feedback in which activated synovial macrophages or fibroblasts induce continuous T cell 
recruitment.7 Results of several animal studies supported the notion that IL-15 has a role 
in RA progression. Ferrari-Lacraz et al generated a mutated IL-15 fused to the constant 
region of a murine IgG2a, which inhibited the IL-15 receptor. This mutated IL-15-IgG pre-
vented the development of collagen-induced arthritis and also blocked disease progression 
in an established disease model.8 Daily intraperitoneal injection of mutated IL-15-IgG in 
collagen-induced arthritis showed reduced clinical scores and reduced cartilage erosions 
relative to controls. Another study demonstrated that in the absence of IL-15 signaling, 
several converging mechanisms of osteoclastogenesis were inhibited in mice.9 In patients 
with RA, IL-15 levels are increased in serum, synovial fluid and bone marrow.4,6 Addition-
ally, serum levels of IL-15 correlated strongly to disease activity.10
These data led us to hypothesize that genetic variants in IL15 are associated with the 
severity of joint destruction in RA. We tested this hypothesis using four data sets of Euro-
pean patients with RA with longitudinal radiological data on joint destruction. All data sets 
included patients who were diagnosed in a period when treatment strategies were less 
aggressive and less controlled than today. These conservative treatment strategies made 




Four data sets consisting of adult European patients with RA were studied. RA was defined 
according to the 1987 American College of Rheumatology criteria in all cohorts except for 
the Lund cohort where the 1958 criteria were used. X-rays of both hands and feet were 
available in all cohorts (table 1).
Leiden Early Arthritis Clinic cohort (Leiden-EAC)
This cohort concerned 600 patients with early RA from the western part of the Netherlands 
who were included in the Leiden-EAC between 1993 and 2006.1 Patients were included 
at time of diagnosis and yearly followed up. X-rays were taken at baseline and on yearly 
follow-up visits for 7 years. In total, 2846 x-ray sets of hands and feet were available. All 
x-rays were chronologically scored by one experienced reader who was unaware of genetic 
or clinical data using Sharp–van der Heijde scores (SHSs) on hands and feet.11 A total of 
499 x-rays (belonging to 60 randomly selected patients with RA) were scored double. The 
correlation coefficient (ICC) within the reader was 0.91. The treatment of these patients 
could be divided into three treatment periods. Patients included in 1993–1995 were ini-
tially treated with non-steroidal anti-inflammatory drugs, patients included in 1996–1998 
were initially treated with chloroquine or salazopyrine and patients included after 1999 
were promptly treated with methotrexate or salazopyrine.
table 1: Characteristics for each cohort.
Cohort
leiden-eAC Groningen sheffield lund
(n=600) (n=275) (n=396) (n=147)
year of diagnosis 1993-2006 1945-2001 1938-2003 1985-1989
Follow-up years* 7 years 14 years Not applicable* 5 years
total no. of X-ray sets 2,846 862 396 781
method of scoring SHS SHS Larsen Larsen
Female n (%) 412 (69) 194 (71) 290 (73) 98 (67)
Age at diagnosis, mean ± sD 56 ± 16 49 ± 13 46 ± 13 51 ± 12
CCP+ n (%) 323 (55) 160 (80) 302 (79) 114 (80)
SHS= Sharp van-der-Heijde score
*Data of Leiden-EAC, Groningen and Lund were collected from baseline onwards during respectively 7, 
14 and 5 years of follow-up. The data of Sheffield were collected once during the disease period, the 
mean disease duration was 15 years (range 3-65 years).
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Groningen
The second set of data involved 275 patients with RA from the northern part of the 
Netherlands who were diagnosed between 1945 and 2001. The follow-up duration after 
diagnosis was limited to 14 years. The mean number of x-ray sets (hands and feet) per 
patient was 3.1 (with a maximum of 8 x-rays per patient). The total number of sets of 
x-rays was 862. The x-rays were scored chronologically by one of two readers using SHS. 
ICCs within readers were >0.90, and those between readers were 0.96. The development 
of joint destruction was significantly different for patients included in the 1990s compared 
to patients included before 1990. This observation is in line with the introduction of treat-
ment with disease-modifying anti-rheumatic drug (DMARD).
Sheffield
The third set of data concerned 396 patients with RA from the area of Sheffield, UK. 
Patients with RA with x-rays available were recruited from the rheumatology department 
of the Royal Hallamshire Hospital in Sheffield between 1999 and 2006 and were diagnosed 
as having RA between 1938 and 2003.12 Patients with RA were assessed once during their 
disease course. The mean ± SD disease duration at assessment was 15±11 years (range: 
3–65 years). X-rays of hands and feet were scored by one reader using a modification 
to Larsen’s score.13 Ten percent of films were scored twice to quantify the intra-observer 
variation by a weighted κ score, which was 0.83.12
Lund
This cohort concerned 183 Swedish patients with early RA who were prospectively fol-
lowed up yearly for 5 years, of whom 147 had x-rays and DNA available.14;15 Patients were 
recruited from primary care units in the area of Lund during 1985–1989. X-rays of hands 
and feet were taken at the start of the study and annually for 5 years, resulting in a total 
of 781 sets of x-rays. X-rays were scored chronologically according to Larsen by one of two 
readers.16 The ICC between the readers determined on 105 x-rays was 0.94. In the inclu-
sion period, immediate DMARD treatment was not common and only half of the patients 
used any DMARD at 5 years of follow-up, most commonly chloroquine, D-penicillamine, 
sodium aurothiomalate and auranofin.14 All patients gave their informed consent, and 
approval was obtained from the local ethical committee of each study.
snP selection and genotyping
The region of IL15, located at chromosome 4q31, plus the regions of the upstream- and 
downstream-situated haplotype blocks were tagged by the algorithm of haploview.17 No 
coding and amino acid changing single-nucleotide polymorphisms (SNPs) are known for 
IL15. One SNP, rs12508866, had a significant association with RA susceptibility in the Well-
come Trust Case Control Consortium data set18 and was therefore forced to be included. 
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Pairwise tagging SNPs were selected from the CEPH/ CEU hapmap data set (phase 2, re-
lease 21, NCBI (National Center for Biotechnology Information) build 35) using haploview 
software (minor allele frequency>0.05, pairwise r2<0.8). A total of 25 SNPs captured all 
SNPs on IL15. Multiplex SNP arrays were designed using Illumina Golden Gate platform, 
according to the protocols recommended by the manufacturer (Illumina, San Diego, Cali-
fornia, USA). Two SNPs (rs9884645 and rs4401531) were excluded as they could not be 
designed in the multiplex SNP array and no good proxy existed. The SNP selection and the 
linkage disequilibrium (LD) information are depicted in figure 1.
Software supplied by Illumina was used to automatically identify the genotypes. Each 
96-well plate consisted of one positive and one negative control. In all plates, the positive 
controls indeed tested positive and the negative controls tested negative. Clusters were 
evaluated and all doubtful calls were checked; after manually evaluating the spectra of 
each cluster, we accepted, recalled or rejected the genotypes. At least 12% were assessed 
in duplicate, with an error rate of <1% for all SNPs except rs7667746, which had an error 
rate of 3.8%. One SNP failed and two SNPs had a success rate of 75%; the remaining SNPs 
Figure 1 LD structure between of 25 tag-SNPs in IL-15.
The depicted data are from 600 Leiden-EAC Dutch RA-patients. The numbers present the r2 between 
the SNPs. The colours refer to D΄. Two SNP could not be designed and no good proxy existed (rs9884645 
no.20, rs4401531 no.24). One SNP failed typing (rs1961720, no.7). Significant SNPs in the analyses of 
Leiden-EAC are marked by an arrow.
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were typed with a success rate of >98% (Supplementary Table 1). None of the SNPs were 
out of Hardy–Weinberg equilibrium (p<0.001).
SNPs that were significantly associated with joint destruction in the first data set were 
genotyped in the other three data sets. SNPs were genotyped with multiplex SNP ar-
rays designed with Sequenom iPLEX, according to the protocols recommended by the 
manufacturer (Sequenom, San Diego, California, USA). Software supplied by the same 
manufacturer was used to automatically identify the genotypes. Each iPLEX consisted of 
at least nine positive and nine negative controls, which were indeed tested positive and 
negative. All doubtful calls were checked manually. DNA samples that still had >30% 
failed SNPs after manual checking were excluded from analysis (n=31). At least 5% of the 
genotypes were assessed in duplicate, with an error rate of <1%. The success rates were 
all >95%. No SNPs were out of Hardy–Weinberg equilibrium.
statistical analysis
Associations between genotypes and radiographic joint destruction were analyzed. Two 
phases were carried out. First, an explorative analysis was performed in the Leiden-EAC. 
In this data set, the tagged SNPs were tested in two ways: additively and recessively. In all 
data sets, the radiological scores were log-transformed to obtain a normal distribution. 
Since phase 1 was an explorative phase, no correction for multiple testing was applied yet 
and SNPs with a p value ≤0.05 were studied in phase 2.
For the analyses in the Leiden-EAC, a multivariate normal regression model for longi-
tudinal data was used with radiological score as response variable. This method analyses 
all repeated measurements at once and takes advantage of the correlation between 
these measurements. The effect of time was entered as a factor in the model, to properly 
capture the mean response profile over time. To test for an association with the rate of 
joint destruction, we conducted an analysis with the SNP and its interaction with time in 
the model. The effect of time in the interaction term was linear. Since the analyses were 
performed on the log scale, the resulting coefficient (β) on the original scale indicates how 
many fold the joint destruction increased per year in the tested genotype compared to 
reference genotype and increases per year by the power of the years of follow-up. Adjust-
ment variables were entered based on their univariate association with joint destruction. 
Adjustments were made for age, gender and the described treatment periods.
For the analyses in Groningen and Lund, we used a multivariate normal regression analy-
sis that was similar to the analysis applied in the Leiden-EAC. Adjustment variables were 
entered based on their univariate association with joint destruction. The Groningen data 
set was adjusted for age and inclusion before 1990 and after 1990, as proxy for DMARD 
treatment. The analysis of Lund was adjusted for age only, since gender and treatment 
were not associated with joint destruction in this data set.
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In the Sheffield data set, each patient had x-rays at one time point. The estimated yearly 
progression rate was calculated to make the scores comparable to the other data sets.19 
This was achieved by dividing the total by the number of disease years at time of x. The 
disease duration at time of x-ray was available for 391 patients. The SNP association was 
tested in a linear regression analysis with log-transformed estimated yearly progression 
rate as outcome variable. No adjustments were applied as none of the tested variables 
was univariately significantly associated with joint destruction. Also, here, the resulting 
estimate reflects how many fold the rate of joint destruction increases per year in the 
presence of a minor allele compared to the absence of this allele. Analyses were performed 
using SPSS version 17.0.
In the present study, the power is the result of the number of patients and the number 
of measurements per patient studied. As shown previously, the precision of the estimate 
increases steadily with increasing numbers of x-rays per patient.20 All three data sets 
studied to verify the results of phase 1 contained (individually and combined) less x-rays 
than the initial data set. Consequently, the power to replicate findings in each data set 
individually as well as in the three replication data sets together was limited in comparison 
to the large amount of x-rays in the discovery data set. Because of differences in study 
designs, the separate data sets could not be combined in one analysis directly. Therefore, 
we decided to test the SNPs in each data set separately, taking advantage of the specific 
data set characteristics, and to subsequently perform a meta-analysis on the results to 
determine the association of the SNPs with the rate of joint destruction. A fixed-effects 
meta-analysis22 with inverse variance weighting was performed in Stata, version 10.1.
It is debatable whether correction for multiple testing should be applied. However, mul-
tiple testing correction using the Benjamini–Hochberg false discovery rate was performed 
in phase 2 to reduce the chance of having false-positive findings. p Values ≤0.05 after 
correction for multiple testing were considered significant.23
Haplotype analyses
Haplotypes of IL15 were studied. Haplotype blocks were defined by Gabriel’s method.24 
Haplotypes were assigned to each individual using PLINK 1.06 requiring a probability >0.8. 
Analyses of the haplotypes were performed with methods similar to those used for the 
analyses of the individual SNPs by now testing the presence of a haplotype compared to 
the absence of the haplotype.
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ResUlts
Discovery phase
IL15 was tagged by 25 SNPs, of which 2 could not be designed, 1 failed typing and 2 did 
not pass quality control. In total, 20SNPs were analyzed in the Leiden-EAC. Five SNPs were 
significantly associated with joint destruction (minor allele): rs2322182(A), rs7667746(G), 
rs7665842(G), rs4371699(A) and rs6821171(C) (figure 2). The recessive analyses fitted the 
Figure 2 Depicted are the median Sharp-van der Heijde scores during 7-years of follow-up of patients 
with different genotypes in phase-1 (Leiden-EAC).
Over seven years, patients with twice the minor alleles of rs2322182, rs7667746, rs7665842, rs4371699 
and rs6821171 had 1.31 (1.07-1.60, P=0.01), 1.86 (1.43-2.41, P<0.01), 1.88 (1.33-2.65, P<0.01), 1.80 
(1.15-2.82, P=0.01) and 0.64 (0.47-0.87, P=0.01) higher rates of joint destruction compared to patient 
with only one or no minor allele. A beta of 1.09 (rs7667746) per year equals to a 1.86 higher rate of joint 
destruction over 7 years, which is similar to 86% increase in rate of joint destruction.
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data best in all five SNPs. Patients homozygous for the minor allele had respectively 1.04-
fold (1.01–1.07, p=0.01), 1.09-fold (1.05–1.13, p<0.01), 1.09-fold (1.04–1.15, p<0.01), 
1.09-fold (1.02–1.16, p=0.01) and 0.94-fold (0.90–0.98, p=0.01) higher rates of joint 
destruction per year as compared to the other patients (table 2). A β of 1.09 per year is 
equal to a 1.83 (=1.097) higher rate of joint destruction over 7 years. Thus, that is, for 
rs7667746, the estimated rate of joint destruction in patients carrying both minor alleles 
was 9% higher per year than that of the other patients; over a period of 7 years, this is 
equal to an 86% (=0.09237) higher rate of joint destruction. In a sub-analysis, analyses 
were also adjusted for anti-CCP, yielding comparable effect sizes (data not shown).
Phase 2
The five significant SNPs were assessed in the other three data sets. Patient characteristics 
are presented in table 1. One SNP, rs7665842, could not be designed by Sequenom. Instead, 
a good proxy, rs6835391 (r2=0.92), was typed. To refer to this proxy, we used rs7665842. 
Possibly, due to insufficient power, none of the five SNPs were statistically significant when 
analyzed in each of the other three data sets separately or when tested in the three cohorts 
combined. Nevertheless, for four of the five SNPs, the effect size in the replication data 
sets went in the same direction as in the initial data set. The five significant SNPs of phase 
1 were analyzed in all 1418 patients of all cohorts in an inverse variance weighting meta-







mAF β 95% Ci P
rs2322182 142705559 ADD A/G 0.44 1.02 1.01 1.04 0.01
REC 1.04 1.01 1.07 5.0*10-3
rs7667746 142708334 ADD G/A 0.33 1.03 1.02 1.05 2.4*10-4
REC 1.09 1.05 1.13 4.0*10-6
rs7665842 142713345 ADD G/A 0.40 1.03 1.01 1.05 0.01
REC 1.09 1.04 1.15 3.8*10-4
rs4371699 142720503 ADD A/C 0.19 1.03 1.00 1.05 0.03
REC 1.09 1.02 1.16 9.4*10-3
rs6821171 142916618 ADD C/A 0.29 0.99 0.97 1.01 0.33
REC 0.94 0.90 0.98 5.0*10-3
MAF: minor allele frequency. 95%CI: 95% confidence interval
SNP data is based on NCBI build 35, dbSNP b125
The β of the additive test represents the relative increase in joint destruction per year per minor allele 
compared to no minor alleles. The β of the recessive test represents the relative increase in joint destruc-
tion per year for two minor alleles compared to no one or no minor alleles on the normal scale.
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analysis in a recessive model. Four SNPs were significant in the meta-analyses: rs7667746 
(p<0.001), rs7665842 (p<0.001), rs4371699 (p=0.01) and rs6821171 (p=0.01)(figure 3).
To correct for multiple testing, we calculated the Benjamini– Hochberg false discovery 
rate q values.23 This revealed that all four SNPs were significant; p values after multiple 
testing correction were as follows: rs7667746 (p<0.01), rs7665842 (p<0.01), rs4371699 
(p=0.02) and rs6821171 (p=0.03).
haplotype analysis
In all data sets, the three SNPs associated with enhanced destruction (rs7667746, 
rs7665842 and rs4371699) were in close LD (r2=0.46–0.83, D′=0.97–1). To obtain further 
insight into the associations found, we performed a haplotype analysis. In the Leiden-EAC, 
two haplotypes with a prevalence >0.1 were found: GGA and AAC (frequencies: 0.19 and 
0.67). Analysis of homozygosity for haplotypes against absence resulted in the following 
for GGA and AAC, respectively: β=1.09 (1.02–1.16, p=0.01) and β=0.97 (0.95–0.998, 
Figure 3 Depicted are the results of the analyses of the individual cohorts and the results of the meta-
analyses performed on the four SNPs that were significant in phase-2.
The effect sizes are the estimated relative progression rates per year for the presence of twice the minor 
allele compared to patients with only one or no minor allele. The p-values in the graphs are uncorrected 
for multiple testing.
The meta-analyses are based on a fixed effect model, which are applied to genetic studies to test wheth-
er there is statistically significant effect; generalisability of the effect is of less importance. As result of this 
choice, the effect size of the meta-analyses should be considered carefully. Consequently, this methods 
is less suitable to estimate the effect size overall. Therefore, the estimated effect of the meta-analysis is 
depicted in gray.
Rs7665842 was typed in the EAC, but could not be designed in the phase-2. Instead rs6835391 (r2=0.92) 
was typed in the other three data sets.
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p=0.032). Haplotype analysis on the whole gene in the Leiden-EAC resulted in two more 
blocks (figure 1), which were both not associated with joint destruction (data not shown).
In the three additional data sets, the same haplotypes were made with similar frequencies 
(frequency: GGA 0.18–0.23 and AAC 0.67–0.69). Meta-analysis of the haplotypes of all data 
sets resulted in β=1.07 (1.02–1.12, p<0.01) for GGA and β=0.99 (0.97–1.01, p=0.16) for 
AAC. These effect sizes were comparable to the results of the individual SNPs alone. Therefore, 
haplotype analyses did not result in additional information on the association discovered.
DisCUssion
The variance in joint destruction between patients is considerable and is thus far scarcely 
understood. We performed a candidate gene study to investigate the association of genetic 
variants with joint destruction. IL15 (4q31) was chosen as candidate gene since there are 
emerging data that IL-15 plays a role in perpetuation of inflammation and affects osteo-
clastogenesis. We tested the association of SNPs tagging IL15 with rate of joint destruction 
in one data set and tested the significant SNPs subsequently in three other data sets. 
Finally, an analysis combining the radiological data of all 1418 patients was performed. 
Four SNPs were observed to associate significantly with progression of joint destruction. 
One SNP, rs6821171, had a protective effect. Three SNPs (rs7667746, rs7665842 and 
rs4371699) that were physically closely related associated with a deteriorative effect on 
joint destruction. Analysis of these three SNPs together in a haplotype analysis did not 
further elucidate the discovered associations of the single SNPs.
The aim was to study the evolution of joint destruction in the most unbiased manner. 
The present study uniquely combines four data sets of patients who started treatment in 
a time when treatment was not as aggressive as nowadays. Since some of the data sets 
covered a period where different treatment regimens were used, analyses were adjusted 
for treatment if relevant.
Replication data sets are ideally larger than the initial data set, since effect sizes are 
generally smaller at a replication stage. However, relatively few large prospective data sets 
exist with both x-rays and DNA available in conventionally treated patients. For each data 
set, the number of patients and the number x-rays were lower than the cohort used in 
phase 1. The data sets available for phase 2 were possibly underpowered to individually 
replicate findings. In the absence of independent replication, there is an increased risk of a 
false-positive finding. To minimise this risk, we summarised data in a meta-analysis to test 
whether the association still holds. An inverse variance weighting meta-analysis yielded 
significant results for all four SNPs. Importantly, the effects of the SNPs went into the same 
direction in each data set, which supports the validity of the results.
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Different methods to score joint destruction were applied: Larsen and SHS. Although 
these methods differ in methodology, sensitivity and ranges of scores, both methods are 
linearly correlated with each other.21,25 Therefore, as long as the effects of genetics are 
tested with the same method within each cohort, the cohort with the different scoring can 
be combined in one weighted meta-analysis. Nonetheless, the absolute scores provided by 
both methods are difficult to compare. In the present study, the relative increase in progres-
sion rate was evaluated; this relative measure has no units and can therefore be compared.
IL-15 plays a role in T cell proliferation and attraction and has a structural homology with 
IL-2.26 IL-15 has pleiotropic and physiological activities in both the innate and acquired im-
mune responses. IL-15 induces T cell proliferation, activates NK-cells, costimulates immu-
noglobulin synthesis by B cells and activates monocytes.27 IL-15 is increased in synovial fluid 
as well as in bone marrow. It is likely to be involved in the perpetuation of inflammation, 
which consequently may drive progression of joint destruction in RA.
The present data support the notion that genetic variants in IL15 are involved in the 
severity of joint destruction. Subsequent studies should elucidate whether the presence of 
these variants results in difference in IL15 expression, in IL15 activity and in other aspects 
of IL15 biology.
In conclusion, with a candidate gene approach evaluating patients of four different 




 1. de Rooy DP, van der Linden MP, Knevel R, et 
al. Predicting arthritis outcomes what can be 
learned from the Leiden Early Arthritis Clinic? 
Rheumatology (Oxford) 2011;50:93–100.
 2. van der Helm-van Mil AH, Kern M, Gregersen 
PK, et al. Variation in radiologic joint destruc-
tion in rheumatoid arthritis differs between 
monozygotic and dizygotic twins and pairs 
of unrelated patients. Arthritis Rheum 
2006;54:2028–30.
 3. Asquith DL, McInnes IB. Emerging cytokine 
targets in rheumatoid arthritis. Curr Opin 
Rheumatol 2007;19:246–51.
 4. Wilkinson PC, Liew FY. Chemoattraction of 
human blood T lymphocytes by interleukin-15. 
J Exp Med 1995;181:1255–9.
 5. McInnes IB, al-Mughales J, Field M, et al. The 
role of interleukin-15 in T-cell migration and 
activation in rheumatoid arthritis. Nat Med 
1996;2:175–82.
 6. Kuca-Warnawin E, Burakowski T, Kurowska W, 
et al. Elevated number of recently activated T 
cells in bone marrow of patients with rheu-
matoid arthritis: a role for interleukin 15? Ann 
Rheum Dis 2011;70:227–33.
 7. McInnes IB, Liew FY. Interleukin 15: a proinflam-
matory role in rheumatoid arthritis synovitis. 
Immunol Today 1998;19:75–9.
 8. Ferrari-Lacraz S, Zanelli E, Neuberg M, et al. 
Targeting IL-15 receptor-bearing cells with an 
antagonist mutant IL-15/Fc protein prevents 
disease development and progression in 
murine collagen-induced arthritis. J Immunol 
2004;173:5818–26.
 9. Djaafar S, Pierroz DD, Chicheportiche R, 
et al. Inhibition of T cell-dependent and 
RANKL-dependent osteoclastogenic processes 
associated with high levels of bone mass in 
interleukin-15 receptor-deficient mice. Arthritis 
Rheum 2010;62:3300–10.
 10. Petrovic-Rackov L, Pejnovic N. Clinical sig-
nificance of IL-18, IL-15, IL-12 and TNF- alpha 
measurement in rheumatoid arthritis. Clin 
Rheumatol 2006;25:448–52.
 11. van der Heijde D. How to read radiographs 
according to the Sharp/van der Heijde method. 
J Rheumatol 2000;27:261–3.
 12. Mewar D, Coote A, Moore DJ, et al. Indepen-
dent associations of anti-cyclic citrullinated 
peptide antibodies and rheumatoid factor with 
radiographic severity of rheumatoid arthritis. 
Arthritis Res Ther 2006;8:R128.
 13. Rau R, Herborn G. A modified version of 
Larsen’s scoring method to assess radiologic 
changes in rheumatoid arthritis. J Rheumatol 
1995;22:1976–82.
 14. Fex E, Jonsson K, Johnson U, et al. Development 
of radiographic damage during the first 5–6 yr 
of rheumatoid arthritis. A prospective follow-
up study of a Swedish cohort. Br J Rheumatol 
1996;35:1106–15.
 15. Lindqvist E, Jonsson K, Saxne T, et al. Course of 
radiographic damage over 10 years in a cohort 
with early rheumatoid arthritis. Ann Rheum Dis 
2003;62:611–6.
 16. Larsen A, Dale K. Standardized radiological 
evaluation of rheumatoid arthritis in therapeu-
tic trials. In: Dumonde DC, Jasani MK, eds. The 
recognition of antirheumatic drugs. Lancaster: 
MTP Press, 1978:285–92.
 17. Barrett JC, Fry B, Maller J, et al. Haploview: 
analysis and visualization of LD and haplotype 
maps. Bioinformatics 2005;21:263–5.
 18. https://www.wtccc.org.uk
 19. Strand V, Landéwé R, van der Heijde D. Using 
estimated yearly progression rates to compare 
radiographic data across recent randomised 
controlled trials in rheumatoid arthritis. Ann 
Rheum Dis 2002;61:ii64–6.
 20. van der Helm-van Mil AH, Knevel R, van der 
Heijde D, et al. How to avoid phenotypic 
misclassification in using joint destruction as 
an outcome measure for rheumatoid arthritis? 
Rheumatology (Oxford) 2010;49:1429–35.
 21. Lassere M. Pooled metaanalysis of radiographic 
progression: comparison of Sharp and Larsen 
methods. J Rheumatol 2000;27:269–75.
111
5
IL15 and radiographic progression
 22. Lebrec JJ, Stijnen T, van Houwelingen HC. 
Dealing with heterogeneity between cohorts 
in genomewide SNP association studies. Stat 
Appl Genet Mol Biol 2010;9:Article 8.
 23. Benjamini Y, Hochberg Y. Controlling the 
false discovery rate: a practical and powerful 
approach to multiple testing. J R Stat Soc B 
1995;57:289–300.
 24. Gabriel SB, Schaffner SF, Nguyen H, et al. The 
structure of haplotype blocks in the human 
genome. Science 2002;296:2225–9.
 25. Pincus T, Larsen A, Brooks RH, et al. Comparison 
of 3 quantitative measures of hand radiographs 
in patients with rheumatoid arthritis: Stein-
brocker stage, Kaye modified Sharp score, and 
Larsen score. J Rheumatol 1997;24:2106–12.
 26. Waldmann TA, Tagaya Y. The multifaceted 
regulation of interleukin-15 expression and the 
role of this cytokine in NK cell differentiation 
and host response to intracellular pathogens. 
Annu Rev Immunol 1999;17:19–49.
 27. Fehniger TA, Caligiuri MA. Interleukin 15: biol-
ogy and relevance to human disease. Blood 
2001;97:14–32.

Association of Genetic variants 
in the IL4 and IL4R Genes with 
the severity of joint Damage in 
Rheumatoid Arthritis: A study in 
seven Cohorts 
A. Krabben, A. G. Wilson, D. P. C. de Rooy, A. Zhernakova, 
E. Brouwer, E. Lindqvist, T. Saxne, G. Stoeken, J. A. B. van Nies, 
R. Knevel, T. W. J. Huizinga, R. E. M. Toes, P. K. Gregersen, 
A. H. M. van der Helm-van Mil





The progression of joint destruction in rheumatoid arthritis (RA) is determined by genetic 
factors. Changes in IL4 and IL4R genes have been associated with RA severity, but this 
finding has not been replicated. This study was undertaken to investigate the association 
between IL4- and IL4R-tagging single-nucleotide polymorphisms (SNPs) and the progres-
sion rate of joint damage in RA in a multi-cohort candidate gene study.
methods
IL4- and IL4R-tagging SNPs (n = 8 and 39, respectively) were genotyped in 600 RA patients 
for whom 2,846 sets of radiographs of the hands and feet were obtained during 7 years of 
follow-up. Subsequently, SNPs significantly associated with the progression of joint dam-
age were genotyped and studied in relation to 3,415 radiographs of 1,953 RA patients; 
these included data sets from Groningen (The Netherlands), Lund (Sweden), Sheffield (UK), 
the North American Rheumatoid Arthritis Consortium (US), Wichita (US), and the National 
Data Bank (US). The relative increase in progression rate per year in the presence of a 
genotype was determined in each cohort. An inverse variance weighting meta-analysis was 
performed on the 6 data sets that together formed the replication phase.
Results
In the discovery phase, none of the IL4 SNPs and 7 of the IL4R SNPs were significantly 
associated with the joint damage progression rate. In the replication phase, 2 SNPs in the 
IL4R gene were significantly associated with the joint damage progression rate (rs1805011 
[P = 0.02] and rs1119132 [P = 0.001]).
Conclusion
Genetic variants in IL4R were identified, and their association with the progression rate of 
joint damage in RA was independently replicated.
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intRoDUCtion
In the last decade it has been recognized that rheumatoid arthritis (RA) needs to be diag-
nosed early and treated promptly with disease-modifying anti-rheumatic drugs (DMARDs) 
in order to successfully interfere with the disease process and the progression to joint 
damage and disability. The progression of joint destruction is highly variable; only a minor-
ity of patients develop rapidly progressive disease. To achieve individualized treatment, the 
severity of the disease outcome needs to be estimated adequately. Ideally, the biologic 
processes underlying the interindividual differences should be understood. Clinical and 
serologic risk factors explain only about one-third of the total variance in joint destruction.1 
Genetic variants are estimated to make a major contribution, consisting of 50–60% of the 
total phenotypic variation.2 Further studies of individual risk factors are needed to increase 
understanding of the processes underlying the progression of joint destruction in RA.
We performed a candidate gene study of the association of IL4 and IL4R with the rate of 
joint destruction in RA. It has been hypothesized that there is an imbalance between Th1 
cells and Th2 cells in RA, with different levels of tumor necrosis factor, interleukin-1 (IL-1), 
IL-6, IL-4, and IL-13.3 IL-4 mainly promotes differentiation of T cells toward Th2 cells.4 The 
role of IL-4 is underscored by observations that the concentration of IL-4 is increased in 
early arthritis but decreased or absent in synovial fluid from patients with established RA.4,5 
Furthermore, in fibroblast-like synoviocytes, IL-4 was shown to suppress RANKL expression 
and increase osteoprotegerin expression, and IL-4–knockout mice are characterized by 
extensive joint destruction,6 suggesting that IL-4 not only has anti-inflammatory effects, 
but also has antiosteoclastogenic effects. The effect of IL-4 is mainly mediated by the IL-4 
receptor α chain (IL-4Rα).
Several genetic studies of the association of susceptibility to, and the severity of, RA with 
IL4 and IL4R genes have already been performed. The IL4 variable-number tandem repeat 
(VNTR) in the third intron was reported to be associated with lower radiographic damage.7 
Prots et al reported an association between IL4R I50V (rs1805010) and the presence of 
bone erosions in patients with a disease duration of >2 years.8 Marinou et al, however, 
found no association of the I50V variant with joint destruction.9 Furthermore, the IL4R 
Q551R variant (rs1801275) has been studied and found not to be associated with suscep-
tibility to or the severity of RA, but to be associated with the presence of RA nodules.7-10
Because of the proposed role of IL4 and its receptor genes and the observation that the 
progression of joint damage is in part heritable, we performed a candidate gene study. 
The genetic variants tagging IL4 and IL4R were determined in 600 patients for whom 
2,846 radiographs were available. Furthermore, 3,415 radiographs of 1,953 patients in 6 




Seven data sets consisting of adult patients diagnosed as having RA according to the 
American College of Rheumatology 1987 criteria11 were studied (Table 1). Informed 
consent was obtained from all patients, and approval was obtained from the local ethics 
committees.
Discovery phase cohort
Six hundred patients with early RA who were included in the Leiden Early Arthritis Clinic 
(EAC) from 1993 to 2006 were studied. Radiographs of the hands and feet were obtained 
at baseline and at yearly follow-up visits for 7 years.1 A total of 2,846 sets of radiographs of 
the hands and feet were available. All radiographs were scored by one experienced reader 
using the modified Sharp/van der Heijde scoring method (SHS).12 The intra class correlation 
coefficient (ICC) was 0.91. The treatment received by these patients differed according to 
3 treatment periods, as previously described.1
Replication phase cohorts
Six data sets were studied (Table 1).1,13-16 These included 280 patients with 872 radiographs 
from Groningen, The Netherlands,1 391 patients with 391 radiographs from Sheffield, 
UK,1,15 147 patients with 781 radiographs from Lund, Sweden,1,13 385 patients with 385 
radiographs from the North American Rheumatoid Arthritis Consortium (NARAC) (14), 101 
patients with 337 radiographs from Wichita, and 649 patients with 649 radiographs from 
the National Data Bank (NDB; US).16
single-nucleotide polymorphism (snP) selection
IL4 and IL4R were captured by haploblocks, using the Haploview algorithm, covering the 
whole gene and 3 kb upstream and downstream of the coding region. Pairwise tagging 
SNPs were selected from the Utah residents with ancestry from northern and western 
Europe (CEPH/CEU) HapMap data set (phase II, release 23a/March 2008) using Haploview 
software (minor allele frequency [MAF] >0.05, pairwise r2 >0.8). There were no known 
amino acid–changing SNPs in IL4 with an MAF of 2:5%. In total, 8 SNPs in IL4 were tagged 
with Haploview, without forcing any SNPs.
In IL4R, there were 7 known amino acid–changing SNPs. Forty-three SNPs tagged the 
IL4R gene region, with forcing these 7 SNPs. Four SNPs located on IL4R failed typing and, 
therefore, 39 IL4R SNPs were successfully tested. The final SNP selection and linkage dis-
equilibrium information are available from the corresponding author upon request.
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In all cohorts, DNA was extracted from whole blood using standard methods. In the discovery 
cohort, genotyping was performed using multiplex SNP arrays designed using an Illumina 
GoldenGate platform, according to the protocols recommended by the manufacturer. In 
the cohorts from Groningen, Lund, and Sheffield, SNPs were typed by multiplex SNP arrays 
designed with a Sequenom iPlex system, according to the protocols recommended by the 
manufacturer. In the NARAC, genome-wide SNP typing was performed using Infinium 
HumanHap550, version 1.0 (Illumina). In the Wichita and NDB cohorts, SNPs were typed 
with an Immunochip, Illumina Infinium High-Density array (Illumina iScan Platform), which 
was recently designed to densely genotype immune-mediated disease loci identified by 
genome-wide association studies of common variants using data. The SNPs identified in 
the discovery phase were retrieved from the genetic databases of the NARAC, Wichita, and 
NDB cohorts. Four of the SNPs identified were not available in the genetic databases for 
the Wichita and NDB cohorts.
statistical analysis
In all data sets, 1 was added to all radiologic scores and then the scores were log-trans-
formed to obtain a normal distribution. Two phases were carried out. First, an explorative 
analysis was performed in the Leiden EAC cohort, testing the tagged SNPs both additively 
and recessively. A multivariate normal regression model for longitudinal data was used 
with repeated radiologic score as a response variable. This model makes use of repeated 
radiologic measurements by taking advantage of within-patient correlation, yielding more 
precise estimates of the progression rates and therefore increasing the power to detect dif-
ferences. This model uses a covariance matrix, allowing the inclusion of patients who had 
missing radiographs at some point during follow-up. The model fit was tested by residual 
analyses.1,17 Adjustment variables were entered based on their single variable association 
with joint destruction. Adjustments were made for age, sex, and the treatment periods 
described previously.1
In the second, replication, phase only the model (recessive or additive) that fit best 
in the discovery phase was tested. Each of the individual replication cohorts had fewer 
radiographs and hence less power than the discovery cohort. Because of differences in 
study designs, the data from the separate replication cohorts could not be combined into 
one analysis directly. Therefore, we decided to test the SNPs in each data set separately, 
taking advantage of the specific data set characteristics, and to subsequently perform a 
meta-analysis. Since the beta values obtained from the analyses of the different cohorts 
all reflected the relative increase in radiologic progression rate per year in patients with a 
certain genotype compared to patients with the common genotype, the estimates could 
be pooled in a meta-analysis.
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In the Groningen, Lund, and Wichita cohorts, multiple radiographs per individual were 
available, and a multivariate normal regression analysis was used, which was similar to 
the analysis applied in the Leiden EAC cohort. Adjustment variables were entered based 
on their single variable association with joint destruction. The Groningen data set was 
adjusted for age and inclusion before or after 1990, as a proxy for DMARD therapy. The 
analysis of the Lund cohort was adjusted for age only, since sex and treatment were not 
associated with joint destruction in this data set. The analysis of the Wichita cohort was 
adjusted for age and sex.
In the Sheffield, NARAC, and NDB data sets, radiographs were obtained from each 
patient at one time point. To derive estimates of the radiologic progression, the estimated 
yearly progression rate was calculated by dividing the total SHS by the number of years 
of disease duration at the time the radiograph was obtained. Also in this analysis, 1 was 
added to the estimated yearly progression rate data before log-transformation. Subse-
quently, the SNP association was tested in a linear regression analysis with log-transformed 
estimated yearly progression rate as the outcome variable. The resulting estimate reflected 
how many fold the rate of joint destruction increases per year in patients with a certain 
genotype compared to patients with the common genotype. No adjustments were applied 
to the analysis of the Sheffield and NARAC data sets, since none of the variables tested 
were significantly associated with joint destruction. Analyses of the NDB data set were 
adjusted for age and sex. SPSS version 17.0 was used.
Since all of the beta values obtained reflected the relative increase in radiologic progres-
sion rate (a relative measure without units), the beta values and standard errors could be 
combined in a fixed-effects meta-analysis with inverse variance weighting.18 The standard 
errors differed between the data sets because the number of radiographs per patient dif-
fered between the cohorts, resulting in more precise estimates of the relative progression 
rates and smaller standard errors in data sets with serial measurements. The meta-analysis 
was performed in Stata, version 10.1.
Multiple testing increases the possibility of incorrectly rejecting the null hypothesis to 
>5%. Therefore, Bonferroni correction for multiple testing was applied in phase 2.
Haplotype analysis
Haplotypes of IL4R were studied. Haplotype blocks were defined using the model described 
by Gabriel et al.19 Haplotypes were assigned to each individual using Plink version 1.07. 
Analyses of the haplotypes were performed with methods similar to those used for the 




A complete overview of the results of all SNPs studied in the discovery phase is avail-
able from the corresponding author upon request. None of the 8 SNPs tagging IL4 were 
significantly associated with the progression of joint destruction in the Leiden EAC cohort.
Analysis of the 39 SNPs in the IL4R gene region revealed 7 SNPs that were significantly 
associated with the progression of joint destruction (Table 2). For 4 SNPs, the recessive 
analysis showed the strongest association (rs4787423 [P = 0.03], rs7191188 [P < 0.01], 
rs6498016 [P = 0.01], and rs1119132 [P = 0.04]), and for 3 SNPs, the additive analysis 
showed the strongest association (rs1805011 [P = 0.01], rs1805015 [P = 0.04], and 
table 2 Results of the SNPs in IL-4R with a significant association with the radiological progression rate 
in the discovery phase.
Discovery phase Replication phase 
(meta-analysis)




 β  95%Ci P no. 
cohorts
P
rs4787423 27274835 0.14 ADD 0.99 0.96 1.01 0.35
REC 0.90 0.83 0.99 0.03 4 0.81
rs1805011 27281373 0.11 ADD 0.96 0.93 0.99 0.01 4 0.02
REC 0.93 0.81 1.07 0.34
rs1805015 27281681 0.16 ADD 0.98 0.95 1.00 0.04 4 0.08
REC 0.99 0.91 1.07 0.76
rs1801275 27281901 0.20 ADD 0.97 0.95 0.99 0.01 4 0.21
REC 0.99 0.93 1.05 0.67
rs7191188 27296912 0.25 ADD 1.02 1.01 1.04 0.01
REC 1.10 1.05 1.15 <0.01 6 0.83
rs6498016 27299289 0.21 ADD 1.01 1.00 1.03 0.16
REC 1.08 1.02 1.14 0.01 6 0.88
rs1119132 27310970 0.13 ADD 1.02 1.00 1.04 0.15
REC 1.09 1.00 1.18 0.04 6 0.001
The β indicates the fold difference in progression rate in the presence of the risk allele or risk genotype. 
The β from the additive model indicates the fold difference in progression rate for each additive minor 
allele present. The β from the recessive model indicates the fold difference in progression rate in patients 
homozygous for the minor allele versus the other patients. For instance patients carrying one minor al-
lele of rs1805011 had a 0.96-fold higher rate of joint destruction compared to patients without a minor 
allele. This corresponds with a 24% (0.961^7=0.76) lower rate of joint destruction over 7 years.
In the replication phase, analyses were only performed for the model with the highest significance level 
in the discovery phase. rs4787423, rs1805011, rs1805015 and rs1801275 were not available in the 
genetic database of Wichita and NDB. An inverse weighted meta-analysis was performed on 4 or 6 
independent cohorts. In the NARAC, Wichita and NDB cohort a proxy SNP for rs1119132 was analyzed; 
rs1859308 (r2=0.92). In the NARAC cohort a proxy for rs4787423 was analyzed; rs3024660 (r2=1).
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rs1801275 [P = 0.01]) (Table 2). In this exploratory phase, no corrections for multiple test-
ing were made, and these 7 variants were studied in the second phase.
Replication phase
A total of 1,953 patients and 3,415 scored radiographs were evaluated. The SNPs 
rs7191188, rs6498016, and rs1119132 were studied in all 6 cohorts (Groningen, Lund, 
Sheffield, NARAC, Wichita, and NDB). For rs1805011, rs4787423, rs1805015, and 
rs1801275, no genotyping data were available for the Wichita and NDB cohorts; hence, 
these SNPs were studied in 4 cohorts (Groningen, Lund, Sheffield, and NARAC). In addition, 
proxy SNPs were analyzed for 2 SNPs in some cohorts. In the NARAC, Wichita, and NDB 
cohorts, a proxy SNP for rs1119132 was analyzed: rs1859308 (r2 = 0.92). In the NARAC 
cohort, a proxy SNP for rs4787423 was analyzed: rs3024660 (r2 = 1). Since all replication 
cohorts had fewer available radiographs than the discovery cohort, the power to find 
significant differences in each of these cohorts was limited, and data were combined in a 
meta-analysis. The analyses were performed by testing either a recessive or an additive as-
sociation, depending on the results obtained in the discovery phase. Of the 7 SNPs studied 
in this phase, 2 were significantly associated with joint progression. These were rs1805011 
(P = 0.02) and rs1119132 (P = 0.001) (Table 2 and Figure 1). These SNPs are in low linkage 
disequilibrium (r2 = 0.01). In a conditional analysis including both SNPs, both remained 
significant (rs1805011 [P = 0.006] and rs1119132 [P = 0.041]), indicating that their effect 
is likely to be independent. After Bonferroni correction for multiple testing for 7 SNPs in 
the replication phase, rs1119132 remained significantly associated with the progression of 
joint damage (Pcorrected = 0.007).
Findings of haplotype analysis
To attempt to further elucidate the associations found, a haplotype analysis was performed 
using the data for the IL4R gene in the Leiden EAC cohort. This resulted in 9 haplotype 
blocks with a minor haplotype frequency of >0.01 (results available from the correspond-
ing author upon request). All haplotypes with a prevalence of >0.1 were tested for an 
association with joint destruction in the EAC cohort. Because of this cutoff, no haplotypes 
that included rs119132 were evaluated. Two haplotypes of one haplotype block showed 
a better association than the independent SNPs (AAA and CGG, consisting of the follow-
ing SNPs: rs1805011, rs1805015, and rs1801275, respectively). These haplotypes were 
analyzed in the replication phase, and no association with the progression of joint damage 
was observed.
Finally, rs1119132 and rs1805011 were studied in anti–citrullinated protein antibody 
(ACPA)–positive and ACPA-negative patients separately. This yielded comparable effect 
sizes in both subgroups (data not shown).
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DisCUssion
The severity of RA is reflected by the severity of radiologic joint destruction. It is highly 
variable between patients, and part of this variance is explained by genetic factors. Several 
studies of IL-4 at the protein level have suggested that this interleukin is relevant in RA.3-6 In 
addition, several genetic studies of IL4 and IL4R and joint damage have been performed,7-10 
though none of the factors identified have been replicated. This prompted us to perform 
the present multi-cohort candidate gene study. We observed that patients carrying 2 minor 
alleles of rs1119132 in IL4R had more severe joint damage progression. Although a minor-
ity of RA patients may have this genetic variant, individual independent replication was 
found in some of the replication cohorts as well as in the meta-analysis of the 6 replication 
cohorts.
In addition to the results for rs1119132, another SNP in IL4R, rs1805011, showed an 
association with joint destruction. In a conditional analysis including both SNPs, both re-
mained significantly associated with the progression of joint damage. These SNPs were in 
low linkage disequilibrium. Since, after applying the conservative Bonferroni correction for 
rs1805011


































































Figure 1 Results of rs1805011 and rs1119132 in the discovery phase (A) and replication phase (B).
A. Presented are the median Sharp van der Heijde scores (SHS) over 7-years of follow-up, per genotype 
in RA-patients of the EAC. The ‘bump’ in the line at year five is caused by missing radiographs of part of 
the patients with rs1119132 genotype AA.
B. Presented is an inverse variance weighted meta-analysis in four cohorts (rs1805011) and six co-
horts (rs1119132). In the NARAC, Wichita and NDB cohort a proxy SNP for rs1119132 was analyzed; 
rs1859308 (r2=0.92). Genotyping data of rs1805011 were not available for the Wichita and NDB cohort.
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multiple testing only rs1119132 remained significant, we did not draw a definite conclu-
sion regarding rs1805011.
SNP I50V (rs1805010) in IL4R was previously found to be associated with joint destruc-
tion in RA.8 Despite studies of the potential functional relevance of this SNP,8,20 the associa-
tion of this variant with joint damage was not observed in the study by Marinou et al9 or 
in our study. Another coding variant on IL4R, Q551R (rs1801275), was not associated with 
joint destruction in prior studies.7-10 In the present study, IL4R Q551R was significantly as-
sociated with joint destruction in the discovery cohort (P = 0.01) but not in the replication 
phase (P = 0.21).
Despite previous in vitro studies and mouse studies showing that IL-4 plays a role in 
suppressing arthritis severity, in the present study no association between SNPs in IL4 and 
joint destruction were observed. An association between IL4 VNTR has been reported 
previously.7 This variant was not included in our study.
We used the classic candidate gene approach, including immune response factors that 
had previously been shown to be involved in RA pathogenesis. This method has a larger 
a priori chance of finding a true association between SNPs and disease severity. However, 
this approach may also result in false-positive or false-negative findings. We studied 6 
replication cohorts in order to reduce the chance of false-positive findings.
In conclusion, we identified and replicated a genetic variant in IL4R predisposing to 
joint damage progression in RA. Further studies of IL-4R at the protein level are needed to 
increase insight on the role of this variant in the pathogenesis of RA progression.
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sUPPlementARy methoDs
Brief description of replication cohorts
Groningen 280 RA-patients from the Northern part of The Netherlands, diagnosed be-
tween 1945 and 2001 were studied. Over a follow-up duration of at most 14 years the 
mean number of X-ray sets (hands and feet) per patient was 3.1 (with a maximum of eight 
X-rays per patient). The total number of sets of X-rays was 872. The X-rays were scored by 
one of two readers using SHS. ICCs within readers were >0.90 and between readers 0.96. 
Patients included in the 90’s were treated with DMARD therapy in contrast to patients 
included before the 1990.
Lund 147 early RA-patients from Sweden, recruited from primary care units in the area of 
Lund during the years 1985-1990 were studied. They were prospectively followed yearly 
during 5 years. In total 781 sets of X-rays were available and scored according to Larsen 
by one of two readers. The ICC between the readers was 0.94. In the inclusion period, im-
mediate DMARD therapy was not common and only half of the patients used any DMARD 
at 5 years follow-up.
Sheffield 391 RA-patients from the area of Sheffield (UK) recruited between 1999 and 
2006 were evaluated. RA-patients were assessed once during their disease course. The 
mean (±SD) disease duration at assessment was 15±11 years (range 3-65 years). X-rays 
of hands and feet were scored by one reader using a modification to Larsen’s score. The 
intra-observer variation by a weighted kappa score was 0.83.
NARAC 385 ACPA-positive RA-patients from the North American Rheumatoid Arthritis 
Consortium who were radiographed between 1953 and 2002, with cross-sectional 
radiological measurements of hands, were studied. The mean (±sd) disease duration at 
assessment was 14±11 years. The radiographs were scored according to SHS by a single 
reader, with an ICC of 0.99.
Wichita 101 patients from one practice in Wichita (Kansas, USA), recruited between 1963 
and 1999 were studied. Patients were followed for a maximum of 15 years. Radiographic 
data were obtained when needed for clinical care. In total, 337 sets of hands X-rays were 
available. All X-rays were scored with SHS by one reader, the within reader ICC was 0.99.
NDB 649 patients included in the National Databank for Rheumatic diseases between 1972 
and 1999, a databank that consists of patients with rheumatic diseases from the USA and 
Canada, were studied. A single time-point X-ray of the hands was available over a follow-
up duration of at most 25 years with a mean (±sd) of 12±6 years. All X-rays were scored 
according to the SHS by the same reader who scored the Wichita X-rays.
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supplementary Figure 1 Residual analyses of the model used in the discovery cohort, including all 
covariates and rs1119132.
These graphs demonstrate the normal distribution of the residuals and that there is no correlation be-
tween genotype and residuals, meaning that the model fits the data.
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supplementary Figure 2 LD structure between the 43 SNPs in IL4-R in the Leiden-EAC
Presented are the nine haploblocks composed of 43 SNPs in the IL-4R gene and with a minor haplotype 
frequency (MHF) > 0.01. All haplotypes with a prevalence >0.1 were tested with joint destruction. Two 
haplotypes (AAA and CGG; rs1805011, rs1805015 and rs1801275, respectively) of one haploblock 
(depicted as block 5) showed a better association with joint destruction then the independent SNPs. 
Analysis of the additional presence of the haplotype in the discovery cohort, resulted in the following 
results for AAA β=1.02, 95%CI=1.00-1.05, p=0.02 and for CGG β=0.97, 95%CI=0.94-1.00 p=0.02. 
AAA and CGG had a frequency of 0.80 and 0.11 in the EAC (discovery cohort).
The frequencies of the AAA and CGG haplotypes were similar in the four additional datasets (frequency 
0.75-0.79 and 0.10-0.15). Meta-analysis of the haplotypes of all datasets resulted in not significant re-
sults. For additive testing of the haplotypes it resulted in p=0.31 for AAA and p=0.64 for CGG.
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supplementary table 1 Overview of the results of all SNPs studied in the discovery phase
gene rs number coordinate model p
IL-4R rs3024530 27258188 ADD n.s.
REC n.s.
rs4787426 27292232 ADD n.s.
REC n.s.
rs1805011 27281373 ADD 0.006
REC 0.335
rs11074852 27208097 ADD n.s.
REC n.s.
rs4547335 27204191 ADD n.s.
REC n.s.
rs1805010 27263704 ADD n.s.
REC n.s.
rs7205704 27308394 ADD n.s.
REC n.s.
rs10852316 27306056 ADD n.s.
REC n.s.
rs1029489 27283718 ADD n.s.
REC n.s.
rs4787423 27274835 ADD 0.354
REC 0.028
rs1801275 27281901 ADD 0.011
REC 0.672
rs1805015 27281681 ADD 0.037
REC 0.764
rs4787956 27285750 ADD n.s.
REC n.s.
rs3024560 27264168 ADD n.s.
REC n.s.
rs2040788 27300443 ADD n.s.
REC n.s.
rs9944340 27301092 ADD n.s.
REC n.s.
rs1805012 27281465 ADD n.s.
REC n.s.
rs1119132 27310970 ADD 0.147
REC 0.038
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supplementary table 1 Overview of the results of all SNPs studied in the discovery phase (continued)
gene rs number coordinate model p
rs6498016 27299289 ADD 0.164
REC 0.006
rs12102586 27285554 ADD n.s.
REC n.s.
rs11648218 27317583 ADD n.s.
REC n.s.
rs16976728 27289213 ADD n.s.
REC n.s.
rs8044444 27236044 ADD n.s.
REC n.s.
rs2234895 27265428 ADD n.s.
REC n.s.
rs8050048 27208885 ADD n.s.
REC n.s.
rs8052962 27234343 ADD n.s.
REC n.s.
rs4787427 27293895 ADD n.s.
REC n.s.
rs2074570 27282658 ADD n.s.
REC n.s.
rs4787948 27248560 ADD n.s.
REC n.s.
rs3024622 27272954 ADD n.s.
REC n.s.
rs7204874 27210788 ADD n.s.
REC n.s.
rs1049631 27283043 ADD n.s.
REC n.s.
rs2239347 27266522 ADD n.s.
REC n.s.
rs6498015 27299125 ADD n.s.
REC n.s.
rs3024613 27271754 ADD n.s.
REC n.s.
rs4238954 27221612 ADD n.s.
REC n.s.
rs4787947 27226266 ADD n.s.
REC n.s.
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supplementary table 1 Overview of the results of all SNPs studied in the discovery phase (continued)
gene rs number coordinate model p
rs8056488 27210230 ADD n.s.
REC n.s.
IL-4 rs2243248 132036543 ADD n.s.
REC n.s.
rs6864565 132075870 ADD n.s.
REC n.s.
rs2243263 132041198 ADD n.s.
REC n.s.
rs17691077 132071250 ADD n.s.
REC n.s.
rs3756752 132101772 ADD n.s.
REC n.s.
rs6883504 132061021 ADD n.s.
REC n.s.
rs17623617 132060397 ADD n.s.
REC n.s.
rs1080001 132077015 ADD n.s.
REC n.s.
*p value >0.05 was assumed not significant (n.s.). ADD = additive model and REC= recessive model.
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Genetic factors account for an estimated 45–58% of the variance in joint destruction in 
rheumatoid arthritis (RA). The serine proteinase granzyme B induces target cell apoptosis, 
and several in vitro studies suggest that granzyme B is involved in apoptosis of chon-
drocytes. Serum levels of granzyme B are increased in RA and are also associated with 
radiographic erosions. The aim of this study was to investigate GZMB as a candidate gene 
accounting for the severity of joint destruction in RA.
methods
A total of 1,418 patients with 4,885 radiograph sets of the hands and feet from 4 indepen-
dent cohorts were studied. First, explorative analyses were performed in 600 RA patients 
in the Leiden Early Arthritis Clinic cohort. Fifteen single-nucleotide poly-morphisms (SNPs) 
tagging GZMB were tested. Significantly associated SNPs were genotyped in data sets 
representing patients from the Groningen, Sheffield, and Lund cohorts. In each data set, 
the relative increase in the annual rate of progression in the presence of a genotype was 
assessed. Data were summarized in a meta-analysis. The association of GZMB with the 
RNA expression level of the GZMB genomic region was tested by mapping expression 
quantitative trait loci (QTLs) on 1,469 whole blood samples.
Results
SNP rs8192916 was significantly associated with the rate of joint destruction in the first 
cohort and in the meta-analysis of all data sets. Patients homozygous for the minor allele 
of rs8192916 had a higher rate of joint destruction per year compared with other patients 
(P 7.8 x 10-4). Expression QTL of GZMB identified higher expression in the presence of the 
minor allele of rs8192916 (P 2.27 x 10-5).
Conclusion
SNP rs8192916 located in GZMB is associated with the progression of joint destruction in 
RA as well as with RNA expression in whole blood.
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intRoDUCtion
Rheumatoid arthritis (RA) is an autoimmune disorder that affects 0.5–1% of the popula-
tion and is associated with significant morbidity, disability, and cost to society. Radiographic 
joint destruction reflects the cumulative burden of inflammation and is considered to be an 
objective measure of the severity of RA1. The degree of joint destruction varies significantly 
between patients. The processes behind this difference are incompletely understood. In-
flammatory markers and auto-antibodies are potent risk factors for joint destruction but 
explain ~30% of the variance in joint destruction2. Results of a twin study suggested 
that genetic factors influence the severity of joint destruction in RA, and a recent study 
in the Icelandic RA population estimated the heritability rate of joint destruction to be 
~45–58%.3,4 Hence, to increase understanding of the processes mediating joint destruc-
tion, it would be beneficial to study genetic variants that could predispose to a severe 
outcome of RA.
Here, we describe a candidate gene study of the association of GZMB with the rate of 
joint destruction. Granzyme B is a serine protease found in the lytic granules of natural 
killer (NK) cells and cytotoxic T lymphocytes. When granzyme B is secreted into the in-
terspace between the NK cell and the target cell, it triggers cell death by apoptosis.5,6 In 
vitro studies have shown that granzyme B has enzymatic activity for the cleavage of ag-
grecan proteoglycans from cultured cartilage matrix and whole cartilage explants;7,8 loss of 
cartilage proteoglycans is an early event in the course of destructive arthritis.9 In addition, 
studies of cartilaginous tissue demonstrated the presence of many granzyme B–positive 
cells among the chondrocytes in the pannus lesion.8 Furthermore, the levels of granzyme 
B were shown to be increased in the synovial fluid of patients with RA compared with 
that of healthy control subjects,10 and increased serum levels were associated with early 
development of radiographic erosions.11 Finally, a genetic variant (rs854350) in GZMB is 
reported to associate with susceptibility to RA.12
These data led us to hypothesize that genetic variants in GZMB are associated with the 
severity of joint destruction in RA. We tested this hypothesis using 4 data sets comprising 
data for European RA patients for whom longitudinal radiography data on joint destruc-
tion were available. All data sets included patients in whom the diagnosis was made during 
a period when treatment strategies were less aggressive and less controlled than they 
are currently. These conservative treatment strategies made the data sets suitable for the 
present study, because the natural disease course was less inhibited. To further investigate 
the findings, the single-nucleotide polymorphisms (SNPs) associated with progression of 




Four data sets comprising data for adult European patients with RA were studied. RA was 
defined according to the 1987 American College of Rheumatology criteria13 in all data 
sets except the Lund data set, for which the 1958 criteria for RA14 were used. Radiographs 
of both the hands and feet were available for all patients (Table 1). All patients provided 
informed consent, and approval was obtained from the local ethics committee for each 
study.
Leiden Early Arthritis Clinic (EAC) cohort
This data set represented 600 patients with early RA from the western part of The Nether-
lands, who were included in the Leiden EAC between 1993 and 2006.2 Patients were in-
cluded at the time of diagnosis and were followed up annually. Radiographs were obtained 
at baseline and at yearly follow-up visits for 7 years. A total of 2,846 sets of radiographs 
of the hands and feet were available. All radiographs were chronologically scored by one 
experienced reader who was unaware of the genetic or clinical data, using the Sharp/van 
der Heijde (SHS) scoring method for the hands and feet.15 A total of 499 randomly selected 
radiographs were scored twice. The within-reader intra class correlation coefficient (ICC) 
was 0.91. Treatment of the patients could be divided into 3 time periods. Patients included 
in 1993–1995 were initially treated with non-steroidal anti-inflammatory drugs, patients 
included in 1996–1998 were initially treated with chloroquine or sulfasalazine, and patients 
included after 1999 were promptly treated with methotrexate or sulfasalazine.
table 1: Characteristics for each dataset.
Cohort
leiden-eAC Groningen sheffield lund
(n=600) (n=275) (n=396) (n=147)
year of diagnosis 1993-2006 1945-2001 1938-2003 1985-1990
Follow-up years* 7 years 14 years Not applicable* 5 years
total no. of X-ray sets 2,846 862 396 781
method of scoring SHS SHS Larsen Larsen
Female n (%) 412 (69) 194 (71) 290 (73) 98 (67)
Age at diagnosis, mean ± sD 56 ± 16 49 ± 13 46 ± 13 51 ± 12
Anti-CCP+ n (%) 323 (55) 160 (80) 302 (79) 114 (80)
SHS= Sharp-van der Heijde score
*Data of Leiden-EAC, Groningen and Lund were from baseline onwards during respectively 7, 14 and 
5 years of follow-up. The data of Sheffield were collected once during the disease period, the mean 
disease duration was 15 years (range 3-65 years).
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Groningen cohort
The second set of data represented 275 RA patients from the northern part of The Neth-
erlands, in whom RA was diagnosed between 1945 and 2001. The duration of follow-up 
after diagnosis was limited to 14 years. The mean number of radiograph sets (hands and 
feet) per patient was 3.1 (maximum of 8 radiographs per patient). The total number of 
radiograph sets was 862. The radiographs were scored chronologically by 1 of 2 readers, 
using the SHS method. The ICC within readers was >0.90 and between readers was 0.96. 
In this data set, patients in whom RA was diagnosed before 1990 had, on average, a more 
progressive course of joint destruction compared with patients in whom RA was diagnosed 
after 1990. This difference in joint destruction progression is consistent with the approach 
of initiating disease-modifying anti-rheumatic drug (DMARD) treatment early, which was 
introduced in the 1990s.
Sheffield cohort
The third data set represented 396 RA patients from the Sheffield, UK area. RA patients 
for whom radiographs were available were recruited from the Rheumatology Department 
of the Royal Hallamshire Hospital in Sheffield between 1999 and 2006.16 RA patients were 
assessed once during their disease course. The mean ± SD disease duration at the time 
of the assessment was 15 ± 11 years (range 3–65 years). Radiographs of the hands and 
feet were scored by one reader using a modification of the Larsen score.17 Ten percent of 
the radiographs were scored twice to quantify intra-observer variation, using a weighted 
kappa value of 0.83.16
Lund cohort
The fourth data set represented 183 Swedish patients with early RA who were prospec-
tively followed up yearly over 5 years; radiographs and DNA were available for 147 of these 
patients.18,19 Patients were recruited from primary care units in the Lund area from 1985 
to 1989. Radiographs of the hands and feet were obtained at the start of the study and 
then annually for 5 years, resulting in a total of 781 sets of radiographs. Radiographs were 
scored chronologically by one of two readers, according to the Larsen method.20 The ICC 
between readers, as determined based on 105 radiographs, was 0.94. During the inclusion 
period, immediate DMARD therapy was not common, and only half of the patients were 
receiving any DMARD at the 5-year follow-up. The DMARDs used most commonly were 
chloroquine, D-penicillamine, sodium aurothiomalate, and auranofin.18
snP selection and genotyping
The region of GZMB plus the haplotype block upstream and downstream of the gene were 
tagged using the pairwise Tagger algorithm developed by de Bakker et al21 and imple-
mented in Haploview.22 Two SNPs (rs8192917 and rs2236338) were known to be amino 
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acid–changing SNPs. One intergenic SNP, rs854350, had a significant association with RA 
susceptibility in the data set of the Wellcome Trust Case Control Consortium.12 These 3 
SNPs were force included. Pairwise-tagging SNPs were selected from the CEPH/CEU Hap-
Map data set (phase II, release 21, NCBI build 35) using Haploview software (minor allele 
frequency [MAF] >0.05, pairwise r2 > 0.8). Sixteen SNPs captured GZMB. Multiplex SNP 
arrays were designed using an Illumina GoldenGate platform, according to the protocols 
recommended by the manufacturer. One SNP could not be designed (rs1951601), but a 
good proxy (rs12433772; r2 = 0.90) was typed instead. The final SNP selection and the 
linkage disequilibrium (LD) information are shown in Figure 1.
Software supplied by Illumina was used to automatically identify the genotypes. Each 
96-well plate consisted of one positive and one negative control. Clusters were evaluated, 
and all doubtful calls were checked. After manually evaluating the spectra of each cluster, 
the genotypes were accepted, recalled, or rejected. At least 12% of the genotypes were 
Figure 1 LD structure between of 16 tag-SNPs in GZMB.
The depicted data are from 600 Leiden RA-patients. The numbers present the r2 between the SNPs. The 
colours refer to D΄. Black arrows point out the amino acid changing SNPs, rs2236338 and rs8192917, and 
the susceptibility SNP of WTCCC, rs854350. These SNPs were forced to include. One SNP, rs1951601, 
could not be designed but a good proxy existed: rs1243372, r2=0.90. One SNP, rs8192920, was not 
analyzed because of low success rate of typing. Significant SNPs in the analyses on the Leiden dataset 
are marked by a white arrow.
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assessed in duplicate, with an error rate of <1% for all SNPs. One SNP, rs8192920, had 
a success rate of 75% and was therefore excluded from further analysis. The remaining 
SNPs were typed with a success rate of >95% (additional information is available from the 
corresponding author). None of the SNPs deviated from Hardy-Weinberg equilibrium (P < 
0.001).
The SNP that was significantly associated with joint destruction in the first cohort was 
genotyped in the other 3 cohorts. The SNP was genotyped as a part of multiplex SNP 
arrays designed with Sequenom iPLEX, according to the protocols recommended by the 
manufacturer. Software supplied by the same manufacturer was used to automatically 
identify the genotypes. Each iPLEX consisted of at least 9 positive controls and 9 negative 
controls. All doubtful calls were checked manually; DNA samples in which >30% of the 
SNPs failed were excluded from analysis (n = 31). At least 5% of the genotypes were 
assessed in duplicate, with an error rate of <1%. The success rates were all >95%. None 
of the SNPs deviated from Hardy-Weinberg equilibrium.
measuring and analyzing GZMB expression levels
The SNP that remained significant after meta-analysis was tested for its association with 
RNA expression of the genomic region of GZMB, by mapping expression quantitative trait 
locus (eQTL) on a data set representing peripheral blood samples obtained from 1,469 
unrelated individuals.23,24 RNA expression was tested using probes with a midpoint position 
<250 kb from the tested SNP, thus testing for a cis effect. Expression QTL effects were 
determined using Spearman’s rank correlation coefficient. If an association was observed, 
it was determined whether other SNPs in the region (n = 583) had a stronger cis-eQTL 
effect. If this was the case, the first analysis was repeated using linear regression with 
adjustment for the strongest associating SNP, in an effort to determine the eQTL effect of 
the assessed SNPs independently of LD with the most strongly associated SNP. Genotypes 
were imputed with HapMap2 (release 24), using Impute version 2. Only SNPs with a MAF 
>5% and a Hardy-Weinberg P value greater than 0.0001 were included for analysis. 
Correction for multiple testing was performed by controlling the false discovery rate at 
5%, permuting the gene expression labels 100 times as previously described.25 Finally, 
to prevent false-positive findings due to primer polymorphisms, SNP–probe combinations 
were excluded from the cis-eQTL analysis when the 50-bp long expression probe mapped 
to a genomic location that contained a known SNP that was showing at least some LD (r2 
> 0.1) with the cis SNP.
statistical analysis
Associations between genotypes and radiographic joint destruction were analyzed in 2 
phases. First, an explorative analysis was performed in the Leiden EAC data set. In this data 
set, the tagged SNPs were tested both additively and recessively. Because phase 1 was an 
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explorative phase, no correction for multiple testing was applied, and SNPs with a P value 
less than or equal to 0.05 were studied in phase 2. For analyses involving the Leiden EAC, 
Groningen, and Lund data sets, a multivariate normal regression model for longitudinal 
data was used, with the radiographic score as the response variable. This method is used 
to analyze all repeated measurements at once and takes advantage of the correlation 
between these measurements. This model is similar to a linear mixed-effects model, but 
no random-effects model is added.26 To model the correlation over time, a heterogeneous 
first-order autoregressive matrix was used, which assumes a stronger correlation for mea-
surements obtained over a shorter period of time compared with those obtained over a 
longer period of time. The effect of time was entered as a factor in the model, to capture 
properly the mean response profile over time.
To test for an association with the rate of joint destruction, an analysis with the SNP and 
its interaction with time (as a linear variable) in the model was conducted. Adjustment 
variables were entered based on their univariate association with joint destruction. In the 
Leiden EAC data set, adjustments were made for age, sex, and the described treatment 
periods. The Groningen data set was adjusted for age and the period before or during 
1990 and the period after 1990, as a proxy for DMARD therapy. The analysis of the Lund 
data set was adjusted for age only, because sex and treatment were not associated with 
joint destruction in this data set.
In the Sheffield data set, each patient had a set of radiographs of the hands and feet 
at one time point. To make the scores comparable with those of the other data sets, the 
estimated yearly progression rate was calculated.27 This was achieved by dividing the total 
Larsen score by the number of disease-years at the time of radiography, resulting in an 
estimation of the rate of joint destruction. Information regarding disease duration at the 
time of radiography was available for 391 patients. The SNP association was tested in a 
linear regression analysis, with the log-transformed estimated yearly progression rate as the 
outcome variable. No adjustments were applied, because none of the tested variables was 
univariately significantly associated with joint destruction. The analyses were performed 
using SPSS version 17.0. In all data sets, the radiographic scores were log-transformed to 
obtain a normal distribution. Because the analyses were performed on the log scale, the 
resulting coefficient on the original scale indicates the fold increase in joint destruction 
per year of follow-up: over a follow-up period of n years, the coefficient increases to the 
power of n.
In the present study, the power to detect genetic effects is a function of the number 
of patients and the number of measurements per patient studied. As shown previously, 
the precision of the estimate increases steadily with increasing numbers of radiographs 
per patient.28 All 3 data sets studied to verify the results obtained in phase 1 contained 
(individually and combined) fewer radiographs than the initial data set. Consequently, the 
power to replicate findings in each data set individually as well as in the 3 replication data 
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sets together could be limited due to the large number of radiographs in the discovery data 
set. Because of differences in study designs, the separate data sets could not be combined 
in one analysis directly. Therefore, the SNPs in each data set were tested separately, thereby 
taking advantage of the specific data set characteristics, and a meta-analysis of the results 
was performed subsequently to determine the association of the SNPs with the rate of 
joint destruction. Because the parameters in all data sets reflect the relative increase in 
the rate of joint destruction per year, the estimates of the individual data sets were pooled 
in a meta-analysis.29 A fixed-effects meta-analysis30 with inverse-variance weighting was 
performed using Stata version 10.1.
ResUlts
Phase 1 (snP identification)
GZMB was tagged by 16 SNPs, one of which was not analyzed because of a low typing 
success rate. From the 15 analyzed SNPs, 2 (rs8192916 and rs12433772) were significantly 
associated with joint destruction in the Leiden EAC data set (Table 2). Patients homozygous 
for the minor allele of rs8192916 had an average 1.05-fold (range 1.02–1.08- fold) in-
crease in the rate of joint destruction per year compared with the rate in the other patients 
(P = 1.2 x 10-3) (Figure 2). Because the estimated rate of progression increases by the power 
of the number of years, a coefficient of 1.05 per year resulted in a 1.41-fold increased rate 
of joint destruction over 7 years. SNP rs12433772 was highly linked to rs8192916, and 
because the effect of rs8192916 was more evident at the subsequent time points, this SNP 
was prioritized for the phase 2 analysis.




mAF Coefficient 95% Ci P
rs8192916 24174200 ADD 0.42 1.01 1.00 1.03 0.11
REC 1.05 1.02 1.08 1.2x10-3
rs12433772 24190515 ADD 0.38 1.02 1.00 1.04 0.02
REC 1.06 1.03 1.09 2.9x10-4
MAF: minor allele frequency. 95%CI: 95% confidence interval
For the tagging process NCBI build 35, dbSNP b125 was applied. To make all coordinates in the paper 
consistent (SNPs and probes) NCBI build 36 was used to report the locations.
The coefficient of the additive test represents the relative increase in joint destruction per year per minor 
allele compared to no minor alleles. The coefficient of the recessive test represents the relative increase 
in joint destruction per year for two minor alleles compared to no one or no minor alleles on the normal 
scale. A coefficient of 1.05 per year indicates 5% higher rate of joint destruction; this implies that over a 
period of 7-years a 41% (1.05^7=1.41) higher rate of joint destruction is achieved.
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Phase 2 (meta-analysis)
SNP rs8192916 was tested in a recessive model in all 3 replication data sets. As expected, 
due to insufficient power of the replication cohorts, the 95% confidence intervals (95% 
CIs) in each of the 3 cohorts separately all included 1 (Figure 3). An inverse-variance weight-
ing meta-analysis was used to analyze rs8192916 in all 1,418 patients. SNP rs8192916 
remained significant (P = 7.8 x 10-4), thereby estimating a higher rate of joint destruction 
per year in patients homozygous for the minor allele compared with the other patients 
Figure 2 Median Sharp-van der Heijde scores over 7 follow-up years of Leiden RA patients with different 
rs8192916 genotypes.
Patients homozygous for the minor allele of rs8192916 had 1.05 (1.02-1.08 P=1.2x10-3) fold rate of 
joint destruction per year than the other patients. This equals a 1.41 fold rate of joint destruction over 
a follow-up of 7 years.
Figure 3 Depicted are the results of the analyses of rs8192916 of all four cohorts and of the final meta-
analysis.
The effect sizes are the estimated relative progression rates per year for the presence of twice the minor 
allele compared to patients with only one or no minor allele.
The meta-analyses are based on a fixed effect model, which are applied to genetic studies to test wheth-
er there is statistically significant effect; generalisability of the effect is of less importance. As result of this 
choice, the effect size of the meta-analyses should be considered carefully. Consequently, this method 
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(Figure 3). This association remained significant (P = 1.2 x 10-2) after conservative correction 
(Bonferroni adjustment) for testing 16 SNPs (the number of SNPs tested in phase 1).
When the association of rs8192916 with the rate of joint destruction was stratified 
for anti–citrullinated protein antibody (ACPA) status, the association was present in both 
subgroups (effect size 1.05 [95% CI 1.02–1.08], P = 1.98 x 10-3 and effect size 1.03 [95% 
CI 0.99–1.08], P = 5.40 x 10-2 for ACPA-negative and ACPA-positive patients, respectively).
measuring and analyzing GZMB expression levels
To further substantiate the observed association of rs8192916 with joint destruction, the 
effect of rs8192916 on RNA expression was studied by cis-eQTL mapping in peripheral 
blood samples obtained from 1,469 unrelated individuals.22
SNP rs8192916 was significantly correlated with RNA expression of 4 different genes: 
GZMB, CTSG, CBLN3, and an unnamed gene with accession no. AK056368 (P = 1.38 x 10-5 
to 6.14 x 10-6) (Table 3). For all 4 genes, a SNP other than rs8192916 was more strongly 
correlated with RNA expression. To assess whether the SNP associated with joint destruc-
tion, rs8192916, had an effect on gene expression independently of the effect of the most 
strongly associated SNPs, the analyses were subsequently adjusted for the strongest SNP. 
After this correction was performed, rs8192916 was still associated with RNA expression 
of the GZMB probe (P = 0.015) (Table 3).





























Depicted information on location of probes is based on NCBI 36.3 build.
* Other SNPs in the region were stronger correlated with the RNA-expression, the strongest are sum-
marized here.
8
 The association of rs8192916 with cis-eQTL was corrected for the strongest correlated SNP*.
Rs8192916 was correlated with the RNA-expression of several probes. Four probes, covering four differ-
ent genes, were significantly correlated to rs8192916. These four correlations were further corrected for 
the SNPs* that correlated strongest with the RNA-expression.
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DisCUssion
The variance in joint destruction between patients with RA is considerable, and the 
mechanisms driving these differences are thus far scarcely understood. We performed a 
candidate gene study to investigate the association of genetic variants in GZMB with joint 
destruction. GZMB (14q11.2) was chosen as a candidate gene, because granzyme B is 
involved in inflammation, and data are emerging that granzyme B could be relevant to 
joint destruction in RA.5-8,10,11 We tested the association of SNPs tagging GZMB with the 
rate of joint destruction in one data set and subsequently tested the significant SNP in 
3 other data sets. Next, a meta-analysis combining the radiographic data of all 1,418 
patients was performed. One SNP, rs8192916 (situated 9 kb upstream of GZMB), was 
observed to associate significantly with progression of joint destruction. The minor allele 
of rs8192916 was associated with a higher rate of joint destruction. We further observed 
that carrying this minor allele of rs8192916 was correlated with higher RNA expression 
of GZMB in whole blood. The present study uniquely combines 4 data sets representing 
patients with a similar European ethnicity who were treated in the prebiologic agent era. 
Hence, the radiographic progression rate of the patients studied here are more reflective 
of the natural course of RA compared with that of recently treated patients. In some data 
sets, patients were included over a wide time span; as treatment strategies changed over 
time, these patients received different treatments. Because different treatment regimens 
are associated with our outcome of interest (joint destruction), the analyses were adjusted 
for treatment, when relevant. Further studies on different patient populations as well as 
those treated with biologic agents would be informative.
Replication data sets are ideally larger than the initial data set; because the effect sizes in 
the discovery data set are likely to be upwardly biased, a smaller effect size is expected at 
a replication stage. Unfortunately, relatively few large prospective data sets exist in which 
both radiographs and DNA are available for conventionally treated patients. The number 
of patients and the number of radiographs in each data set separately were insufficient 
to allow well-powered analyses. Also, the replication data sets combined contained fewer 
radiographic measurements than were included in phase 1. Consequently, the data avail-
able for the phase 2 analysis were expected to be underpowered to replicate findings indi-
vidually. Therefore, data were summarized in an inverse-variance weighting meta-analysis, 
which showed a significant result for rs8192916.
To further substantiate the findings for GZMB, RNA expression was studied and revealed 
a strong signal for rs8192916. To confirm that this correlation was not driven by a linked 
SNP, we sought to identify other SNPs in the region that also associate with RNA expres-
sion. SNP rs2236337 had the strongest correlation with GZMB expression. However, LD 
between rs2236337 and rs8192916 was low (r2 = 0.08). Moreover, the fact that after 
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correction for this SNP, rs8192916 remained significant suggests that the correlation of 
rs8192916 with GZMB expression is likely independent of the influence of rs2236337.
In the current study, GZMB was tagged by pairwise SNP selection, with an MAF of >0.05 
and a pairwise r2 value of >0.8. Inherent to this method, rare variants are not selected. 
Therefore, based on the results of the current study, we cannot exclude the possibility that 
other variants in GZMB also associate with joint destruction.
Granzyme B, which is released by NK cells and T lymphocytes, can induce cell death 
in harmful cells, such as those that are virally infected or malignant.31 Recent findings 
have suggested a role for granzyme B in RA joint destruction as well; the number of 
granzyme B–positive cells is increased in synovium as well as among chondrocytes at the 
site of pannus lesions.8,32
The findings of the current study are consistent with those of previous studies. Possibly, 
the minor variant of rs8291916, or a genetic variant linked to this SNP, induces higher 
expression of granzyme B, leading to more apoptosis in chondrocytes and therefore more 
joint destruction. This would explain the previously observed association of higher serum 
granzyme B levels in patients with erosive disease.11 Another explanation could be the role 
of granzyme B in propagation of the inflammatory response; additional studies are needed 
to determine this.
In conclusion, using a candidate gene approach evaluating patients in 4 different cohorts, 
we observed associations between rs8192916 and an increased rate of joint destruction 
in RA and between rs8192916 and expression profiles of GZMB. Although evaluation of 
rs8192916 at the protein level was not performed, these data suggest that carriage of the 
risk allele may affect the function of GZMB.
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Previous studies indicated that pyridinoline, a collagen crosslink in cartilage and bone, 
might be a good marker to predict joint destruction in patients with rheumatoid arthritis 
(RA), although large prospective studies are lacking. We evaluated the predictive value of 
serum pyridinoline levels for joint destruction, both at baseline for long term prediction 
and during the disease course for near-term prediction.
methods
Patients with early RA from the Leiden Early Arthritis Clinic were studied. Radiographs 
at baseline and yearly during 7 years of follow-up were scored according to the Sharp-
van der Heijde Scoring (SHS) method. Pyridinoline serum levels at baseline and during 
follow-up were measured by ELISA. The association between baseline pyridinoline levels 
and difference in SHS over 7 years was tested, with a multivariate normal regression model. 
Second, the association between pyridinoline levels determined during the disease course 
and progression of SHS over the next year was tested with a multivariable linear regression 
analysis.
Results
Studying baseline pyridinoline serum levels in 437 patients revealed that the mean SHS 
over 7 years was 6% higher for every higher pyridinoline level (nmol/l) at baseline (p = 
0.001). Subsequently, during follow-up (n = 184 patients) the progression in SHS in the 
upcoming year was 17% higher for every higher nmol/l pyridinoline level (p = 0.001). The 
area under the receiver-operation characteristic curve for rapid radiological progression 
was 0.59.
Conclusion
Increased pyridinoline serum levels, both at baseline and during the disease course, are 
associated with more severe joint destruction during the coming year(s), although the 
predictive accuracy as a sole predictor was moderate.
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intRoDUCtion
Predicting an individual patient’s future disease severity is required for decisions for indi-
vidualized treatment. At disease onset it can guide the initial treatment strategy and during 
the disease course it may guide treatment adaptations. The severity of rheumatoid arthritis 
(RA) is often measured using the extent of joint destruction. At present, only part of the 
variance in joint destruction is explained by currently known risk factors, which consist 
mainly of autoantibodies and markers of inflammation.1 Markers of cartilage or bone me-
tabolism have been studied to a lesser extent. Studies have found evidence that C-terminal 
crosslinking telopeptide of type I collagen (CTX-I) and C-terminal crosslinking telopeptide 
of type II collagen (CTX-II)2 were associated with radiologic progression. Pyridinoline is a 
major crosslink of collagen in cartilage and is also present in collagen of bone and other 
tissue as synovium. Based on initial studies it can be presumed that pyridinoline might be a 
good marker for RA as well. Pyridinoline levels are increased in patients with RA compared 
to healthy persons or to patients with other rheumatologic diagnoses.3-6 In addition, some 
studies indicate that pyridinoline levels are higher in cases of active or severe RA.3,4,7-9 Most 
previous studies were performed on urine levels of pyridinoline.
To date no large longitudinal studies on serum pyridinoline levels and severity of joint 
destruction in RA have been performed. We evaluated the predictive value of serum pyr-
idinoline levels for future joint destruction, both at baseline for longterm prediction and 
during the course of RA for more near-term prediction of disease severity.
mAteRiAls AnD methoDs
Patients
Patients included in the Leiden Early Arthritis Clinic (EAC) cohort that fulfilled the 1987 
American College of Rheumatology criteria for RA at baseline or during the first year of 
disease were studied. The Leiden EAC is a large, prospective cohort.1 Briefly, patients were 
referred by general practitioners when arthritis was suspected and were included in the 
EAC cohort if arthritis was confirmed on physical examination and symptom duration was 
< 2 years. At inclusion, patients were queried about their joint symptoms and underwent 
examination. At baseline and at the yearly follow-up visits, blood samples were taken for 
routine diagnostic laboratory screening and serum was stored at –70°C. Radiographs of 
hands and feet, taken at baseline and yearly thereafter during 7 years of follow-up, were 
scored according to the Sharp-van der Heijde Scoring (SHS) method with known time 
order by an experienced reader, blinded to any clinical information. The within-reader ICC 
was 0.91. Written informed consent was obtained from all participants. The study was 
approved by the local medical ethics committee.
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Pyridinoline levels
Pyridinoline serum levels were measured by ELISA (QuickVue; Quidel Corp.), according 
to the manufacturer’s instructions, using stored baseline and follow-up serum samples. 
All baseline and all follow-up ELISA were done at the same point in time. The intra-assay 
coefficient of variation (CV) was 6.8% and the inter-assay CV was 11.1%. The limit of 
detection was 0.5 nmol/l (lower limit of quantification 0.5 nmol/l and upper limit of quan-
tification 12 nmol/l).
statistical analyses
To approximate a normal distribution, all radiological data were log-transformed before 
analyses. First, associations between baseline pyridinoline levels and log-transformed ra-
diographic joint destruction over 7 years were analyzed using a multivariate normal regres-
sion model with radiological score as response variable, testing for a constant difference 
in SHS. This method analyzes all repeated measurements at once and takes advantage of 
the correlation between these measurements. The effect of time was entered as a factor 
in the model, to properly capture the mean response profile over time.10 All analyses were 
adjusted for age, sex, and treatment strategy. The treatment strategies differed according 
to the inclusion period, which was used as a proxy for treatment strategy in the analyses. 
Patients included in 1993–95 were initially treated with non-steroidal anti-inflammatory 
drugs, patients included in 1996–98 were initially treated with chloroquine or salazopyrine, 
and patients included after 1999 were promptly treated with methotrexate or salazopyrine. 
Since the baseline SHS is included in the repeated measurement analyses as the response 
variable, baseline SHS was not also included as an adjustment factor. Next, additional 
adjustments were made including other known risk factors for progression of joint destruc-
tion: anti-cyclic citrullinated peptide (CCP) antibody status, C-reactive protein (CRP) levels, 
body mass index (BMI), and smoking. The analyses were repeated for the total erosion 
score and the total joint space narrowing score as outcomes, adjusted for age, sex, and 
treatment.
The association between pyridinoline levels determined during the disease course and 
progression of joint damage during the next year was studied with a multivariable linear 
regression analysis with log-transformed delta SHS over the upcoming year as response 
variable, adjusting for age, sex, treatment, and disease duration. Thereafter, additional 
adjustments were made for CCP-positivity and CRP level. The first analysis with pyridinoline 
levels during disease course were also repeated with total joint space narrowing score and 
erosion score as outcomes.
To evaluate the prognostic accuracy for clinical practice, the positive and negative likeli-
hood ratios (LR) and area under the receiver-operator characteristic (ROC) curve (AUC) were 
determined. Therefore pyridinoline levels and radiographic progression were recoded as 
binary variables. Radiologic data were categorized using a definition of rapid radiographic 
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progression (increase of SHS ≥ 5 after 1 year) as reported.11 This was done at baseline and 
during the disease course. The cutoff point to categorize pyridinoline levels was determined 
based on the optimal maximum from the ROC curve, with rapid radiological progression 
(RRP) as outcome. Finally, the prognostic accuracy was determined for pyridinoline levels 
on RRP and any progression in joint destruction during the next year (an increase of ≥ 1 
SHS in 1 year). Correlations between CRP and pyridinoline levels were determined with 
Spearman’s correlation coefficients. Analyses were performed using SPSS version 20.0. P 
values < 0.05 were considered significant.
ResUlts
baseline serum pyridinoline levels
Serum pyridinoline levels were determined in 437 patients with early RA, who had median 
symptom duration of 19 weeks. Patient characteristics are provided in Table 1. The median 
serum level was 4.7 nmol/l (range 3.8–6.0). These baseline levels were significantly associ-
ated with the severity of joint damage over 7 years. For every nmol/l increase in pyridinoline 
level at baseline, patients had 6% higher total SHS (β = 1.06, p = 0.001; Figure 1A). After 
adjustment for age, sex, and treatment and also for known risk factors such as anti-CCP 
positivity, CRP levels, BMI, and smoking, the association between serum pyridinoline level 
and joint destruction remained significant (β = 1.06, p = 0.044).
The total SHS is a composite of the total erosion score and joint space narrowing score. 
In order to determine whether serum pyridinoline was associated with bone or cartilage 
destruction in particular, analyses were repeated on these 2 sub-scores. Significant associa-
tions were observed between serum pyridinoline levels at baseline and both the severity 
of erosions and joint space narrowing over time (β = 1.06, p = 0.025, and β = 1.05, p = 
0.002, respectively).
table 1 Characteristics of the RA-patients studied
Patients with baseline 
serum samples (n=437)
Patients with follow-up 
serum samples (n=184)
Age, mean ± SD, years 57 ± 16 56 ± 14
Female sex, n (%) 307 (70) 122 (66)
ACPA positivity, n (%) 227 (52) 121 (66)
CRP level, median (IQR), mg/dL 1.8 (0.8-4.0) 0.7 (0.3-1.4)
SHS, median (IQR) 5 (2-11) 23 (11-46)
For baseline samples, the patient characteristics at baseline are presented. For the follow-up samples, the 
patient characteristics at the time of serum sampling are presented.
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serum pyridinoline levels during the disease course
Follow-up serum samples of 184 patients with RA were studied; the mean disease duration 
at serum sampling was 4 years (± 2 yrs). The median serum level was 3.3 nmol/l (range 
2.6–4.2). Pyridinoline levels measured at baseline and during the disease course were cor-
related (rs = 0.251, p = 0.005; Figure 1B). Subsequently, the association between serum 
Figure 1A Baseline serum pyridinoline levels and
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Figure 1 Associatio  between pyridinoline baseline serum levels with the severity of joint destruction 
over 7 years (A), correlation between baseline serum levels with follow-up serum levels (B), and associa-
tion of pyridinoline follow-up serum levels with progression of joint damage during the next year (C).
Ad Figure 1A Depicted is the predicted SHS from a multivariable normal regression model, with continu-
ous pyridinoline levels, age, gender and treatment, on the y-axis and time on the x-axis. Pyridinoline 
serum levels were analyzed at a continuous level, but divided in quartiles to depict in a graph. The first 
quartile represents the lowest 25% of pyridinoline levels, the second quartile the highest 25% of the 
lowest 50%, the third quartile the lowest 25% of the highest 50% and the forth quartiles represents 
the highest quartile of pyridinoline levels.
Ad Figure 1C Pyridinoline serum levels were analyzed as a continuous variable but divided in quartiles to 
depict in a graph. The first quartile represents the lowest 25% of pyridinoline levels, the second quartile 
the highest 25% of the low st 50%, the third quartile the lowest 25% of the highest 50% and the forth 
quartile represents the highest quartile of pyridinoline levels. Horizontal lines indicate the median, with 
two-sided inter quartile range bars.
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pyridinoline levels and near-term increase in SHS score over the next year was evaluated. 
After adjustment for age, sex, treatment, and disease duration it was observed that for 
every nmol/l increase in pyridinoline level, the progression in SHS over the upcoming year 
was 17% higher (β = 1.17, p = 0.001; Figure 1C). Also including adjustments for anti-CCP 
positivity and CRP level, the association between pyridinoline level and progression in SHS 
over the upcoming year remained significant (β = 1.15, p = 0.003).
Sub-analyses on the erosion or joint space narrowing scores as outcomes also here 
yielded significant results for the severity of bone and cartilage destruction (β = 1.10, p = 
0.014, and β = 1.10, p = 0.025, respectively).
Prognostic accuracy
The optimal maximum of baseline serum pyridinoline levels on the ROC curve with RRP as 
outcome was 4.7480 nmol/l. Patients with a baseline pyridinoline level ≥ 4.8 nmol/l had a 
positive LR of 1.30 for RRP (increase in SHS ≥ 5) during the first year. The negative LR was 
0.77 and AUC was 0.59. When taking any progression in joint destruction in the first year 
as outcome, positive LR was 1.25, negative LR was 0.83, and AUC was 0.56.
The optimal maximum of follow-up serum pyridinoline levels on the ROC curve with 
RRP as outcome was 3.3983 nmol/l. Patients with RA who during the disease course had a 
pyridinoline level ≥ 3.4 nmol/l had a positive LR of 1.49 for RRP (SHS increase ≥ 5) during 
the next year. The negative LR was 0.67 and AUC was 0.61. Taking SHS ≥ 1 during the next 
year as the outcome, the positive LR was 2.00, negative LR was 0.61, and AUC was 0.64.
DisCUssion
We investigated the predictive value of serum pyridinoline levels for future joint destruction 
and observed that increased pyridinoline levels were significantly associated with more 
severe joint destruction. This applied to baseline serum levels and joint damage over 7 
years as well as to serum levels determined during the disease course and joint destruction 
during the upcoming year.
The association between pyridinoline and severity of joint damage was observed to be 
independent of the association of other factors (such as anti-CCP or CRP) with progression 
of joint damage. Although in the multivariable analyses serum pyridinoline was found to 
be an independent risk factor, the positive LR and AUC were moderate. This indicates that 
the serum pyridinoline level alone is insufficient for adequate prediction, but that it will be 
valuable to include serum pyridinoline in combined predictive models.
Intriguingly, serum levels taken at baseline and during the disease course were correlated. 
Further, both serum levels were associated with more severe joint destruction over time. 
Together these data may suggest that patients with more severe radiological progression 
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have increased serum pyridinoline levels at the start of and throughout the disease course. 
Because treatment effect may have influenced the outcome measures, all analyses were 
adjusted for differences in treatment.
The strengths of our study are the large group of patients with RA and the availability 
of high-quality long-term follow-up data. A limitation could be the lack of measured 
deoxypyridinoline. Deoxypyridinoline exists only in bone, and pyridinoline in both cartilage 
and bone. Hence the ratio of these markers can be used to determine whether serum 
pyridinoline was derived from breakdown of cartilage or bone. To make this distinction 
we performed sub-analyses on pyridinoline levels in relation to joint space narrowing and 
erosions. These showed that associations were present for both cartilage loss and bone 
damage.
Another limitation is that our analyses were based on patients from a single cohort. Ad-
ditional large-scale longitudinal studies on the prognostic value of serum pyridinoline levels 
are needed to replicate our findings and to establish the predictive value of this biomarker.
Increased serum pyridinoline levels are of additive value to known serological risk fac-
tors for future joint damage in patients with RA, both at baseline and during the disease 
course. A combination of multiple biomarkers with other risk factors most likely will be 
required to make adequate predictions.
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Anti-citrullinated peptide antibodies (ACPA) and acute phase reactants may be increased 
before arthritis becomes clinically detectable, suggesting that the processes underlying 
rheumatoid arthritis (RA) start pre-clinically. Whether local inflammation occurs in the 
preclinical phase is unknown. Therefore, we studied the small joints of ACPA positive 
arthralgia patients for local subclinical inflammation.
methods
Imaging was performed using 1.5 T extremity MRI. Painful hand or foot joints of 21 ACPA 
positive arthralgia patients without clinical arthritis were imaged. For comparison, hand and 
foot joints of 22 ACPA positive RA patients and 19 symptom free controls were studied. 
Within ACPA positive arthralgia patients, painful and symptom free joint regions were im-
aged. Scoring was performed according to the Outcome Measures in Rheumatology Clini-
cal Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring (RAMRIS) 
method. Analyses were performed on joint region level and focused on inflammation 
(synovitis plus bone marrow oedema).
Results
The mean combined inflammation scores of the metacarpophalangeal/proximal interpha-
langeal joints of controls, painful joints of ACPA positive arthralgia patients and ACPA 
positive RA patients were 0.1, 0.7 and 3.7, respectively ( p<0.001). Likewise, the mean 
combined inflammation scores of the wrist were 0.9, 2.3 and 10.3, respectively ( p<0.001) 
and that of the metatarsophalangeal joints 0.5, 0.9 and 3.8, respectively ( p=0.10). At the 
MCP joints, the combined inflammation score was significantly correlated with C reactive 
protein and erythrocyte sedimentation rate levels (rs=0.83 and rs=0.78, respectively)
Conclusions
The present data suggest that local subclinical inflammation occurs in ACPA positive 
arthralgia patients.
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intRoDUCtion
Recent studies have shown that anti-citrullinated peptide antibodies (ACPA) can be detect-
ed in the serum of ACPA positive rheumatoid arthritis (RA) patients years before arthritis 
becomes clinically detectable.1 C reactive protein (CRP), cytokines and bone degradation 
markers have also been found to be elevated in this phase,2 suggesting that the processes 
underlying the development of RA may start long before clinical arthritis occurs.
Therefore, detailed studies on inflammation in the preclinical phase may enhance our 
understanding of the development of ACPA positive RA.3
It is not yet known whether local inflammation occurs in small joints in the preclinical 
phase. A recent MRI study on knee joints of 13 ACPA positive arthralgia patients showed 
no subclinical inflammation.4 However, ACPA positive RA probably does not start in the 
knee joints, leaving unanswered the question of whether local inflammation is present in 
the preclinical phase of ACPA positive RA.
This study aimed to investigate whether there is subclinical inflammation in painful 
metacarpophalangeal (MCP) joints, the wrist or metatarsophalangeal (MTP) joints in ACPA 
positive arthralgia patients. To this end, MRI scans of painful small joints of ACPA positive 
arthralgia patients were compared with scans of small joints of ACPA positive RA patients 
and of symptom free controls. Then, the results of the MRI scans of painful and symptom 
free joints were compared within ACPA positive arthralgia patients.
methoDs
subjects
Three groups were studied. The first group comprised ACPA positive (anti-CCP2, Immu-
noscan RA Mark 2; Euro-Diagnostica, Arnhem, The Netherlands) patients with painful hand 
or foot joints but without clinical arthritis, who were recruited from the rheumatological 
outpatient clinic in Leiden University Medical Center between May 2011 and July 2012. In 
total, 25 ACPA positive arthralgia patients were recruited; three patients were excluded as 
clinically detectable arthritis was observed by a rheumatologist on the day of the MRI and 
one patient had an MRI artefact due to a metal fragment in his hand, leaving 21 patients 
for evaluation. Per patient, the region of the (most) painful joints (proximal interphalangeal 
(PIP) 2–5, MCP 2–5, wrist or MTP 1–5) was imaged. To allow comparisons within patients, 
the symptom free contralateral side was also scanned. When both sides were painful, an-
other non-painful region was scanned (eg, in case of arthralgia of MCP joints at both sides, 
symptom free MTP joints were scanned). The regions that were scanned in ACPA positive 
arthralgia patients were not fixed in order to allow the flexibility to scan painful joints as 
well as symptom free joints in every patient. The second group of subjects were 22, 1987 
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American College of Rheumatology criteria positive ACPA positive early RA patients. These 
patients were included in the early arthritis cohort (EAC) Leiden between August 2010 
and July 2012. In these RA patients, MRI of the MCP, wrist and MTP joints at the most 
painful side was performed. The third group comprised 19 healthy subjects without joint 
complaints, who underwent MRI of the MCP, wrist and MTP joints at the dominant side. 
Written informed consent was obtained from all participants. The study was approved by 
the local medical ethics committee.
mRi
Imaging was performed on an ONI-MSK-Extreme 1.5 T extremity MRI (GE, Wisconsin, 
USA). Acquired sequences were T1 weighted fast spin echo sequences, T2 weighted fast 
spin echo sequences with fat saturation (both coronal plane), and after intravenous gado-
linium contrast (0.1 mmol/kg), T1 weighted fast spin echo sequences with fat saturation in 
the coronal and axial planes. The field of view was 100 mm for all sequences. For ethical 
reasons, contrast was not administered in healthy controls. MRI scoring was performed 
by two trained readers according to the Outcome Measures in Rheumatology Clinical Tri-
als (OMERACT) Rheumatoid Arthritis MRI Scoring (RAMRIS) method, evaluating erosions, 
bone marrow oedema and synovitis.5,6 The mean scores of the two readers were analyzed 
(within reader intra-class correlation coefficient total RAMRIS score 0.98 and 0.83, and 
between reader intra-class correlation coefficient 0.82).
Analyses
Analyses were performed per different joint regions. The ‘combined inflammation score’ 
(synovitis plus bone marrow oedema) was analyzed using Kruskal–Wallis tests or Mann–
Whitney U tests because of non-normally distributed data. The correlation between the 
painful and symptom free joints in ACPA positive arthralgia patients was tested with 
Spearman’s correlation. SPSS V.20.0 was used. A p value<0.05 was considered significant.
ResUlts
Baseline characteristics of the ACPA positive arthralgia patients, ACPA positive RA patients 
and symptom free controls are presented in table 1. The arthralgic joint regions in the ACPA 
positive arthralgia patients were: MCP joints (n=4), PIP joints (n=4), wrist (n=3) and MTP 
joints (n=10) (see online supplementary table S1 for an overview of the scanned regions).
Given the study question, we specifically studied the inflammatory markers bone mar-
row oedema and synovitis (summed in the combined inflammation score) without the 
erosion score. In the wrist joints, the combined inflammation scores of the symptom free 
controls, ACPA positive arthralgia and ACPA positive RA patients were 0.9, 2.3 and 10.3, 
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respectively ( p<0.001). The combined inflammation scores of the MCP/PIP joints were 0.1, 
0.7 and 3.7, respectively ( p<0.001), and the combined inflammation score of the MTP 
joints 0.5, 0.9 and 3.8, respectively ( p=0.10). When comparing ACPA positive arthralgia 
patients and symptom free controls, the combined inflammation scores were significantly 
higher in the wrist joints of ACPA positive arthralgia patients ( p=0.02), but not in the MCP/
PIP and MTP joints ( p=0.06 and p=0.32, respectively) (figure 1A–C).
Subsequently, we evaluated all MRI features separately. In the wrist, MCP/PIP and MTP 
joints, a gradual increase was observed in all three features when comparing symptom free 
controls, ACPA positive arthralgia patients and ACPA positive RA patients (figure 1D–F).
Next the correlation between local and systemic inflammation in ACPA positive arthral-
gia patients was determined, revealing an association between both CRP and erythrocyte 
sedimentation rate (ESR) and the combined inflammation score of the MCP joints (rs=0.83, 
p=0.01 and rs=0.78, p=0.02, respectively). ACPA or rheumatoid factor levels were not 
correlated with MRI combined inflammation scores in the present study.
Thus far we studied the painful joints of ACPA positive arthralgia patients. Within the 
ACPA positive arthralgia patients, the mean combined inflammation score in the painful 
joints was 1.0 and in the symptom free joints 1.2. In the 21 patients studied, we did not 
observe a significant correlation between these two joint regions (rs=0.32 and p=0.16).







Age, mean ± SD, years 46.2 ± 11.8 47.9 ± 7.9 53.7 ± 15.9
Female sex, n (%) 15 (78.9) 17 (81.0) 12 (54.5)
Symptom duration at the MRI, median 
(IQR), weeks
n/a 34.5 (15.3-114.5) 20 (11-37)
Onset of symptoms
(sub) acute n/a 6 (28.6) 7 (31.8)
gradual n/a 15 (71.4) 15 (68.2)
Morning stiffness, median (IQR), minutes n/a 30 (5-60) 60 (45-120)
Swollen joint count, median (IQR) 0 0 5 (3-12)
Tender joint count, median (IQR) 0 2 (1-3) 6 (5-11)
ACPA level, median (IQR) n/a 326 (94-340) 182 (87-324.3)
RF positivity, n (%) n/a 15 (71.4) 19 (86.4)
RF level, median (IQR) n/a 22 (10.5-120) 20 (11.5-91)
Except where indicated otherwise, values are the number (%) of patients.
Interquartile range (IQR). Standard deviation (SD).
68 tender joint count and 66 swollen joint count were performed.
n/a: not applicable
Symptom duration refers to the period between the first symptom onset of any joint and the MRI date.
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Figure 1D Mean RAMRIS subscores in wrist joints in; controls,






























Figure 1B Combined inflammation score MCP/PIP joints in; controls,
































Figure 1E Mean RAMRIS subscores in MCP/PIP joints in; controls,






























Figure 1C Combined inflammation score MTP joints in; controls,






























Figure 1F Mean RAMRIS subscores in MTP joints in; controls,




























Figure 1A Combined inflammation score wrist joints in; controls,






























Figure 1D Mean RAMRIS subscores in wrist joints in; controls,






























Figure 1B Combined inflammation score MCP/PIP joints in; controls,
































Figure 1E Mean RAMRIS subscores in MCP/PIP joints in; controls,






























Figure 1C Combined inflammation score MTP joints in; controls,






























Figur  1F Mean RAMRIS subscores in MTP joints in; controls,




























Figure 1A Combined inflammation score wrist joints in; controls,






























Figure 1D Mean RAMRIS subscores in wrist joints in; controls,





























Figure 1B Combined inflammation score MCP/PIP joints in; controls,
































Figure 1E Mean RAMRIS subscores in MCP/PIP joints in; controls,






























Figure 1C Combined inflammation score MTP joints in; controls,






























Figure 1F Mean RAMRIS subscores in MTP joints in; controls,




























Figure 1 C mbined inflammation scores (bone marrow edema plus synovitis) (A-C) and separate scores 
for bone marrow edema, synovitis and erosion (D-F) in symptom-free healthy controls, ACPA-positive 
arthralgia-patients and ACPA-positive RA-patients per joint region.
All scores are mean scores of two readers. Horizontal lines represent mean scores. The y-axes were split-
ted as the RA-patients had higher scores than the ACPA-positive arthralgia patients and healthy controls.
The mean combined inflammation-scores of the wrist-joints of the controls, the painful joints of ACPA-
positive arthralgia-patients and ACPA-positive RA-patients were 0.9, 2.3, 10.3, respectively (p<0.001).
The mean combined inflammation-scores of the MCP/PIP-joints were 0.1, 0.7 and 3.7 respectively 
(p<0.001) and that of the MTP-joints 0.5, 0.9, 3.8, respectively (p=0.10). Similarly, for these three groups 
the mean erosion scores were 0.7, 1.8 and 3.8 in the wrist 0.1, 0.3 and 1.2 in the MCP/PIP 0.4, 0.5 and 
1.7 and in the MTP-joints respectively.
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In the follow-up period (mean 9 months (range 1–15 months)), 12 arthralgia patients 
developed RA according to the 2010 American College of Rheumatology/European League 
Against Rheumatism RA criteria. The combined inflammation scores between the arthral-
gia patients that did and did not develop RA were not different, although the number of 
subjects was too low to allow within group comparisons.
DisCUssion
This study has explored whether subclinical inflammation occurs in painful small joints 
of ACPA positive arthralgia patients without clinical synovitis, using MRI to measure 
inflammation sensitively.7 We observed differences between ACPA positive arthralgia 
patients, ACPA positive RA patients and symptom free controls. Furthermore, a correla-
tion between local inflammation, as measured using MRI, and systemic inflammation, 
measured using CRP and ESR, was found in ACPA positive arthralgia patients. These data 
are in line with a study in monkeys showing that subclinical inflammation precedes clinical 
arthritis.8 They are also in line with a recent ultra-sound study and a study reporting an 
increased signal on macrophage position emission tomography in ACPA positive arthralgia 
patients that developed clinical arthritis.9,10 The present data are intriguing as they suggest 
that there is subclinical inflammation in ACPA positive patients in the preclinical phase. An 
example of synovitis and bone marrow oedema, as observed in ACPA positive arthralgia 
patients, is presented in figure 2.
Importantly, the present study used both positive and negative controls (RA patients and 
symptom free controls, respectively). In particular, the latter is crucial, as several studies 
have observed MRI abnormalities to a certain degree in healthy persons.11-13
This study has several limitations. First and most importantly, the numbers of subjects 
studied was small and the RAMRIS scores were quite low. The former is due to the low 
prevalence of ACPA positive arthralgia patients in outpatient clinics and the latter is due 
to measuring in very early disease stages. Consequently, the power to find statistically 
significant differences was limited. The power to perform within patient comparisons in 
particular was low. This was done when comparing within the group of ACPA positive ar-
thralgia patients: MRI inflammation between painful and symptom free joints, level of local 
inflammation with systemic markers of inflammation (ESR and CRP) and MRI inflammation 
scores of patients that developed RA and those who did not develop RA. Larger studies are 
required to address these questions more extensively.
Another limitation is that the duration of follow-up was too short to definitely conclude 
which arthralgia patients progressed to RA. Also, in this respect, further studies with a 
longer follow-up of ACPA positive arthralgia patients are required.
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A third limitation is that, for ethical reasons, the symptom free control group did not 
receive intravenous contrast, which may have underestimated synovitis scores in these 
people. However, differences were also observed in erosion and bone marrow oedema 
scores, evaluations which do not require contrast administration. Furthermore, the scanned 
joint regions were fixed in RA (MCP, wrist and MTP joints at the most painful side) and in 
the controls (MCP, wrist and MTP joints at the dominant site), but not in the ACPA positive 
Figure 2 MR images of ACPA-positive arthralgia patients without clinically detectable arthritis.
(A) MR images of the left hand; the right hand is shown as comparison.
Coronal T1TSE, T2TSE fatsat and T1 fatsat after gadolinium (2Aa, b, c). Axial image at the level of the 
distal radioulnar joint (2Ad). The right hand is shown as comparison: T1 fatsat after gadolinium axial 
(2Ae) and coronal (2Af) without enhancement.
In the left hand; increased volume of soft tissues is appreciated around the distal ulna, intermediate of 
signal intensity on T1 (2Aa) high on T2 (2Ab) (arrow). After gadolinium abundant enhancement of thick-
ened synovium is appreciated around the distal ulna and among the carpal joints as well (arrows 2Ac, d) 
According to the RAMRIS scoring method synovitis was scored. Partial volume is seen at the processus 
styloideus radii (long arrow).
(B) MR images of the left wrist
At the proximal end of the hamate and at the lunate regions of low intensity on the T1 (2Ba) and high 
intensity on T2 (2Bb) and high intensity on T1 after gadolinium (2Bc, d) are appreciated, which repre-
sents bone marrow edema. Furthermore, no enhancement of the synovium is seen (2Bc, d) Therefore, 
no synovitis was scored.
(C) MR images of the left foot (2Ca-c) and left hand (2Cd, e).
The head of metatarsal 5 showed a small lesion (arrows), low on T1 (2Ca), high on T2 (2Cb), enhancing 
after gadolinium (2Cc), which could be an erosion or synovial cyst. Subtle enhancement of synovium is 
seen laterally (arrowhead). A small amount of fluid with rim enhancement of synovium of MTP1 (long 
arrow) is present. No bone marrow edema is appreciated. The left hand shows a subtle amount of high 
signal intensity in MCP5, enhancing after gadolinium (2Cd, e), consistent with subtle synovitis.
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arthralgia patients. This was done in order to ensure that within ACPA positive arthralgia 
patients both joint regions with and without symptoms were evaluated. The number of 
painful joint regions in the arthralgia patients was low and a preset scanning protocol 
might have resulted in imaging of only symptom free joints.
In conclusion, the present study provides suggestive evidence that there is subclinical 
inflammation in ACPA positive arthralgia patients. Large longitudinal studies are needed to 
define the diagnostic or prognostic value of MRI in this preclinical phase.
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supplementary table 1 Overview of scanned joint regions.
Scanned joint region
wrist PIP/MCP MTP
Symptom-free controls 19 19 19
ACPA+ arthralgia patients, symptom-free 
joint region
3 11 6
ACPA+ artralgia patients, painful joint 
region
3 8 10
ACPA+ RA patients 22 22 22
In ACPA-positive arthralgia-patients the most painful joint region was scanned. For comparison within 
patients; in these patients the symptom-free contralateral side was scanned as well. When both sides 
were painful, another non-painful region was scanned. In seven patients this resulted in another joint 
region scanned as symptom-free joint region. Two of them had painful MCP region and symptom-free 
MTP scanned joint region. In five patients the MTP joint region was scanned whereas MCP joint region 
was scanned as symptom-free joint region.
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MRI is increasingly used to measure inflammation in rheumatoid arthritis (RA) research, but 
the correlation to clinical assessment is unexplored. This study determined the association 
and concordance between inflammation of small joints measured with MRI and physical 
examination.
methods
179 patients with early arthritis underwent a 68 tender joint count and 66 swollen joint 
count and 1.5T MRI of MCP (2–5), wrist and MTP (1–5) joints at the most painful side. 
Two readers scored synovitis and bone marrow oedema (BME) according to the OMERACT 
RA MRI scoring method and assessed tenosynovitis. The MRI data were first analyzed 
continuously and then dichotomized to analyze the concordance with inflammation at 
joint examination.
Results
1790 joints of 179 patients were studied. Synovitis and tenosynovitis on MRI were inde-
pendently associated with clinical swelling, in contrast to BME. In 86% of the swollen MCP 
joints and in 92% of the swollen wrist joints any inflammation on MRI was present. In 
27% of the non-swollen MCP joints and in 66% of the non- swollen wrist joints any MRI 
inflammation was present. Vice versa, of all MCP, wrist and MTP joints with inflammation 
on MRI 64%, 61% and 77%, respectively, were not swollen. BME, also in case of severe 
lesions, occurred frequently in clinically non-swollen joints. Similar results were observed 
for joint tenderness.
Conclusions
Inflammation on MRI is not only present in clinically swollen but also in non-swollen joints. 
In particular BME occurred in clinically non-inflamed joints. The relevance of subclinical 
inflammation for the disease course is a subject for further studies.
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intRoDUCtion
In recent years MRI is increasingly being used to measure disease states and treatment re-
sponse in rheumatoid arthritis (RA) research.1 The development of dedicated extremity-MRI 
and validated scoring methodology OMERACT RA MRI scoring (RAMRIS) has boosted the 
use of MRI. MRI has important advantages over conventional radiographs as, in addition to 
structural damage, inflammation of the synovium of the joints, tendons and bone (bone 
marrow oedema, BME) can be visualized and quantified.2,3 BME is not detected by ultrasound 
or radiographs and is a strong predictor of erosive progression.4-13 Recent data suggest that 
the presence of tenosynovitis in early arthritis is associated with progression to RA,14 though 
more studies on this matter are required. Moreover, the exact role of MRI for diagnosing 
or prognostication of patients with early arthritis in clinical practice is not yet established.15
Independent of the purpose of MRI use, it is fundamental to understand to what extent 
abnormalities on MRI are concordant with abnormalities at physical examination of joints. 
A recent study found a moderate correlation between disease activity score in 28 joints 
and inflammation scores on MRI,16 but the association between MRI and joint examination 
has never been studied thoroughly on joint level in patients with early arthritis. Given the 
general conception that MRI is more sensitive than physical examination; we assumed 
that inflammation detected at physical examination can be seen on MRI and that MRI 
may be able to detect more inflammatory lesions than physical examination. We aimed 
to address the following items: (i) To what extent joint swelling (or tenderness) at physical 
examination is associated with inflammation on MRI. (ii) In what proportion of swollen (or 
tender) joints is inflammation present on MRI. (iii) In what proportion of non-swollen (or 
non-tender) joints is inflammation present on MRI. (iv) Finally, we evaluated all joints that 
showed inflammation on MRI and determined how many of these joints are clinically not 
swollen (or non-tender). This last objective addressed the frequency of MRI inflammation 
that is undetected by clinical examination and therefore reflects subclinical inflammation.
PAtients AnD methoDs
Patients
One hundred and seventy-nine patients with early arthritis were included in the Leiden Early 
Arthritis Clinic between August 2010 and February 2012 and underwent MRI at baseline. 
The Early Arthritis Clinic is a population-based inception cohort that includes patients with 
confirmed arthritis and symptoms for <2 years. At baseline, patients and rheumatologists 
completed questionnaires, a 68 tender joint count and 66 swollen joint count was performed 
by trained research nurses and serum was obtained.17 Written informed consent was ob-
tained from all participants. The study was approved by the local medical ethics committee.
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mRi scanning and scoring
The metacarpophalangeal (MCP) joints (second to fifth joints), wrist and (metatarso-
phalangeal) joints (first to fifth joints) at the most painful (or dominant side in case of 
equally severe symptoms at both sides) were scanned with an ONI-MSK-extreme 1.5T 
extremity-MRI-scanner (GE, Wisconsin, USA). For the MCP joints and wrists the following 
sequences were acquired: coronal T1 spin echo (SE) and T2 SE fatsat, and axial T1 SE fatsat 
post-gadolinium. For the MTP joints axial T1 SE and T2 SE fatsat sequences were obtained. 
Because of time limitations (the current protocol takes 75 min), post-gadolinium sequences 
were not obtained for the MTP joints. See the online supplementary methods for a detailed 
scan protocol. Synovitis and BME were quantitatively scored according to RAMRIS.3 Tenosy-
novitis in the MCP joints and wrists was assessed as described by Haavardsholm et al.2 The 
MRIs were scored by two readers independently, blinded to clinical data; the mean scores 
were studied. The within-reader intra class correlation coefficients for the total RAMRIS 
score were 0.98 and 0.83; the between-reader interclass correlation coefficient 0.82.
Analyses
Information on swelling of the MCP joints, wrists and MTP joints at physical examination 
of the scanned joints on the side that was MR-imaged was extracted from the joint count 
data. Joint tenderness is frequently considered as reflecting local inflammation and was 
also studied.
To make the MRI data comparable with the data on physical examination, the following 
items were summed. To calculate the BME score per MCP or MTP joint the score of the 
distal and the proximal bone was summed (range 0–6). Scoring the wrist according to the 
RAMRIS method implies that 15 bones are assessed, though not all of these are located 
around the radioulnar carpal joint that is assessed with physical examination. For the wrist 
we therefore evaluated the highest score of the bones lining the joint space: distally the 
proximal carpal row: scaphoid, lunate, triquetrum and pisiform and proximally the radius 
or ulna. These distal and proximal scores were summed (range 0–6).
The synovitis scores of the MCP and MTP joints were straightforward (range 0–3). The 
synovitis score of the wrist joint was the highest score of the radioulnar and radiocarpal 
compartment (range 0–3).
A swollen or tender joint at physical examination can also be (partly) due to tenosynovitis 
and therefore tenosynovitis was also assessed. To determine the tenosynovitis score per 
MCP joint we added up the scores of the extensor and the flexor tendons around the 
MCP joint (range 0–6). For the wrist, the highest score of the tenosynovitis around the 
extensors and around the flexors were summed (range 0–6). It was not possible to score 
tenosynovitis of the MTPs, because no coronal sequences, perpendicular to the axis of the 
metatarsals, were performed. See also figure 1 and online supplementary table S1 for an 
overview of score calculations.
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First the association between inflammation detected by physical examination and MRI 
was studied per joint type, using logistic regression analyses with the continuous imag-
ing scores as the independent variable and the joint examination results as dependent 
variable. Then, the association between inflammation detected by physical examination 
and by MRI was studied in all joints together. This analysis was done using generalized 
estimated equations as this model takes into account that in every patient 10 joints were 
assessed. Adjustments for age and gender were included. The exchangeable correlation 
matrix was used.
Subsequently the continuous MRI data were dichotomized to compare the concordance 
and discordance with physical examination. First, the cut-off of 1.0 was chosen; this score 
was achieved if the mean of both readers was ≥1.0. Two-by-two tables were made and 
Figure 1 Overview of bones and joints in the wrist assessed for bone marrow oedema and synovitis (A) 
and the tendons assessed for tenosynovitis (B)
A) Coronal plane of the wrist, with the 5 metacarpal heads, trapezium (T1), trapezoid (T2), capitate (C), 
hamate (H), scaphoid (S), lunate (L), triquetrum (T3), pisiform (P), radius (R), ulna (U). The three synovial 
compartments are depicted in different colors: intercarpal (purple), radio-carpal (orange) and radio-ulnar 
(red).
To make the MRI score data comparable to the data at physical examination only the scores of the bones 
and synovial compartments within the dotted line were analysed. The bone marrow oedema score of 
the wrist was the sum of the distal and the proximal part. The distal bone marrow oedema score was 
the highest score among the scores of the scaphoid, lunate, triquetrum and pisiform. The proximal bone 
marrow oedema score was the highest score between the scores of the radius and the ulna. The synovitis 
score of the wrist was the highest score between the radio-carpal and the radio-ulnar compartment.
B) Axial plane of the wrist, with the radius (R) and the ulna (U) and all the tendons. To make one tenosy-
novitis score in the wrist we summed the flexor and the extensor score. The flexor score was the highest 
score among the tendons within the red dotted line. The extensor score was the highest score among 
the tendons within the blue dotted line.
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Baseline characteristics of the 179 patients with early arthritis studied are presented in 
table 1. As shown in table 2, the percentage of patients with at least one clinically swollen 
or tender MCP, wrist and MTP joint ranged between 30% and 40%. Among the MCP and 
MTP joints, the second and the third joints were most frequently swollen and tender. The 
majority of swollen joints at examination (79%) were also tender. Conversely, 49% of the 
Figure 2 Infl ammation features at physical examination and on MRI and their occurrences in MCP, wrist, 
MTP-joints.
Concordance between inflammation at physical examination and on MRI 181
10
table 1 Characteristics of the 179 early arthritis patients
(n=179)
Age, mean ± SD, years 54.1 ± 14.7
Female sex, n (%) 99 (55.3)
Symptom duration at inclusion, median (IQR), weeks 15 (6-27)
Onset of symptoms, n (%)
(sub) acute 75 (43.4)
gradual 92 (51.4)
Morning stiffness, median (IQR), minutes 30 (15-60)
Swollen joint count, median (IQR) 3 (2-6)
Tender joint count, median (IQR) 6 (2-11)
ACPA positivity, n (%) 45 (25.1)
RF positivity, n (%) 54 (30.2)
CRP level, median (IQR) 4 (3-12)
ESR level, median (IQR) 14 (6-33)
Patient classification at baseline, n (%)
RA (2010 ACR/EULAR criteria) 66 (37)
Unclassified arthritis 65 (36)
Psoriatric arthritis 15 (8)
Inflammatory osteoarthritis 12 (7)
Reactive arthritis 6 (3)
Other diagnoses 15 (8)
Interquartile range (IQR). Standard deviation (SD). 68 tender joint count and 66 swollen joint count were 
performed. At the two-weeks visit, when the results of laboratory and radiologic investigations were 
known, patients were classified according to the diagnoses presented.





≥ 1 swollen joint 36% 30% 25%
≥ 1 tender joint 40% 11% 41%
MRI
Synovitis score ≥ 1 26% 60% 7%
Tenosynovitis score ≥ 1 21% 52% n.a.
Bone marrow oedema score ≥ 1 17% 58% 12%
The frequencies at physical examination represent the frequencies of patients with at least 1 swollen or 
tender MCP, wrist or MTP-joint.
The frequencies at MR imaging represent the frequencies of all MCP, wrist or MTP-joints that had a 
synovitis, tenosynovitis or BME score of at least 1.
n.a.= not assessed
For technical reasons some joints on MRI could not be evaluated. Of all 716 MCP-joints; 8 synovitis, 17 
tenosynovitis and 14 BME scores were not assessed. Of all 179 wrists; 1 synovitis, 2 tenosynovitis and 6 
BME scores were not assessed. Of all 895 MTP-joints; 29 synovitis and 45 BME scores were not assessed.
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tender joints were also swollen at physical examination. The relation per joint region is 
depicted in figure 2.
mRi baseline characteristics
Per patient 10 joints (4 MCPs, 1 wrist and 5 MTPs) were scanned. The frequencies of 
synovitis, tenosynovitis and BME are presented in table 2. In the wrists these features 
were more frequently present than in the MCP and MTP joints. Among the MCP joints, 
the second and the third MCPs were most frequently affected by synovitis, tenosynovitis 
and BME. In the wrist, the lunate showed most frequently BME (41% had a score ≥1) and 
among the MTP joints synovitis, tenosynovitis and BME were most often present in MTP1. 
The MRI features of inflammation frequently occurred together (figure 2).
Association between inflammation detected by mRi and physical 
examination
First the association between inflammation on MRI and at physical examination was ana-
lyzed per joint type (eg, all MCP2 joints). The OR on joint swelling for every unit increase in 
MRI score is depicted in figure 3. All three inflammatory measures visualized on MRI were 
significantly associated with the presence of joint swelling at physical examination. Among 














































































































































































































































































































Figure 3 The association between inflammation detected by MRI and physical examination, for every 
MCP and MTP-joint separately.
*=p<0.05. The association between inflammation detected by physical examination and MRI was stud-
ied per joint type, using logistic regression analyses with the continuous imaging scores as independent 
variable and the joint examination result as dependent variable. The Odds Ratio (OR) reflects the ratio 
between the odds on joint swelling and the odds on no joint swelling for every unit increase in MRI score 
per joint type. It was not possible to score tenosynovitis of the MTPs, because here no MR-images right-
angled (coronal planes) were available.
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the MCP joints the strongest associations were observed for MCP2 and MCP3 joints and 
among the MTP joints for MTP3 and MTP4 joints.
Second for all 1790 joints together the association between inflammation detected by 
MRI and physical examination was analyzed. All three inflammatory measures visualized on 
MRI were significantly associated with the presence of joint swelling at physical examina-
tion. Synovitis on MRI was more strongly associated with clinical joint swelling than with 
tenosynovitis or BME. As the MRI inflammation features often occurred together, all three 
features were entered in one analysis, to evaluate which of these variables were indepen-
dently associated with clinical joint swelling. In the MCP joints, synovitis and tenosynovitis 
were independently associated with clinical swelling (OR 3.3 and 2.4, p<0.001), but BME 
was not independently associated with joint swelling (OR 1.2, p=0.13). In the wrist, similar 
results were obtained: synovitis and tenosynovitis were independently associated to clinical 
swelling (OR 2.3 and 1.8, p=0.03), in contrast to BME (OR 1.0, p=0.8) (see online supple-
mentary table S2).
Frequency of mRi inflammation in clinically swollen joints
Subsequently the continuous MRI scoring data were dichotomized and the concordance 
and discordance between inflammation detected by physical examination and MRI stud-
ied (table 3A). Of all swollen MCP joints at physical examination, any MRI measure of 
inflammation was present in 86%, synovitis in 73%, tenosynovitis in 65% and BME in 
50%. Of all swollen wrists, any MRI measure of inflammation was present in 92%, synovi-
tis in 83%, tenosynovitis in 78% and BME in 75%. Of all swollen MTP joints, synovitis was 
seen in 21%, BME in 23% and any of these features in 29%.
Frequency of mRi inflammation in clinically non-swollen joints
Of all non-swollen MCP joints at physical examination, any MRI measure of inflammation 
was observed in 27%, synovitis in 18%, tenosynovitis in 13% and BME in 10%. Of all non-
swollen wrists, any MRI measure of inflammation was observed in 66%, synovitis in 50%, 
tenosynovitis in 41% and BME in 51%. Of all non-swollen MTP joints, any MRI measure of 
inflammation was observed in 13%, synovitis in 5% and BME in 11% (table 3A).
Frequency of clinically non-swollen joints in the presence of inflammation 
on mRi
Subsequently, it was studied how often physical joint examination was normal, given the 
presence of inflammation on MRI, indicating what proportion of MRI abnormalities is clini-
cally not detected.
First all MCP joints that revealed any inflammation on MRI were evaluated. Of these, 
64% were not swollen at physical examination. Then the MRI inflammatory features were 
studied separately. Of all MCP joints that had synovitis, 57% were not swollen. Of all MCP 
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% of swollen joints with MRI 
feature
73% 25% 2%# 65% 18% 2%# 50% 23% 13%
% of not swollen joints with 
MRI feature
18% 2% 0%# 13% 3% 0%# 10% 3% 2%
Given MRI inflammation, % 
of non-swollen joints



























% of swollen joints with MRI 
feature
83% 48% 4%# 78% 48% 7%# 75% 55% 32%
% of not swollen joints with 
MRI feature
50% 10% 0%# 41% 11% 2%# 51% 20% 7%
Given MRI inflammation, % 
of non-swollen joints



















% of swollen joints with MRI 
feature
21% 1%# n.ap. 23% 17% 13%
% of not swollen joints with 
MRI feature
5% 0%# n.ap. 11% 4% 2%
Given MRI inflammation, % 
of non-swollen joints
67% 75%# n.ap. 78% 65% 58%
n.ap.= not applicable because n=0.
† It was not possible to score tenosynovitis of the MTPs, because here no MR-images right-angled (coro-
nal planes) were available.
# these frequencies should be interpreted with discretion, because of the low numbers of joints with 
these scores.
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% of tender joints with MRI 
feature
51% 15% 1%# 42% 9% 1%# 36% 15% 8%
% of not tender joints with 
MRI feature
19% 3% 0%# 15% 4% 0%# 11% 4% 2%
Given MRI inflammation, % 
of non-tender joints



























% of tender joints with MRI 
feature
88% 42% 2%# 83% 41% 5%# 76% 59% 31%
% of not tender joints with 
MRI feature
46% 22% 1%# 37% 13% 3%# 50% 17% 7%
Given MRI inflammation, % 
of non-tender joints



















% of tender joints with MRI 
feature
13% 1% n.ap. 20% 13% 9%
% of not tender joints with 
MRI feature
6% 0% n.ap. 10% 4% 2%
Given MRI inflammation, % 
of non-tender joints
59% 50% n.ap. 62% 49% 45%
n.ap.= not applicable because n=0.
† It was not possible to score tenosynovitis of the MTPs, because here no MR-images right-angled (coro-
nal planes) were available.
# these frequencies should be interpreted with discretion, because of the low numbers of joints with 
these scores.
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joints with tenosynovitis, 54% were not swollen. Of all MCP joints with BME this was 53%. 
Thereafter, these frequencies were determined for more severe inflammatory features on 
MRI (cut-off scores ≥2 and ≥3). The frequencies of MCP joints with synovitis, tenosynovitis 
or BME on MRI that were clinically not swollen, decreased (table 3A).
Next, the wrists that showed inflammation on MRI were evaluated in the same way. Of 
these joints with any inflammation on MRI, 61% were not swollen at physical examination. 
Of all wrists that had synovitis, tenosynovitis or BME, 58%, 54% and 60%, respectively, 
were not swollen. When using higher cut-offs to define MRI inflammation (scores ≥2 and 
≥3), the part of subclinical synovitis (synovitis at MRI but not at physical examination) of all 
detected synovitis decreased. However, in the wrists with tenosynovitis score ≥3 and BME 
score ≥3, 33% and 35% were still clinically not swollen.
When evaluating the MTP joints that showed any inflammation on MRI, 77% were not 
swollen at physical examination. With regards to synovitis, the majority of MTP joints had 
a score of ≥1; 67% of these joints were not swollen at physical examination. For BME, 
78% of the MTP joints that had BME (score ≥1), were not swollen, indicating the presence 
of subclinical inflammation. Also when assessing the MTP joints with high BME scores 
(score ≥3), 58% were clinically not swollen. Hence, the proportion of subclinical BME of all 
detected BME, was the highest in the feet (table 3A).
Analysis on mRi inflammation in relation to joint tenderness at physical 
examination
Since joint tenderness at physical examination can be considered as a sign of inflammation, 
all analyses mentioned above were repeated with joint tenderness instead of joint swelling. 
The association between inflammation on MRI and joint tenderness was less strong (lower 
OR) than the association between joint swelling (see online supplementary table S2). The 
concordance between inflammation on MRI and joint tenderness was almost similar (table 
3B), but the frequency of MRI inflammation in tender MCP joints was less than in swollen 
MCP joints. Also here, when evaluating all joints with any inflammation on MRI, a large 
proportion was not tender at examination (56% for MCP joints, 51% for wrists and 59% 
for MTP joints). Additionally, it was observed that of the joints with relative severe BME 
(score ≥3), 31–45% were still not tender (table 4) and 19–45% were neither swollen nor 
tender. Also here these frequencies were the highest in the feet.
sub-analyses in early RA
Subsequently we questioned whether the results were different when evaluating only the 
subgroup of patients with early arthritis diagnosed with RA (2010 criteria; n=66) at first 
visit. Here the prevalence of all MRI inflammation features was higher than in the total 
group of patients with early arthritis. The concordance analyses were repeated; overall this 
did not yield different conclusions (see online supplementary table S3 A,B).
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serological markers and subclinical inflammation
Additionally, the prevalence of subclinical inflammation in patients positive and patients 
negative for serological markers was evaluated. We observed that BME (score ≥1) was 
more prevalent in non-swollen joints of anti-citrullinated peptide antibody (ACPA) positive 
patients than in that of ACPA negative patients (p=0.01). Synovitis and tenosynovitis were 
not significantly different (p=0.65 and p=0.56, respectively). Similar findings were found 
for rheumatoid factor (RF) RF positive and negative patients (p=0.047, 0.82, 0.17; for BME, 
synovitis and tenosynovitis). When comparing MRI inflammation in non-swollen joints of 
patients with and without a raised C reactive protein (CRP), no different prevalence was 
observed (p=0.82, 0.46 and 0.19, respectively).
DisCUssion
This study investigated whether joint swelling, which is conceived as a reflection of local 
inflammation at physical examination, is associated with inflammation reflected by MRI. 
This study of patients with early arthritis showed that inflammation on MRI is present in 
the large majority of clinically swollen joints and in non-swollen joints. Furthermore, a 
high proportion of joints with MRI inflammation had no signs of clinical inflammation. For 
instance; 35–58% of the joints with severe BME, a MRI feature that was associated with 
erosive progression in other studies, were non-swollen at physical examination.
All three features of inflammation depicted by MRI (synovitis, tenosynovitis and BME) 
were significantly associated with the presence of clinical joint swelling. As expected, 
synovitis had the strongest association. Furthermore, the MRI features of inflammation 
frequently occurred together in the same joint and the association between BME and 
clinical swelling was not independent of synovitis and tenosynovitis.
The highest frequencies of MRI inflammation scores were seen in the wrists. More bones, 
synovium compartments and tendons were assessed in wrists than in MCP and MTP joints. 
With regards to BME in the wrist, we decided not to evaluate all carpal bones included in 
the RAMRIS but only the bones that are located around the joint space. This was done to 
have the same anatomical area investigated by physical examination and MRI. Nonetheless, 
the percentage of joints, swollen and non-swollen, with inflammatory features on MRI was 
higher in wrists than in MCP and MTP joints.
Limitations of the present study are the absence of coronal sequences, perpendicular to 
the axis of the metatarsals, making it impossible to evaluate tenosynovitis of the forefoot. 
The absence of post-contrast images of the foot resulted in less reliable scoring of synovitis, 
because hyperplasic inflamed synovium could not be adequately differentiated from fluid 
in the MTP joints. The absence of post-contrast images may hypothetically have resulted in 
either overestimation or underestimation of MRI synovitis and therefore the present data 
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do not allow drawing definitive conclusions on the association between synovitis detected 
by MRI and physical examination of the foot.
For BME evaluation however, contrast enhancement is not required. Interestingly, of all 
joints with BME score ≥1, the majority was not clinically inflamed and this proportion was 
the highest in the feet. This indicates that with respect to BME, subclinical inflammation 
is most often present in the feet. The fact that MTP joints are more difficult to physically 
examine than other small joints may play a role here.
Hence, we observed that BME is not independently associated with joint swelling and 
that joints with BME are frequently not swollen (in case of joints with a BME score ≥1 this 
concerned 53–78% and in joints with a BME score ≥3 this was 35–58%). BME is previ-
ously observed to be a prognosticator for erosive joint damage progression in RA.6-8,10,18 
In patients with unclassified arthritis, BME was predictive for progression to RA.19 BME is 
also called osteitis, as studies that combined MRI and histology observed inflammatory 
infiltrates at the location of BME. In these samples; osteoclasts were observed nearby, 
suggesting a link between inflammation and erosive bone damage.20 A previous study 
showed that clinically relevant progression of joint damage does occur in patients with RA 
in prolonged remission.21 We showed that BME is also present in the non-swollen joints 
and by knowing that BME is predictive for erosive progression, BME could reflect subclinical 
inflammation predicting progression during periods of low disease activity. Unfortunately, 
in this study we had no longitudinal data and therefore we could not draw conclusions 
about the follow-up of the non-swollen joints with BME.
Because a joint can be clinically swollen due to inflammation of the synovium of the 
joints and the tendons, tenosynovitis was scored in addition to synovitis. Both features 
indeed presented frequently in the same joint. When tenosynovitis was present, synovitis 
occurred in 78–88%. As far as we know this finding is not reported in previous studies and 
more research on the value of tenosynovitis as part of joint inflammation in early arthritis 
is needed.
The evaluation of synovitis and tenosynovitis of the MCP joints and wrists was not 
hampered by technical issues and we observed that synovitis and tenosynovitis occurred 
in clinically non-swollen joints. The frequency of this subclinical inflammation depended 
on the degree of MRI inflammation. For instance, when MRI-synovitis was present with a 
score ≥1, 57–58% of the joints were not swollen and in case of joints with a MRI synovitis 
score ≥2 this was 32–33%. One explanation of this finding is that MRI is more sensitive for 
identifying synovitis than physical joint examination. Alternatively, there are many false-
positive findings if we rely on minimal findings.
Joint swelling was studied as the main parameter for clinical joint inflammation. Joint 
tenderness was assessed as well. The association of inflammation on MRI with swollen 
joints was stronger than with tender joints. This can possibly be explained by the tender 
joint count being more frequently affected by processes other than inflammation.
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In conclusion, this study observed a high frequency of subclinical inflammation in pa-
tients with early arthritis, detected by MRI. The relevance of subclinical inflammation for 
the disease course is a subject for further studies, though previous studies have indicated 
that BME is particularly associated with disease progression.
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MCP5 Flexor MCP5+extensor MCP5 MCP5distal+MCP5proximal
MCP4 Flexor MCP4+extensor MCP4 MCP4distal+MCP4proximal
MCP3 Flexor MCP3+extensor MCP3 MCP3distal+MCP3proximal





Highest score of: I, II, III, IV, V, VI 
(extensors)
+
Highest score of: 1, 2, 3, 4
(flexors)
Highest score of: pisiform, 
triquetrum, lunate, scaphoid 
(distal)
+











n.a.= not assessed. It was not possible to score tenosynovitis of the MTPs, because here no MR-images 
right-angled (coronal planes) were available.
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supplementary table 2 Association between inflammation detected by MRI and physical examina-
tion.
Association with clinically swollen joint
MCP-joints Wrists MTP-joints
OR p OR p OR p
Synovitis 5.9 <0.001 4.0 <0.001 2.0 0.02
Tenosynovitis 5.5 <0.001 2.7 <0.001 n.a. n.a.
Bone marrow oedema 2.3 <0.001 1.7 <0.001 1.4 0.01
All three together in one model:
Synovitis 3.3 <0.001 2.3 0.03 1.1 0.74
Tenosynovitis 2.4 <0.001 1.8 0.03 n.a. n.a.
Bone marrow oedema 1.2 0.13 1.0 0.80 1.3 0.04
Association with clinically tender joint
MCP-joints Wrists MTP-joints
OR p OR p OR p
Synovitis 2.9 <0.001 3.5 <0.001 1.7 0.01
Tenosynovitis 2.5 <0.001 2.4 <0.001 n.a n.a.
Bone marrow oedema 1.8 <0.001 1.7 0.002 1.3 0.003
All three together in one model:
Synovitis 1.9 0.001 2.0 0.09 1.1 0.65
Tenosynovitis 1.5 0.03 1.6 0.07 n.a. n.a.
Bone marrow oedema 1.3 0.03 1.1 0.55 1.3 0.04
All analyses were adjusted for age and gender.
n.a.= not assessed. It was not possible to score tenosynovitis of the MTPs, because here no MR-images 
right-angled (coronal planes) were available.
The association between inflammation detected by physical examination and by MRI was studied in all 
joints together. This analysis was done using Generalized Estimated Equations as this model takes into 
account that in every patient 10 joints were assessed. Adjustments for age and gender were included. 
The Odds Ratio (OR) reflects the ratio between the odds on joint swelling and the odds on no joint 
swelling for every unit increase in MRI score. Depicted are the ORs of the three MRI inflammation fea-
tures tested separately and tested together in one analysis.
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supplementary table 3A Subanalyses in RA patients (n=66): Inflammation on MRI in relation to swell-



























% of swollen joints with MRI 
feature
73% 24% 2%# 65% 19% 4%# 45% 25% 11%#
% of not swollen joints with MRI 
feature
19% 1% 0%# 17% 4% 0%# 14% 3% 1%#
Given MRI inflammation, % of 
non-swollen joints



























% of swollen joints with MRI 
feature
90% 60% 5%# 80% 60% 10%# 79% 63% 37%
% of not swollen joints with MRI 
feature
53% 16% 0%# 51% 18% 2%# 64% 23% 11%
Given MRI inflammation, % of 
non-swollen joints



















% of swollen joints with MRI 
feature
23% 0%# n.ap. 21% 12% 11%
% of not swollen joints with MRI 
feature
7% 1%# n.ap. 15% 8% 4%
Given MRI inflammation, % of 
non-swollen joints
58% 100%# n.ap. 77% 75% 63%
n.ap.= not applicable because n=0.
† It was not possible to score tenosynovitis of the MTPs, because here no MR-images right-angled (coro-
nal planes) were available.
# these frequencies should be interpreted with discretion, because of the low numbers of joints with 
these scores.
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supplementary table 3b Subanalyses in RA patients (n=66): Inflammation on MRI in relation to tender-



























% of tender joints with MRI 
feature
52% 14% 1%# 42% 9% 3%# 32% 14% 6%#
% of not tender joints with MRI 
feature
21% 3% 0%# 20% 7% 0%# 16% 4% 2%#
Given MRI inflammation, % of 
non-tender joints



























% of tender joints with MRI 
feature
96% 57% 4%# 87% 43% 4%# 86% 68% 36%
% of not tender joints with MRI 
feature
48% 14% 0%# 45% 24% 5%# 59% 17% 10%
Given MRI inflammation, % of 
non-tender joints



















% of tender joints with MRI 
feature
15% 1%# n.ap. 22% 13% 8%
% of not tender joints with MRI 
feature
7% 0%# n.ap. 13% 6% 3%
Given MRI inflammation, % of 
non-tender joints
45% 50%# n.ap. 52% 46% 44%
n.ap.= not applicable because n=0.
† It was not possible to score tenosynovitis of the MTPs, because here no MR-images right-angled (coro-
nal planes) were available.
# these frequencies should be interpreted with discretion, because of the very low numbers.
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sUPPlementARy methoDs: mRi sCAn PRotoCol
MR imaging of the hand (wrist and metacarpophalangeal joints) and forefoot (metatar-
sophalangeal joints) was performed within two weeks after inclusion, at the most painful 
side, or in case of completely symmetric symptoms at the dominant side. The presence of 
clinical arthritis at physical examination of the joints that were scanned was not a prereq-
uisite. Two patients were excluded because of contraindications for MR imaging. Patients 
with impaired renal function or known hypersensitivity or allergic reactions to contrast 
media were imaged without contrast administration (n=2).
            MR imaging was performed on a MSK-extreme 1.5T extremity MR imaging system 
(GE, Wisconsin, USA) using a 145mm coil for the foot and a 100mm coil for the hand. The 
patient was positioned in a chair beside the scanner, with the hand or foot fixed in the coil 
with cushions.
            The forefoot was scanned using a T1-weighted fast spin-echo (FSE) sequence in the 
axial plane with repetition time (TR) of 650 ms, echo time (TE) 17ms, acquisition matrix, 
388×288, echo train length (ETL) 2; and a T2-weighted FSE sequence with frequency selec-
tive fat saturation in the axial plane (TR/TE 3000/61.8; acquisition matrix 300x224, ETL7). 
Due to time constraints, imaging of the foot was limited to pre-contrast sequences only.
            In the hand, the following sequences were acquired before contrast injection: T1-
weighted FSE sequence in the coronal plane (TR/TE 650/17ms; acquisition matrix 388×88; 
ETL2); T2-weighted FSE sequence with frequency selective fat saturation in the coronal 
plane (TR/TE 3000/61.8ms; acquisition matrix, 300x224, ETL7). After intravenous injection 
of gadolinium contrast (gadoteric acid, Guerbet, Paris, France, standard dose of 0.1 mmol/
kg) the following sequences were obtained: T1-weighted FSE sequence with frequency 
selective fat saturation in the coronal plane (TR/TE 650/17ms, acquisition matrix 364×224, 
ETL2), T1-weighted FSE sequence with frequency selective fat saturation in the axial plane 
(TR/TE 570/7 ms; acquisition matrix 320x192; ETL2).
            Field-of-view was 100mm for the hand and 140mm for the foot. Coronal sequences 
had 18 slices with a slice thickness of 2mm and a slice gap of 0.2mm. All axial sequences 
had a slice thickness of 3mm and a slice gap of 0.3mm, with 20 slices for the hand and 16 
for the foot. Total imaging time was approximately 75 minutes.
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We recently demonstrated that MRI inflammation is prevalent in clinically non-swollen 
joints of early arthritis patients. In this study we assessed the relevance of this subclinical 
inflammation with regard to radiographic progression.
methods
1,130 joints (unilateral MCP2-5, wrist, and MTP1-5) of 113 early arthritis patients under-
went clinical examination and 1.5T MRI at baseline and radiographs at baseline and 1-year. 
Two readers scored the MRIs for synovitis, bone marrow edema (BME) and tenosynovitis 
according to RAMRIS. Radiographic progression over 1-year was determined using the 
Sharp-van-der-Heijde-scoring method.
Results
On patient level; BME, synovitis and tenosynovitis were associated with radiographic 
progression, independent of known risk factors (p=0.003, 0.001 and 0.011, respectively). 
Of all non-swollen joints (n=932), 232 joints (26%) had subclinical inflammation (≥1 
MRI-inflammation feature present). These joints were distributed among 91% of patients. 
Radiographic progression was present in 4% of non-swollen joints with subclinical inflam-
mation compared to 1% of non-swollen joints without subclinical inflammation (RR3.5, 
95%CI 1.3-9.6). Similar observations were done for BME (RR5.3, 95%CI 2.0-14.0), synovi-
tis (RR3.4, 95%CI 1.2-9.3) and tenosynovitis (RR3.0, 95%CI 0.7-12.7) separately.
Conclusions
Radiographic progression was infrequent but joints with subclinical inflammation had an 
increased risk of radiographic progression within year-1. This demonstrates the relevance 
of MRI-detected subclinical inflammation.
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intRoDUCtion
The severity of radiographic joint destruction varies between RA-patients. Much research 
has been focused on identifying risk factors for radiographic progression, with the ultimate 
aim of achieving individualized medicine at disease onset. Well-known risk factors are 
presence of erosions, presence of RA-related auto-antibodies (rheumatoid factor (RF), anti-
citrullinated-peptide antibodies (ACPA)) and measures of inflammation (C-reactive protein 
(CRP), number of swollen joints (SJC)).
MRI measures inflammation sensitively; it allows assessment of bone marrow edema 
(BME), tenosynovitis and synovitis. Previous studies in wrist and MCP-joints showed that 
inflammation detected with MRI, especially BME, is a strong predictor for radiographic 
progression (Suppl Table 1).1-8 However, none of these studies investigated MRI findings 
in relation to clinical joint inflammation. We recently studied MRI-inflammation in small 
joints that were not swollen at physical examination and observed MRI-inflammation in 
27%, 66% and 13% of non-swollen MCP, wrist and MTP-joints of early arthritis patients.9 
The identification of these inflamed joints may indicate the added value of MRI. How-
ever, the relevance of such subclinical inflammation is supported when it associates with 
radiographic progression. In this study we therefore investigated whether MRI-detected 
subclinical inflammation is associated with radiographic progression.
PAtients AnD methoDs
Patients
Between August 2010 and February 2012, MRI was performed in 179 early arthritis patients 
of the Leiden Early Arthritis Clinic, a population-based inception-cohort including patients 
with confirmed clinical arthritis and symptoms for <2 years. At baseline, questionnaires and 
66-SJCs were performed and serum obtained.10 All patients underwent extremity-MRI at 
baseline; of these 113 had 1-year follow-up including radiographs. Patients without 1-year 
follow-up were less often diagnosed with RA (Suppl Table 2). Of the 113 patients studied, 
53 fulfilled the 2010-criteria for RA at baseline. During the first year, three-quarters of 
the patients were treated with conventional DMARDs.(Table 1) All participants provided 
written informed consent. The study was approved by the local medical ethics committee.
mRi and radiographs
The MCP2-5, wrist and MTP1-5-joints at the most painful side (or dominant side in case of 
equally severe symptoms at both sides) were scanned with a 1.5T-extremity-MRI-scanner 
according to the OMERACT-RAMRIS-protocol. A detailed scan protocol is provided in the 
supplementary methods. Synovitis and BME were scored according to RAMRIS;11 teno-
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synovitis in MCP-joints and wrists was assessed as described elsewhere.12 Two readers 
scored the MR-images independently, blinded to clinical data; the mean scores were 
studied. Within-reader ICCs for the total MRI-inflammation-score were 0.99 and 0.93; the 
between-reader ICC 0.87. The total MRI-inflammation was the sum of synovitis, BME and 
tenosynovitis scores. Subclinical inflammation was defined as inflammation on MRI in clini-
cally non-swollen joints. Radiographs were scored according to the Sharp-van-der-Heijde 
method (SHS) by one reader in chronological order (ICC baseline SHS 0.86). Radiographic 
progression was defined as the difference in SHS between year-1 and baseline.
Analyses
First, to replicate previous associations between MRI-inflammation and radiographic 
progression,1-7 analyses were done on patient level using a linear regression model with 
radiographic progression (continuous variable) as outcome. Univariable and multivariable 
analyses (adjusting for age, gender, ACPA, RF, CRP-level and 66SJC) for total inflammation 
and each MRI feature separately, were performed. Joints that could not be completely 
scored on MRI due to insufficient image-quality (1.1% of all individual scores) were imputed 
with the median value for that feature across all joints or bones within the same patient.
Next, analyses were performed on joint level. For MRI, the sum scores per joint and 
feature were determined according to RAMRIS. Similarly the sum scores per joint on radio-
graphs were determined according to SHS (Suppl methods). Missing MRI-scores were not 
imputed at joint level. To compare frequencies of subclinical inflammation the continuous 
MRI-data was dichotomized; joints with a score ≥1 were considered positive. In sensitivity 
analyses a cut-off ≥2 was evaluated. Joints that progressed ≥1 SHS-point in 1-year were 
considered to have radiographic progression. SPSS version 20.0 was used; p-values <0.05 
were considered significant.
ResUlts
total mRi inflammation on patient level
Table 1 presents baseline characteristics of early arthritis and RA-patients. First, we evalu-
ated the total MRI-inflammation scores in relation to radiographic progression and observed 
that both the total score and the individual MRI-features were associated with radiographic 
progression in early arthritis and RA, independent of known risk factors (p<0.05 except for 
tenosynovitis in RA, Table 2). We herewith replicated previous observations.1-7
subclinical mRi inflammation on patient level
When separating patients’ total MRI-inflammation scores (mean 13.9±12.0) into the scores 
obtained in swollen joints and the scores obtained in non-swollen joints, the mean score 
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Age, mean ± SD, years 54.9 ± 15.7 55.4 ± 15.5
Female sex, n (%) 62 (54.9) 32 (60.4)
Symptom duration at inclusion, median (IQR), weeks 15 (7-32.5) 16.5 (8.8-33.3)
Onset of symptoms, n (%)
(sub) acute 47 (43.1) 20 (38.5)
gradual 61 (56.0) 32 (61.5)
Morning stiffness, median (IQR), minutes 45 (15-82.5) 52.5 (15-112.5)
Swollen joint count, median (IQR) 4 (2-7) 5 (3-10)
Tender joint count, median (IQR) 7 (3-11.5) 8 (4-15.5)
ACPA positivity, n (%) 40 (35.4) 35 (66.0)
RF positivity, n (%) 44 (38.9) 35 (66.0)
CRP level, median (IQR) 6 (3-17.5) 10 (3-19)
ESR level, median (IQR) 19 (6-34) 28 (9-41)
Patient classification at baseline, n (%)
RA (2010 ACR/EULAR criteria) 53 (46.9)
Unclassified arthritis (UA) 37 (32.7)
Psoriatic arthritis 11 (9.7)
Inflammatory osteoarthritis 4 (3.5)
Spondyloarthritis 3 (2.7)
Other diagnoses 5 (4.4)
Treatment within the first year, n (%)†
Methotrexate 48 (42.5) 26 (49.1)
Hydroxychloroquine 26 (23.0) 19 (35.8)
Prednisolon orally 17 (15.0) 13 (24.5)
Sulfasalazine 13 (11.5) 11 (20.8)
Trial medication# 8 (7.1) 7 (13.2)
Anti-TNF∞ 2 (1.8) 2 (3.4)
Leflunomide 2 (1.8) 1 (1.9)
Azathioprine 1 (0.9) 1 (1.9)
No DMARD 26 (23) 4 (7.5)
MRI BME, median (IQR) 5.5 (2.5-11.8) 6.5 (3.3-15.8)
MRI Synovitis, median (IQR) 4.5 (2.5-7.5) 5.0 (2.3-8.0)
MRI Tenosynovitis, median (IQR) 2.8 (0.5-5.5) 3.5 (0.6-5.5)
MRI Any inflammation, median (IQR) 13.0 (7.6-25.5) 16.8 (8.5-30.1)
SHS, median (IQR) 2.0 (0.0-6.0) 2.0 (0.0-4.0)
At patient level medians (IQR) are shown and missing scores were imputed with the median of non-
missing MRI scores of the same feature of the patient. The 66 swollen joint count and 68 tender joint 
count was assessed.
† The total exceeds100% as some patients used several DMARDs in the first year.
#Trial medication refers to a double-blind randomized trial in which patients received tocilizumab and/
or methotrexate.
∞One patient received anti-TNF early in the disease in the IMPROVED trial and the other patient failed 
methotrexate, hydroxychloroquine and sulfasalazine and then received anti-TNF after 353 days.
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in swollen joints was 7.2±9.4 and in non-swollen joints 6.6±7.8. This suggests that the 
cumulative amount of MRI-inflammation in non-swollen joints was comparable to that in 
swollen joints. We subsequently studied non-swollen joints only.
Supplementary Figure 1 showing the number of joints with subclinical inflammation 
reveals that most patients had 1-3 subclinical inflamed joints and only 9% of patient had 
no joints with subclinical inflammation. Comparing the number of subclinical inflamed 
joints between patients with RA and other diagnoses revealed that RA-patients tended 
to have more joints with subclinical inflammation (2.3 versus 1.9, p=0.11). Evaluating the 
different inflammation features separately showed that RA-patients mainly had more joints 
with BME in non-swollen joints (1.6 versus 1.1, p=0.03).
subclinical inflammation on joint level
Next, we investigated subclinical inflammation at joint level. Of all 1,130 joints studied 
932 joints were clinically non-swollen. Of these, 232 (26%) had any subclinical MRI-
inflammation: 17% of non-swollen joints had BME, 16% had synovitis and 21% tenosy-
novitis (Figure 1). Two-percent of the 932 non-swollen joints had radiographic progression 
during year-1 (compared to 8% of the swollen joints). The non-swollen joints with and 
without subclinical MRI-inflammation were compared to determine the relative risks (RR) 
of radiographic progression: 4% of non-swollen joints with any MRI-inflammation had 
radiographic progression versus 1% of the joints without subclinical inflammation (RR 3.5, 
95%CI 1.3-9.6). Similar analyses for the individual MRI-inflammation features revealed 
that BME in non-swollen joints had the highest RR of radiographic progression (RR 5.3, 
table 2 Associations between baseline MRI inflammation and radiographic SHS progression over the 
first year.
Early arthritis patients (n=113) Subgroup of 2010-RA patients (n=53)
Univariable: beta (95% CI) R2 P value beta (95% CI) R2 P value
BME 0.06 (0.02-0.10) 0.13 <0.001 0.06 (0.01-0.11) 0.14 0.006
Synovitis 0.14 (0.05-0.22) 0.13 <0.001 0.12 (-0.02-0.23) 0.11 0.02
Tenosynovitis 0.11 (0.03-0.20) 0.08 0.002 0.07 (-0.05-0.21) 0.04 0.19
Total inflammation 0.04 (0.02-0.06) 0.16 <0.001 0.04 (0.01-0.07) 0.15 0.004
Multi-variable: beta (95% CI) R2a P value beta (95% CI) R2a P value
BME 0.05 (0.01-0.09) 0.16 0.003 0.04 (-0.01-0.10) 0.27 0.04
Synovitis 0.13 (0.03-0.21) 0.18 0.001 0.11 (-0.03-0.21) 0.26 0.04
Tenosynovitis 0.10 (0.01-0.17) 0.14 0.011 0.02 (-0.10-0.13) 0.19 0.76
Total inflammation 0.04 (0.01-0.06) 0.18 <0.001 0.03 (-0.01-0.06) 0.26 0.04
* Linear regression analysis was used. Multi-variable: adjusted for age, gender, RF +/-, CCP +/-, CRP 
level, 66 SJC. R2 represents the explained variability in radiographic progression, by the model. For the 
multivariable model the R2 adjusted (R2a) is presented, which adjusts for the amount of variables included 
in the model. BME=bone marrow edema. Total inflammation=BME + synovitis + tenosynovitis.
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95%CI 2.0-14.0; 7% versus 1%). For synovitis the RR was 3.4 (95%CI 1.2-9.3; 5% versus 
1%). For tenosynovitis the RR was 3.0 (95%CI 0.7-12.7). When repeating these analyses 
in joints that were non-swollen and also non-tender, the RRs obtained were comparable, 
although 95%CIs were broader (Suppl. Figure 2). When analyzing wrist joints only, a higher 
percentage of non-swollen joints with subclinical inflammation was observed (86% versus 
26%) and radiographic progression occurred more frequently (11% versus 3%, Suppl. 
Figure 3). When analyzing radiographic progression in non-swollen hand and foot joints of 
RA-patients (n=53), the RRs went into the same direction for synovitis and BME, but the 
95%CIs were broad.(Suppl. Figure 4) Furthermore, sensitivity analyses with a higher cut-off 










































Figure 1 Distribution of MRI inflammation among clinically non-swollen joints and the percentages of 
joints with radiographic progression during 1-year follow-up.
A joint or bone with a MRI RAMRIS score ≥1 was considered positive. Joints with an increase in SHS of 
≥1 were considered to have radiographic progression. The percentages at the right part of the figure 
represent the absolute risks at radiographic progression in the presence or absence of the MRI feature. 
Dividing these risks by each other results in the relative risk (RR). These were for any MRI inflammation: 
RR 3.5 (95%CI 1.3-9.6), BME: RR 5.3 (95%CI 2.0-14.0), synovitis RR 3.4 (95%CI 1.2-9.3) and tenosy-
novitis RR 3.0 (95%CI 0.7-12.7).
Radiographic progression was detected in 4% of non-swollen joints with MRI inflammation; these joints 
were present in 11 patients (9.7% of all patients).
At joint level (n=1,130) missing variables were not imputed and not analyzed. Missing variables: BME 
n=44, synovitis n=18, tenosynovitis n=15.
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DisCUssion
This study is the first investigating the radiographic outcome of MRI-detected inflam-
mation in clinically non-inflamed joints at disease presentation. We observed that joints 
with subclinical inflammation, especially with BME, had an increased risk of radiographic 
progression during the first year.
Our observation that the total level of MRI-inflammation (in both swollen and non-
swollen joints) was an independent predictor for radiographic progression fits with previ-
ous findings.1-7 Notably, the effect sizes of BME and synovitis in our study were similar 
to those of Boyesen et al. (beta 0.04 and 0.06 for BME and 0.11 and 0.12 for synovitis, 
respectively).1 Furthermore, our finding that subclinical inflammation at disease onset is 
associated with radiographic progression is in line with previous findings on subclinical 
inflammation in RA-patients in clinical remission.13-17
This study has several limitations. First, the sample size, particularly of the RA-group, 
was moderate. Although the effect sizes obtained in the total group and RA-group were 
similar, the 95%CIs of the estimates in the RA-group were broad. Second, radiographic 
progression was infrequent, not only in all early arthritis patients (3% of all joints) but also 
in RA, a group of patients that is more likely to erode (4%). Third, radiographic progres-
sion was defined as ΔSHS on joint level of ≥1,this concerned a small increase but the 
radiographs were scored in chronological order which reduced the chance on measure-
ment errors. Up-to-date treatment-strategies will have contributed to the low prevalence 
of radiographic progression. Furthermore, the frequency of progression was determined 
on joint level, which is relatively uncommon. To obtain a reference, we also analyzed previ-
ously SHS-scored unilateral MCP2-5, wrist and MTP1-5 joints of EAC RA-patients included 
in 1993-1999 and 2000-2006 when different treatment strategies were applied.10 Here, 
using the same definition, radiographic progression during year-1 was present in 15% and 
9% of joints, suggesting that in the currently studied patients treatment had effectively 
reduced radiographic progression. Nonetheless, despite radiographic progression being 
infrequent nowadays, progression was significantly more frequent in joints with subclinical 
inflammation. This suggests that MRI may be valuable to identify joints with increased risk 
of progression despite normal physical examination and current treatment-strategies.
This study mainly increases the comprehension of the connection between inflamma-
tion and structural damage early in the disease. Whether subclinical MRI-inflammation is 
relevant to clinical practice remains a question, as rheumatologists treat patients and not 
joints. Information on subclinical inflamed joints would affect treatment decisions most 
when patients have few clinically swollen joints. A sub-analysis in patients with ≤2 swollen 
joints showed a slight tendency towards more progression in the presence of more sub-
clinically inflamed joints (ΔSHS1.4 in case of ≥3 sub-clinically inflamed joints versus ΔSHS 
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1.0 in case of ≤2 sub-clinically inflamed joints). Larger studies are required to ascertain 
whether information on MRI-inflammation is relevant for clinical practice.
MRI is a sensitive tool and MRI-inflammation has been reported in symptom-free per-
sons.18-20 Nevertheless, present data indicate that MRI-detected subclinical inflammation in 
early arthritis negatively affects radiological outcome.
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supplementary table 1 Summary of previous studies in RA on baseline MRI and radiographic progres-
sion
Reference N MRI Outcome Main result
Haavardsholm et al.(2) 84 Unilateral wrist Radiographic 
progression in hands 
after 1-year
BME and sex independent 
predictors
Boyesen et al.(1) 55 Unilateral wrist Radiographic 
progression in hands 
after 3-years
ESR , MRI synovitis, MRI 
BME independent predictors
Hetland et al.(3) 130 Unilateral wrist and 
MCPs
Radiographic 
progression in hands 
and feet after 2-years
BME independent predictor
Hetland et al.(4) 139 Unilateral wrist and 
MCPs
Radiographic 
progression in hands 
and feet after 5-years
ACPA, BME and baseline 
radiographic damage 
independent predictors
McQueen et al.(6) 42 Unilateral wrist Radiographic 
progression in hands 
and feet after 1-year
Total MRI score>13, MRI 
erosions and ESR
McQueen et al.(7) 31 Unilateral wrist Radiographic 
progression in hands 
and feet after 6-years
BME, pain score, CRP, ESR 
and baseline radiographic 
damage independent 
predictors
Lindegaard et al.(5) 24 Unilateral wrist and 
MCPs
Radiographic erosion 
progression in hands 
after 1-year
MRI erosions and BME 
predictors
Mundwiler et al.(8) 50 MTP3-5 Radiographic 
progression in MTP3-
5 after 1-year
Almost no progression 
without BME
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Supplementary Table 2 Baseline characteristics of 113 early arthritis patients with 1 year radiographs 
and 66 early arthritis patients without 1 year radiographs
Patients with 1 
year radiographs
(n=113)




Age, mean ± SD, years 54.9 ± 15.7 51.9 ± 14.3 0.11
Female sex, n (%) 62 (54.9) 37 (56.1) 0.88
Symptom duration at inclusion, median (IQR), 
weeks
15 (7-32.5) 13 (5-24) 0.10
Morning stiffness, median (IQR), minutes 45 (15-82.5) 15 (15-60) 0.01
Swollen joint count, median (IQR) 4 (2-7) 2 (1-4) <0.001
Tender joint count, median (IQR) 7 (3-11.5) 5 (1-11) 0.11
ACPA positivity, n (%) 40 (35.4) 5 (7.7) <0.001
RF positivity, n (%) 44 (38.9) 10 (15.4) 0.001
CRP level, median (IQR) 6 (3-17.5) 3 (3-7) 0.001
ESR level, median (IQR) 19 (6-34) 10 (6-22) 0.04
Patient classification at baseline, n (%)
RA (2010 ACR/EULAR criteria) 53 (46.9) 13 (19.7) <0.001
Unclassified arthritis (UA) 37 (32.7) 28 (42.4)
Psoriatic arthritis 11 (9.7) 4 (6.1)
Inflammatory osteoarthritis 4 (3.5) 8 (12.1)
Spondyloarthritis 3 (2.7) 0 (0)
Other diagnoses 5 (4.4) 13 (19.7)
MRI BME, median (IQR) 5.5 (2.5-11.8) 3.5 (1.5-6.0) 0.001
MRI Synovitis, median (IQR) 4.5 (2.5-7.5) 3.0 (1.5-5.6) 0.01
MRI Tenosynovitis, median (IQR) 2.8 (0.5-5.5) 1.5 (0.4-30.0) 0.01
MRI Any inflammation, median (IQR) 13.0 (7.6-25.5) 8.8 (4.5-14.0) 0.001
SHS, median (IQR) 2.0 (0.0-6.0) 0.0 (0.0-3.0) 0.004
Of the 179 EAC patients with MRI; 113 patients had a radiograph at one year of follow-up and 66 
patients not.
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supplementary Figure 1 Distribution of the number of joints with any subclinical inflammation per 
patient.
A joint with any subclinical inflammation, is a non-swollen joint with a MRI bone marrow edema (BME) 
score ≥1 and/or synovitis score ≥1 and/or tenosynovitis score ≥1.
1,130 
joints 338
(swollen and tender) OR 
(tender but non-swollen) OR 





































supplementary Figure  2 Distribution of MRI inflammation among clinically non-swollen and non-
tender joints in all early arthritis patients and the percentages of joints with radiographic progression 
during 1-year follow-up.
A joint or bone with a MRI RAMRIS score ≥1 was considered positive. Joints with an increase in SHS of 
≥1 were considered to have radiographic progression. The percentages at the right part of the figure 
represent the absolute risks at radiographic progression in the presence or absence of the MRI feature. 
Dividing these risks by each other results in the relative risk (RR). These were for any MRI inflammation: 
RR 2.6 (95%CI 0.9-7.7), BME: RR 4.2 (95%CI 1.5-11.8), synovitis RR 1.8 (95%CI 0.5-6.5) and tenosy-
novitis RR 2.2 (95%CI 0.4-11.7).











































supplementary Figure 3 Distribution of MRI inflammation among clinically non-swollen wrist joints 
in all early arthritis patients and the percentages of joints with radiographic progression during 1-year 
follow-up
A joint or bone with a MRI RAMRIS score ≥1 was considered positive. Joints with an increase in SHS of 
≥1 were considered to have radiographic progression. The percentages at the right part of the figure 
represent the absolute risks at radiographic progression in the presence or absence of the MRI feature. 
Dividing these risks by each other results in the relative risk (RR). These were ‘infinite” for any MRI inflam-
mation and BME because of 0% progression in the joints/bones without MRI inflammation or without 












































supplementary Figure  4 Distribution of MRI inflammation among clinically non-swollen joints and 
the percentages of joints with radiographic progression during 1-year follow-up, in a subgroup of RA 
patients.
A joint or bone with a MRI RAMRIS score ≥1 was considered positive. Joints with an increase in SHS of 
≥1 were considered to have radiographic progression. The percentages at the right part of the figure 
represent the absolute risks at radiographic progression in the presence or absence of the MRI feature. 
Dividing these risks by each other results in the relative risk (RR). These were for any MRI inflammation: 
RR 3.6 (95%CI 0.9-14.9), BME: RR 4.5 (95%CI 1.2-16.7), synovitis RR 2.1 (95%CI 0.4-8.7) and tenosy-
novitis RR 1.1 (95%CI 0.04-11.3).











































supplementary Figure 5 Sensitivity analyses: Distribution of MRI inflammation, defined as a score of 
≥2, among clinically non-swollen joints and the percentages of joints with radiographic progression dur-
ing 1-year follow-up.
A joint or bone with a MRI RAMRIS score ≥2 was considered positive. Joints with an increase in SHS of 
≥1 were considered to have radiographic progression. The percentages at the right part of the figure 
represent the absolute risks at radiographic progression in the presence or absence of the MRI feature. 
Dividing these risks by each other results in the relative risk (RR). These were for any MRI inflammation: 
RR 5.2 (95%CI 1.9-13.9), BME: RR 4.8 (95%CI 1.7-13.1), synovitis RR 6.1 (95%CI 1.7-18.6) and tenosy-
novitis RR 6.7 (95%CI 1.4-28.7). As a result of using the higher cut-off score of 2, the number of joints 
positive for MRI inflammation declined and the data should be interpreted with caution. (BME positive 





MR imaging of the hand (wrist and metacarpophalangeal joints) and forefoot (metatar-
sophalangeal joints) was performed within two weeks after inclusion, at the most painful 
side, or in case of completely symmetric symptoms at the dominant side. The presence of 
clinical arthritis at physical examination of the joints that were scanned was not a prereq-
uisite. Two patients were excluded because of contraindications for MR imaging. Patients 
with impaired renal function or known hypersensitivity or allergic reactions to contrast 
media were imaged without contrast administration (n=2).
 MR imaging was performed on a MSK-extreme 1.5T extremity MR imaging system (GE, 
Wisconsin, USA) using a 145mm coil for the foot and a 100mm coil for the hand. The 
patient was positioned in a chair beside the scanner, with the hand or foot fixed in the coil 
with cushions.
 The forefoot was scanned using a T1-weighted fast spin-echo (FSE) sequence in the 
axial plane with repetition time (TR) of 650 ms, echo time (TE) 17ms, acquisition matrix, 
388×288, echo train length (ETL) 2; and a T2-weighted FSE sequence with frequency selec-
tive fat saturation in the axial plane (TR/TE 3000/61.8; acquisition matrix 300x224, ETL7). 
Due to time constraints, imaging of the foot was limited to pre-contrast sequences only.
 In the hand, the following sequences were acquired before contrast injection: T1-weighted 
FSE sequence in the coronal plane (TR/TE 650/17ms; acquisition matrix 388×88; ETL2); 
T2-weighted FSE sequence with frequency selective fat saturation in the coronal plane 
(TR/TE 3000/61.8ms; acquisition matrix, 300x224, ETL7). After intravenous injection of 
gadolinium contrast (gadoteric acid, Guerbet, Paris, France, standard dose of 0.1 mmol/
kg) the following sequences were obtained: T1-weighted FSE sequence with frequency 
selective fat saturation in the coronal plane (TR/TE 650/17ms, acquisition matrix 364×224, 
ETL2), T1-weighted FSE sequence with frequency selective fat saturation in the axial plane 
(TR/TE 570/7 ms; acquisition matrix 320x192; ETL2).
 Field-of-view was 100mm for the hand and 140mm for the foot. Coronal sequences had 
18 slices with a slice thickness of 2mm and a slice gap of 0.2mm. All axial sequences had 
a slice thickness of 3mm and a slice gap of 0.3mm, with 20 slices for the hand and 16 for 
the foot. Total imaging time was approximately 75 minutes.
The inter-reader reliability was assessed by computing the interclass correlation for total 
scores of each MR imaging parameter. In addition, a subset of 25 randomly selected MR 
image sets (14%) was scored twice by each reader to determine intra-reader ICC’s. Intra-
reader ICCs for synovitis were 0.93 for reader 1 and 0.64 for reader 2 and interreader ICC 
0.65, for tenosynovitis 0.91, 0.93 and 0.90, for bone marrow edema 0.96, 0.72 and 0.86, 
respectively.
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summing of mRi scores and shs at joint level
To allow comparisons of MRI inflammation and radiographic joint damage at joint level 
several inflammation features were summed. According to RAMRIS, proximal and distal 
bones of MCP and MTP joints were scored separately for BME, these were summed per 
joint. For the wrist, 15 bones were scored for BME; these scores were summed for the wrist 
score. For MRI synovitis, the scores in the MCP and MTP joints were straightforward, in 
the wrist three joints (distal radio-ulnar, radio-carpal and intercarpal joint) were scored and 
summed to obtain the synovitis score in the wrist. For tenosynovitis in the MCP and wrist 
joints, the scores of the flexor and extensor sites were summed. Also for the SHS scores at 
joint level, the scores of erosions and joint space narrowing of the wrist that were assessed 
according to the Sharp van der Heijde scoring method were summed.
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MRI is increasingly used in Rheumatoid arthritis (RA) research. A EULAR task-force recently 
suggested that MRI can improve the certainty of the diagnosis RA. Since this recommenda-
tion may reflect a tendency to use MRI in daily practice, thorough studies on the value 
of MRI are required. Thus far no large studies have evaluated the accuracy of MRI to 
differentiate early RA from other early arthritis patients. We therefore performed a large 
cross-sectional study to determine if patients that are clinically classified with RA differ in 
MRI features compared to patients with other diagnoses.
methods
179 patients presenting with early arthritis (median symptom duration 15.4 weeks) 
underwent 1.5T-extremity MR-imaging of unilateral wrist, metacarpophalangeal and 
metatarsophalangeal joints according to our arthritis protocol, the foot without contrast. 
Images were scored according to OMERACT RAMRIS by two independent readers. Teno-
synovitis was also assessed. The main outcome was fulfilling the 1987 ACR-criteria for 
RA. Test characteristics and areas under the receiver-operator-characteristic-curves (AUCs) 
were evaluated. In sub-analyses the 2010-ACR/EULAR-criteria were used as outcome and 
analyses were stratified for ACPA.
Results
The ACR87-criteria were fulfilled in 43 patients (24.0%). RA-patients had higher scores for 
synovitis, tenosynovitis and bone marrow edema (BME) than non-RA patients (p<0.05). 
ACPA-positive patients had more BME (median scores 6.5 vs. 4.25, p=0.016) than ACPA-
negative patients. For all MRI features the predictive value for the presence of RA was low 
(PPV <50%). For all MRI features the AUCs were <0.70. 2010+1987- patients had less 
synovitis than 2010+1987+ patients (p=0.029)
Conclusion
Although RA-patients had higher scores of MRI-inflammation and ACPA-positive patients 
had more BME, the severity of MRI-inflammation assessed according to RAMRIS does not 
accurately differentiate RA-patients from other early arthritis patients.
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intRoDUCtion
Early identification of rheumatoid arthritis (RA) is important because early initiation of ag-
gressive treatment results in a better outcome.1 However, this requires that RA-patients are 
identified amongst other early arthritis patients. Magnetic Resonance Imaging (MRI) in RA 
is presently mainly used for research purposes. The value of MRI is supported by its sensitiv-
ity to depict changes that are not detectable by physical examination and the association 
of bone marrow edema (BME) with radiographic progression over time.2 A recent EULAR 
taskforce recommended that “in case of diagnostic doubt, MR imaging can improve the 
certainty of a diagnosis of RA”.3 Since this recommendation may reflect a tendency to 
use MRI in daily practice, thorough studies on the value of MRI in a general setting of 
early arthritis patients are required. Thus far no large studies evaluated the accuracy of 
MRI to differentiate RA-patients from early arthritis patients with other diagnoses. The 
majority of studies performed on the diagnostic accuracy primarily evaluated patients with 
undifferentiated arthritis or RA but not the entire spectrum of early arthritis patients.4,5 
Furthermore, they included a low number of early arthritis patients (less than 50) and 
reported variable test characteristics (the sensitivity and specificity of certain MR imaging 
findings ranged between 20–100% and 0–100%). Therefore at present the accuracy to 
differentiate RA patients from other patients with early arthritis is unclear. We performed 
a large cross-sectional study to determine this. The outcome was the diagnosis according 
to classification criteria at two weeks. On purpose we did not explore the additional value 
of MRI when added to clinical diagnoses, but we started with addressing an even more 
basic question, being whether patients that are clinically classified with RA differ in MRI 
features compared to patients with other diagnoses. Because these patients are clinically 
clearly distinctive, amongst other things in the joints that are typically involved and the 
extent of inflammation, we anticipated finding differences at 1.5T extremity MRI of the 
joints most frequently involved in RA. Also, these findings will serve as a basis for further 
future analyses in the current cohort of patients.
mAteRiAls AnD methoDs
Patients
Patients were included in the Leiden Early Arthritis Clinic (EAC). Inclusion required the 
presence of clinically confirmed arthritis of ≥1 joint and symptoms for ≤2-years. Parameters 
collected at inclusion were medical history, questionnaires, joint counts, laboratory tests, 
and radiographs of hands and feet. For a detailed description see reference.6 Anti-citrul-
linated-peptide-antibodies (ACPA) were measured (anti-CCP2; Eurodiagnostica, Arnhem, 
The Netherlands). After two weeks, when the laboratory results were known, patients 
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were diagnosed with RA or other diagnoses according to existing classification criteria, 
blinded to MR findings. RA was classified according to the 1987-criteria; in sub-analyses 
RA according to the 2010-criteria was also studied as outcome. These cross-sectional data 
were studied.
From August 2010 until April 2012, 350 patients were included in the EAC. MR imaging 
was performed in 179 patients based on voluntary participation. The patients with and 
without MR did not significantly differ in age, sex, symptom duration or ACPA status (data 
not shown). The study was approved by the local ethical committee. All patients signed 
informed consent.
mR imaging
MR imaging of the hand (wrist and metacarpophalangeal joints) and forefoot (metatar-
sophalangeal joints) was performed within two weeks after inclusion, at the most painful 
side, or in case of completely symmetric symptoms at the dominant side. The presence of 
clinical arthritis at physical examination of the joints that were scanned was not a prereq-
uisite. Two patients were excluded because of contraindications for MR imaging. Patients 
with impaired renal function or known hypersensitivity or allergic reactions to contrast 
media were imaged without contrast administration (n=2).
MR imaging was performed on a MSK-extreme 1.5T extremity MR imaging system (GE, 
Wisconsin, USA) using a 145 mm coil for the foot and a 100 mm coil for the hand. The 
patient was positioned in a chair beside the scanner, with the hand or foot fixed in the coil 
with cushions.
The forefoot was scanned using a T1-weighted fast spin-echo (FSE) sequence in the 
axial plane with repetition time (TR) of 650 ms, echo time (TE) 17 ms, acquisition matrix, 
388×288, echo train length (ETL) 2; and a T2-weighted FSE sequence with frequency selec-
tive fat saturation in the axial plane (TR/TE 3000/61.8; acquisition matrix 300x224, ETL 7). 
Due to time constraints, imaging of the foot was limited to pre-contrast sequences only.
In the hand, the following sequences were acquired before contrast injection: T1-
weighted FSE sequence in the coronal plane (TR/TE 650/17 ms; acquisition matrix 388×88; 
ETL 2); T2-weighted FSE sequence with frequency selective fat saturation in the coronal 
plane (TR/TE 3000/61.8 ms; acquisition matrix, 300x224, ETL 7). After intravenous injection 
of gadolinium contrast (gadoteric acid, Guerbet, Paris, France, standard dose of 0.1 mmol/
kg) the following sequences were obtained: T1-weighted FSE sequence with frequency 
selective fat saturation in the coronal plane (TR/TE 650/17 ms, acquisition matrix 364×224, 
ETL2), T1-weighted FSE sequence with frequency selective fat saturation in the axial plane 
(TR/TE 570/7 ms; acquisition matrix 320x192; ETL 2).
Field-of-view was 100 mm for the hand and 140 mm for the foot. Coronal sequences 
had 18 slices with a slice thickness of 2 mm and a slice gap of 0.2 mm. All axial sequences 
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had a slice thickness of 3 mm and a slice gap of 0.3 mm, with 20 slices for the hand and 
16 for the foot. Total imaging time was approximately 75 minutes.
mR imaging scoring
MR images were scored by two readers (WS and AK), blinded to clinical data. Each reader 
separately analyzed each set of images and the mean total scores for each feature of 
both readers were used for further analyses. Synovitis, bone marrow edema and erosions 
were scored semi-quantitatively according to OMERACT RAMRIS definitions and score. 
Tenosynovitis in the MCP and wrist joints was evaluated using the method proposed by 
Haavardsholm et al., with tenosynovitis assessed for the flexor and extensor tendons of 
each MCP joint at the same 0-3 scale as for the wrist.7 Tenosynovitis was not assessed in 
the foot because of the lack of axial images.
Total RAMRIS score was defined as the total of all scores including tenosynovitis. Some 
joints could not be completely scored due to insufficient image quality (1.1% of all indi-
vidual scores), in most cases due to incomplete fat suppression or movement artifacts. In 
these cases values were imputed with the median value for that feature across all joints 
or bones within the same patient. The inter-reader reliability was assessed by computing 
the intra-class correlation for total scores of each MR imaging parameter. In addition, a 
subset of 25 randomly selected MR image sets (14.0%) was scored twice by each reader 
to determine intra-reader ICC’s. Intra-reader ICCs for total RAMRIS-score were 0.98 for 
reader 1 and 0.83 for reader 2 and inter-reader ICC for total RAMRIS-score was 0.89. For 
synovitis intra-reader ICCs were 0.93 and 0.64 and inter-reader ICC 0.65, for tenosynovitis 
0.91, 0.93 and 0.90, for bone marrow edema 0.96, 0.72 and 0.86 and for erosions 0.89, 
0.65 and 0.76 respectively.
statistical analysis
The Wilcoxon Rank Sum and Kruskal-Wallis tests were used where appropriate. To evaluate 
the discriminative ability of MRI the area under the receiver-operating-characteristic-curves 
(AUC), test characteristics and positive and negative likelihood ratio (LR+, LR-) were as-
sessed. Optimal cut-off points for dichotomization were determined per MRI feature using 
Youden’s method.8 Analyses were performed using R, version 2.15.0 (R Development Core 
Team). P-values <0.05 were considered significant.
ResUlts
Patient characteristics
Of the 179 patients, 99 were female (55.3%). The median age was 57 years (IQR 20), 
the median symptom duration 15.4 weeks (IQR 21) and 45 (25.1%) of the patients were 
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ACPA-positive. Patients were classified according to the following diagnoses: 1987-RA 
43 (24.0%), UA 88 (49.2%), inflammatory osteoarthritis 12 (6.7%), psoriatic arthritis 15 
(8.4%) and other rheumatic diagnoses 21 (11.7%). The patient characteristics per diagno-
sis are presented in Table 1.
mRi scores per group of diagnoses
The median scores for synovitis, bone marrow edema, erosions and tenosynovitis per joint 
group are presented in Table 2. Figure 1 depicts the scores for patients with different 
diagnoses. Scores for synovitis, tenosynovitis and bone marrow edema seemed higher in 
RA-patients than in early arthritis patients with other diagnoses (Figure 1). Subsequently 
we tested whether patients with RA had different MR imaging results than patients with 
other diagnoses. These differences were statistically significant when comparing RA with 
all patients with other diagnoses. The median scores for RA and other diagnoses were 
respectively 5.5 and 4.0 for synovitis (p=0.003) 3.0 and 1.5 for tenosynovitis (p=0.005), 
and 6.5 and 4.5 for bone marrow edema (p=0.038). The erosion scores were not statisti-
cally significantly different (4.5 and 3.5 for RA and other diagnoses respectively, p=0.15).
Accuracy of mR imaging in differentiating RA from other diagnoses
Next the accuracy to differentiate RA from patients with other diagnoses was evaluated by 
determining the test characteristics and the AUC (Table 2). In the presence of a certain MRI 
feature, the chance that this patient had RA was low (low positive predictive value). The 
AUCs of all features were lower than 0.70.











Age, yrs, median (IQR) 59 (24) 55 (20) 62.5 (9) 47.5 (14) 52.5 (33)
Sex (women/men) 23/20 52/36 7/5 6/9 11/10
Symptom duration, weeks, 
median (IQR)
17.3 (28.2) 10.7 (20) 33.8 (78.5) 30.9 (32.9) 10.6 (17.3)
Rheumatoid factor 
positivity, n(%)
27 (62.8) 21 (23.9) 0 (0.0) 4 (26.7) 2 (9.5)
ACPA positivity, n(%) 21 (48.8) 20 (22.7) 0 (0.0) 3 (20.0) 1 (4.8)
CRP, mg/l, median (IQR) 8 (19) 4 (5) 3 (1) 4 (10) 12 (23)
66 Swollen joint count, 
median (IQR)
7 (8) 2 (3) 3 (3) 5 (3) 2 (4)
RA: rheumatoid arthritis according to the 1987 ACR-criteria, UA: undifferentiated arthritis, OA: inflam-
matory osteoarthritis, PsA: psoriatic arthritis, other: other rheumatic diagnoses including reactive arthritis 
(n=6), spondylarthropathy (n=3) , gout (n=2), pseudogout (1), palindromic arthritis (n=1), paramalignant 
arthritis (n=1), lyme disease (n=1), systemic lupus erythematosus (n=1) RS3PE (n=1), sarcoidosis (1) and 
unspecified other (n=3).


























































































































































































































































































































































































































































RA according to the 1987ACR or 2010 ACR/eUlAR criteria
We subsequently questioned whether the results would be different when the 2010 criteria 
would be used to classify RA. Analyses were repeated with 2010-RA as outcome, yielding 
similar results (Supplementary Figure 1). As many patients classified positive on both crite-
ria sets, we also compared RA-patients that were 1987+/2010+ (n=34), 1987+2010- (n=9) 
and 1987-/2010+ (n=32) (patients with clear diagnoses other than RA and UA were not 
included). This showed that 1987-/2010+patients had lower synovitis scores (median 3.25 
versus 6.0, p=0.029) than 1987+/2010+ patients (Supplementary Figure 2). No differences 
were found between 1987+/2010+ and 1987+/2010-RA.
Synovitis


























Figure 1: RAMRIS-scores for the different MRI features per group of diagnoses
Horizontal lines represent median values. RA: rheumatoid arthritis according to the 1987 ACR-criteria, 
UA: undifferentiated arthritis, OA: inflammatory osteoarthritis, PsA: psoriatic arthritis, other: other 
rheumatic diagnoses including reactive arthritis (n=6), spondylarthropathy (n=3), gout (n=2), pseudo-
gout (1), palindromic arthritis (n=1), paramalignant arthritis (n=1), lyme disease (n=1), systemic lupus 
erythematosus (n=1) RS3PE (n=1), sarcoidosis (1) and unspecified other (n=3). Total RAMRIS: sum of 
synovitis, tenosynovitis, BME and erosion scores.
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Next we evaluated whether RA or UA-patients (according to the 1987-criteria) with 
(n=39) or without ACPA (n=92) had differences in scores. ACPA-positive patients showed 
higher scores for BME (median 6.5) than ACPA-negative patients (median 4.25, p=0.016). 
However, no differences in the extend of synovitis, tenosynovitis and erosions scores were 
observed (Figure 2).
value of hand and foot joints
The RAMRIS is developed for wrists and MCP joints. We also performed MR imaging of the 
forefoot. When we evaluated the scores of hands and feet separately, it was observed that 
the scores in the feet were lower (Table 2), but that the distributions of the scores of hands 




























Figure 2: RAMRIS-scores for the different MRI features per group of diagnoses for RA and UA patients 
with and without ACPA (n=39 and 92 respectively).
Horizontal lines represent median values. For tenosynovitis in the ACPA-negative group many scores are 
clustered at 0. Synovitis p=0.57, tenosynovitis p=0.40, BME p=0.017, erosions p=0.93.
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when the test characteristics were determined with and without the feet, similar results 
were obtained (data not shown).
DisCUssion
Many questions remain to be answered before it can be decided whether 1.5T extremity 
MRI is valuable for use in clinical practice in the field of RA. One of these is a basic question, 
namely whether the abnormalities seen on MRI are different in patients with RA compared 
to early arthritis patients with other diagnoses. The present cross-sectional study set out to 
explore this, making use of an unselected set of early arthritis patients. It was observed that 
among all patients presenting with early arthritis, patients with RA had significantly higher 
synovitis, bone marrow edema and tenosynovitis scores than patients without RA, but also 
that high synovitis, bone marrow edema and tenosynovitis scores were not confined to 
patients diagnosed with RA. Consequently, the ability of MR imaging to differentiate RA 
from non-RA patients was low.
In this study we did not focus on the subset of patients with UA. The number of UA-
patients was relatively low and follow-up data were not yet available. The definite diagnosis 
of these patients can be established after 1 or 2 year time. The present study addressed a 
basic issue by evaluating which differences in MRI features occur between patients with 
different diagnoses. Although several statistically significant differences were found, RA 
patients did not have striking differences in the severity of MRI inflammatory scores. Fur-
thermore, in the presence of a certain MRI feature the chance that this patient had RA was 
low (low positive predictive value). As the undifferentiated arthritis patients group included 
patients that will go on to develop rheumatoid arthritis and other diagnoses, results may 
differ when final diagnoses are used to define groups. Particularly, prospective studies 
are required to determine whether MRI is valuable for classification of patients that are 
clinically undefined. Follow-up of the studied cohort of patients is currently underway and 
will be presented in future studies.
Our study has several limitations. The joints scanned are the joint regions that are most 
commonly involved in RA, also the RAMRIS method was developed for RA. Patients with 
other diagnoses may have abnormalities in structures that were not scanned or scored, 
being for instance inflammation in other joints or capsulitis. When a protocol would be 
developed for use in practice in RA patients, the joints as assessed here will likely be 
included. Adding other small joints, for instance interphalangeal joints or other structures 
may possibly enhance the discriminative ability. This is subject for further studies.
One strength of our study was that we scanned MTP joints in addition to the more often 
assessed wrist and MCP joints. This seems relevant because foot involvement is common in 
early RA and abnormalities may be found even when the hand MR imaging results are nor-
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mal.9,10 Unfortunately time constraints prohibited the addition of axial and post-contrast 
imaging of the foot. However the contribution of the foot to total scores was generally 
low. This was not only true for synovitis, for which the lack of gadolinium contrast might 
have decreased sensitivity, but also for bone marrow edema and erosions. The MRI features 
were similarly distributed in hand and foot. Thus findings from this study do not support 
routine inclusion of MRI of the foot and hand/wrist MRI is probably adequate, however 
studies with a more complete assessment of the MTP joints including post-contrast imag-
ing are necessary for a more definite recommendation.
Although many clinical studies have been performed comparing the 1987 and 2010 
criteria for RA, to the best of our knowledge no MRI studies on this subject have been 
published. We observed no difference in MRI scores between RA when classifying RA 
according to the 1987 ACR-criteria or the 2010ACR/EULAR-criteria. However a majority 
of patients overlapped between these two groups. When assessing the patients that were 
positive for both or for one of these sets of criteria separately, we did observe that RA-
patients fulfilling 2010 criteria but not the 1987-criteria had less synovitis. These baseline 
MRI data suggest that patients that only fulfill the 2010-criteria have a milder disease; an 
observation which is in line with the results of studies comparing the long-term outcome 
of RA when using the different classification criteria for RA.11
Because it has been suggested that ACPA+ and ACPA- disease are separate entities 
of RA,12 we performed stratified analyses. ACPA-positive patients had significantly more 
BME than ACPA-negative patients. As BME is a predictor for progression of joint destruc-
tion,3 this observation is in line with ACPA-positive RA being a more severe disease. Only 
one earlier study has explored the relation between ACPA and BME, also reporting a 
significantly higher proportion of patients with BME in the ACPA+ group.13 Furthermore, 
subclinical inflammation including bone marrow edema has been observed in ACPA 
positive arthralgia patients (although no ACPA- control group was present in that study).14 
This observation also relates to the recent observation that ACPA may be able to directly 
activate osteoclasts.15 Altogether these data support the use of MRI to further increase the 
understanding of the relation between these two risk markers for severe RA, as MRI is the 
only imaging modality able to show BME.
In conclusion, MRI inflammatory scores were higher in RA than in other diagnoses and 
ACPA-positive patients had more BME than ACPA-negative patients. Nonetheless, the se-
verity of MRI-inflammation assessed according to RAMRIS does not accurately differentiate 
patients fitting ACR criteria for RA at one time point from other early arthritis patients.
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supplementary Figure 1: RAMRIS-scores for the different MRI features for RA patients according to 
1987 and 2010 criteria































supplementary Figure 2: RAMRIS-scores for the different MRI features for RA patients fulfilling both 
the 1987 and 2010 criteria and one of these two sets of criteria.
Horizontal lines represent median values. 1987-/2010+ versus 1987+/2010+ patients: synovitis 
p=0.029. All other combinations p>0.05.
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Synovitis





















supplementary Figure 3: RAMRIS-scores for the different MRI features per group of diagnoses, sepa-
rated for hand and foot joints
Box and whisker plots showing median, interquartile and range of scores separately for the hand (wrist 
and MCP joints combined, white) and forefoot (grey). Tenosynovitis was only assessed in the hand.
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To determine whether T1 post-Gadolinium chelate images (T1Gd) can replace T2-weighted 
images (T2) for evaluating bone marrow edema (BME), thereby allowing shortening the 
Magnetic Resonance Imaging (MRI) protocol in rheumatoid arthritis (RA).
methods
In 179 early arthritis patients and 43 advanced RA patients wrist and metacarpophalangeal 
joints were imaged on a 1.5T extremity MRI system with a standard protocol (coronal 
T1-, T2 fat saturated and coronal and axial T1 fat saturated after Gd). BME was scored 
according to OMERACT RAMRIS by two observers with and without T2-images available. 
Agreement was assessed using ICCs for semi-quantitative scores and test characteristics 
with T2 images as reference.
Results
4,048 and 989 bones were assessed in 179 early arthritis and 43 advanced RA patients 
respectively. Agreement between scores based on T2 and T1Gd images was excellent (intra 
class correlation coefficients (ICC) 0.80-0.99). On bone level sensitivity and specificity of 
BME on T1Gd compared to T2 were high for both patient groups and both readers (all 
≥80%).
Conclusion
T1Gd and T2 images are equally suitable for evaluating BME. Because contrast is usually 
administered to assess (teno)synovitis, a short MRI protocol of T1 and T1Gd is sufficient 
in RA.
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intRoDUCtion
Bone marrow edema (BME) is one of the main features of rheumatoid arthritis (RA) that can 
be seen on magnetic resonance imaging (MRI).1,2 BME is an independent predictor of sub-
sequent radiographic progression in early RA.3-5 The OMERACT Rheumatoid Arthritis MRI 
Scoring system (RAMRIS) is a standardized scoring system for the assessment of synovitis, 
bone marrow edema and erosions on MRI in RA. It defines BME as a lesion within trabecu-
lar bone, with ill-defined margins and signal characteristics consistent with increased water 
content, i.e. high signal on T2-fatsat and STIR images and low signal on T1.6
RAMRIS recommends that imaging includes T1-weighted sequences before and follow-
ing contrast agent administration, and T2-weighted images with frequency selective fat 
saturation (T2) or short tau inversion recovery (STIR) if frequency selective fat suppression 
is not available. T1-weighted images are primarily used to assess erosions and synovitis, 
whereas T2 images are used to evaluate BME. However, T1-weighted sequences with 
gadolinium-chelate (Gd) contrast-enhancement and fat-suppression (T1Gd) produce im-
ages very similar to T2 images (Figure 1). Although the RAMRIS core set of MRI acquisitions 
does not describe the use of fat-suppression for the post-contrast T1, in practice this is 
routinely used to enhance visibility of enhancement and to differentiate enhancement 
from fatty tissue on fast spin echo sequences, which exhibit a high signal of fat secondary 
to J-coupling.7 Previous studies performed in the knee, ankle and foot have shown that 
T2- fat-suppressed or STIR images and T1Gd MRI images demonstrate almost identical 
imaging patterns for BME.8,9
Figure 1: Typical appearance of BME on both sequences
Coronal T2 weighted fat-suppressed (a) and contrast enhanced T1-weighted fat-suppressed images 
(b) of the wrist in the same patient showing an almost identical pattern of BME., The majority of high 
intra-articular signal on T2 (a) enhances (b) consistent with synovitis; a small amount of fluid is present 
in the radiocarpal joint.
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Scanning of unilateral hand, wrist and foot joints according to RAMRIS protocol takes 
>60 minutes. T1Gd images form an essential part of the protocol as they are essential to 
assess synovitis and tenosynovitis.10-12 If T1Gd images could also be used to score BME 
in small hand and foot joints, valuable imaging time might be saved by leaving out T2 
sequences which account for approximately 20-25% of the examination time. A shorter 
protocol would reduce costs and the discomfort of patients and increase the accessibility 
of MR. Therefore we aimed to evaluate whether T1Gd images can replace T2 images for 
scoring of BME, without loss of information. We studied patients with early arthritis and 
active advanced RA to ensure that the results observed were not dependent on the severity 
of the BME lesions.
mAteRiAls AnD methoDs
Patients
Two groups of patients were studied. The first group consisted of 179 patients presenting 
with early arthritis to the rheumatologic outpatient clinic of the Leiden University Medical 
Center, the Netherlands. Forty-three (24%) of these patients fulfilled the ACR87 criteria 
for RA, the others were diagnosed as undifferentiated arthritis (n=88, 49%), inflammatory 
osteoarthritis (n=12, 7%), psoriatic arthritis (n=15, 8%) and other rheumatic diagnoses 
(n=21, 12%). The median age was 57 years (interquartile range (IQR) 45-66) and 99 (55%) 
were female. Forty-five (25%) patients were anti-citrullinated peptide antibody (ACPA) 
positive. The median disease activity score (DAS44) score was 2.5 (IQR1.9-3.0).13
The second group consisted of 43 advanced RA patients with RA according to ACR87 
criteria with a DAS44 higher than 2.4. Their disease was active despite treatment with 
conventional disease modifying anti-rheumatic drugs including maximal tolerable doses 
of methotrexate. The median age was 57 (IQR 51-62) and 31 (72%) were female. All 
advanced RA patients were positive for ACPA.
mRi
Examinations were performed on a MSK Extreme 1.5 Tesla extremity scanner (GE, Wiscon-
sin, USA). The complete recommended RAMRIS imaging set was acquired for the wrist and 
MCP. Joints were scanned at the most painful, or if indifferent, dominant side.
The following sequences were acquired: T1-weighted fast spin echo (FSE) sequence in 
the coronal plane (repetition time (TR)/echo time (TE) 650/17 ms; acquisition matrix 388 
× 288; echo train length (ETL) 2); T2-weighted FSE sequence with frequency selective fat 
saturation in the coronal plane (TR/TE 3000/61.8 ms; acquisition matrix, 300 x 224, ETL 
7). All sequences were acquired separately for the wrist and MCP joints, limited by the 
field of view of 100mm. Gd-chelate contrast agent (gadoteric acid, Guerbet, Paris, France) 
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was administered intravenously at a standard dose of 0.1 mmol/kg. After injection, T1-
weighted FSE sequence with frequency selective fat saturation (T1Gd) in the coronal plane 
was performed (TR/TE 650/17 ms, acquisition matrix 364 × 224, ETL 2) and a T1Gd in the 
axial plane (TR/TE 570/7 ms; acquisition matrix 320 × 192; ETL 2). Again all sequences were 
acquired for both wrist and MCP joints. Field-of-view was 100mm for all sequences. Coro-
nal sequences had 18 slices with a slice thickness of 2mm and a slice gap of 0.2mm while 
the axial sequence had 20 slices with a slice thickness of 3mm and a slice gap of 0.3mm.
image assessment
BME was defined as a lesion within the trabecular bone with ill-defined margins and high 
signal intensity on the T2 or T1Gd images. It was scored on a 0-3 scale for each bone 
according to OMERACT RAMRIS score by two trained readers independently.6 Scores 
were defined as 0=0%; 1=1-33%; 2=34-66%, 3=67-100% of bone affected up to 1 cm 
from the joint. In case of erosions or cysts, this percentage corresponds to the part of the 
remaining bone affected. Scoring was performed once on T2 images and a second time 
on T1Gd at least two weeks apart and with images anonymized and their order random-
ized between sessions. 14% of the early arthritis MRI imaging sets were read twice to 
determine the intra-reader reliability of scoring.
Image quality was assessed by one reader separately for the T2 weighted and T1Gd 
images on a 0-4 scale. Scores assigned were 0 completely not assessable, 1 partly not 
assessable, 2 poor, 3 adequate and 4 good image quality, taking into account motion 
artifacts, signal and contrast to noise ratios and other factors influencing image quality.
statistics
Image quality scores were compared by Wilcoxon signed ranks test. Differences in BME 
scores were compared using a paired Student’s t-test and the correlation between the 
sequences was assessed using a Pearson correlation coefficient. Because it is desirable for 
scores on both sequences to have not only good correlation, but also to yield similarity in 
absolute BME scores, agreement between scores was assessed using intra class correlation 
coefficients (ICC) for absolute agreement. Agreement was also visualized by means of 
Bland-Altman plots in order to detect systemic biases.
Assessments for the presence or absence of BME were made both on individual bone level 
and at patient level (BME present in any joint). At bone level, a score of ≥1 in any individual 
bone was considered positive. Similarly, at patient level, a total score of ≥1 was considered 
positive. Sensitivity and specificity of T1Gd were determined with presence of BME on T2 
as the reference standard. When values were missing on either T1Gd or T2, these bones 
were discarded from both assessments. The data of both readers were assessed separately, 
to validate that results obtained were not based on one single reader. We decided that, in 
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order to be able to replace T2 with T1Gd, acceptable levels of agreement were: Pearson 
correlation coefficient and ICC of ≥0.80 and sensitivity ≥80% as assessed by two readers.
ResUlts
In the early arthritis group three patients did not receive Gd due to the presence of a low 
estimated glomerular filtration rate or refusal of the patient. Thus in 176 early arthritis and 
43 advanced RA patients, 4048 and 989 bones were evaluated. The intra-reader ICCs for 
BME on T2 were 0.96 for reader 1 and 0.72 for reader 2. Missing values were present for 
reader 1 and 2 in 22 and 39 (0.5-1.0%) bones on T2 and 20 and 21 (0.5-0.5%) bones on 
T1Gd in early arthritis and 24 and 36 (2.4-3.6%) bones on T2 and 21 and 23 (2.1-2.3%) 
bones on T1Gd in advanced RA patients.
Figure 2: Image quality
Image quality for both sequences in early arthritis (a) and advanced RA (b). Scores: 4 good image quality, 
3 adequate image quality, 2 poor image quality, 1 partly not assessable, 0 completely not assessable.
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image quality
In early arthritis patients, BME could be assessed in 174 patients on T2 (98.9%) and 175 
patients on T1Gd (99.4%). Images were partly not assessable (image quality score 1) in 
nine patients on T2 and six patients on T1Gd. In advanced RA BME could be assessed in 
all 43 patients, although images were partly not assessable in ten patients on T2 and six 
patients on T1Gd. In both patient groups incomplete fat suppression was the reason for 
being partly not assessable. Completely not assessable scans were very rare (less than 2%, 
see Figure 2) and were all caused by excessive motion artifacts. Overall image quality was 
rated better on T1Gd than on T2 images. The median image quality score was four on 
T1Gd and three on T2 in both early arthritis and advanced RA (both p<0.001). In case of 
partly not assessable images (score of 1), the parts of the image that were assessable were 
still used for all further analyses.
table 1. Presence and scores of BME and measures of correlation and test characteristics at patient level
Early arthritis (n=176) Advanced RA (n=43)
Reader 1 Reader 2 Reader 1 Reader 2
Prevalence
BME prevalence, T2 143 (81.3%) 152 (86.4%) 41 (95.3%) 40 (93.0%)
BME prevalence, T1Gd 146 (83.0%) 159 (90.3%) 40 (93.0%) 43 (100%)
Concordance of T2 and 
T1Gd for presence of 
BME
165 (93.8%) 155 (88.1%) 40 (93.0%) 40 (93.0%)



















Median score T2 (IQR) 3 (1-6) 3.5 (2-9) 8 (3-20) 6 (2-20)
Median score T1Gd (IQR) 3 (1-6) 5 (2-9) 7 (3-19) 8 (5-17)
ICC between T2 and 
T1Gd (95% CI)
0.99 (0.98-0.99) 0.87 (0.82-0.90) 0.99 (0.98-0.99) 0.93 (0.86-0.96)
- ICC, Wrist only (95% 
CI)
0.98 (0.97-0.98) 0.86 (0.81-0.90) 0.99 (0.99-1.00) 0.94 (0.88-0.96)
- ICC, Metacarpals only 
(95% CI)
0.98 (0.97-0.98) 0.85 (0.80-0.88) 0.90 (0.81-0.94) 0.80 (0.66-0.89)
Paired t-test was applied to test for differences in median scores between T2 and T1gd in early arthritis: 
p=0.73 (reader 1) and 0.27 (reader 2); and in advanced RA: p= 0.91 (reader 1) and 0.52 (reader 2). Pres-
ence of BME defined as a score of ≥1. T2 sequence is the reference standard for sensitivity and specificity. 
Intra reader ICC’s for agreement between scores based on T2 and on T1Gd.
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Prevalence of bme in RA
In early arthritis patients, BME (a score of ≥1) was present in 143 (81.3%) and 152 (86.4%) 
patients on T2 images and 146 (83.0%) and 159 (90.3%) patients on T1Gd images for 
reader 1 and 2 respectively (Table 1). In advanced RA patients, BME was present in 41 
(95.3%) and 40 (93.0%) patients on T2 images and 40 (93.0%) and 43 (100.0%) patients 
on T1Gd images for reader 1 and 2 respectively. Thus BME was present in the majority of 
patients in both groups. BME scores were higher in advanced than in early RA (Table 1).
When evaluating the presence of BME in individual bones, in early arthritis BME was 
present in 677 (16.7%) and 921 (23.1%) bones on T2 images and 683 (17.0%) and 1023 
(25.6%) bones on T1Gd for reader 1 and 2 respectively (Table 2). Likewise, in advanced RA 
patients, BME was present in 311 (32.7%) and 299 (31.3 %) bones on T2 images and 307 
(32.3%) and 372 (39.0%) bones on T1Gd images for reader 1 and 2.
Comparison of bme evaluated on a semi-quantitative scale
First we compared the BME scores between both sequences (Table 1). In early arthritis 
patients, median scores were 3 on T2 and 3.5 on T1Gd for reader 1 (p=0.73) and 3.5 on 
T2 and 5 on T1Gd images for reader 2 (p=0.27). In advanced RA patients, median scores 
were 8 on T2 and 7 on T1Gd for reader 1 (p=0.91) and 6 on T2 and 8 on T1Gd images for 
reader 2 (p=0.52).
Figure 3 shows scores based on T1Gd plotted against scores on T2, showing a high 
degree of correlation between scores on T2 and T1Gd (early arthritis r=0.99 and 0.87 for 
reader 1 and 2, and advanced RA r=0.99 and 0.94).
table 2. Presence of BME and test characteristics in individual bones
Early arthritis (n=176) Advanced RA (n=43)
Reader 1 Reader 2 Reader 1 Reader 2
Individual bone level
Total bones 4048 989
Missing values, T2 22 (0.5%) 39 (1.0%) 36 (3.6%) 24 (2.4%)
Missing values, T1Gd 21 (0.5%) 20 (0.5%) 23 (2.3%) 21 (2.1%)
Assessed bones 4017 3995 950 955
BME prevalence, T2 677 (16.7%) 921 (23.1%) 311 (32.7%) 299 (31.3%)
BME prevalence, T1Gd 683 (17.0%) 1023 (25.6%) 307 (32.3%) 372 (39.0%)
Concordance of T2 and T1Gd 
for presence of BME
3839 (95.6%) 3523 (88.2%) 894 (94.1%) 814 (85.2%)
Discordance >1 point 5 (0.1%) 21 (0.5%) 21 (2.2%) 10 (1.0%)
- Sensitivity of T1Gd 87.3% (84.5-89.7%) 80.0% (77.3-82.5%) 90.4% (86.4-93.3%) 88.6% (84.3%-91.9%)
- Specificity of T1Gd 97.2% (96.6-97.8%) 90.7% (89.6-91.7%) 95.9% 94.0-97.3%) 83.7% (80.6-86.4%)
BME=bone marrow edema. Presence of BME defined as a score of ≥1. T2 sequence is the reference 
standard for sensitivity and specificity. Intra reader ICC’s for agreement between scores based on T2 and 
on T1Gd.
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using ICCs. In early arthritis, the ICC’s for both readers were 0.87 and 0.99; in advanced RA 
these were 0.99 and 0.93 (Table 1). Bland-Altman plots (Figure 4) revealed little systematic 
differences (reader 2 had slightly higher scores on T1Gd) and acceptable 95% limits of 
agreement for the differences in scores.
Comparison of the presence or absence of bme
For clinical application, determining the presence or absence of BME might be more 
important than the score on a semi-quantitative scale. We assessed test characteristics of 
T1Gd with T2-images as the reference standard with a score of ≥1 as cut-off for positivity. 
Analyses were done at the individual bone level and showed that sensitivity was ≥80% 
Figure 3: Correlation between total BME scores scored on T1Gd and T2 sequences.
Scores for observer 1 in early arthritis (a) and advanced RA (b) and for observer 2 in early arthritis (c) and 
advanced RA (d). Scores on T2 on the horizontal and scores on T1Gd on the vertical axis. Solid line: linear 
regression line; dashed line indicates the best possible (1:1) correlation.
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and specificity ≥ 83% (Table 2) in the various tested combinations. When evaluating the 
test characteristics of the presence of BME at the patient level, also a high sensitivity was 
observed, ≥ 95% for both readers. However, the specificity was low with a broad 95%CI, 
which is partly explained by the low number of patients without BME (17-33 early arthritis 
patients and 0-3 advanced RA patients depending on reader and sequence). A high level 
of agreement between T1Gd and T2 was also illustrated by the high concordance in bones 
that were scored as having BME and the low frequency of discordance of more than one 
point (≤0.5% in early RA and ≤2.2% in advanced RA (Table 2).
Reliability analysis (inter-reader agreement)
Finally we also assessed the reliability of scoring between both readers when evaluating 
T2 or T1Gd. The ICCs were high for both sequences (all ≥0.83, Table 3), indicating good 
inter-reader agreement under all investigated conditions.
Figure 4: Bland-Altman plots of total patient BME scores on T1Gd and T2 sequences
Bland-Altman plots for observer 1 in early arthritis (a) and advanced RA (b) and for observer 2 in early 
arthritis (c) and advanced RA (d). The difference (T1Gd-T2) between paired measurements are plotted 
against the mean of the two measurements. The middle line in each graph shows the bias between the 
two measurement methods. The observation that the line is located around 0 indicates that systematic 
bias was low; although reader 2 achieved slightly higher scores on T1Gd and showed some heterosce-
dasticity on both sequences (variance increases with an increase in score), which was also present to a 
lesser extent in advanced RA for reader 1. The dashed lines show the ± 95% limits of agreement.
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table 3. Interreader ICCs for BME scores at patient and bone level
Patient Bone
Early arthritis Advanced RA Early arthritis Advanced RA
T2 BME 0.86 (0.80-0.90) 0.91 (0.84-0.95) 0.77 (0.75-0.79) 0.86 (0.84-0.88)
- Wrist 0.90 (0.86-0.93) 0.96 (0.92-0.98) 0.79 (0.77-0.80) 0.87 (0.85-0.89)
- Metacarpals 0.75 (0.67-0.81) 0.67 (0.45-0.81) 0.71 (0.68-0.74) 0.81 (0.75-0.86)
T1Gd BME 0.88 (0.69-0.94) 0.93 (0.87-0.96) 0.80 (0.77-0.82) 0.85 (0.83-0.86)
- Wrist 0.89 (0.72-0.95) 0.95 (0.90-0.97) 0.80 (0.76-0.83) 0.84 (0.82-0.87)
- Metacarpals 0.83 (0.77-0.88) 0.66 (0.46-0.80) 0.78 (0.75-0.80) 0.85 (0.81-0.87)
Inter reader ICCs for total BME score per patient and for individual bone scores between the two readers, 
by patient group and imaging sequence used.
DisCUssion
T1Gd images have almost the same yield as T2 images in displaying BME. Our results show 
that BME is equally well assessed on either sequence. Thus, when coronal fat-suppressed 
T1 weighted images after Gd-chelate contrast administration are routinely obtained as part 
of the imaging protocol, as is the case within the OMERACT RAMRIS core imaging set, T2 
or STIR images are redundant and can be eliminated from the imaging protocol, reducing 
total imaging time by approximately 20-25%.
Historically RA has been considered a disease that mainly involved the synovium, with 
erosions caused by pannus invasion. It was only after the introduction of MRI that it was 
observed that inflammatory processes take place within the bone, as reflected by BME-like 
abnormalities on MR. Although for some years it remained unclear what the significance 
of BME was, it has now been shown that BME detected by MRI reflects the formation 
of inflammatory infiltrates in the bone marrow in RA.14 Histological examination of BME 
reveals a number of cell types, including macrophages, plasma cells, CD8+ T cells and B 
cells.15 Stressing the importance of this process is the finding that BME is the strongest 
imaging predictor of erosive progression that has been identified to date.1
On MRI BME can be observed due to the focally increased water content in the bone 
marrow, partly or entirely replacing normal bone marrow fat. Signal intensity is low on T1 
sequences and high on T2 or STIR sequences. BME also enhances with intravenous Gd.16 
The appearance of bone marrow on T1Gd images is very similar to T2 or STIR images 
before Gd contrast administration.8,9
Previously it has been shown in the knee, ankle and foot of patients with non-rheumatic 
diseases that T2 or STIR images and T1Gd images are equally suitable to assess BME and 
other bone marrow abnormalities.8,9 In early RA, findings from Tamai et al. suggest that 
T1Gd images visualize bone marrow edema with high specificity compared to T2.11 Our 
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study is, as far as we know, the first focussing specifically on the sequences required to 
image BME in RA.
The standardized use of fat suppression on the T1Gd sequence aids in identifying en-
hancing BME in the fatty bone marrow. Protons in both fatty and aqueous environment 
have high signal intensity on T2FSE and can be differentiated by using fat saturation, 
identifying the water as high signal intensity (Figure 1a). Nowadays fat saturation in 
combination with T2FSE is routinely included in musculoskeletal imaging protocols. The 
same additional value of fat saturation is used in the contrast enhanced T1FSE sequences, 
facilitating the depicting of Gd enhancement (high on T1) in the high signal intensity of 
fatty marrow (Figure 1b). Our results show that detection of BME on T1Gd is similar to that 
on T2 images. In addition, better image quality favors the T1Gd sequence. One limitation 
of using only T1Gd sequence is that small effusions, bright on T2 but not enhancing on 
T1Gd, may be harder to detect. Three patients did not receive Gd and thus these could be 
considered failures for the T1Gd images; however whenever contrast administration is not 
feasible, T2 can always be used as a fallback option.
Within the imaging protocol for arthritis as used in our hospital, the T2 sequence takes 
approximately four minutes out of twenty for the complete protocol for one joint area. 
Thus eliminating the T2 sequence from the imaging protocol results in a 20% reduction 
of imaging time. Especially when imaging multiple joint areas in one session, shortening 
of the imaging time in combination with more robust sequences decreases the chance of 
unsuccessful MRI examinations.
A limitation of our study was that we performed semi-quantitative measurements rather 
than quantitative measurements of BME volume. However this reflects current research 
practice where RAMRIS is the predominantly used method of semi-quantification. More-
over, previous studies have shown the measured volume of BME to be almost identical 
regardless of imaging sequence.8,9 Also, our method requires the administration of Gd, 
however this is usually not an issue, as this is needed for the assessment of synovitis and 
tenosynovitis.
Strengths of our study include the large number of patients studied, the inclusion of both 
early arthritis and advanced rheumatoid arthritis patients and the data having evaluated 
by two readers. The consistency in the findings between readers and between patients 
with different severity of BME lesions and different severity of RA support the validity of 
our results.
In conclusion, T1Gd and T2 images are equally suitable for scoring BME in early arthritis 
patients and advanced RA. For RAMRIS scoring, a short protocol of T1 and T1Gd is suf-
ficient.
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Magnetic Resonance Imaging (MRI) is increasingly used in Rheumatoid Arthritis (RA) 
research to depict local inflammation. According to the RAMRIS-protocol intravenous 
(IV) contrast is administered to assess synovitis and tenosynovitis. We studied whether 
IV-contrast can be eliminated, decreasing imaging time, cost and invasiveness.
methods
Wrist MRIs of 93 early arthritis patients were evaluated by two readers for synovitis of the 
radio-ulnar, radio-carpal and intercarpal joints, according to RAMRIS, and for tenosynovitis 
in ten compartments. Scores of MR-images without IV-contrast-enhancement were com-
pared to scores obtained when evaluating all, including contrast-enhanced, MRI-images as 
reference. Subsequently a literature review and pooled analysis of data from the present 
and two previous studies were performed.
Results
At individual joint/tendon level, sensitivity to detect synovitis without contrast was 91% 
and 72%, respectively, for the two readers and specificity 51% and 81%, with contrast-
enhanced images as reference standard. For tenosynovitis sensitivity was 67% and 54%, 
respectively and specificity 87% and 91%. Pooled data analysis revealed an overall sensitiv-
ity of 81% and specificity of 50% for evaluation of synovitis. Variations in tenosynovitis 
scoring systems hindered pooled analyses.
Conclusion
Eliminating IV-contrast decreased specificity for synovitis and sensitivity for tenosynovitis, 
indicating that IV-contrast remains essential for an optimal assessment.
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intRoDUCtion
Magnetic Resonance Imaging (MRI) is increasingly used in research of Rheumatoid Ar-
thritis (RA). MRI has high sensitivity to depict local inflammation in the form of synovitis, 
tenosynovitis and bone marrow edema.1 The scanning protocol is standardized in the 
OMERACT Rheumatoid Arthritis MRI scoring (RAMRIS) method.2 OMERACT recommended 
MRI sequences include non-contrast enhanced T2 weighted fat saturated images (T2) or 
short tau inversion recovery (STIR) images to evaluate bone marrow edema,2 whereas pre- 
and post-gadolinium contrast T1-weighted images (T1Gd) have been recommended for 
evaluation of synovitis and tenosynovitis.2–4
The use of intravenous (IV) gadolinium contrast has drawbacks; it is an invasive proce-
dure, it is costly and it prolongs the imaging required time. Synovitis and tenosynovitis 
normally exhibit high signal intensity both on T2 and T1Gd images (illustrated in Supple-
mentary Figure 1). We therefore hypothesized that it is possible to evaluate synovitis and 
tenosynovitis on T2 instead of T1Gd. When IV-contrast administration could be eliminated 
this would make MRI more patient-friendly and would increase accessibility.
The objective of this study was to determine whether IV contrast administration could 
be eliminated from the scanning protocol when assessing synovitis and tenosynovitis. This 
was achieved by a study of 93 early arthritis patients, a literature review and an analysis of 
pooled data from the above-mentioned material and two previous studies.
mAteRiAls AnD methoDs
Patients
Between July 2011 and April 2012 MR imaging was performed in 93 early arthritis patients 
at the first visit of the Leiden Early Arthritis Clinic; for further reading on the Leiden EAC 
see.5 These patients were part of a larger group in whom MRI was performed; the current 
study concerns a subgroup in which an extra axial T2-weighted sequence of the wrist 
was obtained. All patients provided informed consent and the study was approved by the 
institutional review board.
mRi
MRI of the wrist was performed at the most painful or the dominant side in case of equally 
severe symptoms. Coronal T1-weighted images and coronal and axial T2-weighted im-
ages with fat suppression were acquired. After IV contrast injection, coronal and axial 
T1-weighted images with fat suppression were acquired (full MRI protocol provided in the 
Supplementary Methods).
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Anonymized datasets were scored twice by two experienced readers (WS and AK), us-
ing all acquired images (Gdset), and using only unenhanced images (T2set). The order of 
examinations was randomized and there was an interval of at least two months between 
assessments. Images were scored for synovitis according to RAMRIS on a 0-3 scale for 
the radio-ulnar, radio-carpal and the combined intercarpal and carpometacarpophalangeal 
joints.2 Tenosynovitis was evaluated in 10 tendons/compartments on a 0-3 scale as de-
scribed by Haavardsholm et al.4
Reference standard and statistics
Gadolinium enhanced image scores were the reference standard. Comparisons were made 
for the two readers independently and for the agreement between readers. To deter-
mine whether the same absolute scores were obtained by both methods, scores were 
compared with weighted kappa statistic and intra class correlation coefficient (ICC) for 
absolute agreement. Furthermore, the sensitivity and specificity were calculated at both 
joint/tendon level and at patient level, with scores ≥1 considered positive at both joint/
tendon and patient level.
literature review and pooled data analysis
Available literature up to November 2013 was searched; central terms in our search were 
‘arthritis’, ‘synovitis’, ‘tenosynovitis’, ‘gadolinium contrast’ and ‘MRI’ (full search strategy 
provided in the Supplementary Methods). Studies comparing findings on MRI for synovitis 
and tenosynovitis with and without IV-contrast were reviewed. For synovitis we performed 
a pooled data analysis; raw data were obtained from the literature6 or obtained via personal 
communication7 and combined to determine overall test characteristics. For tenosynovitis, 
due to different scoring systems used we could not perform a pooled data analysis.
ResUlts
Data from 92 patients were analyzed, as one MRI was excluded because of severe artifacts 
caused by a metallic foreign body. Patient characteristics are listed in Supplementary table 
1. Based on reader 1 scores for Gdset (the reference standard) MRI synovitis was pres-
ent in 162 joints (59%) and 81 patients (88%); tenosynovitis was present in 153 tendon 
compartments (17%) and 52 patients (57%).
Agreement for total synovitis and tenosynovitis scores
For total scores within each patient, Bland-Altman plots showed acceptable levels of agree-
ment (Figure 1). For tenosynovitis there was a tendency towards more variation with higher 
scores (heteroscedasticity) especially for reader 2. There was little systematic bias for both 
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readers between the sets with and without contrast. ICCs between the T2set (without 
contrast) and Gdset (with gadolinium contrast) images were 0.75 (95%CI 0.54-0.86) and 
0.82 (95%CI 0.74-0.88) for synovitis for the two readers, respectively and 0.72 (95%CI 
0.60-0.81) and 0.57 (95%CI 0.42-0.70) for tenosynovitis, indicating moderate to good 
agreement for total synovitis and tenosynovitis scores.
test characteristics on patient level
When evaluating the presence of synovitis at patient level without gadolinium contrast (the 
T2set), the sensitivity was 96% and 78%, respectively, for the two readers and the specific-
ity was 36% and 71%. When tenosynovitis was assessed using the T2set the sensitivity 
was 89% and 71% and the specificity 40% and 68% (Table 1).




























































































Figure 1: Bland-Altman plots of assessment of synovitis and tenosynovitis with and without gadolinium 
enhancement
Bland-Altman plots for total scores for synovitis (upper row) and tenosynovitis (lower row) for reader 
1 (left) and reader 2 (right). The differences (T2set - Gdset) between paired measurements are plotted 
against the means of the two measurements. The middle line in each graph shows the systematic bias 
between the two measurement methods. The observation that the line is located around 0 indicates that 
systematic bias was low. The upper en lower lines show the ± 95% limits of agreement. For tenosynovitis 
variation increases with higher scores for reader 2.
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Agreement for individual joint/tendon scores
Subsequent analyses were performed on joint level with Gdset images as reference. 
Weighted Kappa’s for agreement of synovitis scores in individual joints based on T2set 
and Gdset were 0.65 (95%CI 0.49-0.81) and 0.71 (95%CI 0.63-0.80) for the two readers, 
indicating good agreement. For tenosynovitis corresponding values were 0.52 (95%CI 
0.36-0.68) and 0.46 (95%CI 0.33-0.60), indicating moderate agreement.
table 1: 2x2-table, and sensitivity and specificity of assessment of synovitis and tenosynovitis at joint/








T2set+ 148 56 T2set+ 90 29
T2set- 14 58 T2set- 35 122
Sensitivity 91% Sensitivity 72%
Specificity 51% Specificity 81%
Tenosynovitis
Reader 1
Gdset+ Gdset- Tenosynovitis 
Reader 2
Gdset+ Gdset-
T2set+ 103 97 T2set+ 73 74
T2set- 50 670 T2set- 62 711
Sensitivity 67% Sensitivity 54%







T2set+ 78 7 T2set+ 45 10
T2set- 3 4 T2set- 13 24
Sensitivity 96% Sensitivity 78%
Specificity 36% Specificity 71%
Tenosynovitis
Reader 1
Gdset+ Gdset- Tenosynovitis 
Reader 2
Gdset+ Gdset-
T2set+ 46 24 T2set+ 37 13
T2set- 6 16 T2set- 15 27
Sensitivity 89% Sensitivity 71%
Specificity 40% Specificity 68%
Presence of synovitis and tenosynovitis in individual joints and tendons and in patients with (Gdset) 
and without (T2set) IV contrast. Synovitis was evaluated in 276 sites (three wrist joints in 92 patients) 
and tenosynovitis was evaluated in 920 sites (10 wrist compartments in 92 patients) as described in the 
methods.
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test characteristics on joint/tendon level
The sensitivity to detect synovitis without gadolinium contrast was 91% and 72%, respec-
tively, for the 2 readers and the specificity 51% and 81%. Similarly, for tenosynovitis the 
sensitivity was 67% and 54% and the specificity 87% and 91% for the two readers (Table 
1).
large discrepancies in scores in individual joints/tendons
Differences ≥ 1 point between T2set and Gdset scores in individual joints or tendons were 
present in only 1.8% of joints for synovitis and 0.3-0.5% of tendons for tenosynovitis. 
These cases were reviewed for the cause of this discrepancy. Importantly for synovitis, in 
all cases areas of high signal on T2 were seen without enhancement on T1Gd images, 
indicating false-positive results on T2 due to effusion (Fig. 2). For tenosynovitis no clear 
explanation was found.
literature review and pooled data analysis
Supplementary table 2 lists all studies that were identified and results of each individual 
study; two studies evaluated synovitis and one other study assessed tenosynovitis with and 
without contrast.6–8 The tendency on the findings on joint/tendon level were consistent 
across studies: low specificity for synovitis; low sensitivity for tenosynovitis. The only excep-
tion was assessment of synovitis at 0.2T extremity MRI (as compared to 1.0 or 1.5T for 
other studies), where sensitivity was low.7 Figure 2 shows the sensitivity and specificity 
for synovitis obtained with 1.0/1.5T MRI in different studies. For synovitis, raw data of 
three studies were pooled on joint level; the overall sensitivity to detect synovitis without 
Sensitivity synovitis without IV contrast








Specificity synovitis without IV contrast








Figure 2: Sensitivity and specificity of evaluation of synovitis without IV contrast in separate studies and 
in a combined analysis
Plot of sensitivity and specificity estimates of MRI without IV contrast for individual joints and tendons. 
(A) Sensitivity and (B) specificity. Point estimates of sensitivity and specificity from each study are shown 
as solid diamonds for the first reader and as open diamonds for the second reader in each study. The 
solid lines represent 95% CIs.
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gadolinium was 81% and the overall specificity 50% (Figure 2, Supplementary table 3). 
For tenosynovitis no pooling could be performed due to differences in the scoring methods 
used.
DisCUssion
MRI is sensitive to detect inflammation, but is also time-consuming and costly. We investi-
gated the consequences of eliminating IV gadolinium contrast administration in a cohort of 
early arthritis patients and subsequently analyzed pooled data from this study and two pre-
viously published studies, identified by a literature review. We observed that the sensitivity 
and specificity were markedly decreased when eliminating the post-IV contrast sequences.
Gadolinium administration adds to the cost and duration of the examination and in-
creases patient discomfort. Furthermore it is contraindicated in patients with severe renal 
failure due to the risk of nephrogenic systemic fibrosis.9 For assessment of bone marrow 
edema and erosions no gadolinium contrast is necessary.6,7 However, based on our findings 
and the literature review, IV contrast is necessary for optimal assessment of synovitis and 
tenosynovitis.
A strength of our study is that we included patients at early disease stage when inflam-
mation is usually limited and MRI may be of additional value in detecting it. Furthermore, 
we did not limit inclusion to a single diagnosis, which makes our results more widely 
applicable.
A limitation is that we only assessed wrist joints and not MCP joints. We chose this for 
time reasons, as we prioritized to acquire axial T2-weighted fat suppressed images in order 
to have optimal sequences for assessment of synovitis and especially tenosynovitis without 
contrast injection. Secondly, we only made cross-sectional comparisons, so sensitivity to 
change, important for clinical trials, could not be compared. However, as cross-sectional 
data alone documented that non-contrast enhanced sequences cannot replace contrast-
enhanced, longitudinal data are less relevant. Finally, our data were obtained in early 
arthritis patients with relatively low inflammation scores, and may not be generalizable to 
patients with more advanced disease.
In conclusion, eliminating gadolinium contrast gave a low specificity for synovitis and 
low sensitivity for tenosynovitis. Consequently, MRI without IV contrast injection cannot be 
recommended for evaluation of synovitis and tenosynovitis.
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supplementary table 1: Patient characteristics
Patients (n=92) EAC total population 
(1993-2011, n=2748)
P value
Age, years (mean, SD) 55.8 ±13.5 51.6±17.1 0.02
Female sex, n (%) 49 (53.3) 1640 (59.7) 0.22
Symptom duration in weeks, median (IQR) 13.0 (4.8-29.0) 14.0 (6.0-31.0) 0.67
Swollen joint count (66-SJC), median (IQR) 3.0 (2.0-5.8) 4.0 (2.0-9.0) 0.22
Tender joint count (68-TJC), median (IQR) 6.5 (2.3-10.0) 5.0 (3.0-9.0) 0.21
RF positive, n (%) 28 (30.4) 800 (29.5) 0.85
ACPA positive, n (%) 23 (25.0) 628 (28.0) 0.52
Patient classification at baseline, n (%)
RA (2010 criteria) 35 (38.0) 1060 (38.6) 0.92#
Undifferentiated arthritis 36 (39.1) 827 (30.1)
Inflammatory osteoarthritis 6 (6.5) 127 (4.6)
Psoriatic arthritis 7 (7.6) 187 (6.8)
Other rheumatic diagnoses 8 (8.7) 547 (19.9)
Except where indicated otherwise, values are number (%) of patients. SD, standard deviation; IQR, 
interquartile range; 66-SJC, 66 swollen joint count; 68-TJC, 68 tender joint count; RF, Rheumatoid fac-
tor; ACPA, anti-citrullinated peptide antibodies. A chi-square test was used for nominal variables and 
the Student’s t test or Mann-Whitney U-test for continuous variables. Student’s t test was performed 
when variables are presented as mean and a Mann-Whitney U-test was performed when variables are 
presented as median. #The frequency of RA versus non-RA was tested.















































































































































































































































































































































































































































































































































































































































































































supplementary table 3: Pooled data from literature for synovitis: 2x2-table, and sensitivity and speci-
ficity of assessment of synovitis and tenosynovitis at joint/tendon level without contrast injection, with 
contrast enhanced MRI findings as standard reference.
Ostergaard at el. Gdset+ Gdset- Total
T2set+ 101 16 117 PPV: 86%
T2set- 13 20 33 NPV: 61%





Tamai et al. Gdset+ Gdset- Total
T2set+ 613 316 929 PPV: 66%
T2set- 175 312 487 NPV: 64%





Pooled data from Stomp et al, 
Ostergaard et al and Tamai et al.
Gdset+ Gdset- Total
T2set+ 862 388 1250 PPV: 69%
T2set- 202 390 592 NPV: 66%





Number of joints scored positive on T2set and Gdset; data from two other studies and pooled data from 
the present study as well as studies by Østergaard et al and Tamai et al.(6,7) For studies that reported 
data on multiple readers, only scores of one reader were used (results were comparable independent 
of the combination of readers selected). PPV: positive predictive value; NPV: negative predictive value.





Example of synovitis and tenosynovitis as visualized by T1-weighted postcontrast and T2-weighted se-
quences. Upper row: T1-weighted coronal (left) and axial (right) images after gadolinium administra-
tion. Bottom row: corresponding T2-weighted coronal (left) and axial (right) images before gadolinium 
administration. Synovitis of the radioulnar, radiocarpal and intercarpal joints and flexor tenosynovitis is 
clearly visible on both sequences.
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supplementary figure 1b
Example of large discrepancy in synovitis score between T1-weighted postcontrast and T2-weighted 
sequences. Upper row: T1-weighted coronal (left) and axial (right) images after gadolinium administra-
tion. Bottom row: corresponding T2-weighted coronal (left) and axial (right) images before gadolinium 
administration. Effusion in the radioulnar and radiocarpal joints results in high signal on T2-weighted 
images without enhancement on post-gadolinium images.




MR imaging of wrist was performed within two weeks after inclusion, at the most painful 
side, or in case of completely symmetric symptoms at the dominant side. The presence of 
clinical arthritis at physical examination of the wrist was not a prerequisite. MR imaging 
was performed on a MSK-extreme 1.5T extremity MR imaging system (GE, Wisconsin, 
USA) using a 100mm coil. The patient was positioned in a chair beside the scanner, with 
the hand fixed in the coil with cushions.
The following sequences were acquired before contrast injection: T1-weighted FSE 
sequence in the coronal plane (TR/TE 650/17ms; acquisition matrix 388×88; ETL2); T2-
weighted FSE sequence with frequency selective fat saturation in the coronal and axial 
plane (TR/TE 3000/61.8ms; acquisition matrix, 300x224, ETL7).
After intravenous injection of gadolinium contrast (gadoteric acid, Guerbet, Paris, France, 
standard dose of 0.1 mmol/kg) the following sequences were obtained: T1-weighted FSE 
sequence with frequency selective fat saturation in the coronal plane (TR/TE 650/17ms, 
acquisition matrix 364×224, ETL2), T1-weighted FSE sequence with frequency selective fat 
saturation in the axial plane (TR/TE 570/7ms; acquisition matrix 320x192; ETL2).
Field-of-view was 100mm. Coronal sequences had 18 slices with a slice thickness of 2mm 
and a slice gap of 0.2mm. All axial sequences had 20 slices with a slice thickness of 3mm 
and a slice gap of 0.3mm. Total imaging time was approximately 25 minutes.
Literature review
For the literature review PubMed was searched with a broad search strategy using the 
search term (“gadolinium” OR “contrast” OR “enhancement”) AND (“synovitis” OR 
“arthritis” OR “tenosynovitis”) AND (“MRI” OR “MR” OR “magnetic resonance”). This 
yielded 1035 results (November 2013). Abstracts were screened and we selected studies 
that reported on findings on gadolinium contrast-enhanced images compared to findings 
on images obtained without gadolinium contrast in MRI of joints of the hand of adult pa-
tients with any type of arthritis. For relevant studies (n=3) full-text articles were obtained. 
Furthermore, references of obtained full-text articles were screened for further relevant 
studies, which did not yield any additional studies. Of the three studies that were found, 
two were relevant for synovitis and one for tenosynovitis.
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Rheumatoid arthritis frequently involves inflammation of the forefoot. At present Magnetic 
Resonance Imaging (MRI) is increasingly used, mostly for research purposes, to detect 
inflammation. Given the sensitivity of MRI, a relevant issue is to discern pathology from 
normal variations as abnormalities have been observed in healthy persons.1–4 In particular it 
is unknown whether regular physical exercise or wearing a particular shoe type affects MRI 
results. Bone marrow edema has been described in (sometimes asymptomatic) athletes.5 
Since wearing high-heels shifts pressure from the heel to the heads of the metatarsal 
bones,6–8 we hypothesized that this might result in acute abnormalities of the forefoot 
similar to changes secondary to trauma or repetitive stress. We performed a single-blind 
crossover study to determine this.
Three healthy females (17-18 years) underwent 1.5T MRI examinations of the dominant 
foot before (8am) and after (5pm) a school-day, with provoked walking distance and visual-
analogue-scale pain score. Activities, pain and symptoms were recorded twice every hour. 
Flat shoes were worn on day 1 and high heels (mean height 9.48cm) on day 2. Subjects 
wore flat shoes for one week before both examinations. MRI of the forefoot included 
T1 weighted and T2 weighted fat-suppressed scans, both in three orthogonal directions. 
Evaluation was performed by two readers independently who were blinded to the study 
day. In case of disagreement a third reader, a musculoskeletal radiologist, took the judg-
ment. The study was approved by the institutional review board and all participants gave 
their written informed consent.
The subjects walked 6.7, 6.1 and 6.5 km on day 1 and 8.1, 7.0 and 7.1 km on day 2, 
including 15-minutes of stair climbing. VAS-pain scores remained low (range 0-2) on day 
1 but increased to 5-8 at the end of day 2. Pain was predominantly located at the forefoot 
area. One subject (a fanatic gymnast) had extensive bone marrow edema of the medial 
sesamoid bone adjacent to the first MTP joint, which was unchanged over all four MRI’s. 
No other abnormalities were seen on all 8am MRIs, and neither on the forefoot MRI at 5pm 
at day 1. All 5pm MRIs taken on day 2 revealed plantar subcutaneous edema, consistently 
located at the medial forefoot, extending over 25-34mm proximal to the metatarsopha-
langeal (MTP) joints (figure 1). Since during high-heel wearing the pressure point is at or 
distal to the MTP joints, this edema may have been caused by soft tissue strain due to 
tensile loading.6 Two subjects also developed subcutaneous edema dorsal to the metatarsal 
heads, probably as a direct result of entrapment of the forefoot. Importantly, no other 
changes, such as synovitis, joint effusion, bone marrow edema, enthesitis, (intermetatarsal) 
bursitis, tenosynovitis or plantar fasciitis, were observed.
Thus, in the present case series we observed that physical exercise of moderate intensity 
and high heeled exercise does not cause bone marrow edema or deep soft tissue abnor-
malities. The pain that was experienced when performing physical exercise and wearing 
high heels was probably related to the presence of subcutaneous edema, plantar typically 
proximal to the MTP joints. The major limitation of these data is that the number of sub-
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jects studied is small. Nonetheless all individuals evaluated showed remarkably consistent 
results. Altogether, these data therefore imply that wearing high-heels is not associated 
with short-term structural abnormalities. The long-term effects of high heel-wearing re-
main unknown. These results are relevant when interpreting forefoot MRI-examinations of 
rheumatoid or orthopedic patients
Figure 1: (A) High heels worn by the three subjects. (B,C) Sagittal T2-weighted fat-suppressed image 
at the level of the second metatarsal bone before (B) and after (C) a day of high heel wearing shows 
subcutaneous edema at the plantar and dorsal side. Note the proximal location to the MTP joints on the 
plantar side (arrow).
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Rheumatoid arthritis (RA) is an auto-immune disease that is characterized by symmetric 
polyarthritis of especially the small hand and foot joints. RA is prevalent and has major 
consequences on physical functioning, which has a big impact on daily life and work 
ability and also has socio-economic consequences. During the last decades the treatment 
for RA has dramatically improved, and a lot of new effective drugs have become available. 
From previous studies we learned that early recognition and treatment will result in a 
better outcome. This is already applied in daily practice. However, these treatments are 
not without side-effects and are not for free. Therefore, the question remains how can 
we discriminate patients/persons that will develop RA from those that will not? What are 
predictive factors for development of RA? And when a patient has RA what will be his/her 
prognosis? What are predictive factors for the disease course?
PARt i: UnClAssiFieD ARthRitis AnD the Risk on DeveloPment oF 
RheUmAtoiD ARthRitis
In 2010 new classification criteria for RA were established, to classify RA patients earlier in 
the disease course. Thereafter, several studies focused on the characteristics and outcome 
of this new group of RA patients. The overall conclusion was that the 2010 criteria allow 
earlier diagnosis of RA, although also resulting in a bigger group of over diagnosed patients 
with self-limiting disease.1-4 However, the group of unclassified arthritis (UA) patients also 
changed, as a consequence of the new RA group.
In chapter 2 we evaluated characteristics and outcomes of UA according to the 2010 
criteria from the Leiden EAC. We found that 2010-UA patients had milder baseline char-
acteristics than 1987-UA patients. To evaluate the outcome of the UA patients we used 
different outcomes, because there is no ultimate outcome definition for RA diagnosis. We 
used three different outcomes that can be seen as surrogates for RA: 1987 criteria fulfill-
ment during the first year, DMARD initiation during the first year and persistent disease on 
the long term (no remission).
During follow-up, 24% of the 2010-UA patients still fulfilled the 1987 RA criteria 
compared to 32% of the 1987-UA patients. The 2010-UA patients started less frequent 
DMARD therapy and reached more frequent sustained DMARD free remission. However, 
the percentage of UA patients that developed RA during the first year would probably be 
even higher when looking at the natural course of the disease of these patients, assuming 
that treatment could have prevented them from developing RA. Although, the majority of 
these patients were enrolled when aggressive DMARD treatment of UA was uncommon.
In order to determine whether classification according to the 2010 criteria was congru-
ent with risk estimation by the ‘Van der Helm prediction rule’,5 both methods were applied 
to 1987-UA patients. The majority who did not fulfill the 2010 criteria was also in the low 
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risk group of the prediction rule. However, 30% of 2010 criteria positive patients were 
predicted to have a low risk on RA and during the course of the disease these patients 
achieved more frequent DMARD free sustained remission than other 2010 criteria positive 
patients. Evaluation of congruency of both methods is formally not correct, as the 2010 
criteria are meant for classification and the prediction rule is meant to estimate individual 
patient’ probability of fulfilling the 1987 criteria at an early stage. On the other hand, the 
2010 criteria will most likely also be used for individual patients in the clinic. Overall can be 
concluded that UA in the era of the 2010 criteria is less prevalent and milder at presenta-
tion and in outcome, but 24% of the 2010-UA patients still fulfill the 1987 criteria within 
one year, which implies that careful clinical observation of 2010-UA patients is indicated.
(Figure 1)
We were quite surprised to find such a high percentage of 2010-UA patients still pro-
gressing into RA during the first year. Therefore, in chapter 3 we also looked at in other 
cohorts to study the percentage of the 2010-UA patients that develop RA during follow-
up. We studied 2010-UA patients from the early arthritis cohorts from Leiden, Birmingham 
UK and Amsterdam.1,2,6 This resulted in 24%, 26%, and 12% of the 2010-UA-patients 
fulfilling the 1987 criteria after one year, respectively. However, some of these patients 
already fulfilled the 1987 criteria at baseline. In 1987-and-2010-UA patients, 15%, 21%, 
and 9% respectively developed 1987 RA at one year. Because these early RA patients are 
missed at baseline, we tried to find prognostic markers for RA development and evalu-
ated the prognostic accuracy of ACPA and the ‘Van der Helm prediction rule’ in 2010-UA 
patients. In these 1987-and-2010-UA patients that developed 1987 RA at one year, 0-6% 
of the patients were ACPA positive and 0-1% had high prediction scores. Consequently, 
a large majority of the UA patients with an unfavorable outcome was not recognized by 










Figure 1 Disease phases of RA, including the percentages of patients evolving from one phase through 
another. 1% of the normal population develops 1987-RA, adapted from Scott et al (7). 30% of the 
arthralgia patients (ACPA positive) progress to 1987-RA, adapted from Van de Stadt et al (8). 32% of 
1987-UA patients and 24% of 2010-UA patients develop 1987-RA, adapted from chapter 2 of this the-
sis. 34% of 1987-UA patients and 46% of 2010-UA patients develop remission, adapted from chapter 2 
of this thesis. Approximately 23% of 1987-RA patients and 27% of 2010-RA patients develop remission, 
adapted from v. Nies et al (9). 33% of 1987-RA patients develop (under monotherapy with MTX) RRP 
and 67% does not, adapted from K. Visser et al (10).
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these prognostic tools. Therefore, ACPA and the Leiden prediction rule are not useful in 
identifying these patients. Because the high percentage of 2010-UA patients still develop-
ing RA and these prognostic tools are not useful in this group of patients, we concluded 
that other predictive markers should be developed for 2010-UA patients.
PARt ii: GenetiC AnD seRoloGiC FACtoRs in PReDiCtinG RADioGRAPhiC 
PRoGRession in RheUmAtoiD ARthRitis
When a patient is diagnosed with RA the disease course is not yet known, due to a lot of 
variation in the disease course of RA. Some patients will rapidly progress in a very erosive 
and disabling disease, while others will develop remission. An objective and commonly 
used outcome measure of the disease course of RA is the rate of radiographic progression. 
It is measured most sensitively with hand and foot radiographs that are serially taken over 
time and scored using a validated quantitative scoring method.
First, in chapter 4 biomarkers for radiographic progression are summarized in a review. 
In this review we evaluated the published (and partly non-published) data on genetic, 
serologic and imaging biomarkers for the severity of joint destruction in RA. In genetics the 
combination of low prevalence of variations and small effect sizes means that large data 
sets are necessary. Unfortunately, large data sets on long-term longitudinal radiographic 
joint destruction are scarce. Furthermore, a relevant question to consider is when a genetic 
association is true. The first level of evidence is the p-value, which is insufficient to indicate 
whether a variant can be true. More reliable is replication. In case a variant is statistically 
significant associated in several independent cohorts, the chance that the observation 
reflects a chance-finding is importantly reduced. Even more convincing are data that 
support the finding at a different level, like at mRNA expression or protein level. In the 
ideal situation the pathway or mechanism via which a genetic risk factor influences the 
disease is understood.(Figure 2) In this review, genetic variants in 28 genes were evaluated; 
variants in 10 genes (CD40, IL2RA, IL4R, IL15, OPG, DKK1, SOST, GRZB, MMP9, SPAG16) 
were evidently replicated in independent data sets and for five variants (IL2RA, DKK1, 
GRZB, MMP9, SPAG16) there was also evidence for an association at the functional level. 
We evaluated several serological biomarkers like; auto-antibodies (RF, ACPA, anti-CarP), 
markers related to inflammation (ESR, CRP) and proteinases or components of the extracel-
lular matrix of bone or cartilage (MMP3, CTX-I, CTX-II, COMP, TIMP1, PYD, RANKL/OPG, 
CXCL13). Finally, we evaluated markers that can be visualized by ultrasound or MRI, like; 
erosions, bone marrow edema, synovitis and tenosynovitis. Several studies showed that 
bone marrow edema and synovitis detected by MRI are strong predictors for radiographic 
progression and some showed that inflammation detected with ultrasound also predicted 
radiographic progression. We also found that serological and imaging markers generally 
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have larger effect sizes than genetic markers. This might be due to the fact that serological 
and imaging markers are more closely related to the phenotype. Until now, the majority 
of these known risk factors have not yet been included in risk models. Future studies will 
reveal whether adding and combing all these different biomarkers will increase the predic-
tive accuracy of risk models predicting radiographic progression in RA. However, adding a 
predictive marker should be cost-effective; add additional clinically relevant prediction to 
the model and should not be too expensive, time consuming or invasive.
In the following chapters four genetic biomarkers and one serologic biomarker for radio-
graphic progression are evaluated. In chapter 5-7 we investigated four candidate genes for 
their association with radiographic joint destruction. All four genes were investigated on a 
candidate gene study approach. This means that all genes were selected on the individual 
high ‘a prior chance’ of being associated to radiographic joint destruction. According to 
literature these genes were more prone to be associated to radiographic progression and 
therefore these genes were independently tested for an association to radiographic joint 
destruction. The purpose of these studies was not to find every possible association, but to 
find true associations of genetic variants. On the one hand this resulted in a low chance of 
false-positive findings, but on the other hand a high chance of false-negative findings, as 
this latter aspect was not the aim of these studies. For each gene, these SNPs were selected 
that tagged the whole gene. In all studies we used a similar strategy. First we tested all 
tagging SNPs in a first (identification) cohort. As already mentioned earlier (in chapter 4); a 
significant genetic association in one cohort is not sufficient to indicate whether a genetic 
association is true. You need at least replication and even more convincing would be data 









Figure 2 The level of evidence in genetic studies. The higher into the pyramid, the higher the level of 
evidence.
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SNPs that were significantly associated to radiographic joint destruction in phase one and 
testing these in other (replication) cohorts. When a SNP was also significantly associated 
to radiographic progression in a replication cohort, the chance of having a false-positive 
finding will be reduced. Ideally, you would like to confirm that the finding is really true by 
showing functional data as well.
In chapter 5 we investigated the association of genetic variants in IL15 with radiographic 
progression rate in RA. Several studies showed that IL-15 plays a role in maintaining inflam-
mation and affecting osteoclastogenesis.11,12 In patients with RA, IL-15 levels are increased 
in serum, synovium and bone marrow.13,14 Additionally, serum levels of IL-15 correlated 
strongly to disease activity.15 Therefore, we investigated whether genetic variants in IL15 
are associated with the severity of joint destruction in RA. Five SNPs were significantly as-
sociated with the rate of radiographic progression in the first phase (Leiden EAC) and were 
genotyped in three other cohorts (Groningen, Lund (SE) and Sheffield (UK)). Independent 
replication was not obtained, possibly due to insufficient power in the replication cohorts. 
However, a meta-analysis of all four data sets resulted in significant results for four SNPs 
(rs7667746, rs7665842, rs4371699, rs6821171). These SNPs remained significant after 
correction for multiple testing. This suggests that these four genetic variants in IL15 are as-
sociated with radiographic progression in RA. Further studies should demonstrate whether 
the presence of these variants results in difference at functional level of IL15.
In chapter 6 we studied the association between IL4 and IL4R tagging SNPs and the 
rate of radiographic progression in RA. Previous studies showed that IL-4 has an anti-
inflammatory effect, as well as an anti-osteoclastogenic effect.16,17 The effect of IL-4 is 
mainly mediated by the IL-4 receptor alpha chain (IL4-Ralpha). Several genetic studies of 
IL4 and IL4R and joint damage have been performed,18-21 though none of the factors 
identified have been replicated. This prompted us to perform this multi cohort candidate 
gene study. In the first phase (Leiden EAC), none of the IL4 SNPs and seven of the IL4R 
SNPs were significantly associated with the rate of radiographic progression. These seven 
SNPs were analyzed in four (Groningen, Lund (SE), Sheffiled (UK), NARAC (US)) or six 
(Groningen, Lund (SE), Sheffield (UK), NARAC (US), Wichita (US), NDB (US)) other cohorts 
(depending on the availability of the genotyping of the particular SNPs in the cohorts). In 
this candidate gene study more cohorts were available in the second phase. Therefore, we 
could perform an independent replication, which consisted of a meta-analysis of only the 
additional cohorts in the second phase. In the replication phase, two SNPs in the IL4R gene 
were significantly associated with the rate of radiographic progression. One of these two 
SNPs remained significant after correcting for multiple testing. This SNP (rs1119132) was 
recessively associated to joint damage progression, which means that carrying both minor 
alleles results in more severe joint damage progression and only a minority of RA patients 
will have this homozygous recessive variant. Nevertheless, we did find an independent 
replication in some of the replication cohorts as well as in the meta-analysis of the six 
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replication cohorts. In conclusion, we identified and replicated a genetic variant in IL4R 
predisposing to radiographic progression in RA. Further studies of IL-4R at a functional 
level are needed to confirm this finding and to increase insight on the role of this variant in 
the pathogenesis of RA progression.
In chapter 7 we investigated Granzyme B (GZMB) as candidate gene for radiographic 
progression in RA. GZMB is a serine protease found in the lytic granules of natural killer 
(NK) cells and cytotoxic T lymphocytes and can induce cell death. Previous studies suggest 
a role for GZMB in RA joint destruction as well, because the number of GZMB-positive cells 
is increased in synovium as well as among chondrocytes at the site of a pannus lesion.22-24 
Therefore, we tested whether genetic variants in GZMB were associated to radiographic 
progression. Two SNPs were significantly associated to radiographic progression in the first 
phase (Leiden EAC). However, these two SNP were highly correlated and therefore only 
the strongest one (rs8192916) was tested in the second phase. The data available for the 
second phase were expected to be underpowered for individual replication and therefore 
this SNP was tested in a meta-analysis of all four datasets (Leiden EAC, Groningen, Lund 
(SE), Sheffield (UK)), and resulted in a significant association with radiographic progression. 
This association remained significant after correcting for multiple testing. The minor allele 
of this SNP was associated with a higher rate of joint destruction. This significant remaining 
SNP was also tested for its association with RNA expression of the genomic region of 
GZMB. This resulted in a higher expression of GZMB RNA in the presence of the minor 
allele of this SNP. In conclusion, this suggests that this genetic variant located in GZMB is 
associated with radiographic progression as well as with RNA expression in whole blood 
in RA.
In chapter 8 we evaluate the predictive value of serum pyridinoline (PYD) levels for joint 
destruction. PYD is a major crosslink of collagen in cartilage, bone and synovium. Previous 
studies showed that PYD levels are increased in patients with RA compared to healthy 
persons and PYD levels are higher in cases of active or severe disease.25 Most previous stud-
ies were performed on urine levels of PYD. However, no large scale longitudinal studies on 
serum PYD levels and radiographic progression in RA have been performed. We evaluated 
the predictive value of serum PYD levels for future joint destruction, both at baseline for 
long-term prediction and during the disease course for near-term prediction. Evaluating 
baseline PYD serum levels revealed that these baseline levels were significantly associated 
with the rate of radiographic progression over seven years and also independent of known 
risk factors for joint destruction, like; age, sex, treatment, ACPA status, CRP level, BMI and 
smoking. Furthermore, the PYD levels during follow-up were significantly associated to the 
rate of radiographic progression the upcoming year and also independent of the known 
risk factors. Although serum PYD was found to be an independent risk factor, the accuracy 
(measured by the AUC) of PYD levels on the rate of radiographic progression was moder-
ate. Therefore, increased PYD serum levels, both at baseline and during the disease course, 
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are associated with a higher rate of radiographic progression during the coming year(s), 
though the predictive accuracy as a sole predictor was moderate. Therefore, it could be 
valuable to include serum PYD in combined predictive models to predict radiographic 
progression in RA patients.
PARt iii: mRi in PAtients with ARthRAlGiA AnD eARly ARthRitis
MRI is becoming more and more important in RA research. MRI is highly useful because 
it is a very sensitive measure, especially for inflammation. An important feature of MRI is 
the detection of inflammation inside the bone. In this part we investigated the process 
that is going on in the (partly clinical invisible) early disease stages of RA. Additionally, we 
investigated whether MRI can distinguish RA patients from other early arthritis patients.
From previous studies we know that ACPA, RF and acute phase reactants are already 
present years before the first symptoms of RA emerge, which suggests that there is a pre-
clinical phase in RA.26 However, it was still unknown whether local inflammation occurs in 
the joints in the preclinical phase. A MRI study on knee joints of 13 ACPA positive arthralgia 
patients showed no subclinical inflammation.27 However, ACPA positive RA probably does 
not start in knee joints, leaving the question whether local inflammation is present in the 
preclinical phase of ACPA positive RA unanswered. In chapter 9 we studied small joints of 
21 ACPA positive arthralgia patients on local subclinical inflammation. The inflammation 
detected by MRI was compared among; small joints of controls (n=19) (without joint com-
plains), small joints of ACPA positive arthralgia patients and small joints of ACPA positive 
RA patients (n=22). This study showed that ACPA positive arthralgia patients had more 
MRI detected inflammation in the PIP/MCP and wrist joints, than controls without joint 
complains and lower MRI detected inflammation than ACPA positive RA patients. These 
data suggest that local subclinical inflammation occurs in ACPA positive arthralgia patients. 
Probably there is already an inflammation process going on in small joints before the joints 
are clinically inflamed and can be detected by physical examination as swollen joints.
The next question was whether MRI detectable inflammation is congruent to inflam-
mation detected by physical examination in joints of arthritis patients. Possibly there are 
inflamed joints that are missed by physical examination. In chapter 10 the association 
and concordance between inflammation of small joints measured with MRI and physical 
examination, was determined. We studied 1,790 joints of 179 patients from the Leiden 
EAC. In these joints; synovitis and tenosynovitis on MRI were independently associated 
with clinical swelling, in contrast to bone marrow edema (BME). In the majority (~90%) of 
the swollen MCP joints and swollen wrists any inflammation on MRI was present. In 27% 
of the non-swollen MCP joints and in 66% of the non-swollen wrists any MRI inflammation 
was present. Vice versa, of all MCP, wrist and MTP joints with inflammation on MRI 64%, 
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61% and 77% respectively were not swollen. BME, also in case of severe lesions, occurred 
frequently in clinically non-swollen joints. Additionally, similar results were observed for 
joint tenderness. In conclusion, inflammation on MRI is not only present in clinically swollen 
but also in non-swollen joints. In particular BME occurred in clinically non-inflamed joints. 
From previous studies we know that BME is an independent predictor of radiographic 
progression.28-33 Moreover, although we found a high percentage of joints with subclinical 
inflammation, we know that MRI is very sensitive and probably in some cases too sensitive. 
Therefore, we wanted to know what the relevance of subclinical inflammation is for the 
disease course.
In chapter 11 we assessed the relevance of this subclinical inflammation with regard 
to radiographic progression during the first year. The major reasons to choose for radio-
graphic progression as an outcome measure were; a commonly used outcome in RA, its 
objectiveness and because the score at joint level can be subtracted. Physical functioning 
or disease activity would be other interesting parameters, but are not useful in analyses at 
joint level. However, these parameters could be interesting when translating into clinical 
practice in the future. In this study we first tried to replicate what others already found, 
to be sure that the data behaves similar and the predefined assumptions also apply on 
our data set. Indeed, we also found that BME, synovitis and tenosynovitis were associated 
with radiographic progression, independent of known risk factors. Next, we investigated 
the relevance of the subclinical inflammation. Of all non-swollen joints, 26% of the joints 
had subclinical inflammation. Radiographic progression was present in 4% of non-swollen 
joints with subclinical inflammation compared to 1% of non-swollen joints without 
subclinical inflammation. Similar observations were done for the inflammation features 
separately; BME 7% versus 1%, synovitis 5% versus 1% and tenosynovitis 4% versus 
1%. Therefore, although radiographic progression was infrequent, joints with subclinical 
inflammation had an increased risk of radiographic progression within the first year. This 
demonstrates the relevance of MRI detected subclinical inflammation. Although, it is dif-
ficult to translate it into clinical practice, because these analyses were done on joint level 
and the rheumatologist treats patients and not joints and these joints with subclinical 
inflammation were distributed among 91% of the patients. Therefore, this study mainly 
increases the comprehension of the connection between inflammation and structural dam-
age early in the disease.
The EULAR taskforce recently suggested that MRI can improve the certainty of the diag-
nosis RA.34 Since this recommendation may reflect a tendency to use MRI in daily practice, 
thorough studies on the value of MRI are required. Thus far no large studies have evaluated 
the accuracy of MRI to differentiate early RA from other early arthritis patients. In chapter 
12 we performed a large cross-sectional study to determine if patients that are clinically 
classified with RA differ in MRI features compared to patients with other diagnoses.
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We observed that among all patients presenting with early arthritis, RA patients had 
significant higher scores for synovitis, tenosynovitis and BME than non-RA patients. Al-
though for all MRI inflammation features the negative predictive value for RA was good 
(>0.80), the positive predictive value for RA was low (<0.50). For all MRI features the AUCs 
were <0.70. Additionally we compared ACPA positive and negative UA and RA patients 
and found that ACPA positive patients had more BME than ACPA negative patients. From 
previous studies we know that BME is a strong independent predictor for progression of 
joint destruction and therefore this is in line with ACPA positive RA being a more severe 
disease.35 Furthermore, we compared the patients fulfilling the 2010 and 1987 criteria 
for RA, by dividing them in four groups, either fulfilling both sets, only one set or none. 
We observed that patients fulfilling the 2010 criteria but not the 1987 criteria had less 
synovitis. This suggests that patients that only fulfill the 2010 criteria have a milder disease, 
which is in line with the results of previous studies.
In conclusion, although RA patients had higher scores of MRI inflammation and ACPA 
positive patients had more BME, the severity of MRI inflammation does not accurately dif-
ferentiate RA patients from other early arthritis patients. However, particularly interesting 
is whether MRI can have additional value in the group of patients that are classified as UA 
and will develop into RA. Therefore, large longitudinal studies are required to determine 
whether MRI is valuable for classification of patients that are clinically undefined.
PARt iv: mRi sCAn PRotoCol RevisiteD
In this part the scan protocol for MRI is revisited. The OMERACT MRI in RA working group 
developed and validated a semi-quantitative scoring method system (RAMRIS).36-38 The 
scoring system recommends having at least the following sequences: imaging in two 
planes with T1-weighted images before and after intravenous gadolinium contrast and 
a T2-weighted fat saturated sequence. This set of sequences is very time consuming and 
therefore costly and not patient friendly. Therefore, ideally less sequences and no contrast 
administration is necessary.
On MRI BME can be observed due to the focally increased water content in the bone 
marrow, partly or entirely replacing normal bone marrow fat. Therefore, BME signal inten-
sity is low on T1 weighted sequences and high on T2 weighted fat saturated sequences. 
Additionally, BME also enhances with intravenous gadolinium on T1 weighted fat saturated 
sequences after gadolinium contrast administration and are very similar to T2 weighted fat 
saturated sequences with regard to BME presentation.
In chapter 13 we evaluated whether T1 weighted post-gadolinium images (T1Gd) can 
replace T2 weighted images (T2) for evaluating BME. We observed that the total BME 
scores did not differ between the two sequences (T1Gd and T2). Intra-reader ICC’s be-
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tween scores based on T2 and T1Gd images were all excellent (0.80-0.99). The sensitivity 
and specificity of BME on T1Gd compared to T2 was high. Inter-reader ICC’s were excellent 
regardless of the image set used (all>0.83).
In conclusion, on T1Gd images equal scores for bone marrow edema were scored com-
pared to the standard T2 images. Therefore, for RAMRIS scoring, a short protocol of T1 
and T1 fat saturated post gadolinium sequences might be sufficient. This results in a 20% 
reduction of imaging time. Additionally, T2 weighted sequences are more prone, than T1 
weighted sequences, to artifacts due to magnetic field inhomogeneity and movement. 
Especially when imaging multiple joint areas in one session, shortening of the imaging 
time in combination with more robust sequences decreases the chance of unsuccessful 
MR examinations.
According to the RAMRIS protocol and the additional protocol for tenosynovitis scoring 
by Haavardsholm, intravenous contrast is administrated to assess synovitis and tenosynovi-
tis on the T1 weighted post contrast images. However, synovitis and tenosynovitis normally 
exhibit high signal intensity both on T2 weighted and T1 weighted post contrast images. 
In chapter 14 we studied whether intravenous contrast administration can be eliminated 
from the scanning protocol, decreasing imaging time, cost and invasiveness.
At individual joint/tendon level, compared to contrast-enhanced images, sensitivities to 
detect synovitis without contrast were 72% and 91% for both readers and the specificities 
52% and 81%. Similarly, for tenosynovitis the sensitivities were 54 and 67% and specifici-
ties 88% and 91%. A review of literature showed overall high sensitivity and low specific-
ity to evaluate synovitis and low sensitivity and high specificity to evaluate tenosynovitis 
without contrast-enhancement. An explanation for the high sensitivity and low specificity 
for scoring synovitis on T2 weighted images, might be due to the fact that on T2 weighted 
images hyperplastic inflamed synovium could not be adequately differentiated from fluid in 
the joints. In conclusion, eliminating intravenous contrast administration decreases speci-
ficity for synovitis and sensitivity for tensosynovitis, indicating that intravenous contrast 
administration remains essential for an optimal assessment.
An additional remark on comparing MRI scoring on different sequences is that BME, 
synovitis and tenosynovitis scoring on MRI according to the RAMRIS method does not 
imply there will always be inflammation present that can be seen as pathology. MRI is 
known to be very sensitive and therefore low grade scoring of these features could also 
be physiological normal variations. Therefore, these results of scoring on other sequences, 
then were recommended by the RAMRIS method, do not automatically imply that scoring 
should result in worse results. More important is the clinical consequence of the score and 
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another important measure is sensitivity to change, which could be an important measure 
in clinical trials.
In chapter 15 we investigated the possible influence of a normal daily intervention on 
the images made with MRI. As wearing high heels shifts pressure from the heel to the 
heads of the metatarsal bones, we hypothesized that this might result in acute abnor-
malities of the forefoot similar to changes secondary to trauma or repetitive stress. We 
performed a single-blind crossover study to determine this. Flat shoes were worn on the 
first day and high heels on the second day and MRI was made twice on both days; at the 
beginning of the day and at the end of the day. No BME or deep soft tissue abnormalities 
were caused by wearing high heels for a day. The only changed abnormality was revealed 
on all MRI scans taken at the end of day two; plantar subcutaneous edema, consistently 
located at the medial forefoot extending proximal to the MTP joints. These data imply 
that wearing high heels is not associated with short-term structural abnormalities. The 
long-term effects of wearing high heels remain unknown. These results are relevant when 
interpreting forefoot MRI examinations of rheumatoid or orthopedic patients.
GeneRAl ConClUsion
In this thesis we tried to answer the following questions:
1) How can we discriminate patients/persons that will develop RA from those that will not? 
What are predictive factors for development of RA?
2) What will be the prognosis of a RA patient? What are predictive factors for the disease 
course of RA?
1) how can we discriminate patients/persons that will develop RA from 
those that will not? what are predictive factors for development of RA?
In chapter 12, we found that among early arthritis patients RA patients had higher MRI 
inflammation scores. However, the accuracy to differentiate RA patients from other early 
arthritis patients was low. Nevertheless, in clinical practice patients will first be classified 
according to clinical and serological findings, which will result in a remaining group only 
consisting of UA patients who can possibly be differentiated by MRI findings.
In chapter 2 and 3 we looked into differentiating of UA patients. We found that even 
after applying the new, more sensitive, 2010 criteria set for RA to early arthritis patients, 
24% still developed RA during the first year. This showed the lack of the 2010 criteria 
in classifying all RA patients at baseline. We tried to find prediction factors for 2010-UA 
patients that developed RA. However, ACPA positivity and the ‘van der Helm-prediction 
model’ could not differentiate these patients.
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In chapter 9, we studied patients in an even earlier phase then UA, we studied ACPA 
positive arthralgia patients. We found that in this early phase of the disease local subclini-
cal inflammation was already present on MRI. This confirms the existence of a pre-clinical 
phase of RA and the importance of MRI by detecting subclinical inflammation. Therefore, 
MRI might be of help in predicting RA development in this phase of the disease.
2) what will be the prognosis of a RA patient? what are predictive factors 
for the disease course of RA?
In chapter 10 and 11 we also found subclinical inflammation in the clinical non-swollen 
joints in early arthritis patients. To investigate the relevance of this subclinical inflammation 
in these clinically non-swollen joints, we looked for radiographic progression after one year. 
We found that joints with subclinical inflammation had an increased risk of radiographic 
progression. This suggests that MRI detected subclinical inflammation is relevant and can 
predict for a more severe disease course.
In chapter 5 to 7 we found four IL15, one IL4R and one GZMB SNPs that were associ-
ated to a more severe disease course. Additionally, in chapter 8 we found pyridinoline, a 
serological marker, associated to a more severe disease course.
Furthermore, in chapter 13 to 15 we investigated the MRI scanning protocol, to scan 
more efficient and accurate. We found that BME could also be scored on the T1 weighted 
sequence after contrast administration and therefore the scanning protocol can be re-
duced by eliminating the T2 weighted sequences. We also found that the sequences after 
contrast administration were essential for optimal assessment of synovitis and tenosyno-
vitis. Furthermore, we showed that wearing high heels is not associated with structural 
abnormalities on the short time.
FUtURe PeRsPeCtives/ChAllenGes
During the last decades treatment of RA has become very effective, which has resulted in 
a less severe outcome of RA, with very minor radiographic progression. Furthermore, as 
we know from previous research early intervention might alter the natural course of RA. 
This is why the future of RA should be focused on identifying patients earlier in the 
disease, and treating or possibly first tight monitoring of very early RA. This is why research 
should be focused on identifying predictors for RA development. This is done frequently in 
patients classified as UA, but the opportunities are in the even earlier phases of the disease. 
We know from previous studies that anti-bodies and acute phase reactants are already 
present years before the first symptoms, which suggest there is a pre-clinical phase in RA. 
However, predictors for RA development in a very early phase can be very specific, but 
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the challenge is to remain sensitive. For example, arthralgia patients and especially ACPA 
and/or RF positive arthralgia patients have an elevated risk of developing RA, but when a 
patient also has arthritis (UA patient) the chance of developing RA will be even higher. The 
further away from the full blown RA phenotype, the lower the risk of progressing into RA 
and the more difficult it is to differentiate.
Another important focus point in RA research should be personalized medicine. The 
one RA patient does not exist. Firstly, future research should therefore be focused on pre-
dicting the disease course of the individual patient. Secondly, research should be focused 
on predicting treatment responsiveness (and adverse reactions) in the individual patients. 
These two should then be combined to make a personalized treatment decision in each 
RA patient. I expect that in the near future there will probably be sophisticated tools to 
calculate which treatment step should be taken in each patient, based on the prediction 
of his/her disease course and the prediction of his /her responsiveness to each treatment.
Another important focus in RA research is already mRi, but might become even more 
important. MRI is a very sensitive tool to measure (sub)clinical inflammation. Furthermore, 
MRI can measure BME, which is a very strong predictor of progressive disease. Therefore, 
I expect that MRI could become an important tool for therapeutic decision making and 
predicting prognosis. In clinical trials MRI will be even more important to measure the 
impact of disease-suppressing therapy on the course of synovitis and bone marrow edema, 
because some studies already showed sub-clinical inflammation in patients in clinical 
remission.39-43
Future research is necessary to face these challenges and this might eventually lead to 
the no longer existence of RA.
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Reumatoïde artritis (RA) is een auto-immuun ziekte die wordt gekenmerkt door symme-
trische polyartritis van vooral de kleine hand- en voet gewrichten. RA komt in 0,5-1% 
van de bevolking voor en kan grote consequenties voor het fysieke functioneren van de 
patiënt en zijn/haar dagelijkse leven hebben. Daarnaast kunnen de sociaal-economische 
consequenties voor de samenleving van significant belang zijn. De afgelopen jaren is de 
behandeling van RA drastisch verbeterd en is er veel nieuwe en effectieve medicatie be-
schikbaar gekomen. Verder hebben we uit eerdere studies geleerd dat vroege herkenning 
en behandeling resulteert in een betere uitkomst, dat tegenwoordig al wordt toegepast in 
de klinische praktijk. Deze behandelingen zijn echter niet zonder bijwerkingen en bepaald 
niet goedkoop. Daarom zijn er belangrijke vragen die beantwoord moeten worden, zoals: 
Hoe kunnen we patiënten/personen die RA gaan ontwikkelen onderscheiden van de 
patiënten/personen die geen RA ontwikkelen? Wat zijn voorspellende factoren voor het 
ontwikkelen van RA? Wat is de prognose van een patiënt met RA? Wat zijn voorspellende 
factoren voor het verloop van de ziekte?
Deel i: onGeClAssiFiCeeRDe ARtRitis en het RisiCo vooR het 
ontwikkelen vAn RheUmAtoïDe ARtRitis
In 2010 is er nieuwe set van classificatie criteria voor RA tot stand gekomen, om RA 
patiënten in een eerder stadium van de ziekte te kunnen classificeren. Daarna kwamen 
er verschillende studies die zich richtten op het onderzoeken van de kenmerken en uitkom-
sten van deze nieuwe groep RA patiënten. De gemeenschappelijke conclusie was dat de 
2010-criteria patiënten in een eerder stadium van de ziekte als RA kan classificeren, maar 
met als gevolg een grotere groep over-geclassificeerde patiënten met ‘self limiting disease’. 
Als gevolg van de veranderingen in de nieuwe groep RA patiënten, verandert de groep 
ongeclassificeerde artritis (UA) patiënten ook.
In hoofdstuk 2 hebben we de kenmerken en uitkomsten van UA volgens de 2010-criteria 
bekeken in de Leiden EAC. We vonden dat 2010-UA patiënten mildere baseline kenmerken 
hadden dan 1987-UA patiënten. Om de uitkomsten van de UA patiënten te evalueren, ge-
bruikten we verschillende uitkomstmaten. Dit deden we omdat er geen ultieme uitkomst 
definitie voor RA bestaat. We gebruikten drie verschillende uitkomsten die kunnen worden 
gezien als surrogaten voor RA: Zij die voldoen aan de 1987 criteria gedurende het eerste 
jaar, zij die een DMARD starten gedurende het eerste jaar en zij die een blijvende ziekte 
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hebben op de langere termijn (geen remissie). Gedurende de follow-up, voldeden 24% 
van de 2010-UA patiënten alsnog aan de 1987 RA criteria, vergeleken met 32% van de 
1987-UA patiënten. De 2010-UA patiënten startten minder vaak een DMARD behandeling 
en bereikten vaker een blijvende DMARD vrije remissie. Maar het percentage UA patiënten 
dat RA ontwikkelt gedurende het eerste jaar zou waarschijnlijk hoger zijn als we naar het 
natuurlijk verloop van de ziekte zouden kijken, aangenomen dat de behandeling voorkomt 
dat zij RA ontwikkelen. Ook al is de meerderheid van deze patiënten geïncludeerd in de tijd 
dat een agressieve DMARD behandeling nog niet gebruikelijk was.
Vervolgens keken we of de classificatie volgens de 2010 criteria congruent was aan de 
risicoschatting door het ‘Van der Helm voorspel model’. Beide methoden werden toegepast 
op 1987-UA patiënten. Het merendeel van de 1987-UA patiënten dat niet voldeed aan de 
2010 criteria viel in de laagrisicogroep van het voorspel model. Terwijl maar 30% van de 
2010 criteria positieve patiënten in de laagrisicogroep. Deze groep patiënten bereikte vaker 
DMARD vrije remissie dan de andere 2010 criteria positieve patiënten. Wel moet worden 
gezegd dat evaluatie van congruentie tussen beiden methoden formeel niet correct is, 
omdat de 2010 criteria set bedoeld is voor classificatie en het voorspel model bedoeld 
is voor individuele voorspelling. Toch zullen de 2010 criteria ook worden toegepast op 
individuele patiënten in de kliniek. In het algemeen kan worden geconcludeerd dat UA in 
het perspectief van de 2010 criteria, minder vaak voorkomt en milder is in voorkomen en 
in uitkomst, maar dat nog steeds 24% van de 2010-UA patiënten binnen 1 jaar aan de 
1987 criteria voldoet. Dit betekent dat 2010-UA patiënten klinisch goed vervolgd moeten 
worden.
We waren nogal verrast over het feit dat een zo hoog percentage 2010-UA patiënten 
nog RA ontwikkelt gedurende het eerste jaar. Daarom hebben wij in hoofdstuk 3 ook 
in andere cohorten gekeken naar het percentage 2010-UA patiënten dat RA ontwikkelt 
gedurende follow-up. We keken naar 2010-UA patiënten uit vroege artritis cohorten van 
Leiden, Birmingham (UK) en Amsterdam. Daaruit bleek dat respectievelijk 24%, 26% en 
12% van de 2010-UA patiënten aan de 1987 criteria voldeed na 1 jaar. Een deel van deze 
patiënten voldeed echter al aan deze 1987 criteria op baseline. Van de patiënten die zowel 
1987- en 2010-UA waren, voldeed na 1 jaar nog respectievelijk 15%, 21% en 9%, aan de 
1987 criteria. Omdat deze vroege RA patiënten worden gemist op baseline, probeerden wij 
voorspellende factoren voor RA ontwikkeling te vinden. In deze context evalueerden wij 
de voorspellende accuraatheid van anti-cyclisch gecitrullineerde proteïnen (ACPA) en ‘het 
Van der Helm voorspel model’ in 2010-UA patiënten. Van de 1987-en 2010-UA patiënten 
die 1987 RA ontwikkelden gedurende het eerste jaar, was 0-6% ACPA positief en 0-1% 
had een hoge score volgens het voorspel model. Hieruit kan geconcludeerd worden dat 
het grootste deel van de UA patiënten die een slechte uitkomst hebben, niet worden 
herkend door deze voorspellende factoren. Daarom hebben ACPA en het voorspel model 
geen toegevoegde waarde in het identificeren van deze patiënten. Omdat een dusdanig 
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hoog percentage 2010-UA patiënten RA ontwikkelt en deze voorspellende factoren geen 
toegevoegde waarde hebben bij deze patiënten, concluderen wij dat er andere voorspel-
lende factoren voor RA ontwikkeld moeten worden.
Deel ii: GenetisChe en seRoloGisChe FACtoRen vooR het 
vooRsPellen vAn toenAme vAn RADioloGisChe GewRiChtssChADe 
in RheUmAtoïDe ARtRitis
Als er bij een patiënt RA wordt gediagnosticeerd is het ziekte verloop nog onbekend, 
want RA kent een grote variatie in ziekte verloop. Sommige patiënten hebben een zeer 
progressief ziekteverloop, naar een erosieve en immobiliserende ziekte, terwijl anderen 
remissie bereiken. Een objectieve en vaak gebruikte methode om de ziekte toename in RA 
te meten is doormiddel van de toename van radiologische gewrichtsschade. De meest ac-
curate methode om dit te meten is met röntgenfoto’s van zowel handen als voeten die op 
meerdere tijdstippen zijn gemaakt en gescoord volgens een gevalideerde en kwantitatieve 
scoring methode.
Allereerst worden in hoofdstuk 4 biomarkers voor toename van radiologische ge-
wrichtsschade besproken in een review. Hierin bespreken we gepubliceerde (en deels 
ongepubliceerde) data van genetische, serologische en beeldvormende biomarkers voor de 
ernst van gewrichtsschade in RA. In de genetica zorgt de combinatie van lage prevalentie 
van variaties en een klein effect ervoor dat grote datasets nodig zijn. Helaas zijn grote 
datasets met longitudinale radiologische gewrichtsschade data op lange termijn zeldzaam. 
Verder is een interessante vraag: wanneer is een genetische associatie waar. Het eerste 
mogelijke bewijs is de p-waarde, die alleen niet voldoende aantoont dat een variant waar 
is. Betrouwbaarder is replicatie. Als een variant statistische significant geassocieerd is in 
meerdere onafhankelijke cohorten, is de kans dat de bevinding op toeval berust drastisch 
verkleind. Nog overtuigender is data die de bevinding op een ander niveau ondersteunt, 
zoals op mRNA of eiwit niveau. In de meest ideale situatie wordt ook het ‘pathway’ of 
het mechanisme begrepen via welke de genetische risicofactor de ziekte beïnvloedt. In 
dit review worden genetische varianten in 28 genen geëvalueerd; varianten in 10 genen 
(CD40, IL2RA, IL4R, IL15, OPG, DKK1, SOST, GRZB, MMP9, SPAG16) werden gerepliceerd 
in onafhankelijke data sets en voor vijf varianten (IL2RA, DKK1, GRZB, MMP9, SPAG16) 
werd ook bewijs gevonden voor een associatie op functioneel niveau. We evalueerden 
zeven serologische varianten, zoals; auto-antilichamen (RF, ACPA, anti-CarP), markers ge-
relateerd aan inflammatie (BSE, CRP) en proteasen of componenten van de extracellulaire 
matrix van bot en kraakbeen (MMP3, CTX-I, CTX-II, COMP, TIMP1, PYD, RANKL/OPG, 
CXCL13). Tenslotte hebben we ook gekeken naar markers die zichtbaar gemaakt kunnen 
worden door echo of MRI, zoals; erosies, beenmerg oedeem, synovitis en tenosynovitis. 
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Meerdere studies hebben laten zien dat beenmerg oedeem en synovitis zichtbaar op MRI 
sterke voorspellers zijn voor toename van radiologische gewrichtsschade en anderen 
laten zien dat inflammatie op echo hier ook voor voorspelt. Tijdens het evalueren van al 
deze biomarkers zagen wij dat serologische en beeldvormende markers grotere effecten 
hadden dan genetische markers. Dit kan komen doordat serologische en beeldvormende 
biomarkers dichter bij het fenotype staan. Tot op heden wordt het merendeel van deze 
bekende risicofactoren niet toegevoegd aan risicomodellen. Toekomstige studies zullen 
moeten aantonen of het toevoegen en combineren van deze verschillende biomarkers 
de voorspellende accuraatheid van risicomodellen die de toename van radiologische ge-
wrichtsschade in RA voorspellen, zal verbeteren. Maar voordat een voorspellende marker 
kan worden toegevoegd, moet de marker ook kosteneffectief zijn; de marker moet klinisch 
relevante voorspelling toevoegen, maar ook niet te duur zijn, te veel tijd in beslag nemen 
of te invasief zijn.
In de volgende vier hoofstukken worden vier genetische en één serologische biomarker 
voor toename van radiologische gewrichtsschade geëvalueerd. In hoofstuk 5-7 onder-
zochten we vier kandidaat genen op hun associatie met radiologische gewrichtsschade. 
Alle vier de genen werden onderzocht volgens een kandidaat gen studiebenadering. Dit 
houdt in dat alle genen zijn geselecteerd op basis van de individuele hoge vooral kans op 
het hebben van een associatie met radiologisch gewrichtsschade. Volgens de literatuur 
hebben deze genen een verhoogde kans op een associatie met radiologische gewrichts-
schade. Het doel van deze studies was niet het vinden van elke mogelijke associatie, maar 
het vinden van ware associaties van genetische varianten. Aan de ene kant resulteerde 
dit in een kleine kans op het vinden van fout-positieve associaties, maar aan de andere 
kant een grote kans op het vinden van fout-negatieve associaties. Hoewel dit laatste ook 
niet het doel van de studies was. Voor elk gen zijn die SNPs gekozen die het hele gen 
taggen. Verder gebruikten we in alle studies dezelfde strategie. Allereerst testten we alle 
SNPs in een eerste (identificatie) cohort. Zoals al eerder genoemd (in hoofdstuk 4); een 
significante genetische associatie in één cohort is niet voldoende om aan te tonen dat een 
genetische associatie ook een ware associatie is. Voor meer overtuigendere data heb je 
minimaal replicatie nodig en nog overtuigender is data dat de associatie op functioneel 
niveau onderschrijft. De volgende stap was daarom ook om de SNPs die significant geas-
socieerd waren met de toename van radiologische gewrichtsschade te testen in een ander 
(replicatie) cohort. Wanneer een SNP ook significant geassocieerd was met radiologische 
gewrichtsschade in het replicatie cohort, was de kans op een fout-positieve associatie 
verkleind. In de sommige gevallen hebben we de associatie nog kunnen bevestigen met 
functionele data.
In hoofstuk 5 onderzochten we de associatie van genetische varianten in IL15 met de 
snelheid van toename in radiologische gewrichtsschade in RA. Verschillende studies laten 
zien dat IL-15 een rol speelt in het onderhouden van inflammatie en beïnvloeden van 
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osteoclastogenesis. Bij patiënten met RA, zijn de IL-15 levels in het serum, het synovium en 
in het beenmerg verhoogd. Verder zijn IL-15 levels sterk gecorreleerd aan ziekte activiteit. 
Daarom onderzochten wij of genetische varianten in IL-15 geassocieerd zijn met de ernst 
van gewrichtsschade in RA. Vijf SNPs waren significant geassocieerd met de snelheid van 
radiologische gewrichtsschade in de eerste fase (Leiden EAC) en werden dan ook ‘gegeno-
typeerd’ in drie andere cohorten (Groningen, Lund (Sw) en Sheffield (UK)). Onafhankelijke 
replicatie werd niet behaald, waarschijnlijk door het ontbreken van genoeg power in de 
replicatie cohorten. Maar een meta-analysis van alle vier de cohorten resulteerde in een 
significant resultaat voor alle vier de SNPs (rs7667746, rs7665842, rs4371699, rs6821171). 
Deze SNPs bleven significant na correctie voor ‘multiple testing’. Dit suggereert dat deze 
vier genetische varianten in IL15 geassocieerd zijn met toename van radiologische ge-
wrichtsschade in RA. Verdere studies zouden nog moeten aantonen of de aanwezigheid 
van deze varianten ook daadwerkelijk leidt tot een verschil op functioneel niveau van IL15.
In hoofdstuk 6 keken we naar de associatie tussen IL4 en IL4R tagging SNPs en de 
snelheid van radiologische gewrichtsschade in RA. Eerdere studies lieten zien dat IL-4 een 
anti-inflammatoir en anti-osteoclastisch effect heeft. Het effect van IL-4 wordt voorna-
melijk gemedieerd door deIL-4 receptor alpha keten (IL4-Ralpha). Er zijn al verschillende 
genetische studies naar IL4 en IL4R en gewrichtsschade gedaan, maar geen van de vari-
anten die zijn gevonden zijn gerepliceerd. Daarom hebben wij een multi-cohort kandidaat 
studie gedaan. In de eerste fase (Leiden EAC) waren geen van de IL4 SNPs en zeven van 
de IL4R SNPs significant geassocieerd met de snelheid van radiologische gewrichtsschade. 
Deze zeven significante SNPs werden geanalyseerd in vier (Groningen, Lund (Sw), Sheffiled 
(UK), NARAC (US)) of zes (Groningen, Lund (Sw), Sheffield (UK), NARAC (US), Wichita (US), 
NDB (US)) andere cohorten (afhankelijk van de beschikbaarheid van de genotypes van de 
verschillende SNPs in de cohorten). In deze kandidaat gen studie waren meer cohorten 
beschikbaar in de tweede fase. Daarom konden we nu wel onafhankelijke replicatie be-
werkstelligen, die bestond uit een meta-analyse van alleen de extra cohorten in de tweede 
fase. In de replicatie fase waren twee SNPs in het IL4R gen significant geassocieerd met de 
snelheid van radiologische gewrichtsschade. Eén van deze twee SNPs bleef ook significant 
na correctie voor ‘multiple testing’. Deze SNP (rs1119132) was recessief geassocieerd met 
radiologische gewrichtsschade toename. Dit betekent dat het dragen van beiden minor al-
lelen resulteert in meer ernstige gewrichtsschade toename en dat maar een klein deel van 
de RA patiënten deze homozygote recessieve variant zal dragen. Desondanks vonden we 
zowel onafhankelijke replicatie in sommige replicatie cohorten als in de meta-analyse van 
de zes replicatie cohorten. Concluderend, identificeerden en repliceerden we een geneti-
sche variant in IL4R, die geassocieerd is met radiologische gewrichtsschade in RA. Verdere 
studies naar IL-4R op functioneel niveau zijn nodig om deze bevinding te bevestigen en 
beter te begrijpen wat de rol is van deze variant in de pathogenese van RA.
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In hoofdstuk 7 onderzochten we Granzyme B (GZMB) als kandidaat gen voor radiolo-
gische gewrichtsschade in RA. GZMB is een serine protease dat in lytische granules van 
‘natural killer’(NK) cellen en cytotoxische T lymfocyten zit en cel dood kan induceren. 
Eerdere studies suggereerden al een rol voor GZMB in RA gewrichtsdestruktie, vanwege de 
toename van GZMB-positieve cellen in synovium en tussen chondrocyten op de plek van 
een pannus laesie. Daarom onderzochten wij of er genetische varianten in GZMB geasso-
cieerd zijn met toename van radiologische gewrichtsschade. Twee SNPs waren significant 
geassocieerd met radiologische gewrichtsschade in de eerste fase (Leiden EAC). Deze twee 
SNPs waren sterk gecorreleerd en daarom werd alleen de sterkste SNP (rs8192916) getest 
in de tweede fase. Omdat de data in de tweede fase onvoldoende was voor onafhankelijke 
replicatie, werd deze SNP getest in een meta-analyse van alle vier de datasets (Leiden 
EAC, Groningen, Lund (Sw) en Sheffield (UK)). Dit resulteerde in een significante associatie 
met radiologische gewrichtsschade. Deze associatie bleef ook significant na correctie voor 
‘multiple testing’. De minor allel van deze SNP was geassocieerd met een hogere snelheid 
van gewrichtsschade. Ook de associatie tussen RNA expressie en de genomische regio van 
GZMB werd geanalyseerd. Dit resulteerde in een hogere expressie van GZMB RNA bij aan-
wezigheid van de minor allel van deze SNP. Geconcludeerd kan worden dat dit suggereert 
dat deze genetische variant in GZMB geassocieerd is met de toename van radiologische 
gewrichtsschade en RNA expressie in het bloed in RA.
In hoofdstuk 8 evalueerden we de voorspellende waarde van serum pyridinoline (PYD) 
levels in gewrichtsdestructie. PYD is een belangrijke schakel in collageen van kraakbeen, 
bot en synovium. Eerdere studies lieten zien dat PYD levels verhoogd zijn in RA patiënten 
vergeleken met gezonde personen en dat PYD levels verhoogd zijn in geval van actieve 
of ernstige ziekte. De meeste eerdere studies zijn uitgevoerd met urine PYD levels. Grote 
longitudinale studies met serum PYD levels en radiologische gewrichtsschade in RA zijn 
er niet. Wij evalueerden de voorspellende waarde van serum PYD voor toekomstige 
gewrichtsschade, zowel op baseline voor lange termijn voorspelling als gedurende de 
ziekte voor korte termijn voorspelling. Evaluatie van de baseline PYD serum levels toonde 
aan dat de baseline levels significant geassocieerd zijn met de snelheid van radiologische 
gewrichtsschade over zeven jaar en ook onafhankelijk van bekende risico factoren voor 
gewrichtsschade, zoals; leeftijd, geslacht, behandeling, ACPA status, CRP level, BMI en 
roken. Ook waren de PYD levels gedurende follow-up significant geassocieerd met de 
snelheid van radiologische gewrichtsschade voor het eerst volgende jaar en ook onafhan-
kelijk van bekende risico factoren. Ook al vonden we dat een hoog PYD serum level een 
onafhankelijke risico factor was, de accuraatheid (gemeten doormiddel van de AUC) van 
PYD level als voorspeller voor de snelheid van radiologische gewrichtsschade was matig. 
Daarom kan geconcludeerd worden dat een verhoogd PYD serum level, zowel op base-
line als gedurende de ziekte, geassocieerd is met een hogere snelheid van radiologische 
gewrichtsschade gedurende het volgende jaar/de volgende jaren, maar de voorspellende 
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accuraatheid als een losse voorspeller is matig. Daarom kan het belangrijk zijn om serum 
PYD toe te voegen aan een voorspel model met meerdere voorspellers om radiologische 
gewrichtsschade in RA patiënten te voorspellen.
Deel iii: mAGnetiC ResonAnCe imAGinG vAn PAtiënten met 
ARtRAlGie en vRoeGe ARtRitis
Magnetic Resonance Imaging (MRI) wordt steeds belangrijker in het onderzoek naar RA. 
De weergave van hoog anatomisch detail samen met de afbeelding van inflammatie ma-
ken MRI een interessante nieuwe modaliteit bij het onderzoek naar vroege detectie van RA. 
Naast de detectie van inflammatie in de gewrichten, is inflammatie in het bot zichtbaar en 
van potentiële meerwaarde ten opzichte van conventioneel onderzoek en echografie. In 
dit deel onderzochten we diverse MR parameters in de (deels klinisch onzichtbare) vroege 
ziekte fases van RA. Verder onderzochten we of MRI RA patiënten kan onderscheiden van 
andere patiënten met vroege artritis.
Van eerdere studies weten we dat ACPA, RF en acute fase eiwitten al jaren voor de eerste 
symptomen van RA tot uiting komen, aanwezig zijn. Dit suggereert dat er een pre-klinische 
fase in RA bestaat. Het was alleen nog onduidelijk of er ook lokale inflammatie in de 
gewrichten plaats vindt in deze pre-klinische fase. Een MRI studie van knie gewrichten van 
13 ACPA positieve artralgie patiënten liet geen subklinische inflammatie zien. Maar hoogst 
waarschijnlijk begint RA niet in de knie gewrichten en dus laat dit de vraag open of er lokale 
inflammatie aanwezig is in de pre-klinische fase van ACPA positieve RA. In hoofdstuk 9 
onderzochten we de kleine gewrichten van 21 ACPA positieve artralgie patiënten op lokale 
subklinische inflammatie. De inflammatie gedetecteerd met MRI werd vergeleken tussen 
kleine gewrichten van controles (n=19)(zonder gewrichtsklachten), kleine gewrichten van 
ACPA positieve artralgie patiënten en kleine gewrichten van ACPA positieve RA patiënten 
(n=22). Deze studie liet meer inflammatie op MRI in de PIP/MCP en pols gewrichten zien in 
ACPA positieve artralgie patiënten in vergelijking tot controles zonder gewrichtsklachten 
en minder dan in de gewrichten van ACPA positieve RA patiënten. Deze data suggereren 
dat lokale subklinische inflammatie aanwezig is in ACPA positieve artralgie patiënten. 
Waarschijnlijk is er al een inflammatie proces gaande in de kleine gewrichten, voordat 
deze gewrichten klinisch ontstoken zijn en opgemerkt worden als gezwollen gewrichten 
bij lichamelijk onderzoek.
De volgende vraag was of inflammatie in de gewrichten van artritis patiënten, die 
gedetecteerd wordt met MRI, overeenkomt met inflammatie die gedetecteerd wordt bij 
lichamelijk onderzoek. In hoofdstuk 10 onderzochten we de associatie en congruentie 
tussen inflammatie van de kleine gewrichten gemeten met MRI en door middel van licha-
melijk onderzoek. We onderzochten 1.790 gewrichten van 179 patiënten van de Leiden 
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EAC. In deze gewrichten waren zowel synovitis als tenosynovitis op MRI onafhankelijk 
geassocieerd met klinische zwelling, in tegenstelling tot beenmerg oedeem (BME). In het 
merendeel (~90%) van de gezwollen MCP pols gewrichten was enige inflammatie te zien 
op MRI. In 27% van de niet gezwollen MCP gewrichten en 66% van de niet gezwol-
len polsen was enige inflammatie te zien. Daar tegenover staat dat van alle MCP, pols 
en MTP gewrichten met enige inflammatie op MRI, respectievelijk 64%, 61% en 77%, 
niet gezwollen waren. BME, zowel kleine als grotere laesies, kwam vaak voor in klinisch 
niet gezwollen gewrichten. Bovendien vonden we soortgelijke resultaten voor pijnlijke 
gewrichten. Geconcludeerd kan worden dat inflammatie op MRI niet alleen aanwezig is 
in klinisch gezwollen gewrichten, maar ook in niet gezwollen gewrichten. Van belang is 
dat BME ook voorkomt in klinische niet gezwollen gewrichten. Van eerdere studies weten 
we dat BME een onafhankelijke voorspeller is voor radiologische gewrichtsschade. Echter 
of alle met MRI gedetecteerde BME klinische relevant is voor het verloop van de ziekte, is 
onbekend.
In hoofdstuk 11 onderzochten we de relevantie van deze MRI gedetecteerde subklini-
sche inflammatie in relatie tot radiologische gewrichtsschade gedurende het eerste jaar. De 
belangrijkste redenen voor het kiezen van radiologische gewrichtsschade als een uitkomst, 
is omdat dit veel gebruikt wordt in RA, het een objectieve maat is en omdat de score op 
joint niveau apart kan worden bekeken. Fysieke functie en ziekte activiteit zijn natuur-
lijk ook interessante uitkomstmaten, maar niet te gebruiken op gewrichtsniveau. Deze 
uitkomstmaten kunnen wel een belangrijke rol spelen bij het vertalen naar de klinische 
praktijk in de toekomst. In deze studie probeerden we allereerst te repliceren wat anderen 
al vonden, om er zeker van te zijn dat deze data zich het zelfde gedragen en dat dus de 
vooraf bedachte aannames ook van toepassing zijn op deze data. Wij vonden inderdaad 
ook dat BME, synovitis en tenosynovitis geassocieerd zijn met radiologische gewrichts-
schade, onafhankelijk van bekende risico factoren. Daarna onderzochten we de relevantie 
van de subklinische inflammatie. Ongeveer 26% van alle niet gezwollen gewrichten had 
subklinische inflammatie. Radiologische gewrichtsschade was aanwezig in 4% van alle niet 
gezwollen gewrichten met subklinische inflammatie, in vergelijking tot 1% van alle niet 
gezwollen gewrichten zonder subklinische inflammatie. Soortgelijke bevindingen vonden 
we voor de inflammatie parameters apart; BME 7% versus 1%, synovitis 5% versus 1% 
en tenosynovitis 4% versus 1%. Daarom kan worden geconcludeerd dat, ook al komt 
radiologische gewrichtsschade bijna niet voor, gewrichten met subklinische inflammatie 
wel een verhoogde kans op radiologische gewrichtsschade hebben binnen het eerste jaar. 
Dit laat de relevantie zien van MRI gedetecteerde subklinische inflammatie. Vooralsnog is 
het lastig te vertalen in de klinische praktijk, omdat deze analyses op gewrichtsniveau zijn 
gedaan. Een reumatoloog behandelt een patiënt en niet een gewricht en bovendien waren 
de gewrichten met subklinische inflammatie verdeeld over 91% van de patiënten. Daarom 
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kan deze studie vooralsnog vooral iets bijdragen aan het beter begrijpen van de connectie 
tussen inflammatie en structurele schade in de vroege ziekte.
De EULAR taskforce heeft recent gesuggereerd dat MRI kan helpen bij onzekerheid 
over de diagnose RA. Omdat deze aanbevelingen neigen naar het gebruik van MRI in de 
dagelijkse praktijk, zijn goede studies naar de waarde van MRI nodig. Tot nog toe is er geen 
grote studie gedaan, waarin wordt gekeken naar de accuraatheid van MRI voor differenti-
atie van vroege RA van andere vroege artritis patiënten. In hoofdstuk 12 hebben we een 
grote cross-sectionele studie gedaan, om te bepalen of patiënten die klinisch geclassificeerd 
worden als RA andere MRI eigenschappen hebben dan patiënten met andere diagnoses. 
We vonden dat tussen alle patiënten met vroege artritis, RA patiënten een hogere score 
voor synovitis, tenosynovitis en BME hadden ten opzichte van de patiënten zonder RA. 
Ook al was de negatief voorspellende waarde van alle MRI inflammatie parameters voor 
RA goed (>0,80), de positief voorspellende waarde voor RA was laag (<0,50). Voor alle 
MRI parameters waren de AUCs <0,70. Ook hebben we gekeken naar ACPA positieve en 
negatieve UA en RA patiënten en vonden dat de ACPA positieve patiënten meer BME had-
den dan de ACPA negatieve patiënten. Van eerdere studies weten we dat BME een sterke 
onafhankelijke voorspeller is voor toename van gewrichtsschade en dat komt overeen met 
het feit dat ACPA positieve RA een ernstiger ziektebeeld kent. Verder hebben we patiënten 
die voldeden aan de 2010 criteria voor RA vergeleken met patiënten die voldeden aan 
de 1987 criteria voor RA. Dit deden we door de patiënten in vier groepen in te delen; of 
ze voldeden aan beide criteria sets, of aan één of aan geen van beiden. We vonden dat 
patiënten die aan de 2010 criteria voldeden maar niet aan de 1987 criteria minder synovitis 
hadden. Dit suggereert dat patiënten die alleen aan de 2010 criteria voldoen een mildere 
ziekte hebben, wat overeenkomt met resultaten van eerdere studies. Geconcludeerd kan 
worden dat ook al hebben RA patiënten hogere inflammatie scores op MRI en ACPA posi-
tieve patiënten meer BME, de ernst van de MRI inflammatie kan niet accuraat RA patiënten 
differentiëren tussen andere vroege artritis patiënten. Een interessante vraag zou zijn of 
MRI een toegevoegde waarde kan hebben in een groep patiënten die UA hebben en RA 
gaan ontwikkelen. Hiervoor zijn grote longitudinale studies nodig die kunnen laten zien 
of MRI een toegevoegde waarde kan hebben in het classificeren van patiënten die klinisch 
ongeclassificeerd zijn.
Deel iv: mRi sCAn PRotoCol heRzien
In dit deel hebben we het MRI scan protocol herzien. De OMERACT MRI in RA werkgroep 
ontwikkelde en valideerde een semi-kwantitatieve scoringsmethode systeem (RAMRIS). 
In het protocol wordt aanbevolen om minimaal de volgende vijf sequenties te maken: 
in twee richtingen (coronaal en axiaal) T1-gewogen sequenties voor en na intraveneus 
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(Gadolinium-Chelaat) contrast en een T2-gewogen vet onderdrukte sequentie in één 
richting. Deze set van sequenties neemt veel tijd in beslag en is daarom zeer kostbaar en 
niet erg patiëntvriendelijk. Het verkorten van dit protocol zou kunnen leiden tot een betere 
kosten-effectiviteit verhouding en zou patiënt vriendelijker zijn.
Op MRI is BME zichtbaar door plaatselijke toename van watergehalte in het beenmerg, 
door gedeeltelijk of geheel vervangen van het beenmerg vet. Daarom is de signaalinten-
siteit van BME laag op T1-gewogen sequenties en hoog op T2 gewogen vet onderdrukte 
sequenties. BME licht ook op met intraveneus gadolinium op T1 gewogen vet onderdrukte 
sequenties en dit ziet er bijna net zo uit als op T2 gewogen vet onderdrukte sequenties.
In hoofdstuk 13 onderzochten we of voor de beoordeling van BME de T1 gewogen 
post-gadolinium sequenties (T1Gd) de T2 gewogen sequenties (T2) zou kunnen vervangen. 
We zagen dat totale BME scores niet verschilden tussen de twee sequenties (T1Gd en 
T2). Intrareader ICCs tussen de scores op T2 en T1Gd sequentie waren allemaal uitste-
kend (0,80-0,99). De sensitiviteit en specificiteit van BME op T1Gd vergeleken met T2 
was hoog. Interreader ICCs waren uitstekend, ongeacht de beelden set die werd gebruikt 
(allemaal>0,83).
Geconcludeerd kan worden dat T1Gd sequenties dezelfde scores voor BME opleverden 
als de standaard T2 sequenties. Daarom zou voor het scoren volgens de RAMRIS een kort 
protocol met T1 en T1 vet onderdrukte post- gadolinium sequenties voldoende moeten 
zijn. Dit zou dan resulteren in 20% reductie van de scan tijd. Daarnaast zijn T2 gewogen 
sequenties gevoeliger voor artefacten dan de T1 gewogen sequenties door magnetisch 
veld heterogeniteit en beweging. Vooral wanneer in één sessie meerdere gewrichten afge-
beeld moeten worden, zorgt een verkorting van de scan tijd in combinatie met robuustere 
sequenties voor een kleinere kans dat de MRI beelden mislukken.
Volgens het RAMRIS protocol en het extra protocol voor tenosynovitis score door 
Haavardsholm, is intraveneus contrast toediening nodig om synovitis en tenosynovitis te 
scoren op T1 gewogen post-contrast beelden. Synovitis en tenosynovitis geven echter 
zowel op T1 gewogen post-contrast beelden als op T2 gewogen beelden een hoog signaal. 
In hoofdstuk 14 onderzochten we of intraveneuze contrast toediening weggelaten kan 
worden in het MRI scan protocol, zodat de scan tijd kan worden verkort, de kosten omlaag 
gaan en de invasiviteit voor de patiënt afneemt.
We vergeleken de scores voor synovitis en tenosynovitis op T2 gewogen vet onderdrukte 
sequenties(T2) met de scores op de volgens het protocol T1 gewogen sequenties na toe-
diening van contrast (T1Gd). Op individueel gewricht/pees niveau was de sensitiviteit om 
synovitis op sequenties zonder contrast te detecteren 72% en 91% voor beide lezers en de 
specificiteit 52% en 81%, vergeleken met sequenties na contrast. Voor tenosynovitis was 
de sensitiviteit 54% en 67% en de specificiteit 88% en 91%. Een review van de literatuur 
liet zien dat bij het scoren van beelden zonder contrast, synovitis een hoge sensitiviteit 
en lage specificiteit heeft en tenosynovitis een lage sensitiviteit en hoge specificiteit. Een 
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verklaring voor de hoge sensitiviteit en lage specificiteit voor het scoren van synovitis op 
beelden zonder contrast, zou kunnen zijn dat op T2 gewogen sequenties hypervasculaire 
synoviale woekering en vocht in het gewricht niet goed te onderscheiden zijn. Gecon-
cludeerd kan worden dat bij het weglaten van de toediening van contrast de specificiteit 
van synovitis en de sensitiviteit van tenosynovitis omlaag gaan en dat onderstreept dat 
intraveneus contrast toedienen essentieel blijkt voor een optimale beoordeling
Een extra opmerking over het vergelijken van de scores op de verschillende MRI sequen-
ties is hierbij wel op zijn plaats. Het scoren van BME, synovitis en tenosynovitis volgens de 
RAMRIS methode houdt niet altijd in dat de inflammatie die wordt gezien ook daadwerke-
lijk pathologisch is. MRI staat bekend als een erg gevoelig meetinstrument en daarom kan 
aangenomen worden dat lage scores van sommige parameters ook fysiologisch normale 
variaties kunnen zijn. Daarom is het ook niet automatisch zo dat de resultaten van het 
scoren op andere sequenties, dan volgens de RAMRIS methode, slechtere resultaten ople-
veren. Belangrijker is wat de klinische consequentie van de score is. Ook is het belangrijk 
om te weten wat de sensitiviteit voor verandering is, wat een belangrijke maat in klinische 
trials kan zijn.
In hoofdstuk 15 onderzochten we het mogelijke effect van mechanische belasting van 
de voorvoet op MRI bevindingen. Omdat het dragen van hoge hakken de druk naar de 
voorvoet en de kopjes van de metatarsalia verplaatst, veronderstelden wij dat dit zou kun-
nen resulteren in afwijkingen aan het bot of de weke delen. We deden een ‘single-blind 
cross-over studie’ om dit te bepalen. Op de eerste dag droegen de proefpersonen platte 
schoenen en op de tweede dag droegen ze hoge hakken. De MRI’s werden op beide 
dagen twee keer per dag gemaakt; aan het begin en aan het einde van de dag. Er werden 
geen BME of diepe weke delen afwijkingen gezien, veroorzaakt door het dragen van hoge 
hakken voor een dag. De enige afwijking was op alle MRI beelden aan het einde van dag 
twee (na het dragen van hoge hakken) te zien: plantair subcutaan oedeem, altijd in de 
mediale voorvoet proximaal van de MTP gewrichten. Deze data laten zien dat het dragen 
van hoge hakken niet geassocieerd is met korte termijn structurele afwijkingen. De lange 
termijn effecten van het dragen van hoge hakken blijft echter onduidelijk. Deze resultaten 
zijn relevant bij het interpreteren van MRI beelden van de voorvoet van reumatische en 
orthopedische patiënten.
AlGemene ConClUsie
In dit proefschrift probeerden we de volgende vragen te beantwoorden:
1) Hoe kunnen we patiënten/personen die RA gaan ontwikkelen onderscheiden van de 
patiënten/personen die geen RA ontwikkelen? Wat zijn voorspellende factoren voor de 
ontwikkeling van RA?
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2) Wat is de prognose van een RA patiënt? Wat zijn voorspellende factoren voor het ziekte 
verloop van RA?
1) In hoofdstuk 12 vonden we dat RA patiënten hogere MRI inflammatie scores hadden dan 
andere vroege artritis patiënten. Helaas was de accuraatheid om RA patiënten van andere 
vroege artritis patiënten te differentiëren laag. In de klinische praktijk worden patiënten 
eerst geclassificeerd op basis van klinische en serologische bevindingen. De overgebleven 
groep bestaande uit UA patiënten kunnen mogelijk onderscheiden worden met MRI bevin-
dingen. In hoofdstuk 2 en 3 keken we naar de differentiatie van deze UA patiënten. We 
zagen dat zelfs na het toepassen van de meer gevoelige 2010 criteria voor RA, nog 24% 
RA ontwikkelden gedurende het eerste jaar. Dit laat zien dat de 2010 criteria tekort schiet 
bij het classificeren van RA op baseline. We probeerden voorspellende factoren te vinden 
voor UA patiënten die RA ontwikkelen. Helaas konden ACPA status en het ‘Van der Helm 
voorspel model’ deze patiënten niet differentiëren.
In hoofdstuk 9 deden we onderzoek met patiënten in een nog eerdere fase dan UA; in 
ACPA positieve artralgie patiënten. We zagen in deze vroege fase van de ziekte al lokale 
subklinische inflammatie op MRI. Dit bevestigt de aanwezigheid van een pre-klinische fase 
van RA en het belang van MRI daarin. In deze fase van de ziekte zou MRI kunnen helpen 
in het voorspellen welke patiënten RA zullen ontwikkelen.
2) In hoofdstuk 10 en 11 zagen we met behulp van MRI subklinische inflammatie in de 
klinisch niet gezwollen gewrichten in vroege artritis patiënten. Om de relevantie van 
deze subklinische inflammatie in de klinisch niet gezwollen gewrichten te onderzoeken, 
keken we naar radiologische toename van gewrichtsschade na één jaar. We vonden dat 
gewrichten met subklinische inflammatie een verhoogd risico hadden op radiologische 
gewrichtsschade toename. Dit suggereert dat MRI gedetecteerde subklinische inflammatie 
relevant is en kan voorspellen voor een ernstiger ziekte beloop.
In hoofdstuk 5 tot 7 vonden we vier IL15, één IL4R en één GZMB SNPs die geassocieerd 
zijn met een ernstiger ziekte beloop. In hoofdstuk 8 vonden we ook een serologische 
marker, pyridinoline, die geassocieerd is met een ernstiger ziekte beloop.
Ten slotte onderzochten we in hoofdstuk 13 tot 15 het huidige MRI scan protocol, met als 
doel; dit protocol efficiënter en accurater te maken. We vonden dat beenmerg oedeem 
(BME) ook gescoord kan worden op een T1 gewogen sequentie na contrast toediening 
en daarom kan nu het scan protocol verkort worden door de T2 gewogen sequenties 
weg te laten. Ook vonden we dat sequenties na toediening van contrast essentieel zijn 
om synovitis en tenosynovitis goed te kunnen scoren. Ook hebben we laten zien dat het 
dragen van hoge hakken niet zorgt voor structurele afwijkingen op de korte termijn.
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toekomst PeRsPeCtieven/UitDAGinGen
Gedurende de afgelopen decennia is de behandeling van RA zeer effectief geworden, wat 
heeft geresulteerd in een minder ernstige uitkomst van RA, met zeer weinig radiologische 
gewrichtsschade toename. Verder hebben we uit eerdere onderzoeken geleerd dat vroege 
interventie het natuurlijk ziekte beloop van RA kan stoppen. Daarom zou de behandeling 
van RA zich in de toekomst nog meer moeten richten op het de vroege detectie van RA 
patiënten, om hen vervolgens te behandelen of mogelijk eerst goed te monitoren in het geval 
van heel vroege RA. Daarom zou het onderzoek gericht moeten zijn op het identificeren van 
voorspellende factoren voor het ontwikkelen van RA. Dit is al veel gedaan in UA patiënten, 
maar de kansen liggen in de eerdere fases van de ziekte. We weten van eerdere studies dat 
anti-lichamen en acute fase eiwitten al jaren aanwezig zijn, voordat de eerste symptomen zich 
openbaren. Dit suggereert dat er een pre-klinische fase bestaat in RA. Het lastige is dat voor-
spellende factoren voor RA ontwikkeling in een heel vroege fase van de ziekte erg specifiek 
kunnen zijn, maar de uitdaging zit hem in om ook sensitief te blijven. Een voorbeeld in artralgie 
patiënten en dan vooral ACPA en/of RF positieve artralgie patiënten is dat zij een verhoogd ri-
sico hebben om RA te ontwikkelen, maar als deze patiënten ook artritis hebben (UA patiënten) 
is de kans op RA nog veel hoger. Hoe verder je af zit van het daadwerkelijke RA fenotype, hoe 
kleiner de kans op ontwikkeling van RA en hoe moeilijker het is om te differentiëren.
Een andere belangrijke pijler in RA onderzoek zou ‘personalized medicine’ moeten zijn. De 
ene RA patiënt is de ander niet. Allereerst zou het onderzoek zich meer moeten richten op het 
voorspellen van het ziekte beloop in de individuele patiënt. Ten tweede, zou het onderzoek zich 
moeten richten op het voorspellen van de effectiviteit van een behandeling (en de bijwerkingen) 
in de individuele patiënt. Deze twee zouden dan gecombineerd moeten worden om een per-
soonlijke behandelkeuze te maken in iedere RA patiënt. Ik verwacht dat er in de nabije toekomst 
handige tools zullen zijn om te berekenen welke behandel stap genomen moet worden in iedere 
patiënt, gebaseerd op de voorspelling van zijn ziekte beloop en effectiviteit van elke behandeling.
Een ander belangrijk onderwerp in RA onderzoek is mRi. MRI is nu al een belangrijk on-
derwerp in RA onderzoek, maar zal mogelijk in de toekomst alleen nog maar belangrijker 
worden. MRI is een sensitief instrument om (sub)klinische inflammatie te meten. MRI is 
het één van de weinige niet invasieve instrumenten waarmee BME, een sterke voorspeller 
voor progressieve ziekte, kan worden gemeten. MRI zou een belangrijk instrument kun-
nen worden in het maken van behandel keuzes en het voorspellen van de prognose van 
de patiënt. In klinische trials zal MRI steeds belangrijker worden voor het meten van de 
effectiviteit van ziekte onderdrukkende behandelingen, op het verloop van synovitis en 
beenmerg oedeem. Zo zijn er al studies die hebben aangetoond dat er sprake kan zijn van 
subklinische inflammatie op MRI in patiënten in klinische remissie.
Om al deze uitdagingen in het onderzoek naar RA aan te gaan, is er nog veel onderzoek 
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